{"PMC5923487": [], "54b1aa9288d2c87dfe3b26d6289b41c4dcdb6982": [["When the hosts are humans, emerging viruses can present major public health issues, as exemplified by the AIDS pandemic.", [["AIDS", "DISEASE", 106, 110], ["humans", "ORGANISM", 19, 25], ["humans", "SPECIES", 19, 25], ["humans", "SPECIES", 19, 25]]], ["Therefore, heuristic approaches to identify nascent diseases before they become pandemic would be valuable.", [["nascent diseases", "PROBLEM", 44, 60], ["pandemic", "PROBLEM", 80, 88], ["diseases", "OBSERVATION", 52, 60]]], ["Unfortunately, the current patient-based and epidemiological approaches are ill-suited in this regard because they are largely responsive and not predictive.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34]]], ["Alternative approaches based on virus evolutionary ecology might have greater potential to predict virus emergence.", [["Alternative approaches", "TREATMENT", 0, 22]]], ["However, given the difficulties encountered when studying metazoan viruses in this context, the development of new model systems is greatly desirable.", [["the difficulties", "PROBLEM", 15, 31], ["metazoan viruses", "PROBLEM", 58, 74], ["new model systems", "PROBLEM", 111, 128], ["new", "OBSERVATION_MODIFIER", 111, 114], ["greatly", "OBSERVATION_MODIFIER", 132, 139], ["desirable", "OBSERVATION_MODIFIER", 140, 149]]]], "PMC7135795": [["Purpose ::: IntroductionThe aim of this study was to detect the frequency of EBV by in situ hybridization in surgically removed tonsils and adenoids, to look for differences between them, and to define the correlation between EBV and adenoid hyperplasia.Materials and methodsWe studied 165 samples of adenoid and tonsil tissue.", [["tonsils", "ANATOMY", 128, 135], ["adenoids", "ANATOMY", 140, 148], ["adenoid hyperplasia", "ANATOMY", 234, 253], ["samples", "ANATOMY", 290, 297], ["adenoid", "ANATOMY", 301, 308], ["tonsil tissue", "ANATOMY", 313, 326], ["adenoid hyperplasia", "DISEASE", 234, 253], ["EBV", "ORGANISM", 77, 80], ["tonsils", "ORGAN", 128, 135], ["adenoids", "ORGAN", 140, 148], ["EBV", "ORGANISM", 226, 229], ["adenoid hyperplasia", "CANCER", 234, 253], ["adenoid", "CANCER", 301, 308], ["tonsil tissue", "TISSUE", 313, 326], ["EBV", "SPECIES", 77, 80], ["this study", "TEST", 35, 45], ["EBV", "PROBLEM", 77, 80], ["adenoids", "PROBLEM", 140, 148], ["EBV", "PROBLEM", 226, 229], ["adenoid hyperplasia", "PROBLEM", 234, 253], ["adenoid and tonsil tissue", "PROBLEM", 301, 326], ["tonsils", "ANATOMY", 128, 135], ["adenoids", "OBSERVATION", 140, 148], ["adenoid", "ANATOMY", 234, 241], ["hyperplasia", "OBSERVATION", 242, 253], ["adenoid", "ANATOMY", 301, 308], ["tonsil tissue", "ANATOMY", 313, 326]]], ["The resection of adenoids was done to relieve upper respiratory tract obstruction.", [["adenoids", "ANATOMY", 17, 25], ["upper respiratory tract", "ANATOMY", 46, 69], ["respiratory tract obstruction", "DISEASE", 52, 81], ["adenoids", "ORGAN", 17, 25], ["upper", "ORGANISM_SUBDIVISION", 46, 51], ["respiratory tract", "ORGANISM_SUBDIVISION", 52, 69], ["The resection of adenoids", "TREATMENT", 0, 25], ["upper respiratory tract obstruction", "PROBLEM", 46, 81], ["resection", "OBSERVATION", 4, 13], ["adenoids", "OBSERVATION", 17, 25], ["upper", "ANATOMY_MODIFIER", 46, 51], ["respiratory tract", "ANATOMY", 52, 69], ["obstruction", "OBSERVATION", 70, 81]]], ["There were 80 adenoid samples.", [["adenoid samples", "ANATOMY", 14, 29], ["adenoid samples", "CANCER", 14, 29], ["80 adenoid samples", "PROBLEM", 11, 29]]], ["They were divided in two groups: one group with 32 children from 12 to 24 months of age (mean, 18 months) and the second group with 48 children from 25 months to 15 years old.Materials and methodsTonsils were obtained from 85 patients, from 3 to 13 years old (mean, 5.6 years).", [["Tonsils", "ANATOMY", 196, 203], ["children", "ORGANISM", 51, 59], ["children", "ORGANISM", 135, 143], ["Tonsils", "CANCER", 196, 203], ["patients", "ORGANISM", 226, 234], ["children", "SPECIES", 51, 59], ["children", "SPECIES", 135, 143], ["patients", "SPECIES", 226, 234]]], ["They underwent surgery (tonsillectomy with or without adenoidectomy) due to recurrent tonsillitis (42 patients) or hyperplasia with upper airway obstruction (43 patients).Materials and methodsThe removed adenoids and tonsils were fixed in 10% formalin and embedded in paraffin.", [["upper airway", "ANATOMY", 132, 144], ["adenoids", "ANATOMY", 204, 212], ["tonsils", "ANATOMY", 217, 224], ["tonsillitis", "DISEASE", 86, 97], ["hyperplasia", "DISEASE", 115, 126], ["airway obstruction", "DISEASE", 138, 156], ["formalin", "CHEMICAL", 243, 251], ["formalin", "CHEMICAL", 243, 251], ["paraffin", "CHEMICAL", 268, 276], ["patients", "ORGANISM", 102, 110], ["upper airway", "ORGANISM_SUBDIVISION", 132, 144], ["patients", "ORGANISM", 161, 169], ["adenoids", "ORGAN", 204, 212], ["tonsils", "ORGAN", 217, 224], ["formalin", "SIMPLE_CHEMICAL", 243, 251], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 161, 169], ["surgery", "TREATMENT", 15, 22], ["tonsillectomy", "TREATMENT", 24, 37], ["adenoidectomy", "TREATMENT", 54, 67], ["recurrent tonsillitis", "PROBLEM", 76, 97], ["hyperplasia", "PROBLEM", 115, 126], ["upper airway obstruction", "PROBLEM", 132, 156], ["The removed adenoids and tonsils", "TREATMENT", 192, 224], ["surgery", "OBSERVATION", 15, 22], ["tonsillectomy", "OBSERVATION", 24, 37], ["recurrent", "OBSERVATION_MODIFIER", 76, 85], ["tonsillitis", "OBSERVATION", 86, 97], ["hyperplasia", "OBSERVATION", 115, 126], ["upper", "ANATOMY_MODIFIER", 132, 137], ["airway", "ANATOMY", 138, 144], ["obstruction", "OBSERVATION", 145, 156], ["adenoids", "OBSERVATION", 204, 212], ["tonsils", "ANATOMY", 217, 224]]], ["Tissue sections 5 \u03bcm thick were stained with hematoxylin and eosin for histological analysis and others submitted to the in situ hybridization (ISH).", [["Tissue sections", "ANATOMY", 0, 15], ["hematoxylin", "CHEMICAL", 45, 56], ["eosin", "CHEMICAL", 61, 66], ["Tissue sections", "MULTI-TISSUE_STRUCTURE", 0, 15], ["hematoxylin", "SIMPLE_CHEMICAL", 45, 56], ["eosin", "SIMPLE_CHEMICAL", 61, 66], ["Tissue sections", "TEST", 0, 15], ["hematoxylin", "TEST", 45, 56], ["eosin", "TEST", 61, 66], ["histological analysis", "TEST", 71, 92]]], ["The ISH was carried out with the EBER probes from Novocastra, which consists of a mixture of oligonucleotides EBER (EBER 1 and EBER 2, of 30 base length).", [["Novocastra", "GENE_OR_GENE_PRODUCT", 50, 60], ["EBER 1", "GENE_OR_GENE_PRODUCT", 116, 122], ["EBER 2", "GENE_OR_GENE_PRODUCT", 127, 133], ["EBER probes", "DNA", 33, 44], ["Novocastra", "PROTEIN", 50, 60], ["The ISH", "TEST", 0, 7], ["the EBER probes", "TEST", 29, 44], ["a mixture of oligonucleotides EBER", "TREATMENT", 80, 114]]], ["The EBER probe was labeled with fluorescein isothiocyanate (FITC).", [["fluorescein isothiocyanate", "CHEMICAL", 32, 58], ["fluorescein isothiocyanate", "CHEMICAL", 32, 58], ["FITC", "CHEMICAL", 60, 64], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 32, 58], ["FITC", "SIMPLE_CHEMICAL", 60, 64], ["EBER probe", "DNA", 4, 14], ["The EBER probe", "TREATMENT", 0, 14], ["fluorescein isothiocyanate (FITC", "TREATMENT", 32, 64], ["EBER probe", "OBSERVATION", 4, 14]]], ["The detection of the hybridization products was achieved by using the Novocastra universal detection system.", [["Novocastra", "GENE_OR_GENE_PRODUCT", 70, 80], ["Novocastra", "PROTEIN", 70, 80], ["the hybridization products", "TREATMENT", 17, 43]]], ["The positive control of the reaction was a previously tested EBV-positive nasopharynx carcinoma.", [["nasopharynx carcinoma", "ANATOMY", 74, 95], ["nasopharynx carcinoma", "DISEASE", 74, 95], ["EBV", "ORGANISM", 61, 64], ["nasopharynx carcinoma", "CANCER", 74, 95], ["the reaction", "PROBLEM", 24, 36], ["a previously tested EBV", "PROBLEM", 41, 64], ["positive nasopharynx carcinoma", "PROBLEM", 65, 95], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["positive", "OBSERVATION_MODIFIER", 65, 73], ["nasopharynx", "ANATOMY", 74, 85], ["carcinoma", "OBSERVATION", 86, 95]]], ["The slides were analyzed on a standard optical microscope, by only one observer.Materials and methodsThe intensity of positiveness to EBV was classified as mild, moderate, and strong.Materials and methodsWe have compared the results obtained from adenoid tissue from children under 24 months of age and older than 25 months, both EBV positive, and tonsillar tissue and adenoid tissue, both EBV positive.Adenoid tissue ::: ResultsIn the first group (12\u201324 months of age) with 32 children, 11 were EBV positive (34.3%), and 21 were EBV negative (65.6%).", [["adenoid tissue", "ANATOMY", 247, 261], ["tonsillar tissue", "ANATOMY", 348, 364], ["adenoid tissue", "ANATOMY", 369, 383], ["Adenoid tissue", "ANATOMY", 403, 417], ["EBV", "ORGANISM", 134, 137], ["adenoid tissue", "TISSUE", 247, 261], ["children", "ORGANISM", 267, 275], ["EBV", "ORGANISM", 330, 333], ["tonsillar tissue", "TISSUE", 348, 364], ["adenoid tissue", "TISSUE", 369, 383], ["EBV", "ORGANISM", 390, 393], ["Adenoid tissue", "TISSUE", 403, 417], ["children", "ORGANISM", 478, 486], ["EBV", "ORGANISM", 496, 499], ["EBV", "ORGANISM", 530, 533], ["children", "SPECIES", 267, 275], ["children", "SPECIES", 478, 486], ["EBV", "SPECIES", 330, 333], ["EBV", "SPECIES", 530, 533], ["a standard optical microscope", "TREATMENT", 28, 57], ["EBV", "TEST", 134, 137], ["adenoid tissue", "PROBLEM", 247, 261], ["EBV positive, and tonsillar tissue and adenoid tissue", "PROBLEM", 330, 383], ["EBV positive", "TEST", 496, 508], ["EBV", "TEST", 530, 533], ["mild", "OBSERVATION_MODIFIER", 156, 160], ["moderate", "OBSERVATION_MODIFIER", 162, 170], ["strong", "OBSERVATION_MODIFIER", 176, 182], ["EBV positive", "OBSERVATION", 330, 342], ["tonsillar tissue", "ANATOMY", 348, 364], ["adenoid tissue", "ANATOMY", 369, 383], ["EBV positive", "OBSERVATION", 390, 402]]], ["In the second group (25 months to 15 years old) with 48 samples, 35 were EBV positive (72.9%) and 13 were EBV negative (27%).", [["samples", "ANATOMY", 56, 63], ["EBV", "ORGANISM", 73, 76], ["EBV", "ORGANISM", 106, 109], ["EBV", "SPECIES", 106, 109], ["EBV", "TEST", 73, 76], ["EBV", "TEST", 106, 109]]], ["We found positive cells inside and outside the germinative center.", [["cells", "ANATOMY", 18, 23], ["germinative center", "ANATOMY", 47, 65], ["cells", "CELL", 18, 23], ["positive cells", "PROBLEM", 9, 23], ["positive cells", "OBSERVATION", 9, 23]]], ["EBV was found in respiratory epithelial cells of adenoid in one case.", [["respiratory epithelial cells", "ANATOMY", 17, 45], ["adenoid", "ANATOMY", 49, 56], ["EBV", "ORGANISM", 0, 3], ["respiratory epithelial cells", "CELL", 17, 45], ["adenoid", "ORGAN", 49, 56], ["respiratory epithelial cells", "CELL_TYPE", 17, 45], ["EBV", "SPECIES", 0, 3], ["EBV", "PROBLEM", 0, 3], ["respiratory epithelial cells of adenoid", "PROBLEM", 17, 56], ["respiratory epithelial cells", "OBSERVATION", 17, 45], ["adenoid", "OBSERVATION", 49, 56]]], ["In relation to intensity, we classified 68 cases (85%) as mild, 6 cases as moderate (7.5%), and 6 cases as strong (7.5%) positiveness to EBV.", [["EBV", "ORGANISM", 137, 140], ["EBV", "TEST", 137, 140], ["mild", "OBSERVATION_MODIFIER", 58, 62], ["moderate", "OBSERVATION_MODIFIER", 75, 83]]], ["Considering all adenoid samples, we obtained 46 positive cases (57.5%).Tonsillar tissue ::: ResultsAmong the 85 tonsil samples, 25 cases (29.4%) were EBV positive, and 60 patients (70.5%) were EBV negative.", [["adenoid samples", "ANATOMY", 16, 31], ["Tonsillar tissue", "ANATOMY", 71, 87], ["tonsil samples", "ANATOMY", 112, 126], ["adenoid samples", "CANCER", 16, 31], ["Tonsillar tissue", "TISSUE", 71, 87], ["tonsil samples", "CANCER", 112, 126], ["EBV", "ORGANISM", 150, 153], ["patients", "ORGANISM", 171, 179], ["EBV", "ORGANISM", 193, 196], ["patients", "SPECIES", 171, 179], ["EBV", "SPECIES", 150, 153], ["EBV", "SPECIES", 193, 196], ["all adenoid samples", "TEST", 12, 31], ["positive cases", "TEST", 48, 62], ["Tonsillar tissue", "TEST", 71, 87], ["tonsil samples", "TEST", 112, 126], ["cases", "TEST", 131, 136], ["EBV", "TEST", 150, 153], ["EBV", "TEST", 193, 196]]], ["The intensity was found mild in 21 cases (84%), moderate in 1 case (4%), and strong in 3 cases (12%).DiscussionThe adenoid, being an immunologic organ, enlarges with recurrent infections by virus, bacteria, allergy, and also unknown stimuli.", [["adenoid", "ANATOMY", 115, 122], ["organ", "ANATOMY", 145, 150], ["infections", "DISEASE", 176, 186], ["allergy", "DISEASE", 207, 214], ["adenoid", "CANCER", 115, 122], ["organ", "ORGAN", 145, 150], ["mild in 21 cases", "PROBLEM", 24, 40], ["The adenoid", "PROBLEM", 111, 122], ["an immunologic organ", "PROBLEM", 130, 150], ["recurrent infections", "PROBLEM", 166, 186], ["virus", "PROBLEM", 190, 195], ["bacteria", "PROBLEM", 197, 205], ["allergy", "PROBLEM", 207, 214], ["mild", "OBSERVATION_MODIFIER", 24, 28], ["moderate", "OBSERVATION_MODIFIER", 48, 56], ["adenoid", "ANATOMY", 115, 122], ["recurrent", "OBSERVATION_MODIFIER", 166, 175], ["infections", "OBSERVATION", 176, 186]]], ["This last condition is known as idiopathic benign hyperplasia.DiscussionIt is well known that EBV has a tropism for the oral and nasopharynx regions, and that is associated with lymphoproliferation.", [["benign hyperplasia", "ANATOMY", 43, 61], ["oral", "ANATOMY", 120, 124], ["nasopharynx regions", "ANATOMY", 129, 148], ["idiopathic benign hyperplasia", "DISEASE", 32, 61], ["lymphoproliferation", "DISEASE", 178, 197], ["benign hyperplasia", "PATHOLOGICAL_FORMATION", 43, 61], ["EBV", "ORGANISM", 94, 97], ["oral", "ORGANISM_SUBDIVISION", 120, 124], ["nasopharynx", "ORGAN", 129, 140], ["EBV", "SPECIES", 94, 97], ["idiopathic benign hyperplasia", "PROBLEM", 32, 61], ["a tropism for the oral and nasopharynx regions", "PROBLEM", 102, 148], ["lymphoproliferation", "PROBLEM", 178, 197], ["known as", "UNCERTAINTY", 23, 31], ["idiopathic", "OBSERVATION_MODIFIER", 32, 42], ["benign", "OBSERVATION_MODIFIER", 43, 49], ["hyperplasia", "OBSERVATION", 50, 61], ["nasopharynx", "ANATOMY", 129, 140], ["associated with", "UNCERTAINTY", 162, 177], ["lymphoproliferation", "OBSERVATION", 178, 197]]], ["EBV is carried by more than 90% of the population worldwide.", [["EBV", "ORGANISM", 0, 3], ["EBV", "SPECIES", 0, 3], ["EBV", "PROBLEM", 0, 3]]], ["The role of oropharyngeal epithelial cells as a reservoir of EBV was already suggested.", [["oropharyngeal epithelial cells", "ANATOMY", 12, 42], ["oropharyngeal epithelial cells", "CELL", 12, 42], ["EBV", "ORGANISM", 61, 64], ["oropharyngeal epithelial cells", "CELL_TYPE", 12, 42], ["EBV", "SPECIES", 61, 64], ["oropharyngeal epithelial cells", "PROBLEM", 12, 42], ["EBV", "PROBLEM", 61, 64], ["oropharyngeal epithelial", "ANATOMY", 12, 36], ["cells", "OBSERVATION", 37, 42]]], ["In a previous study by our group, we used in situ hybridization to detect EBV in patients with recurrent tonsillitis and idiopathic benign hypertrophy, and we found the virus in both groups.DiscussionMany authors [10], [11], [12], [13] have described the presence of EBV in the upper airway tract, using different methods, such as ELISA, PCR (polymerase chain reaction), immunohistochemical, and in situ hybridization.", [["upper airway tract", "ANATOMY", 278, 296], ["tonsillitis", "DISEASE", 105, 116], ["idiopathic benign hypertrophy", "DISEASE", 121, 150], ["EBV", "ORGANISM", 74, 77], ["patients", "ORGANISM", 81, 89], ["[11]", "SIMPLE_CHEMICAL", 219, 223], ["[12]", "SIMPLE_CHEMICAL", 225, 229], ["[13]", "SIMPLE_CHEMICAL", 231, 235], ["EBV", "ORGANISM", 267, 270], ["upper airway", "ORGANISM_SUBDIVISION", 278, 290], ["tract", "ORGANISM_SUBDIVISION", 291, 296], ["patients", "SPECIES", 81, 89], ["EBV", "SPECIES", 74, 77], ["a previous study", "TEST", 3, 19], ["EBV", "PROBLEM", 74, 77], ["recurrent tonsillitis", "PROBLEM", 95, 116], ["idiopathic benign hypertrophy", "PROBLEM", 121, 150], ["the virus in both groups", "PROBLEM", 165, 189], ["EBV in the upper airway tract", "PROBLEM", 267, 296], ["different methods", "TREATMENT", 304, 321], ["ELISA", "TEST", 331, 336], ["PCR (polymerase chain reaction", "PROBLEM", 338, 368], ["recurrent", "OBSERVATION_MODIFIER", 95, 104], ["tonsillitis", "OBSERVATION", 105, 116], ["idiopathic", "OBSERVATION_MODIFIER", 121, 131], ["benign", "OBSERVATION_MODIFIER", 132, 138], ["hypertrophy", "OBSERVATION", 139, 150], ["virus", "OBSERVATION", 169, 174], ["EBV", "OBSERVATION", 267, 270], ["upper", "ANATOMY_MODIFIER", 278, 283], ["airway tract", "ANATOMY", 284, 296]]], ["Niedobitek et al. [14], [15] have shown that EBV attacks the B lymphocytes, which are the primary target of infection in patients with infectious mononucleosis.", [["B lymphocytes", "ANATOMY", 61, 74], ["infection", "DISEASE", 108, 117], ["infectious mononucleosis", "DISEASE", 135, 159], ["EBV", "ORGANISM", 45, 48], ["B lymphocytes", "CELL", 61, 74], ["patients", "ORGANISM", 121, 129], ["B lymphocytes", "CELL_TYPE", 61, 74], ["patients", "SPECIES", 121, 129], ["EBV attacks the B lymphocytes", "PROBLEM", 45, 74], ["infection", "PROBLEM", 108, 117], ["infectious mononucleosis", "PROBLEM", 135, 159], ["EBV", "OBSERVATION", 45, 48], ["B lymphocytes", "OBSERVATION_MODIFIER", 61, 74], ["infection", "OBSERVATION", 108, 117], ["infectious", "OBSERVATION_MODIFIER", 135, 145], ["mononucleosis", "OBSERVATION", 146, 159]]], ["Takimoto et al. [16] have observed a small number of B lymphocytes in the nasopharynx that work as a reservoir to EBV, comparing tissue samples from patients with suspected nasopharyngeal carcinoma and non-neoplastic tissue samples from adenoid.", [["B lymphocytes", "ANATOMY", 53, 66], ["nasopharynx", "ANATOMY", 74, 85], ["tissue samples", "ANATOMY", 129, 143], ["nasopharyngeal carcinoma", "ANATOMY", 173, 197], ["non-neoplastic tissue samples", "ANATOMY", 202, 231], ["adenoid", "ANATOMY", 237, 244], ["nasopharyngeal carcinoma", "DISEASE", 173, 197], ["B lymphocytes", "CELL", 53, 66], ["nasopharynx", "ORGAN", 74, 85], ["EBV", "ORGANISM", 114, 117], ["tissue samples", "TISSUE", 129, 143], ["patients", "ORGANISM", 149, 157], ["nasopharyngeal carcinoma", "CANCER", 173, 197], ["non-neoplastic tissue samples", "TISSUE", 202, 231], ["adenoid", "ORGAN", 237, 244], ["B lymphocytes", "CELL_TYPE", 53, 66], ["patients", "SPECIES", 149, 157], ["EBV", "SPECIES", 114, 117], ["B lymphocytes in the nasopharynx", "PROBLEM", 53, 85], ["tissue samples", "TEST", 129, 143], ["nasopharyngeal carcinoma", "PROBLEM", 173, 197], ["non-neoplastic tissue samples from adenoid", "PROBLEM", 202, 244], ["small", "OBSERVATION_MODIFIER", 37, 42], ["lymphocytes", "OBSERVATION", 55, 66], ["nasopharynx", "ANATOMY", 74, 85], ["nasopharyngeal", "ANATOMY", 173, 187], ["carcinoma", "OBSERVATION", 188, 197], ["non-neoplastic tissue", "OBSERVATION", 202, 223], ["adenoid", "ANATOMY", 237, 244]]], ["Ikeda et al. [10] have studied normal tonsils and have concluded that the tonsillar lymphocytes have the function of a reservoir and a place of EBV replication.", [["tonsils", "ANATOMY", 38, 45], ["tonsillar lymphocytes", "ANATOMY", 74, 95], ["tonsils", "ORGAN", 38, 45], ["tonsillar lymphocytes", "CELL", 74, 95], ["EBV", "ORGANISM", 144, 147], ["tonsillar lymphocytes", "CELL_TYPE", 74, 95], ["EBV", "SPECIES", 144, 147], ["the tonsillar lymphocytes", "PROBLEM", 70, 95], ["a reservoir", "TREATMENT", 117, 128], ["EBV replication", "TREATMENT", 144, 159], ["tonsils", "ANATOMY", 38, 45], ["tonsillar", "ANATOMY", 74, 83], ["lymphocytes", "OBSERVATION", 84, 95]]], ["In spite of the suggestion that EBV may be involved in adenoid hypertrophy, there are few large-scale studies on the presence of EBV in adenoid and tonsillar tissue simultaneously.DiscussionIt is very interesting to note the high level of positiveness of EBV in adenoids, when it is compared with tonsil tissue.", [["adenoid", "ANATOMY", 55, 62], ["adenoid", "ANATOMY", 136, 143], ["tonsillar tissue", "ANATOMY", 148, 164], ["adenoids", "ANATOMY", 262, 270], ["tonsil tissue", "ANATOMY", 297, 310], ["adenoid hypertrophy", "DISEASE", 55, 74], ["EBV", "ORGANISM", 32, 35], ["adenoid", "ORGAN", 55, 62], ["EBV", "ORGANISM", 129, 132], ["adenoid", "CANCER", 136, 143], ["tonsillar tissue", "TISSUE", 148, 164], ["EBV", "ORGANISM", 255, 258], ["adenoids", "ORGAN", 262, 270], ["tonsil tissue", "TISSUE", 297, 310], ["EBV", "SPECIES", 32, 35], ["EBV", "PROBLEM", 32, 35], ["adenoid hypertrophy", "PROBLEM", 55, 74], ["EBV in adenoid and tonsillar tissue", "PROBLEM", 129, 164], ["EBV in adenoids", "PROBLEM", 255, 270], ["may be involved", "UNCERTAINTY", 36, 51], ["hypertrophy", "OBSERVATION", 63, 74], ["few", "OBSERVATION_MODIFIER", 86, 89], ["large", "OBSERVATION_MODIFIER", 90, 95], ["-scale", "OBSERVATION_MODIFIER", 95, 101], ["EBV", "OBSERVATION", 129, 132], ["adenoid", "ANATOMY", 136, 143], ["tonsillar tissue", "ANATOMY", 148, 164], ["adenoids", "OBSERVATION", 262, 270], ["tonsil tissue", "ANATOMY", 297, 310]]], ["We know that adenoid tissue grows mainly between 3 and 5 years of age.", [["adenoid tissue", "ANATOMY", 13, 27], ["adenoid tissue", "TISSUE", 13, 27], ["adenoid tissue", "PROBLEM", 13, 27], ["adenoid tissue", "OBSERVATION", 13, 27]]], ["Adenoid hyperplasia under 24 months of age is uncommon, and this fact is not yet very well studied.", [["Adenoid hyperplasia", "ANATOMY", 0, 19], ["Adenoid hyperplasia", "DISEASE", 0, 19], ["Adenoid", "ORGAN", 0, 7], ["Adenoid hyperplasia", "PROBLEM", 0, 19], ["hyperplasia", "OBSERVATION", 8, 19]]], ["For this reason, we have divided our patients into two groups; one with patients between 12 and 24 months and the other, with patients older than 25 months.", [["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 126, 134]]], ["We found 34.3% of adenoid tissue with EBV-positive cells in the first group.", [["adenoid tissue", "ANATOMY", 18, 32], ["cells", "ANATOMY", 51, 56], ["adenoid tissue", "TISSUE", 18, 32], ["EBV", "ORGANISM", 38, 41], ["cells", "CELL", 51, 56], ["EBV-positive cells", "CELL_TYPE", 38, 56], ["adenoid tissue", "PROBLEM", 18, 32], ["EBV", "TEST", 38, 41], ["positive cells", "PROBLEM", 42, 56], ["adenoid tissue", "ANATOMY", 18, 32], ["EBV", "OBSERVATION", 38, 41], ["positive cells", "OBSERVATION", 42, 56]]], ["Would this hyperplasia be the one called \u201cidiopathic benign hyperplasia,\u201d due in part to the proliferative action of EBV?DiscussionThe adenoid tissue of the group of children above 25 months of age presented a high percentage (72.9%) of EBV-positive cells, almost twice as many, suggesting that it becomes easier to be infected with aging.DiscussionComparing the positiveness to EBV between adenoids and tonsils, we have verified that adenoids are more frequently positive for EBV (57.5%) than tonsils (29.4%).", [["benign hyperplasia", "ANATOMY", 53, 71], ["adenoid tissue", "ANATOMY", 135, 149], ["cells", "ANATOMY", 250, 255], ["adenoids", "ANATOMY", 391, 399], ["tonsils", "ANATOMY", 404, 411], ["adenoids", "ANATOMY", 435, 443], ["tonsils", "ANATOMY", 494, 501], ["hyperplasia", "DISEASE", 11, 22], ["hyperplasia", "DISEASE", 60, 71], ["benign hyperplasia", "PATHOLOGICAL_FORMATION", 53, 71], ["EBV", "ORGANISM", 117, 120], ["adenoid tissue", "TISSUE", 135, 149], ["children", "ORGANISM", 166, 174], ["EBV", "ORGANISM", 237, 240], ["cells", "CELL", 250, 255], ["EBV", "ORGANISM", 379, 382], ["adenoids", "ORGAN", 391, 399], ["tonsils", "ORGAN", 404, 411], ["adenoids", "ORGAN", 435, 443], ["EBV", "ORGANISM", 477, 480], ["tonsils", "ORGAN", 494, 501], ["EBV-positive cells", "CELL_TYPE", 237, 255], ["children", "SPECIES", 166, 174], ["EBV", "SPECIES", 477, 480], ["this hyperplasia", "PROBLEM", 6, 22], ["idiopathic benign hyperplasia", "PROBLEM", 42, 71], ["EBV", "PROBLEM", 117, 120], ["EBV-positive cells", "PROBLEM", 237, 255], ["EBV between adenoids and tonsils", "PROBLEM", 379, 411], ["adenoids", "PROBLEM", 435, 443], ["EBV", "TEST", 477, 480], ["tonsils", "TEST", 494, 501], ["hyperplasia", "OBSERVATION", 11, 22], ["idiopathic", "OBSERVATION_MODIFIER", 42, 52], ["benign", "OBSERVATION_MODIFIER", 53, 59], ["hyperplasia", "OBSERVATION", 60, 71], ["EBV", "OBSERVATION", 117, 120], ["positive cells", "OBSERVATION", 241, 255], ["infected", "OBSERVATION", 319, 327], ["tonsils", "ANATOMY", 404, 411], ["adenoids", "OBSERVATION", 435, 443]]], ["Kobayashi et al. [13] found a similar percentage of EBV positive cells in tonsils.", [["cells", "ANATOMY", 65, 70], ["tonsils", "ANATOMY", 74, 81], ["EBV", "ORGANISM", 52, 55], ["cells", "CELL", 65, 70], ["tonsils", "ORGAN", 74, 81], ["EBV positive cells", "CELL_TYPE", 52, 70], ["EBV positive cells in tonsils", "PROBLEM", 52, 81], ["EBV positive cells", "OBSERVATION", 52, 70], ["tonsils", "ANATOMY", 74, 81]]], ["Some authors have demonstrated that EBV is equally distributed in the Waldeyer's ring; however, this is not in agreement with our findings.", [["EBV", "ORGANISM", 36, 39], ["EBV", "PROBLEM", 36, 39], ["EBV", "OBSERVATION", 36, 39], ["equally", "OBSERVATION_MODIFIER", 43, 50], ["distributed", "OBSERVATION_MODIFIER", 51, 62]]], ["Considering the intensity of positiveness, there were no significant differences.", [["no", "UNCERTAINTY", 54, 56], ["significant", "OBSERVATION_MODIFIER", 57, 68]]], ["EBV was found in the tonsillar parenchyma and in the parafollicular region, or inside the germinal center.", [["tonsillar parenchyma", "ANATOMY", 21, 41], ["parafollicular region", "ANATOMY", 53, 74], ["germinal center", "ANATOMY", 90, 105], ["EBV", "ORGANISM", 0, 3], ["tonsillar parenchyma", "MULTI-TISSUE_STRUCTURE", 21, 41], ["germinal center", "MULTI-TISSUE_STRUCTURE", 90, 105], ["EBV", "SPECIES", 0, 3], ["EBV", "PROBLEM", 0, 3], ["tonsillar", "ANATOMY", 21, 30], ["parenchyma", "ANATOMY_MODIFIER", 31, 41], ["parafollicular", "ANATOMY", 53, 67], ["region", "ANATOMY_MODIFIER", 68, 74], ["germinal", "ANATOMY_MODIFIER", 90, 98]]], ["It was also found in the adenoid epithelium, though rarely.", [["adenoid epithelium", "ANATOMY", 25, 43], ["adenoid epithelium", "TISSUE", 25, 43], ["the adenoid epithelium", "PROBLEM", 21, 43], ["adenoid epithelium", "ANATOMY", 25, 43]]]], "PMC7126404": [["IntroductionThe development of the innate immune system is essential for new-born animals to survive, especially when exposed to infectious diseases that are responsible for high morbidity and mortality.", [["infectious diseases", "DISEASE", 129, 148], ["infectious diseases", "PROBLEM", 129, 148], ["high morbidity", "PROBLEM", 174, 188]]], ["During the first few months of life new-born calves have a weakened immunity as the granulocyte function and complement activity are low (Cervenak, Kacskovics, 2009, Cortese, 2008); and the calves also lack specific immunity (Boysen et al, 2006, Stefaniak et al, 2012).", [["granulocyte", "ANATOMY", 84, 95], ["calves", "ORGANISM", 45, 51], ["granulocyte", "CELL", 84, 95], ["calves", "ORGANISM", 190, 196], ["calves", "SPECIES", 45, 51], ["calves", "SPECIES", 190, 196], ["calves", "SPECIES", 190, 196], ["the granulocyte function", "TEST", 80, 104], ["complement activity", "TEST", 109, 128], ["Kacskovics", "TEST", 148, 158]]], ["Protection obtained from colostrum falls as the immunoglobulins decline usually from the seventh day of life.", [["colostrum", "ANATOMY", 25, 34], ["colostrum", "ORGANISM_SUBSTANCE", 25, 34], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 48, 63], ["immunoglobulins", "PROTEIN", 48, 63], ["Protection", "TREATMENT", 0, 10], ["colostrum falls", "PROBLEM", 25, 40], ["the immunoglobulins decline", "PROBLEM", 44, 71]]], ["This is at a time when their specific antibodies are at a low concentration; which then develops as the calves grow (Stefaniak et al., 2011).", [["calves", "ORGANISM", 104, 110], ["antibodies", "PROTEIN", 38, 48], ["calves", "SPECIES", 104, 110]]], ["During this period of low immunity the animals are more susceptible to infections including bovine respiratory disease (BRD).", [["respiratory", "ANATOMY", 99, 110], ["infections", "DISEASE", 71, 81], ["bovine respiratory disease", "DISEASE", 92, 118], ["BRD", "DISEASE", 120, 123], ["animals", "ORGANISM", 39, 46], ["bovine", "ORGANISM", 92, 98], ["respiratory", "ORGANISM_SUBDIVISION", 99, 110], ["bovine", "SPECIES", 92, 98], ["bovine", "SPECIES", 92, 98], ["BRD", "SPECIES", 120, 123], ["infections", "PROBLEM", 71, 81], ["bovine respiratory disease (BRD)", "PROBLEM", 92, 124], ["low immunity", "OBSERVATION_MODIFIER", 22, 34], ["infections", "OBSERVATION", 71, 81], ["respiratory disease", "OBSERVATION", 99, 118]]], ["BRD is a complex and multifactorial disease caused by bacteria and viruses and is one of the most important diseases of cattle.", [["BRD", "DISEASE", 0, 3], ["cattle", "ORGANISM", 120, 126], ["cattle", "SPECIES", 120, 126], ["cattle", "SPECIES", 120, 126], ["BRD", "PROBLEM", 0, 3], ["a complex and multifactorial disease", "PROBLEM", 7, 43], ["bacteria", "PROBLEM", 54, 62], ["viruses", "PROBLEM", 67, 74], ["complex", "OBSERVATION_MODIFIER", 9, 16], ["multifactorial", "OBSERVATION_MODIFIER", 21, 35], ["disease", "OBSERVATION", 36, 43], ["bacteria", "OBSERVATION", 54, 62], ["viruses", "OBSERVATION", 67, 74], ["one of the most important", "OBSERVATION_MODIFIER", 82, 107], ["diseases", "OBSERVATION", 108, 116]]], ["Estimated losses to the cattle industry from BRD is more than US$3 billion every year (Griffin, 1997).", [["BRD", "DISEASE", 45, 48], ["cattle", "ORGANISM", 24, 30], ["cattle", "SPECIES", 24, 30], ["cattle", "SPECIES", 24, 30], ["BRD", "SPECIES", 45, 48], ["Estimated losses", "PROBLEM", 0, 16], ["losses", "OBSERVATION_MODIFIER", 10, 16]]], ["The main causative bacteria are: Mycoplasma bovis, and Mycoplasma dispar for which there are currently no commercial vaccines; and the Pasteurellaceae family of which the most pathogenic is Mannheimia haemolytica (Singh et al., 2011).", [["Mycoplasma bovis", "DISEASE", 33, 49], ["Mycoplasma dispar", "DISEASE", 55, 72], ["Mycoplasma bovis", "ORGANISM", 33, 49], ["Mycoplasma dispar", "ORGANISM", 55, 72], ["Mannheimia haemolytica", "ORGANISM", 190, 212], ["Mycoplasma bovis", "SPECIES", 33, 49], ["Mycoplasma dispar", "SPECIES", 55, 72], ["Mannheimia haemolytica", "SPECIES", 190, 212], ["Mycoplasma bovis", "SPECIES", 33, 49], ["Mycoplasma dispar", "SPECIES", 55, 72], ["Mannheimia haemolytica", "SPECIES", 190, 212], ["The main causative bacteria", "PROBLEM", 0, 27], ["Mycoplasma bovis", "PROBLEM", 33, 49], ["Mycoplasma dispar", "PROBLEM", 55, 72], ["commercial vaccines", "TREATMENT", 106, 125], ["Mannheimia haemolytica", "PROBLEM", 190, 212], ["main", "OBSERVATION_MODIFIER", 4, 8], ["bacteria", "OBSERVATION", 19, 27], ["Mycoplasma bovis", "OBSERVATION", 33, 49], ["Mannheimia haemolytica", "OBSERVATION", 190, 212]]], ["Viruses including PI3V and BRSV have an important role in BRD, not only in the pathogenesis of the disease but also by suppressing the host immunity (Cusack et al., 2003).", [["BRD", "DISEASE", 58, 61], ["PI3V", "GENE_OR_GENE_PRODUCT", 18, 22], ["BRSV", "ORGANISM", 27, 31], ["PI3V", "PROTEIN", 18, 22], ["BRSV", "SPECIES", 27, 31], ["PI3V", "SPECIES", 18, 22], ["BRSV", "SPECIES", 27, 31], ["Viruses", "PROBLEM", 0, 7], ["PI3V", "PROBLEM", 18, 22], ["BRSV", "PROBLEM", 27, 31], ["BRD", "PROBLEM", 58, 61], ["the disease", "PROBLEM", 95, 106], ["BRD", "OBSERVATION", 58, 61], ["disease", "OBSERVATION", 99, 106]]], ["Calves are usually vaccinated during the first weeks of life.", [["Calves", "ORGANISM", 0, 6], ["Calves", "SPECIES", 0, 6]]], ["However, calf immunisation may be adversely affected by interference from maternal antibodies or unfavourable environmental conditions.", [["calf", "ORGANISM_SUBDIVISION", 9, 13], ["maternal antibodies", "PROTEIN", 74, 93], ["calf", "SPECIES", 9, 13], ["calf immunisation", "TREATMENT", 9, 26], ["maternal antibodies", "PROBLEM", 74, 93], ["unfavourable environmental conditions", "PROBLEM", 97, 134], ["calf", "ANATOMY", 9, 13]]], ["Therefore, the effective vaccination of pregnant cows and the subsequent colostrum intake by their offspring can enhance the immune response of new-born calves.IntroductionThe aim of the study was to investigate the level of passive immunity acquired by calves that have been fed colostrum derived only from their own dam which was vaccinated pre-partum for M. haemolytica, PI3V and BRSV, or from their own unvaccinated dam in the control group.Experimental procedure ::: Material and methodsTo investigate the effect of stimulating the calf's immune system by vaccinating their dams, pregnant cows were vaccinated with BRSV-PI3V-M. haemolytica antigens.", [["colostrum", "ANATOMY", 73, 82], ["cows", "ORGANISM", 49, 53], ["colostrum", "ORGANISM_SUBDIVISION", 73, 82], ["calves", "ORGANISM", 153, 159], ["calves", "ORGANISM", 254, 260], ["colostrum", "ORGANISM", 280, 289], ["M. haemolytica", "ORGANISM", 358, 372], ["PI3V", "GENE_OR_GENE_PRODUCT", 374, 378], ["BRSV", "ORGANISM", 383, 387], ["calf", "ORGANISM", 537, 541], ["immune system", "ANATOMICAL_SYSTEM", 544, 557], ["dams", "ORGANISM", 579, 583], ["cows", "ORGANISM", 594, 598], ["BRSV", "ORGANISM", 620, 624], ["PI3V-M. haemolytica antigens", "ORGANISM", 625, 653], ["BRSV-PI3V-M. haemolytica antigens", "PROTEIN", 620, 653], ["cows", "SPECIES", 49, 53], ["calves", "SPECIES", 153, 159], ["calves", "SPECIES", 254, 260], ["M. haemolytica", "SPECIES", 358, 372], ["BRSV", "SPECIES", 383, 387], ["calf", "SPECIES", 537, 541], ["cows", "SPECIES", 594, 598], ["BRSV", "SPECIES", 620, 624], ["M. haemolytica", "SPECIES", 630, 644], ["calves", "SPECIES", 254, 260], ["colostrum", "SPECIES", 280, 289], ["M. haemolytica", "SPECIES", 358, 372], ["PI3V", "SPECIES", 374, 378], ["BRSV", "SPECIES", 383, 387], ["BRSV", "SPECIES", 620, 624], ["M. haemolytica", "SPECIES", 630, 644], ["the effective vaccination of pregnant cows", "TREATMENT", 11, 53], ["the subsequent colostrum intake", "TREATMENT", 58, 89], ["the study", "TEST", 183, 192], ["haemolytica", "PROBLEM", 361, 372], ["BRSV", "PROBLEM", 383, 387], ["stimulating the calf's immune system", "TREATMENT", 521, 557], ["pregnant cows", "TREATMENT", 585, 598], ["BRSV", "TEST", 620, 624], ["haemolytica antigens", "PROBLEM", 633, 653], ["new", "OBSERVATION_MODIFIER", 144, 147], ["calf", "ANATOMY", 537, 541]]], ["The immune response in the calves was analysed and multiple parameters measured as described later.Cattle ::: Material and methodsTwelve pregnant Holstein Friesians cows were sourced from a commercial 2000 head dairy farm.", [["calves", "ORGANISM", 27, 33], ["cows", "ORGANISM", 165, 169], ["head", "ORGANISM_SUBDIVISION", 206, 210], ["calves", "SPECIES", 27, 33], ["cows", "SPECIES", 165, 169], ["multiple parameters", "TEST", 51, 70], ["immune response", "OBSERVATION", 4, 19], ["calves", "ANATOMY", 27, 33]]], ["Two groups of six cows were housed separately.", [["cows", "ORGANISM", 18, 22], ["cows", "SPECIES", 18, 22]]], ["Experimental procedures and animal management protocols were carried out in accordance with the requirements of the Local Ethics Committee on Animal Experimentation.Vaccination of pregnant cows ::: Material and methodsOne group of six cows were vaccinated with 5 ml of inactivated vaccine composed of BRSV-PI3V-M. haemolytica antigens (Bovilis\u00aeBovipast RSP, MSD Animal Health, The Netherlands).", [["cows", "ORGANISM", 189, 193], ["cows", "ORGANISM", 235, 239], ["BRSV", "ORGANISM", 301, 305], ["PI3V", "ORGANISM", 306, 310], ["M. haemolytica", "ORGANISM", 311, 325], ["cows", "SPECIES", 189, 193], ["cows", "SPECIES", 235, 239], ["BRSV", "SPECIES", 301, 305], ["M. haemolytica", "SPECIES", 311, 325], ["BRSV", "SPECIES", 301, 305], ["M. haemolytica", "SPECIES", 311, 325], ["Experimental procedures", "TREATMENT", 0, 23], ["animal management protocols", "TREATMENT", 28, 55], ["six cows", "TREATMENT", 231, 239], ["inactivated vaccine", "TREATMENT", 269, 288], ["BRSV", "TEST", 301, 305], ["haemolytica antigens", "TEST", 314, 334], ["Bovilis", "TEST", 336, 343]]], ["These subcutaneous vaccinations were in the lateral neck region and were done twice, at 8 and 4 weeks, before the expected delivery dates.", [["subcutaneous", "ANATOMY", 6, 18], ["lateral neck region", "ANATOMY", 44, 63], ["lateral neck", "MULTI-TISSUE_STRUCTURE", 44, 56], ["These subcutaneous vaccinations", "TREATMENT", 0, 31], ["subcutaneous", "ANATOMY", 6, 18], ["lateral", "ANATOMY_MODIFIER", 44, 51], ["neck", "ANATOMY", 52, 56], ["region", "ANATOMY_MODIFIER", 57, 63]]], ["The same experimental design was carried out for the six remaining cows administrating PBS.The calves ::: Material and methodsDirectly after parturition the new-born calves were separated from their dams and kept in the separate groups from vaccinated\u2013\u2018experimental\u2019 and unvaccinated dams.", [["cows", "ORGANISM", 67, 71], ["calves", "ORGANISM", 95, 101], ["calves", "ORGANISM", 166, 172], ["dams", "ORGANISM", 199, 203], ["dams", "ORGANISM", 284, 288], ["calves", "SPECIES", 95, 101], ["calves", "SPECIES", 166, 172], ["cows administrating PBS", "TREATMENT", 67, 90], ["calves", "ANATOMY", 95, 101], ["new", "OBSERVATION_MODIFIER", 157, 160]]], ["The calves were kept according to the standard breeding regulations and fed colostrum derived from their own dams by oral pathway (in a dose of 2 L per calf three times a day) for three consecutive days after delivery.", [["colostrum", "ANATOMY", 76, 85], ["oral", "ANATOMY", 117, 121], ["calves", "ORGANISM", 4, 10], ["colostrum", "ORGANISM", 76, 85], ["dams", "ORGANISM", 109, 113], ["oral", "ORGANISM_SUBDIVISION", 117, 121], ["calf", "ORGANISM_SUBDIVISION", 152, 156], ["calves", "SPECIES", 4, 10], ["calf", "SPECIES", 152, 156], ["oral pathway", "TREATMENT", 117, 129], ["delivery", "TREATMENT", 209, 217], ["calves", "ANATOMY", 4, 10]]], ["The total level of colostrum immunoglobulins was determined using a colostrometer for the measurement of specific gravity in bovine colostrum.", [["colostrum", "ANATOMY", 132, 141], ["colostrum", "ORGANISM", 19, 28], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 29, 44], ["bovine", "ORGANISM", 125, 131], ["colostrum", "ORGANISM_SUBSTANCE", 132, 141], ["colostrum immunoglobulins", "PROTEIN", 19, 44], ["bovine", "SPECIES", 125, 131], ["colostrum", "SPECIES", 19, 28], ["bovine", "SPECIES", 125, 131], ["colostrum immunoglobulins", "TREATMENT", 19, 44], ["a colostrometer", "TREATMENT", 66, 81], ["specific gravity in bovine colostrum", "TREATMENT", 105, 141], ["total", "OBSERVATION_MODIFIER", 4, 9], ["bovine colostrum", "OBSERVATION", 125, 141]]], ["After that the calves were kept in individual pens and fed with raw milk without the presence of any contaminated infectious agents for 1 month and then fed milk replacer.", [["milk", "ANATOMY", 68, 72], ["calves", "ORGANISM", 15, 21], ["milk", "ORGANISM_SUBSTANCE", 68, 72], ["calves", "SPECIES", 15, 21], ["milk replacer", "TREATMENT", 157, 170]]], ["Rectal temperatures, general condition and the presence of respiratory signs were recorded daily.", [["Rectal", "ANATOMY", 0, 6], ["respiratory", "ANATOMY", 59, 70], ["Rectal", "ORGAN", 0, 6], ["Rectal temperatures", "TEST", 0, 19], ["respiratory signs", "PROBLEM", 59, 76]]], ["Blood samples for laboratory analysis were collected from vena jugularis externa of calves at weekly intervals for 12 weeks.The analyses of immune parameters ::: Material and methods", [["Blood samples", "ANATOMY", 0, 13], ["vena jugularis externa", "ANATOMY", 58, 80], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["vena jugularis externa", "MULTI-TISSUE_STRUCTURE", 58, 80], ["calves", "ORGANISM", 84, 90], ["calves", "SPECIES", 84, 90], ["vena jugularis", "SPECIES", 58, 72], ["Blood samples", "TEST", 0, 13], ["laboratory analysis", "TEST", 18, 37], ["vena", "ANATOMY", 58, 62], ["jugularis externa", "ANATOMY", 63, 80]]]], "788a72e4f5b0bee2f5f2e944fc0aff60a8e6924a": [["Dear Editor,Coronavirus disease-19 (COVID-19) is now a global pandemic.", [["Coronavirus disease", "DISEASE", 12, 31], ["Coronavirus disease", "PROBLEM", 12, 31], ["COVID", "TEST", 36, 41], ["a global pandemic", "PROBLEM", 53, 70], ["Coronavirus disease", "OBSERVATION", 12, 31], ["global", "OBSERVATION_MODIFIER", 55, 61], ["pandemic", "OBSERVATION", 62, 70]]], ["Italy was the first European country to be hit by the infection, which has currently been diffused everywhere across Europe.", [["infection", "DISEASE", 54, 63], ["the infection", "PROBLEM", 50, 63], ["infection", "OBSERVATION", 54, 63], ["diffused", "OBSERVATION_MODIFIER", 90, 98]]], ["Fever, cough, muscle aches, dyspnea, and fatigue can be presenting symptoms, as well as smell and taste dysfunction, usually in presence of a patent nasopharyngeal airway.", [["muscle", "ANATOMY", 14, 20], ["nasopharyngeal airway", "ANATOMY", 149, 170], ["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 7, 12], ["muscle aches", "DISEASE", 14, 26], ["dyspnea", "DISEASE", 28, 35], ["fatigue", "DISEASE", 41, 48], ["taste dysfunction", "DISEASE", 98, 115], ["muscle", "ORGAN", 14, 20], ["nasopharyngeal airway", "MULTI-TISSUE_STRUCTURE", 149, 170], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 7, 12], ["muscle aches", "PROBLEM", 14, 26], ["dyspnea", "PROBLEM", 28, 35], ["fatigue", "PROBLEM", 41, 48], ["presenting symptoms", "PROBLEM", 56, 75], ["smell and taste dysfunction", "PROBLEM", 88, 115], ["a patent nasopharyngeal airway", "PROBLEM", 140, 170], ["cough", "OBSERVATION", 7, 12], ["muscle", "ANATOMY", 14, 20], ["aches", "OBSERVATION", 21, 26], ["dyspnea", "OBSERVATION", 28, 35], ["patent", "OBSERVATION", 142, 148], ["nasopharyngeal airway", "ANATOMY", 149, 170]]], ["Therefore, the American Academy of Otolaryngology-Head and Neck Surgery and the British Association of Otorhinolaryngology advised patients with sudden-onset loss of smell and/or taste to self-isolate [1] .Dear Editor,Additionally, Sungnak et al. [2] recently demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry factors are highly expressed in nasal epithelial cells together with innate immune genes, evidencing the central role of the nose in transmitting the infection to the rest of the body.", [["nasal epithelial cells", "ANATOMY", 377, 399], ["nose", "ANATOMY", 470, 474], ["body", "ANATOMY", 524, 528], ["loss of smell", "DISEASE", 158, 171], ["acute respiratory syndrome coronavirus", "DISEASE", 285, 323], ["infection", "DISEASE", 495, 504], ["patients", "ORGANISM", 131, 139], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 327, 337], ["nasal epithelial cells", "CELL", 377, 399], ["nose", "ORGAN", 470, 474], ["body", "ORGANISM_SUBDIVISION", 524, 528], ["nasal epithelial cells", "CELL_TYPE", 377, 399], ["innate immune genes", "DNA", 414, 433], ["patients", "SPECIES", 131, 139], ["severe acute respiratory syndrome coronavirus", "SPECIES", 278, 323], ["SARS-CoV", "SPECIES", 327, 335], ["sudden-onset loss of smell", "PROBLEM", 145, 171], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 278, 323], ["SARS", "TEST", 327, 331], ["CoV", "TEST", 332, 335], ["entry factors", "PROBLEM", 339, 352], ["nasal epithelial cells", "PROBLEM", 377, 399], ["innate immune genes", "TREATMENT", 414, 433], ["the infection", "PROBLEM", 491, 504], ["Head", "ANATOMY", 50, 54], ["Neck", "ANATOMY", 59, 63], ["severe", "OBSERVATION_MODIFIER", 278, 284], ["acute", "OBSERVATION_MODIFIER", 285, 290], ["respiratory syndrome", "OBSERVATION", 291, 311], ["nasal", "ANATOMY", 377, 382], ["epithelial cells", "OBSERVATION", 383, 399], ["central", "ANATOMY_MODIFIER", 450, 457], ["nose", "ANATOMY", 470, 474], ["infection", "OBSERVATION", 495, 504], ["body", "ANATOMY", 524, 528]]], ["Another feature of SARS-CoV-2 infection is that it seems to produce absent or minimal symptoms of nasal congestion or rhinorrhea, while other viral rhinitis (i.e., adenovirus, rhinovirus, influenza virus, etc.) are characterized by typical nasal symptoms, including sneezing, rhinorrhea, and nasal congestion [1] ; additionally, the nasal mucosa usually appears swollen, edematous, and with seromucous exudate.", [["nasal", "ANATOMY", 98, 103], ["nasal", "ANATOMY", 240, 245], ["nasal", "ANATOMY", 292, 297], ["nasal mucosa", "ANATOMY", 333, 345], ["edematous", "ANATOMY", 371, 380], ["seromucous exudate", "ANATOMY", 391, 409], ["SARS-CoV-2 infection", "DISEASE", 19, 39], ["nasal congestion", "DISEASE", 98, 114], ["rhinorrhea", "DISEASE", 118, 128], ["viral rhinitis", "DISEASE", 142, 156], ["adenovirus, rhinovirus, influenza virus", "DISEASE", 164, 203], ["sneezing", "DISEASE", 266, 274], ["rhinorrhea", "DISEASE", 276, 286], ["nasal congestion", "DISEASE", 292, 308], ["SARS-CoV-2", "ORGANISM", 19, 29], ["nasal", "ORGANISM_SUBDIVISION", 98, 103], ["adenovirus", "ORGANISM", 164, 174], ["rhinovirus", "ORGANISM", 176, 186], ["influenza virus", "ORGANISM", 188, 203], ["nasal", "ORGANISM_SUBDIVISION", 240, 245], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 333, 345], ["influenza virus", "SPECIES", 188, 203], ["SARS-CoV-2", "SPECIES", 19, 29], ["SARS", "PROBLEM", 19, 23], ["CoV-2 infection", "PROBLEM", 24, 39], ["minimal symptoms", "PROBLEM", 78, 94], ["nasal congestion", "PROBLEM", 98, 114], ["rhinorrhea", "PROBLEM", 118, 128], ["other viral rhinitis", "PROBLEM", 136, 156], ["adenovirus", "PROBLEM", 164, 174], ["rhinovirus", "PROBLEM", 176, 186], ["influenza virus", "PROBLEM", 188, 203], ["typical nasal symptoms", "PROBLEM", 232, 254], ["sneezing", "PROBLEM", 266, 274], ["rhinorrhea", "PROBLEM", 276, 286], ["nasal congestion", "PROBLEM", 292, 308], ["the nasal mucosa", "PROBLEM", 329, 345], ["swollen", "PROBLEM", 362, 369], ["edematous", "PROBLEM", 371, 380], ["seromucous exudate", "PROBLEM", 391, 409], ["SARS", "OBSERVATION", 19, 23], ["CoV", "OBSERVATION_MODIFIER", 24, 27], ["infection", "OBSERVATION", 30, 39], ["minimal", "OBSERVATION_MODIFIER", 78, 85], ["nasal", "ANATOMY", 98, 103], ["congestion", "OBSERVATION", 104, 114], ["rhinorrhea", "OBSERVATION", 118, 128], ["rhinitis", "OBSERVATION", 148, 156], ["nasal", "ANATOMY", 240, 245], ["symptoms", "OBSERVATION", 246, 254], ["rhinorrhea", "OBSERVATION", 276, 286], ["nasal", "ANATOMY", 292, 297], ["congestion", "OBSERVATION", 298, 308], ["nasal mucosa", "ANATOMY", 333, 345], ["swollen", "OBSERVATION", 362, 369], ["edematous", "OBSERVATION", 371, 380], ["seromucous", "OBSERVATION_MODIFIER", 391, 401], ["exudate", "OBSERVATION", 402, 409]]], ["Pathological changes depend on the virus type.", [["Pathological changes", "PROBLEM", 0, 20], ["the virus type", "PROBLEM", 31, 45], ["virus type", "OBSERVATION_MODIFIER", 35, 45]]], ["Microscopic observation by means of nasal cytology reveals mucosal disarrangement.", [["nasal cytology", "ANATOMY", 36, 50], ["mucosal", "ANATOMY", 59, 66], ["mucosal", "PATHOLOGICAL_FORMATION", 59, 66], ["Microscopic observation", "TEST", 0, 23], ["nasal cytology", "TEST", 36, 50], ["mucosal disarrangement", "PROBLEM", 59, 81], ["nasal", "ANATOMY", 36, 41], ["mucosal", "ANATOMY", 59, 66], ["disarrangement", "OBSERVATION", 67, 81]]], ["Cellular infiltration usually starts within a day since the onset of the infection: neutrophils, lymphocytes, and exfoliated epithelial cells characterize its cytopathological feature [3] .", [["Cellular", "ANATOMY", 0, 8], ["neutrophils", "ANATOMY", 84, 95], ["lymphocytes", "ANATOMY", 97, 108], ["epithelial cells", "ANATOMY", 125, 141], ["infection", "DISEASE", 73, 82], ["neutrophils", "CELL", 84, 95], ["lymphocytes", "CELL", 97, 108], ["exfoliated epithelial cells", "CELL", 114, 141], ["neutrophils", "CELL_TYPE", 84, 95], ["lymphocytes", "CELL_TYPE", 97, 108], ["exfoliated epithelial cells", "CELL_TYPE", 114, 141], ["Cellular infiltration", "PROBLEM", 0, 21], ["the infection", "PROBLEM", 69, 82], ["neutrophils", "TEST", 84, 95], ["lymphocytes", "TEST", 97, 108], ["exfoliated epithelial cells", "PROBLEM", 114, 141], ["infiltration", "OBSERVATION", 9, 21], ["infection", "OBSERVATION", 73, 82], ["neutrophils", "ANATOMY", 84, 95], ["lymphocytes", "ANATOMY", 97, 108], ["exfoliated epithelial cells", "OBSERVATION", 114, 141]]], ["\"Ciliocytophthoria\" is the main sign of cell injury and is characterized by condensed nuclear chromatin, marginalization of nucleoli, inclusion bodies, intranuclear halo, and cytoplasmic vacuoles [4] .", [["cell", "ANATOMY", 40, 44], ["nuclear chromatin", "ANATOMY", 86, 103], ["nucleoli", "ANATOMY", 124, 132], ["bodies", "ANATOMY", 144, 150], ["intranuclear halo", "ANATOMY", 152, 169], ["cytoplasmic vacuoles", "ANATOMY", 175, 195], ["cell", "CELL", 40, 44], ["nuclear chromatin", "CELLULAR_COMPONENT", 86, 103], ["nucleoli", "CELLULAR_COMPONENT", 124, 132], ["inclusion bodies", "CELLULAR_COMPONENT", 134, 150], ["intranuclear halo", "CELLULAR_COMPONENT", 152, 169], ["cytoplasmic vacuoles", "CELLULAR_COMPONENT", 175, 195], ["Ciliocytophthoria", "PROBLEM", 1, 18], ["cell injury", "PROBLEM", 40, 51], ["condensed nuclear chromatin", "PROBLEM", 76, 103], ["nucleoli, inclusion bodies", "PROBLEM", 124, 150], ["main", "OBSERVATION_MODIFIER", 27, 31], ["cell injury", "OBSERVATION", 40, 51], ["condensed", "OBSERVATION_MODIFIER", 76, 85], ["nuclear chromatin", "OBSERVATION", 86, 103], ["nucleoli", "ANATOMY", 124, 132], ["inclusion bodies", "OBSERVATION", 134, 150], ["intranuclear halo", "OBSERVATION", 152, 169], ["cytoplasmic vacuoles", "OBSERVATION", 175, 195]]], ["Conversely, the \"hyperchromatic supranuclear stria\" (SNS) [5] , corresponding to the Golgi apparatus, constitutes a marker for the anatomical and functional integrity of the ciliated cells; its rarefaction or disappearance during viral infections is a sign of cellular distress [6] .Dear Editor,Given these premises, we performed nasal cytology in 18 COVID-19 patients (5 males, 13 females; median age 50 years [range 26-63]) enrolled in a Hospital close to the first northern-Italian cluster in order to evidence analogies with and differences to the patterns of the other viral upper respiratory infections.Dear Editor,All patients showed very few neutrophils and reduction of the SNS.", [["hyperchromatic supranuclear stria", "ANATOMY", 17, 50], ["Golgi apparatus", "ANATOMY", 85, 100], ["ciliated cells", "ANATOMY", 174, 188], ["cellular", "ANATOMY", 260, 268], ["nasal cytology", "ANATOMY", 330, 344], ["neutrophils", "ANATOMY", 650, 661], ["SNS", "ANATOMY", 683, 686], ["viral infections", "DISEASE", 230, 246], ["respiratory infections", "DISEASE", 586, 608], ["Golgi", "CELLULAR_COMPONENT", 85, 90], ["ciliated cells", "CELL", 174, 188], ["cellular", "CELL", 260, 268], ["patients", "ORGANISM", 360, 368], ["patients", "ORGANISM", 625, 633], ["neutrophils", "CELL", 650, 661], ["SNS", "ANATOMICAL_SYSTEM", 683, 686], ["ciliated cells", "CELL_TYPE", 174, 188], ["neutrophils", "CELL_TYPE", 650, 661], ["patients", "SPECIES", 360, 368], ["patients", "SPECIES", 625, 633], ["the \"hyperchromatic supranuclear stria", "PROBLEM", 12, 50], ["the ciliated cells", "PROBLEM", 170, 188], ["its rarefaction", "PROBLEM", 190, 205], ["viral infections", "PROBLEM", 230, 246], ["cellular distress", "PROBLEM", 260, 277], ["nasal cytology", "TEST", 330, 344], ["the other viral upper respiratory infections", "PROBLEM", 564, 608], ["very few neutrophils", "PROBLEM", 641, 661], ["the SNS", "TREATMENT", 679, 686], ["hyperchromatic", "OBSERVATION_MODIFIER", 17, 31], ["supranuclear stria", "OBSERVATION", 32, 50], ["ciliated cells", "OBSERVATION", 174, 188], ["rarefaction", "OBSERVATION_MODIFIER", 194, 205], ["viral infections", "OBSERVATION", 230, 246], ["cellular distress", "OBSERVATION", 260, 277], ["viral", "OBSERVATION_MODIFIER", 574, 579], ["upper", "ANATOMY_MODIFIER", 580, 585], ["respiratory", "ANATOMY", 586, 597], ["infections", "OBSERVATION", 598, 608], ["SNS", "ANATOMY", 683, 686]]], ["None of the specimens had ciliocytophthoria or other signs of cell injury (Fig. 1) marks of cell damage were consistent with the mild nasal symptoms experienced by the 18 patients.", [["specimens", "ANATOMY", 12, 21], ["cell", "ANATOMY", 62, 66], ["cell", "ANATOMY", 92, 96], ["nasal", "ANATOMY", 134, 139], ["ciliocytophthoria", "DISEASE", 26, 43], ["cell", "CELL", 62, 66], ["cell", "CELL", 92, 96], ["nasal", "ORGANISM_SUBDIVISION", 134, 139], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["the specimens", "TEST", 8, 21], ["ciliocytophthoria", "PROBLEM", 26, 43], ["cell injury", "PROBLEM", 62, 73], ["cell damage", "PROBLEM", 92, 103], ["the mild nasal symptoms", "PROBLEM", 125, 148], ["cell injury", "OBSERVATION", 62, 73], ["cell damage", "OBSERVATION", 92, 103], ["consistent with", "UNCERTAINTY", 109, 124], ["mild", "OBSERVATION_MODIFIER", 129, 133], ["nasal", "ANATOMY", 134, 139], ["symptoms", "OBSERVATION", 140, 148]]], ["In fact, only 33.3% (n = 6) of them had rhinorrhea and another 33.3% (n = 6) showed nasal obstruction, while 66.6% (n = 12) reported a smell impairment, which slowly improved over time.", [["nasal", "ANATOMY", 84, 89], ["rhinorrhea", "DISEASE", 40, 50], ["nasal obstruction", "DISEASE", 84, 101], ["smell impairment", "DISEASE", 135, 151], ["nasal", "ORGAN", 84, 89], ["rhinorrhea", "PROBLEM", 40, 50], ["nasal obstruction", "PROBLEM", 84, 101], ["a smell impairment", "PROBLEM", 133, 151], ["rhinorrhea", "OBSERVATION", 40, 50], ["nasal", "ANATOMY", 84, 89], ["obstruction", "OBSERVATION", 90, 101], ["smell impairment", "OBSERVATION", 135, 151], ["slowly", "OBSERVATION_MODIFIER", 159, 165], ["improved", "OBSERVATION_MODIFIER", 166, 174]]], ["Recently, it was evidenced that the neuroinvasive and neurotropic potential of SARS-CoV-2 seems to be site-specific for the olfactory cells [1, 7] .", [["olfactory cells", "ANATOMY", 124, 139], ["SARS", "DISEASE", 79, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 79, 89], ["olfactory cells", "CELL", 124, 139], ["olfactory cells", "CELL_TYPE", 124, 139], ["SARS-CoV", "SPECIES", 79, 87], ["SARS", "PROBLEM", 79, 83]]], ["Therefore, a possible explanation is that SARS-CoV-2 causes a mild nasal inflammation, but it has a transient neurotoxic effect on the olfactory system.", [["nasal", "ANATOMY", 67, 72], ["olfactory system", "ANATOMY", 135, 151], ["SARS", "DISEASE", 42, 46], ["nasal inflammation", "DISEASE", 67, 85], ["neurotoxic", "DISEASE", 110, 120], ["SARS-CoV-2", "ORGANISM", 42, 52], ["nasal", "ORGAN", 67, 72], ["olfactory system", "ANATOMICAL_SYSTEM", 135, 151], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 42, 46], ["a mild nasal inflammation", "PROBLEM", 60, 85], ["a transient neurotoxic effect on the olfactory system", "PROBLEM", 98, 151], ["mild", "OBSERVATION_MODIFIER", 62, 66], ["nasal", "ANATOMY", 67, 72], ["inflammation", "OBSERVATION", 73, 85], ["transient", "OBSERVATION_MODIFIER", 100, 109], ["neurotoxic effect", "OBSERVATION", 110, 127]]], ["The lack of clear cytopathological damage evidenced by nasal cytology could support this hypothesis.Dear Editor,In conclusion, although the rarefaction of the SNS is a non-specific marker of cell injury, it represents the only evident sign of cellular distress in the context of COV-ID-19.", [["nasal cytology", "ANATOMY", 55, 69], ["cell", "ANATOMY", 191, 195], ["cellular", "ANATOMY", 243, 251], ["nasal", "ORGAN", 55, 60], ["SNS", "ANATOMICAL_SYSTEM", 159, 162], ["cell", "CELL", 191, 195], ["cellular", "CELL", 243, 251], ["clear cytopathological damage", "PROBLEM", 12, 41], ["nasal cytology", "TEST", 55, 69], ["this hypothesis", "PROBLEM", 84, 99], ["the SNS", "PROBLEM", 155, 162], ["a non-specific marker of cell injury", "PROBLEM", 166, 202], ["cellular distress", "PROBLEM", 243, 260], ["COV", "TEST", 279, 282], ["clear", "OBSERVATION_MODIFIER", 12, 17], ["cytopathological damage", "OBSERVATION", 18, 41], ["nasal", "ANATOMY", 55, 60], ["cytology", "OBSERVATION", 61, 69], ["rarefaction", "OBSERVATION", 140, 151], ["non-specific", "OBSERVATION_MODIFIER", 168, 180], ["cell injury", "OBSERVATION", 191, 202], ["cellular distress", "OBSERVATION", 243, 260]]], ["Larger studies have to confirm these preliminary results.", [["Larger studies", "TEST", 0, 14]]], ["To our knowledge, this is the first report in the current literature that used nasal cytology to investigate SARS-CoV-2 infection from a rhinologic point of view, and we believe that this noninvasive technique can be useful to study COVID-19 in the future for clinical and research purposes [8] .Statement of EthicsThis research was conducted in accordance with the ethical principles originating in the Declaration of Helsinki, and written informed consent was obtained from all subjects.Disclosure StatementThe authors have no conflicts of interest to declare.Funding SourcesThe authors did not receive any funding.Author ContributionsM.G. and M.N. designed the study, participated in data collection and analyses, drafted and approved the final version of this paper.", [["nasal", "ANATOMY", 79, 84], ["infection", "DISEASE", 120, 129], ["CoV-2", "ORGANISM", 114, 119], ["SARS-CoV-2", "SPECIES", 109, 119], ["nasal cytology", "TEST", 79, 93], ["SARS", "PROBLEM", 109, 113], ["2 infection", "PROBLEM", 118, 129], ["this noninvasive technique", "TREATMENT", 183, 209], ["COVID", "TEST", 233, 238], ["the study", "TEST", 660, 669], ["data collection", "TEST", 687, 702], ["analyses", "TEST", 707, 715]]], ["E.M.C.T. participated in data analysis and manuscript preparation, M.C. and G.C. provided critical comments, and approved the final version of this paper.", [["data analysis", "TEST", 25, 38]]]], "PMC7149472": [["Capacity or Concealment?While global health issues have gained more attention in international relations scholarship of late (e.g., Chorev 2012; Kamradt-Scott and Rushton 2012; Graham 2014; Hanrieder 2014; Davies, Kamradt-Scott, and Rushton 2015; Kamradt-Scott 2015; Worsnop 2017b), little of this work directly examines variation in the timeliness of reporting.", [["Concealment", "OBSERVATION", 12, 23]]], ["Existing global public health scholarship that does analyze this issue finds only a weak positive association between health capacity and reporting (McAlarnen et al. 2014).", [["a weak positive association between health capacity", "PROBLEM", 82, 133], ["global", "OBSERVATION_MODIFIER", 9, 15]]], ["But, this work either does not examine variation across states (Chan et al. 2010; Mondor et al. 2012), or the empirical work on reporting delays does not theorize about how political factors might influence outbreak reporting or test these factors against alternative explanations like surveillance capacity (see Brownstein et al. 2008; Davies 2012; Kluberg et al. 2016).Capacity or Concealment?Scholarship on state compliance behavior and treaty implementation offers insight into delayed outbreak reporting and incomplete compliance with IHR reporting requirements.", [["surveillance capacity", "TEST", 286, 307], ["Concealment", "OBSERVATION", 383, 394]]], ["Prevailing views of compliance behavior fall into two broad categories: the \u201cmanagerial\u201d approach argues that noncompliance is inadvertent and often due to a lack of state capacity to meet the terms of an agreement.", [["a lack of state capacity", "PROBLEM", 156, 180]]], ["Alternatively, the \u201cenforcement\u201d approach contends that compliance is based on a cost-benefit calculation\u2014states will only comply when it is beneficial to do so and will shirk their commitments if they can do so with minimal cost.Capacity or Concealment?Since many international agreements threaten limited international costs for noncompliance and evidence suggests that most states follow through with their international commitments most of the time, some suggest that a lack of domestic capacity prevents states from following through with their commitments (Mitchell 1994; Chayes and Chayes 1998; Weiss and Jacobson 2000; Simmons 2002; Tallberg 2002; Gray 2014; Cole 2015).", [["noncompliance", "PROBLEM", 331, 344], ["Concealment", "OBSERVATION", 242, 253]]], ["Instead, states generally want to abide by their commitments, but doing so often requires legal, bureaucratic, economic, or other specialized expertise, not to mention absolute political control, that many states lack.Capacity or Concealment?This approach contrasts with the enforcement perspective, which argues that the assumption that states would comply with their commitments if only they could paints too banal a picture of compliance decision-making.", [["absolute political control", "TREATMENT", 168, 194], ["Concealment", "OBSERVATION", 230, 241]]], ["From this perspective, reputational interests and reciprocity matter most, and states base their compliance behavior on the likelihood of material or normative punishment.Capacity or Concealment?On the other hand, compliance decisions also have domestic political consequences (Martin and Simmons 1998).", [["Concealment", "OBSERVATION", 183, 194]]], ["Some scholars focus on regime type and its influence on leaders\u2019 domestic political interests, finding that democracies are more likely to comply because constituents pressure their governments to follow through with their commitments (see, for example, Gaubatz 1996; Mansfield, Milner, and Rosendorff 2002; Neumayer 2002).", [["scholars", "OBSERVATION", 5, 13]]], ["Indeed, compliance with agreements dealing with politically charged issues like the environment, trade, human rights, territory, or arms control, for example, can have different domestic consequences in different types of states.", [["human", "ORGANISM", 104, 109], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["arms control", "TREATMENT", 132, 144], ["different types", "OBSERVATION_MODIFIER", 203, 218]]], ["In short, governments only comply when the benefits of doing so outweigh the international and/or domestic level costs, and noncompliance from this perspective is thus due to a failure of enforcement.Capacity or Concealment?Bringing these arguments to bear on the IHR reflects the two explanations for lags in disease outbreak reporting already mentioned.", [["a failure of enforcement", "PROBLEM", 175, 199], ["lags in disease outbreak", "PROBLEM", 302, 326], ["Concealment", "OBSERVATION", 212, 223]]], ["But, weak surveillance capacity can delay outbreak discovery, which means that, in spite of the government's good intentions, significant time passes between the start of the outbreak and when it is publicly communicated.", [["weak surveillance capacity", "PROBLEM", 5, 31], ["weak", "OBSERVATION_MODIFIER", 5, 9]]], ["From this perspective, states will only be likely to report and follow through with commitments to the IHR when they anticipate minimal costs for doing so.Capacity or Concealment?Since its inception in 1951, the IHR have sought to encourage rapid reporting by addressing both of these issues.", [["Concealment", "OBSERVATION", 167, 178]]], ["In terms of capacity, the regulations have always required that states meet minimum disease surveillance capabilities at points of entry.", [["minimum disease surveillance capabilities", "PROBLEM", 76, 117], ["capacity", "OBSERVATION", 12, 20]]], ["In terms of reducing the costs of reporting and ensuring that other states do not impose trade and travel barriers that have little public health rationale, the regulations have always laid out the maximum measures that other states can take in the name of protection from disease spread.", [["disease spread", "PROBLEM", 273, 287], ["disease", "OBSERVATION", 273, 280]]], ["But, the regulations originally only applied to three diseases (cholera, plague, and yellow fever), and even with respect to those diseases, states frequently imposed more restrictive measures than allowed by the regulations, and outbreak reporting was often delayed, if it happened at all (Carvalho and Zacher 2001).", [["cholera, plague, and yellow fever", "DISEASE", 64, 97], ["three diseases", "PROBLEM", 48, 62], ["cholera", "PROBLEM", 64, 71], ["plague", "PROBLEM", 73, 79], ["yellow fever", "PROBLEM", 85, 97], ["those diseases", "PROBLEM", 125, 139], ["diseases", "OBSERVATION", 131, 139]]], ["In 2005, states revised the IHR, and several of the changes aimed to further encourage outbreak reporting.Capacity or Concealment?The new IHR contain the following seven key revisions:3The regulations now apply to a broader range of public health events called \u201cPublic Health Emergencies of International Concern\u201d (PHEIC);They allow the WHO to decide whether an event constitutes a PHEIC;They require that states meet certain minimum domestic outbreak surveillance and response capacities in addition to capacities at points of entry;They require states to notify the WHO of events that may constitute a PHEIC within 24 hours;They allow the WHO to rely on nonstate sources of information about outbreaks;They allow the WHO to issue recommendations to states about the appropriate response to outbreaks including whether states should impose trade and travel barriers;And they allow the WHO to publicize states\u2019 failure to report outbreaks as well as the imposition of overly restrictive trade and travel barriers.Capacity or Concealment?These changes not only aim to overcome the technical obstacles to compliance, but they also aim to decrease the costs of outbreak reporting relative to the benefits.", [["Concealment", "OBSERVATION", 118, 129], ["restrictive trade", "OBSERVATION", 975, 992], ["Concealment", "OBSERVATION", 1025, 1036]]], ["And, expanding the scope of the IHR lets states know that they should be reporting a wider range of health threats.Capacity or Concealment?Other revisions aim at manipulating the costs of outbreak reporting.", [["Other revisions", "TREATMENT", 139, 154], ["Concealment", "OBSERVATION", 127, 138]]], ["And, giving the WHO the authority to issue recommendations about whether trade and travel barriers are warranted and the ability to publicize states\u2019 failure to follow these guidelines is meant to increase the costs of imposing unduly restrictive measures during an outbreak and reduce the costs of outbreak reporting.Capacity or Concealment?In practice, however, these strategies are not completely effective.", [["unduly restrictive measures", "TREATMENT", 228, 255], ["unduly restrictive", "OBSERVATION_MODIFIER", 228, 246], ["Concealment", "OBSERVATION", 330, 341]]], ["The launch of an external evaluation process (called the Joint External Evaluation) to monitor progress on the core capacities is a promising step, but states voluntarily submit to these external evaluations (World Health Organization 2016a).", [["an external evaluation process", "TEST", 14, 44], ["the Joint External Evaluation", "TEST", 53, 82], ["the core capacities", "PROBLEM", 107, 126], ["these external evaluations", "TEST", 181, 207]]], ["As such, weak capacity may still play a role in reporting delays.", [["weak capacity", "PROBLEM", 9, 22]]], ["The 2014 Ebola crisis offers an example.", [["Ebola", "DISEASE", 9, 14], ["Ebola crisis", "OBSERVATION", 9, 21]]], ["The slow response to the outbreak was due in part to weak surveillance capacity in Guinea, Liberia, and Sierra Leone.", [["weak surveillance capacity", "PROBLEM", 53, 79], ["slow", "OBSERVATION_MODIFIER", 4, 8]]], ["It is telling that Nigeria\u2014a country with far greater resources than Guinea, Liberia, or Sierra Leone\u2014was able to quash the spread of Ebola in the country by implementing several of the capacities recommended by the IHR, including contact tracing, monitoring of contacts, and rapid isolation of potentially infectious cases (Fasina et al. 2014).Capacity or Concealment?At the same time, however, the relationship between weak capacity and reporting may be more complicated in some cases.", [["Ebola", "DISEASE", 134, 139], ["Ebola", "ORGANISM", 134, 139], ["the capacities", "PROBLEM", 182, 196], ["contact tracing", "TEST", 231, 246], ["weak capacity", "PROBLEM", 421, 434], ["Ebola", "OBSERVATION", 134, 139], ["Concealment", "OBSERVATION", 357, 368]]], ["For example, in the aftermath of the 1994 outbreak of plague in Surat, India, a WHO team of investigators \u201cconcluded that the lack of adequate diagnostic equipment in the affected area led to overreporting and subsequent panic\u201d (Cash and Narasimhan 2000, 1361).", [["plague", "DISEASE", 54, 60], ["panic", "DISEASE", 221, 226]]], ["It is therefore possible that weak surveillance capacity sometimes leads to underreporting and sometimes leads to jumping the gun and overreporting.", [["weak surveillance capacity", "PROBLEM", 30, 56], ["therefore possible", "UNCERTAINTY", 6, 24], ["weak", "OBSERVATION_MODIFIER", 30, 34]]], ["This possibly indeterminate relationship raises the possibility that other factors may also play a role in reporting lags.Capacity or Concealment?Furthermore, during recent outbreaks including the 2014 outbreak of Ebola and the 2009 H1N1 pandemic, close to 25 percent of states imposed trade and travel barriers that went beyond WHO recommendations, largely for domestic political reasons (Rhymer and Speare 2017, 11; Worsnop 2017b, 366).", [["Ebola", "DISEASE", 214, 219], ["H1N1", "DISEASE", 233, 237], ["Ebola", "ORGANISM", 214, 219], ["Ebola", "PROBLEM", 214, 219], ["possibly", "UNCERTAINTY", 5, 13], ["indeterminate", "OBSERVATION_MODIFIER", 14, 27], ["raises the possibility", "UNCERTAINTY", 41, 63], ["Concealment", "OBSERVATION", 134, 145]]], ["As such, states that discover outbreaks also continue to face incentives to conceal them in order to avoid other states\u2019 costly reactions.Capacity or Concealment?So, is it primarily a capacity issue, or is intentional concealment also at work?", [["costly reactions", "PROBLEM", 121, 137], ["Concealment", "OBSERVATION", 150, 161]]], ["But, I argue that weak capacity is not the whole story\u2014states also intentionally conceal outbreaks to avoid economic and political harm.Trade and Travel Barriers, Outbreak Concealment, and the IHRThough surveillance capacity may be a prerequisite for rapid reporting, states face real incentives to intentionally conceal an outbreak after it is discovered.", [["weak capacity", "PROBLEM", 18, 31]]], ["Evidence of outbreak concealment due to fear of economic harm dates back to the plague epidemics in medieval Europe.", [["outbreak concealment", "PROBLEM", 12, 32], ["economic harm dates", "PROBLEM", 48, 67], ["outbreak", "OBSERVATION", 12, 20]]], ["To prevent economic damage from quarantine and trade route closures, local health authorities often downplayed the severity of outbreaks (Porter 1999; see also von Tigerstrom 2005, 42).", [["economic damage", "PROBLEM", 11, 26], ["quarantine and trade route closures", "TREATMENT", 32, 67], ["economic", "OBSERVATION_MODIFIER", 11, 19], ["damage", "OBSERVATION", 20, 26]]], ["The 1991 outbreak of cholera in Peru, the 1994 outbreak of the plague in India, the 2003 outbreak of SARS in China, the 2009 H1N1 pandemic, and the 2014 Ebola outbreak reveal a similar dynamic.Trade and Travel Barriers, Outbreak Concealment, and the IHRIn January 1991, an epidemic of cholera broke out in Peru, spreading to other countries in the region including Chile, Colombia, and Ecuador.", [["cholera", "DISEASE", 21, 28], ["plague", "DISEASE", 63, 69], ["SARS", "DISEASE", 101, 105], ["H1N1 pandemic", "DISEASE", 125, 138], ["Ebola", "DISEASE", 153, 158], ["cholera", "DISEASE", 285, 292], ["SARS", "PROBLEM", 101, 105], ["cholera", "PROBLEM", 285, 292], ["region", "ANATOMY_MODIFIER", 348, 354], ["Colombia", "OBSERVATION", 372, 380]]], ["Losses to India's economy associated with the outbreak, including the cost of trade and travel barriers imposed against it by other states, totaled more than US $2 billion (Cash and Narasimhan 2000, 1362).Trade and Travel Barriers, Outbreak Concealment, and the IHRIn its handling of the 2002 outbreak of SARS, China took its cue from the experience of states like Peru and India and did not make the outbreak public.", [["Losses", "DISEASE", 0, 6], ["SARS", "DISEASE", 305, 309], ["the outbreak", "PROBLEM", 42, 54], ["SARS", "PROBLEM", 305, 309]]], ["It is widely acknowledged that fear of economic and political costs in part motivated China's behavior and that SARS would have been better contained had China reported the outbreak earlier (Mackey and Liang 2012; Huang 2013).Trade and Travel Barriers, Outbreak Concealment, and the IHRDuring the 2009 H1N1 pandemic, countries again imposed measures that went beyond WHO recommendations.", [["SARS", "DISEASE", 112, 116], ["H1N1 pandemic", "DISEASE", 302, 315], ["SARS", "PROBLEM", 112, 116]]], ["On April 26, 2009, the WHO declared the H1N1 influenza pandemic a public health emergency (the first such declaration since the entry into force of the new IHR in 2007).", [["influenza", "DISEASE", 45, 54], ["H1N1 influenza pandemic", "SPECIES", 40, 63], ["the H1N1 influenza", "PROBLEM", 36, 54], ["H1N1", "OBSERVATION", 40, 44]]], ["That same day, the WHO recommended that states not impose trade and travel restrictions because these barriers would not prevent the spread of the disease (World Health Organization 2009).", [["these barriers", "TREATMENT", 96, 110], ["the disease", "PROBLEM", 143, 154]]], ["Despite these recommendations, 47 states went ahead and imposed barriers against H1N1-affected states anyway (Worsnop 2017b, 366).", [["H1N1", "PROBLEM", 81, 85]]], ["Interestingly, most of these trade barriers targeted the United States as it was one of the states most affected by H1N1.Trade and Travel Barriers, Outbreak Concealment, and the IHRThe 2014 Ebola outbreak offers a recent example of states imposing restrictions that go against WHO guidance.", [["H1N1", "DISEASE", 116, 120], ["Ebola", "DISEASE", 190, 195], ["H1N1", "PROBLEM", 116, 120], ["H1N1", "OBSERVATION", 116, 120]]], ["After declaring the Ebola outbreak a public health emergency on August 8, 2014, the WHO recommended against a \u201cgeneral ban on international travel or trade\u201d (World Health Organization 2014b).", [["Ebola", "DISEASE", 20, 25]]], ["In spite of this guidance, the WHO received close to 600 complaints citing overly restrictive trade or travel barriers related to Ebola and followed up with 47 states in cases where the WHO considered the measures to be excessive (World Health Organization 2015b, 4).", [["Ebola", "DISEASE", 130, 135], ["Ebola", "ORGANISM", 130, 135]]], ["There is evidence that even at the local level communities concealed cases of Ebola for fear of the human and economic costs of the public health response, which too often included cordons sanitaires that cut the community off from access to food and medical care (Onishi 2014).Trade and Travel Barriers, Outbreak Concealment, and the IHRThese examples illustrate that a government that discovers an outbreak can expect to be the target of other states\u2019 trade and travel restrictions once the outbreak is made public.", [["Ebola", "DISEASE", 78, 83], ["Ebola", "ORGANISM", 78, 83], ["human", "ORGANISM", 100, 105], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["Ebola", "PROBLEM", 78, 83], ["Ebola", "OBSERVATION", 78, 83]]], ["Disease outbreaks impose many costs on affected states including loss of productivity due to illness and death.", [["loss of productivity", "DISEASE", 65, 85], ["illness", "DISEASE", 93, 100], ["death", "DISEASE", 105, 110], ["Disease outbreaks", "PROBLEM", 0, 17], ["loss of productivity", "PROBLEM", 65, 85], ["illness", "PROBLEM", 93, 100], ["death", "PROBLEM", 105, 110]]], ["Additionally, outbreaks are followed by changes in consumer behavior domestically and in tourist and business activity internationally due to both fear of disease and to disease control measures that can have a public health rationale, like temporary school and business closures (Lempel, Epstein, and Hammond 2009; Copeland et al. 2013).", [["disease", "PROBLEM", 155, 162], ["disease control measures", "TREATMENT", 170, 194], ["disease", "OBSERVATION", 155, 162]]], ["Overly restrictive trade and travel barriers imposed by other states inflict additional costs that are often unnecessary from a public health perspective, according to the WHO and other health experts (see, for example, Cooper et al. 2006; Ferguson et al. 2006; Colizza et al. 2007; Vincent et al. 2009; World Health Organization 2009; Cowling et al. 2010; Poletto et al. 2014; Selvey, Ant\u00e3o, and Hall 2015).Trade and Travel Barriers, Outbreak Concealment, and the IHRThe economic costs extend beyond the direct economic impact of the barriers themselves.", [["the IHRThe economic costs", "TREATMENT", 461, 486], ["restrictive", "OBSERVATION_MODIFIER", 7, 18], ["trade", "OBSERVATION_MODIFIER", 19, 24]]], ["In the case of Ebola, for example, private companies pulled employees out of the region and stopped operations\u2014especially in the mining and agricultural sectors\u2014and airlines like British Airways and Emirates halted flights to the region (Economist 2014; World Bank 2014).", [["Ebola", "DISEASE", 15, 20], ["Ebola", "ORGANISM", 15, 20], ["operations", "TREATMENT", 100, 110], ["Ebola", "OBSERVATION", 15, 20], ["Airways", "ANATOMY", 187, 194]]], ["This behavior by private actors is encouraged by the fact that governments themselves imposed barriers against Ebola-affected countries.", [["Ebola", "DISEASE", 111, 116], ["Ebola", "ORGANISM", 111, 116]]], ["As such, those states that stand to lose more from publicizing an outbreak should be slower to report.Trade and Travel Barriers, Outbreak Concealment, and the IHRI identify two types of states that may be particularly vulnerable to trade and travel barriers after reporting an outbreak and so face strong incentives to conceal in order to not provoke those barriers: states that are economically vulnerable and states that are politically vulnerable.", [["an outbreak", "PROBLEM", 274, 285]]], ["Highly trade-exposed states, then, may choose to delay reporting and try to contain the outbreak themselves first, away from the public eye.", [["eye", "ANATOMY", 136, 139], ["eye", "ORGAN", 136, 139], ["public eye", "ANATOMY", 129, 139]]], ["Beyond the international costs, harm to domestic agricultural producers could translate into a loss of political support for the government.", [["political support", "TREATMENT", 103, 120]]], ["If it becomes clear that a country concealed an outbreak, it could face punishment from the international community as well.", [["clear", "OBSERVATION", 14, 19]]], ["China's experience during the SARS outbreak is a case in point.", [["SARS", "DISEASE", 30, 34]]], ["Punishment for concealment comes later, if at all, and would most likely be in the form of rhetorical admonishment rather than immediate material costs.", [["rhetorical admonishment", "TREATMENT", 91, 114]]], ["WHO has limited power to enforce reporting requirements and, furthermore, aside from the SARS case, has been reluctant to name and shame states for being slow to report (Kamradt-Scott 2016, 411).", [["SARS", "DISEASE", 89, 93]]], ["All governments depend on some level of popular support to stay in office and govern effectively; they take the reaction of the public and other domestic actors into account when making policy.", [["popular support", "TREATMENT", 40, 55]]], ["Domestic constituents in these states may fear that the disregard of international law could translate into the domestic sphere, or disregard of international law may cost a leader support at home simply because the population values keeping commitments (Fearon 1994; Slaughter 1995; Finnemore and Sikkink 1998; Kelley 2007; Tomz 2007).", [["a leader support", "TREATMENT", 172, 188]]], ["Either way, governments in high rule-of-law states are more likely to follow through with institutional commitments because not doing so could result in a loss of domestic political support.", [["domestic political support", "TREATMENT", 163, 189]]], ["Importantly, these states should see concealment as particularly costly after the new IHR enter into force because the new regulations strengthen the obligation on states to quickly report outbreaks.Trade and Travel Barriers, Outbreak Concealment, and the IHRImportantly, if high rule-of-law states are more likely to report outbreaks after the IHR revision, then this would not only support the contention that governments consider domestic political consequences when making compliance decisions, but would also provide evidence of institutional effects\u2014at least for one group of states.", [["the IHR revision", "TREATMENT", 341, 357], ["revision", "OBSERVATION", 349, 357]]], ["Kelley (2007) makes a similar institutional effects argument in her study of which states uphold their commitments to the International Criminal Court (ICC).", [["her study", "TEST", 64, 73]]], ["Rule of law actually had a negative influence on the behavior of states that had not ratified.", [["negative", "OBSERVATION", 27, 35]]], ["This study cannot compare state parties to the IHR to states that are not because the IHR have universal membership.", [["This study", "TEST", 0, 10]]], ["Instead, I compare behavior before and after the revised IHR enter into force.Trade and Travel Barriers, Outbreak Concealment, and the IHRThis logic produces the following hypotheses:Trade and Travel Barriers, Outbreak Concealment, and the IHRI test these hypotheses against the alternative that would expect capacity to drive state behavior:Timeliness as Compliance ::: Measuring the Timeliness of Outbreak Reporting@!start@#!start#5#!sep#fn5#!sep#fn#!end#@!end@I also consider the time from the start of the outbreak to the first public report a good approximation of state compliance with the IHR.", [["the IHRI test", "TEST", 236, 249], ["the IHR", "TREATMENT", 592, 599]]], ["On its face, then, compliance seems easy to identify.", [["face", "ANATOMY", 7, 11]]], ["Though the WHO has the final say on which events constitute a PHEIC, it is less clear which events \u201cmay constitute\u201d a PHEIC and thus require reporting to the WHO.", [["PHEIC", "DISEASE", 62, 67]]], ["The IHR contain a decision instrument to help states make this determination (World Health Organization 2005, Annex 2).", [["a decision instrument", "TREATMENT", 16, 37]]], ["The decision instrument does contain a list of diseases that must always be notified to the WHO, but, this list is not exhaustive.", [["diseases", "PROBLEM", 47, 55]]], ["In two other sets of circumstances, states must use an algorithm to determine whether an event should be reported to the WHO.", [["an algorithm", "TEST", 52, 64]]], ["A second list identifies certain diseases that should always lead states to use the algorithm.", [["certain diseases", "PROBLEM", 25, 41], ["the algorithm", "TEST", 80, 93]]], ["States should also use the algorithm for \u201cany event of potential international public health concern, including those of unknown causes or sources and those involving other events or diseases\u201d (World Health Organization 2005, Annex 2).", [["the algorithm", "TREATMENT", 23, 36], ["diseases", "PROBLEM", 183, 191]]], ["Once the decision is made to use the algorithm, states are asked to consider whether the event is serious, unusual, or unexpected, the risk of international spread, and the risk of international trade or travel restrictions being imposed.", [["international spread", "PROBLEM", 143, 163], ["travel restrictions", "TREATMENT", 204, 223]]], ["Even though the WHO has issued guidance for how to use the decision instrument (World Health Organization 2008), in some cases, it might not be clear whether a failure to report is a case of noncompliance, or just a reasonable difference of opinion about whether the event should have been reported according to the algorithm.", [["failure", "OBSERVATION", 160, 167]]], ["For example, say a state reports an outbreak within 24 hours of detecting it, but does not do so through the official National IHR Focal Point.", [["Focal", "OBSERVATION_MODIFIER", 131, 136]]], ["Considering that a case of \u201cnoncompliance\u201d would ignore the fact that the outbreak was still quickly publicly communicated, which is the overall goal behind the specific requirements of the IHR.", [["the IHR", "TREATMENT", 186, 193]]], ["I examine the following key independent variables: surveillance capacity (health expenditures as a percentage of gross domestic product [GDP] and internet coverage), trade exposure, dependence on the agricultural sector, domestic political opposition, domestic commitment to rule of law, and whether the new IHR were in force at the start of the outbreak.7 As a measure of surveillance capacity, I use total (private + public) health expenditures as a percentage of GDP (World Bank 2016).", [["GDP", "SIMPLE_CHEMICAL", 466, 469], ["internet coverage", "TREATMENT", 146, 163], ["surveillance capacity", "TEST", 373, 394], ["new", "OBSERVATION_MODIFIER", 304, 307], ["IHR", "OBSERVATION", 308, 311]]], ["Because health spending is a broad measure that does not necessarily capture outbreak surveillance capacity, I also include internet coverage.", [["internet coverage", "TREATMENT", 124, 141]]], ["Access to the internet has been associated with reduced outbreak reporting lags (Wilson and Brownstein 2009; McAlarnen et al. 2014; Smith et al. 2014), and the proliferation of internet-based surveillance systems for health-related events makes this an important variable to consider (Brownstein et al. 2008; Davies 2012; Katz et al. 2017).", [["health-related events", "PROBLEM", 217, 238], ["associated with", "UNCERTAINTY", 32, 47], ["reduced", "OBSERVATION_MODIFIER", 48, 55]]], ["I use data from the World Bank (2016) coding the number of individuals (per 100 population) that have used the internet over the past year.Key Explanatory Variables ::: DataTo measure the level of trade exposure and dependence on the agricultural sector, I use the sum of exports and imports of goods and services as a share of gross domestic product (GDP) and the value added of the agricultural sector as a percentage of GDP, respectively (World Bank 2016).", [["GDP", "CHEMICAL", 352, 355], ["GDP", "CHEMICAL", 423, 426], ["GDP", "CHEMICAL", 423, 426], ["GDP", "SIMPLE_CHEMICAL", 352, 355], ["GDP", "SIMPLE_CHEMICAL", 423, 426], ["trade exposure", "OBSERVATION", 197, 211], ["dependence", "OBSERVATION_MODIFIER", 216, 226]]], ["To measure domestic political opposition, I follow Allee and Huth (2006).", [["political opposition", "OBSERVATION", 20, 40]]], ["They use the following coding to define a government as facing strong domestic political opposition: Executives in democratic countries are considered to face strong domestic political opposition when their governing coalition does not control a majority of seats in the primary legislative or parliamentary body.", [["body", "ANATOMY", 308, 312], ["body", "ORGANISM_SUBDIVISION", 308, 312], ["parliamentary body", "ANATOMY", 294, 312]]], ["As they do, I define a democracy as a state that scores a 6 or above on the Polity IV data project's 21-point Polity scale, which captures the competitiveness and regulation of political participation, the openness and competitiveness of executive recruitment, and constraints on the chief executive, and ranges from \u201310 (strongly autocratic) to 10 (strongly democratic) (Marshall, Jaggers, and Gurr 2014).", [["the Polity IV data", "TREATMENT", 72, 90], ["recruitment", "OBSERVATION_MODIFIER", 248, 259]]], ["Democratic governments are coded as facing strong domestic opposition if they do not control a majority of votes in the legislature.", [["legislature", "ANATOMY", 120, 131]]], ["Nondemocratic governments are coded as facing strong domestic opposition if in the past year a change in the chief executive occurred through a \u201cforceful seizure of power\u201d\u2014a \u201c1\u201d in the Polity IV data project's Xrreg (Regulation of Chief Executive) variable.", [["seizure", "DISEASE", 154, 161]]], ["The final variable is binary, coding a state as a \u201c1\u201d if either of the previous conditions are true, and \u201c0\u201d otherwise.Key Explanatory Variables ::: DataTo code domestic commitment to rule of law, I use data from the Worldwide Governance Indicators Dataset, which ranges from \u20132.5 (weak) to 2.5 (strong) (Kaufmann, Kraay, and Mastruzzi 2010).", [["variable", "OBSERVATION_MODIFIER", 10, 18]]], ["Though previous studies of outbreak reporting have not found a relationship between regime type and reporting (Kluberg et al. 2016), scholars associate regime type with compliance behavior generally, and some have argued that democracies are more open about information during disease outbreaks (Vu 2011, 4\u20135).", [["previous studies", "TEST", 7, 23]]], ["As such, I include a measure of democracy using the Polity score (Marshall, Jaggers, and Gurr 2014).Controls ::: DataGeneral level of development measured through economic wealth could also affect behavior, so I include GDP per capita data from the World Bank (2016).", [["GDP", "CHEMICAL", 220, 223]]], ["And, as an alternative to trade exposure and dependence on the agricultural sector for capturing potential economic costs of reporting, I include the total contribution of travel and tourism to GDP (as a percentage of GDP) from the World Bank (2017b).", [["GDP", "CHEMICAL", 194, 197], ["GDP", "SIMPLE_CHEMICAL", 194, 197], ["GDP", "SIMPLE_CHEMICAL", 218, 221]]], ["Lastly, existing studies show that reporting lags have decreased over time (Chan et al. 2010; Mondor et al. 2012), so to account for potential time trends, I include the year the outbreak started.The Duration in Days from Outbreak Start to Public Communication ::: Analysis and ResultsResults support the argument that a cost-benefit calculation, rather than capacity alone, influences state behavior.", [["existing studies", "TEST", 8, 24], ["Analysis", "TEST", 265, 273], ["a cost-benefit calculation", "TEST", 319, 345], ["decreased", "OBSERVATION_MODIFIER", 55, 64]]], ["The results are shown as hazard rates, which indicate the impact of a given variable on the rate of outbreak reporting relative to a baseline hazard of 1.00.", [["hazard rates", "TEST", 25, 37]]], ["Coefficients greater than one proportionately increase the rate while coefficients less than one proportionately reduce the rate.", [["the rate", "TEST", 55, 63], ["the rate", "TEST", 120, 128]]], ["As an example, a hazard rate of 0.5 would mean that the rate at which countries report is cut in half and they would be two times less likely to report.The Duration in Days from Outbreak Start to Public Communication ::: Analysis and ResultsThe results show that health spending (Model 1) is not significantly associated with reporting, and in fact the substantive effect is negative\u2014the opposite of what would be expected.", [["a hazard rate", "TEST", 15, 28], ["Analysis", "TEST", 221, 229]]], ["Internet coverage, however, increases the speed of reporting in Models 1, 2, and 4 (it is not significant in the full model, Model 3).", [["Internet coverage", "TREATMENT", 0, 17]]], ["Yet, even controlling for surveillance capacity with health spending and internet coverage, both trade exposure and domestic political opposition are significantly associated with increases in reporting lags (Model 2).", [["surveillance capacity", "TEST", 26, 47], ["internet coverage", "TREATMENT", 73, 90]]], ["States that face higher potential economic and political costs for reporting are less likely to report on any given day than states facing lower costs for doing so.The Duration in Days from Outbreak Start to Public Communication ::: Analysis and ResultsModel 3 is the full model; it shows that the findings about trade exposure and domestic political opposition are robust to the inclusion of other variables.", [["Analysis", "TEST", 233, 241], ["domestic", "OBSERVATION_MODIFIER", 332, 340], ["political opposition", "OBSERVATION", 341, 361]]], ["In terms of the other controls, four are significantly associated with reporting: a larger agricultural sector is negatively associated with reporting, which is consistent with the finding about trade exposure.", [["consistent with", "UNCERTAINTY", 161, 176]]], ["In addition, GDP per capita is negatively associated with reporting, as is a higher level of domestic rule of law, while a higher percentage of GDP made up by travel and tourism encourages reporting.", [["GDP", "CHEMICAL", 13, 16], ["GDP", "CHEMICAL", 144, 147], ["GDP", "CHEMICAL", 13, 16], ["GDP", "SIMPLE_CHEMICAL", 13, 16], ["GDP", "SIMPLE_CHEMICAL", 144, 147]]], ["These last two findings are somewhat surprising, and I return to them below.The Duration in Days from Outbreak Start to Public Communication ::: Analysis and Results", [["Analysis", "TEST", 145, 153]]]], "PMC7318901": [["IntroductionCovid-19 is a pandemic disease with presentations that range from asymptomatic cases, to mild respiratory infection, to severe acute respiratory syndrome with associated mortality [1].", [["respiratory", "ANATOMY", 106, 117], ["pandemic disease", "DISEASE", 26, 42], ["respiratory infection", "DISEASE", 106, 127], ["acute respiratory syndrome", "DISEASE", 139, 165], ["IntroductionCovid", "TREATMENT", 0, 17], ["a pandemic disease", "PROBLEM", 24, 42], ["asymptomatic cases", "PROBLEM", 78, 96], ["mild respiratory infection", "PROBLEM", 101, 127], ["severe acute respiratory syndrome", "PROBLEM", 132, 165], ["mild", "OBSERVATION_MODIFIER", 101, 105], ["respiratory infection", "OBSERVATION", 106, 127], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["acute", "OBSERVATION_MODIFIER", 139, 144], ["respiratory syndrome", "OBSERVATION", 145, 165]]], ["The causative organism (coronavirus SARS-CoV-2) is transmitted via fomites, droplets and aerosols carrying infective particles usually originating from an infected person\u2019s respiratory tract [2\u20134].", [["respiratory", "ANATOMY", 173, 184], ["coronavirus SARS-CoV-2", "ORGANISM", 24, 46], ["respiratory tract", "ORGANISM_SUBDIVISION", 173, 190], ["coronavirus SARS-CoV", "SPECIES", 24, 44], ["person", "SPECIES", 164, 170], ["coronavirus SARS-CoV-2", "SPECIES", 24, 46], ["The causative organism", "PROBLEM", 0, 22], ["coronavirus SARS", "PROBLEM", 24, 40], ["CoV", "TEST", 41, 44], ["aerosols carrying infective particles", "PROBLEM", 89, 126], ["infected", "OBSERVATION", 155, 163], ["respiratory tract", "ANATOMY", 173, 190]]], ["There is concern that healthcare workers may contract Covid-19 during aerosol generating procedures (AGP) performed on patients carrying the disease [5].", [["Covid-19", "CHEMICAL", 54, 62], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["Covid", "TEST", 54, 59], ["aerosol generating procedures", "TREATMENT", 70, 99]]], ["This has been shown to be of particular importance in bronchoscopy, endotracheal intubation and extubation [3].IntroductionPhacoemulsification surgery is one of the most common operations performed worldwide [6].", [["endotracheal", "ANATOMY", 68, 80], ["bronchoscopy", "TEST", 54, 66], ["endotracheal intubation", "TREATMENT", 68, 91], ["IntroductionPhacoemulsification surgery", "TREATMENT", 111, 150], ["endotracheal intubation", "OBSERVATION", 68, 91]]], ["Some ophthalmologists have concerns that it may be an AGP based on the high-speed oscillations used to generate ultrasonic energy and the aerosol or \u2018vapour\u2019 plume that is sometimes observed during energy delivery.", [["AGP", "GENE_OR_GENE_PRODUCT", 54, 57], ["AGP", "PROTEIN", 54, 57], ["an AGP", "PROBLEM", 51, 57], ["ultrasonic energy", "TREATMENT", 112, 129], ["the aerosol", "TREATMENT", 134, 145], ["\u2018vapour\u2019 plume", "TREATMENT", 149, 163], ["energy delivery", "TREATMENT", 198, 213]]], ["Other studies have investigated this by engaging the phacoemulsification probe at an air-fluid interface and within model eyes [7, 8].", [["eyes", "ANATOMY", 122, 126], ["eyes", "ORGAN", 122, 126], ["Other studies", "TEST", 0, 13], ["the phacoemulsification probe", "TREATMENT", 49, 78], ["an air-fluid interface", "TEST", 82, 104], ["phacoemulsification", "OBSERVATION", 53, 72], ["fluid interface", "OBSERVATION", 89, 104]]], ["The detection of SARS-CoV-2 genetic material in conjunctival swabs in a small proportion of affected patients has raised the possibility of transmission of Covid-19 disease by this aerosol [9, 10].", [["conjunctival swabs", "ANATOMY", 48, 66], ["Covid-19 disease", "DISEASE", 156, 172], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 17, 27], ["conjunctival swabs", "PATHOLOGICAL_FORMATION", 48, 66], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 17, 25], ["Covid-19", "SPECIES", 156, 164], ["The detection", "TEST", 0, 13], ["SARS", "PROBLEM", 17, 21], ["CoV", "TEST", 22, 25], ["conjunctival swabs", "TEST", 48, 66], ["Covid", "TEST", 156, 161], ["this aerosol", "TREATMENT", 176, 188], ["conjunctival", "ANATOMY", 48, 60], ["small", "OBSERVATION_MODIFIER", 72, 77]]], ["It is unknown how long it will take for the pandemic to be controlled, whether and when effective vaccinations or treatments will be developed, and how routine medical care may be performed in a manner that is safe for patients and healthcare workers.", [["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 219, 227], ["effective vaccinations", "TREATMENT", 88, 110], ["treatments", "TREATMENT", 114, 124], ["routine medical care", "TREATMENT", 152, 172]]], ["The purpose of this paper is to evaluate different methods of reducing visible aerosol generation during phacoemulsification surgery.Different sizes of phacoemulsification tips ::: Setting ::: MethodsTwo phacoemulsification tips (2.2, 0.9 mm Intrepid FMS, 2.75, 0.9 mm ABS; Alcon, Camberley, Surrey) were used with matching clear corneal wounds (ClearCut; Alcon, Camberley, Surrey).Dry/wet status of the cornea ::: Setting ::: MethodsThe cornea was wetted by application of BSS on the surface.", [["corneal wounds", "ANATOMY", 330, 344], ["cornea", "ANATOMY", 404, 410], ["cornea", "ANATOMY", 438, 444], ["surface", "ANATOMY", 485, 492], ["corneal", "TISSUE", 330, 337], ["wounds", "PATHOLOGICAL_FORMATION", 338, 344], ["cornea", "TISSUE", 404, 410], ["cornea", "ORGAN", 438, 444], ["BSS", "SIMPLE_CHEMICAL", 474, 477], ["surface", "CELLULAR_COMPONENT", 485, 492], ["reducing visible aerosol generation", "TREATMENT", 62, 97], ["phacoemulsification surgery", "TREATMENT", 105, 132], ["MethodsTwo phacoemulsification tips", "TREATMENT", 193, 228], ["FMS", "TEST", 251, 254], ["mm ABS", "TEST", 266, 272], ["Alcon, Camberley, Surrey)", "TREATMENT", 274, 299], ["matching clear corneal wounds", "PROBLEM", 315, 344], ["Methods", "TREATMENT", 427, 434], ["aerosol generation", "OBSERVATION", 79, 97], ["sizes", "OBSERVATION_MODIFIER", 143, 148], ["phacoemulsification", "OBSERVATION", 152, 171], ["corneal", "ANATOMY", 330, 337], ["wounds", "OBSERVATION", 338, 344], ["wet", "OBSERVATION", 386, 389], ["cornea", "ANATOMY", 404, 410], ["cornea", "ANATOMY", 438, 444], ["wetted", "OBSERVATION_MODIFIER", 449, 455], ["surface", "OBSERVATION_MODIFIER", 485, 492]]], ["Drying of the corneal surface was achieved using cellulose eye spears (Weck-Cel, Beaver-Visitec International, Oxford, UK).Suction and blowing air ::: Setting ::: MethodsSuction was achieved using a standard Yankauer suction tip at maximal suction and a Bair Hugger\u2122 (3 M, Minnesota, USA) was used to blow ambient-temperature air in the vicinity of the surgical field.Hydroxypropyl methylcellulose 2% on the corneal surface ::: Setting ::: MethodsThe use of hydroxypropyl methylcellulose (HPMC) 2% (Aurovisc; Aurolab, Madurai, India & Beaver-Visitec International, Oxford, UK) on the corneal surface was compared with BSS.", [["corneal surface", "ANATOMY", 14, 29], ["eye", "ANATOMY", 59, 62], ["corneal surface", "ANATOMY", 408, 423], ["corneal surface", "ANATOMY", 584, 599], ["Hydroxypropyl methylcellulose", "CHEMICAL", 368, 397], ["hydroxypropyl methylcellulose", "CHEMICAL", 458, 487], ["HPMC", "CHEMICAL", 489, 493], ["Hydroxypropyl methylcellulose", "CHEMICAL", 368, 397], ["hydroxypropyl methylcellulose", "CHEMICAL", 458, 487], ["corneal surface", "TISSUE", 14, 29], ["Hydroxypropyl methylcellulose", "SIMPLE_CHEMICAL", 368, 397], ["hydroxypropyl methylcellulose", "SIMPLE_CHEMICAL", 458, 487], ["HPMC", "SIMPLE_CHEMICAL", 489, 493], ["corneal surface", "MULTI-TISSUE_STRUCTURE", 584, 599], ["MethodsSuction", "TREATMENT", 163, 177], ["a standard Yankauer suction tip", "TREATMENT", 197, 228], ["maximal suction", "TREATMENT", 232, 247], ["a Bair Hugger\u2122", "TREATMENT", 252, 266], ["Hydroxypropyl methylcellulose", "TREATMENT", 368, 397], ["Methods", "TREATMENT", 440, 447], ["hydroxypropyl methylcellulose (HPMC)", "TREATMENT", 458, 494], ["Aurolab", "TREATMENT", 509, 516], ["corneal", "ANATOMY", 14, 21], ["surface", "ANATOMY_MODIFIER", 22, 29], ["temperature air", "OBSERVATION", 314, 329], ["surgical", "OBSERVATION", 353, 361], ["corneal", "ANATOMY", 408, 415], ["corneal", "ANATOMY", 584, 591]]], ["The duration between the reduction in aerosolisation with the application of HPMC and the observation of aerosol was measured six sequential times.", [["HPMC", "CHEMICAL", 77, 81], ["the reduction", "TREATMENT", 21, 34], ["aerosolisation", "TREATMENT", 38, 52], ["HPMC", "TREATMENT", 77, 81], ["aerosol", "TREATMENT", 105, 112], ["reduction", "OBSERVATION_MODIFIER", 25, 34]]], ["Copious BSS irrigation was used to clear the residual HPMC between each trial.Static/dynamic setting ::: Setting ::: MethodsThe static setting was achieved by mounting the phacoemulsification probe on a vertical stand for fixation and the tip was introduced 2.5 mm (using a reference mark on the sleeve) toward the centre of the AAC reproducing standard orientation (Fig. 1).", [["HPMC", "CHEMICAL", 54, 58], ["AAC", "DNA", 329, 332], ["Copious BSS irrigation", "TREATMENT", 0, 22], ["Methods", "TREATMENT", 117, 124], ["fixation", "TREATMENT", 222, 230], ["the tip", "TREATMENT", 235, 242], ["a reference mark on the sleeve", "TREATMENT", 272, 302], ["irrigation", "OBSERVATION", 12, 22], ["residual HPMC", "OBSERVATION", 45, 58], ["phacoemulsification", "OBSERVATION", 172, 191], ["tip", "OBSERVATION_MODIFIER", 239, 242]]], ["In the dynamic trial, the surgeon handled the phacoemulsification probe to move the tip inside the AAC to simulate nuclear sculpting, longitudinally along its axis.ResultsThis model used a human cadaveric corneoscleral rim and an AAC to demonstrate aerosol production during phacoemulsification.", [["nuclear", "ANATOMY", 115, 122], ["corneoscleral rim", "ANATOMY", 205, 222], ["nuclear", "CELLULAR_COMPONENT", 115, 122], ["human", "ORGANISM", 189, 194], ["corneoscleral rim", "TISSUE", 205, 222], ["AAC", "DNA", 99, 102], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 189, 194], ["the phacoemulsification probe", "TREATMENT", 42, 71], ["a human cadaveric corneoscleral rim", "TREATMENT", 187, 222], ["an AAC", "TREATMENT", 227, 233], ["aerosol production", "TREATMENT", 249, 267], ["phacoemulsification", "TREATMENT", 275, 294], ["phacoemulsification", "OBSERVATION", 46, 65], ["tip", "OBSERVATION_MODIFIER", 84, 87], ["AAC", "OBSERVATION", 99, 102], ["nuclear sculpting", "OBSERVATION", 115, 132], ["axis", "ANATOMY", 159, 163], ["aerosol production", "OBSERVATION", 249, 267], ["phacoemulsification", "OBSERVATION", 275, 294]]], ["Phacoemulsification was performed using a standard 2.75-mm phacoemulsification tip with typical ultrasound and phacofluidic settings (Fig. 2, Video 1).", [["Phacoemulsification", "TREATMENT", 0, 19], ["a standard 2.75-mm phacoemulsification tip", "TREATMENT", 40, 82], ["typical ultrasound", "TEST", 88, 106], ["phacofluidic settings", "TREATMENT", 111, 132]]], ["No visible aerosol was identified when using the 2.2-mm tip with identical ultrasound and phacofluidic settings (Fig. 3, Video 2).ResultsThe aerosol produced by the 2.75-mm tip did not vary depending on corneal wetting.", [["corneal", "ANATOMY", 203, 210], ["corneal", "TISSUE", 203, 210], ["visible aerosol", "PROBLEM", 3, 18], ["the 2.2-mm tip", "TREATMENT", 45, 59], ["identical ultrasound", "TEST", 65, 85], ["visible", "OBSERVATION_MODIFIER", 3, 10], ["aerosol", "OBSERVATION", 11, 18], ["corneal", "ANATOMY", 203, 210]]], ["This aerosol was still evident when the corneal surface was dried (Video 3).", [["corneal surface", "ANATOMY", 40, 55], ["corneal surface", "TISSUE", 40, 55], ["This aerosol", "TREATMENT", 0, 12], ["corneal", "ANATOMY", 40, 47]]], ["Attempts to aspirate the aerosol plume generated by negative pressure or suction using Yankauer suction were unsuccessful (Fig. 4a, Video 4).", [["the aerosol plume", "TREATMENT", 21, 38], ["suction", "TREATMENT", 73, 80], ["Yankauer suction", "TREATMENT", 87, 103], ["pressure", "OBSERVATION_MODIFIER", 61, 69]]], ["Downward positive air pressure using forced air at ambient temperature altered the morphology of the plume generated, redirecting the upward aerosol plume downwards and then laterally along the ocular surface (Fig. 4b, Video 5).ResultsCoating the corneal surface with HPMC resulted in a prominent change: no visible aerosol production was demonstrated during phacoemulsification in the static model where the handpiece was fixed within the AAC (Fig. 5, Video 6).", [["ocular surface", "ANATOMY", 194, 208], ["corneal surface", "ANATOMY", 247, 262], ["HPMC", "CHEMICAL", 268, 272], ["corneal surface", "TISSUE", 247, 262], ["HPMC", "SIMPLE_CHEMICAL", 268, 272], ["Downward positive air pressure", "PROBLEM", 0, 30], ["forced air at ambient temperature", "PROBLEM", 37, 70], ["the upward aerosol plume", "TREATMENT", 130, 154], ["a prominent change", "PROBLEM", 285, 303], ["visible aerosol production", "PROBLEM", 308, 334], ["phacoemulsification", "TREATMENT", 359, 378], ["positive", "OBSERVATION_MODIFIER", 9, 17], ["air pressure", "OBSERVATION", 18, 30], ["air", "OBSERVATION_MODIFIER", 44, 47], ["upward", "OBSERVATION_MODIFIER", 134, 140], ["aerosol plume", "OBSERVATION", 141, 154], ["laterally", "ANATOMY_MODIFIER", 174, 183], ["ocular", "ANATOMY", 194, 200], ["surface", "ANATOMY_MODIFIER", 201, 208], ["corneal", "ANATOMY", 247, 254], ["surface", "OBSERVATION_MODIFIER", 255, 262], ["prominent", "OBSERVATION_MODIFIER", 287, 296], ["no", "UNCERTAINTY", 305, 307], ["visible", "OBSERVATION_MODIFIER", 308, 315], ["aerosol production", "OBSERVATION", 316, 334], ["phacoemulsification", "OBSERVATION", 359, 378]]], ["This effect lasted for an average of 67 \u00b1 8 s (range 63\u201372 s) of continuous phacoemulsification in the static model (Video 7).ResultsWhen continuous phacoemulsification was performed in a dynamic fashion, with the 2.2-mm tip mimicking the longitudinal action of nuclear sculpting, no visible aerosol generation was discerned during the majority of the movement.", [["nuclear", "ANATOMY", 262, 269], ["nuclear", "CELLULAR_COMPONENT", 262, 269], ["continuous phacoemulsification", "TREATMENT", 65, 95], ["continuous phacoemulsification", "TREATMENT", 138, 168], ["visible aerosol generation", "PROBLEM", 284, 310], ["phacoemulsification", "OBSERVATION", 76, 95], ["no", "UNCERTAINTY", 281, 283], ["visible", "OBSERVATION_MODIFIER", 284, 291], ["aerosol generation", "OBSERVATION", 292, 310]]], ["The exception was noted where the tip was just proximal to the corneal wound when the aerosol plume was clearly visualised (Video 8).DiscussionSince the advent of the Covid-19 pandemic, the risk to healthcare workers contracting the disease from potentially infectious droplets and aerosol during AGPs has been explored by several studies analysing the pattern of droplet spread during simulated medical interventions [11, 12].DiscussionPublished simulations have attempted to model aerosol generation during phacoemulsification using video recording and application of the ultrasound energy at either an air-fluid interface or using model eyes [7, 8].", [["corneal wound", "ANATOMY", 63, 76], ["eyes", "ANATOMY", 640, 644], ["corneal", "PATHOLOGICAL_FORMATION", 63, 70], ["wound", "PATHOLOGICAL_FORMATION", 71, 76], ["eyes", "ORGAN", 640, 644], ["the tip", "TREATMENT", 30, 37], ["the corneal wound", "PROBLEM", 59, 76], ["the aerosol plume", "TREATMENT", 82, 99], ["the disease", "PROBLEM", 229, 240], ["infectious droplets", "TREATMENT", 258, 277], ["aerosol during AGPs", "TREATMENT", 282, 301], ["several studies", "TEST", 323, 338], ["droplet spread", "PROBLEM", 364, 378], ["simulated medical interventions", "TREATMENT", 386, 417], ["model aerosol generation during phacoemulsification", "TREATMENT", 477, 528], ["video recording", "TEST", 535, 550], ["the ultrasound energy", "TEST", 570, 591], ["an air-fluid interface", "TEST", 602, 624], ["tip", "OBSERVATION_MODIFIER", 34, 37], ["corneal", "ANATOMY", 63, 70], ["wound", "OBSERVATION", 71, 76], ["aerosol plume", "OBSERVATION", 86, 99], ["infectious", "OBSERVATION_MODIFIER", 258, 268], ["droplet spread", "OBSERVATION", 364, 378], ["fluid interface", "OBSERVATION", 609, 624]]], ["The former is not representative of the closed system that is required for effective and safe phacoemulsification.", [["effective and safe phacoemulsification", "TREATMENT", 75, 113], ["closed", "OBSERVATION", 40, 46], ["phacoemulsification", "OBSERVATION", 94, 113]]], ["Similarly, model eyes have different structural properties to the human eye and findings using these models may be challenged on these grounds.DiscussionAACs are utilised in corneal graft surgery for donor tissue preparation [13].", [["eyes", "ANATOMY", 17, 21], ["eye", "ANATOMY", 72, 75], ["corneal graft", "ANATOMY", 174, 187], ["tissue", "ANATOMY", 206, 212], ["eyes", "ORGAN", 17, 21], ["human", "ORGANISM", 66, 71], ["eye", "ORGAN", 72, 75], ["corneal graft", "TISSUE", 174, 187], ["tissue", "TISSUE", 206, 212], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["these models", "TREATMENT", 95, 107], ["corneal graft surgery", "TREATMENT", 174, 195], ["donor tissue preparation", "TREATMENT", 200, 224], ["different", "OBSERVATION_MODIFIER", 27, 36], ["structural properties", "OBSERVATION", 37, 58], ["human eye", "ANATOMY", 66, 75], ["corneal", "ANATOMY", 174, 181], ["graft", "OBSERVATION", 182, 187]]], ["Once the human corneoscleral rim is mounted on the AAC, a single leak-free chamber is formed allowing the maintenance of \u2018intraocular pressure\u2019.", [["corneoscleral rim", "ANATOMY", 15, 32], ["intraocular", "ANATOMY", 122, 133], ["human", "ORGANISM", 9, 14], ["corneoscleral rim", "MULTI-TISSUE_STRUCTURE", 15, 32], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["the AAC", "TREATMENT", 47, 54], ["a single leak-free chamber", "PROBLEM", 56, 82], ["\u2018intraocular pressure\u2019", "TREATMENT", 121, 143], ["corneoscleral rim", "ANATOMY", 15, 32], ["leak", "OBSERVATION", 65, 69], ["free chamber", "OBSERVATION", 70, 82], ["intraocular pressure", "OBSERVATION", 122, 142]]], ["This model allows simulated surgery for lamellar graft procedures using human cadaveric tissue and addresses the above limitations of other experimental models.DiscussionWe utilised a novel application of this model to consistently demonstrate the aerosol or \u2018vapour\u2019 plume that is observed in the real world setting during phacoemulsification with a 2.75-mm tip.", [["lamellar graft", "ANATOMY", 40, 54], ["tissue", "ANATOMY", 88, 94], ["lamellar graft", "TISSUE", 40, 54], ["human", "ORGANISM", 72, 77], ["cadaveric tissue", "TISSUE", 78, 94], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["simulated surgery", "TREATMENT", 18, 35], ["lamellar graft procedures", "TREATMENT", 40, 65], ["human cadaveric tissue", "TREATMENT", 72, 94], ["this model", "TREATMENT", 205, 215], ["the aerosol", "TREATMENT", 244, 255], ["\u2018vapour\u2019 plume", "TREATMENT", 259, 273], ["phacoemulsification", "TREATMENT", 324, 343], ["a 2.75-mm tip", "TREATMENT", 349, 362], ["lamellar graft", "OBSERVATION", 40, 54]]], ["The plume appears to originate from the corneal wound.", [["corneal wound", "ANATOMY", 40, 53], ["corneal wound", "PATHOLOGICAL_FORMATION", 40, 53], ["the corneal wound", "PROBLEM", 36, 53], ["plume", "OBSERVATION_MODIFIER", 4, 9], ["appears to originate", "UNCERTAINTY", 10, 30], ["corneal", "ANATOMY", 40, 47], ["wound", "OBSERVATION", 48, 53]]], ["This may be due to vibration transmitted from the phacoemulsification probe to the lip of the corneal wound.", [["lip", "ANATOMY", 83, 86], ["corneal wound", "ANATOMY", 94, 107], ["lip", "ORGAN", 83, 86], ["corneal wound", "PATHOLOGICAL_FORMATION", 94, 107], ["the phacoemulsification probe", "TREATMENT", 46, 75], ["the corneal wound", "PROBLEM", 90, 107], ["may be due to", "UNCERTAINTY", 5, 18], ["vibration", "OBSERVATION", 19, 28], ["phacoemulsification", "OBSERVATION", 50, 69], ["lip", "ANATOMY_MODIFIER", 83, 86], ["corneal", "ANATOMY", 94, 101], ["wound", "OBSERVATION", 102, 107]]], ["It is impossible to determine whether the aerosol generation seen with this experimental set up is due to agitation of moisture on the surface of the cornea or small amounts of BSS that can egress through the corneal wound around the probe.", [["surface", "ANATOMY", 135, 142], ["cornea", "ANATOMY", 150, 156], ["corneal wound", "ANATOMY", 209, 222], ["agitation", "DISEASE", 106, 115], ["cornea", "ORGAN", 150, 156], ["BSS", "SIMPLE_CHEMICAL", 177, 180], ["corneal wound", "PATHOLOGICAL_FORMATION", 209, 222], ["the aerosol generation", "PROBLEM", 38, 60], ["agitation", "PROBLEM", 106, 115], ["small amounts of BSS", "PROBLEM", 160, 180], ["the corneal wound", "PROBLEM", 205, 222], ["cornea", "ANATOMY", 150, 156], ["small", "OBSERVATION_MODIFIER", 160, 165], ["amounts", "OBSERVATION_MODIFIER", 166, 173], ["corneal", "ANATOMY", 209, 216], ["wound", "OBSERVATION", 217, 222]]], ["Visible aerosol following phacoemulsification with a dry cornea supports the latter.", [["cornea", "ANATOMY", 57, 63], ["cornea", "ORGAN", 57, 63], ["phacoemulsification", "TREATMENT", 26, 45], ["a dry cornea", "PROBLEM", 51, 63], ["aerosol", "OBSERVATION", 8, 15], ["phacoemulsification", "OBSERVATION", 26, 45]]], ["The reduction in visible aerosol seen with the 2.2-mm tip may be explained by less wound leakage.", [["wound", "ANATOMY", 83, 88], ["wound", "PATHOLOGICAL_FORMATION", 83, 88], ["The reduction in visible aerosol", "TREATMENT", 0, 32], ["the 2.2-mm tip", "TREATMENT", 43, 57], ["less wound leakage", "PROBLEM", 78, 96], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["visible", "OBSERVATION_MODIFIER", 17, 24], ["aerosol", "OBSERVATION", 25, 32], ["2.2-mm", "OBSERVATION_MODIFIER", 47, 53], ["may be explained", "UNCERTAINTY", 58, 74], ["less", "OBSERVATION_MODIFIER", 78, 82], ["wound", "OBSERVATION_MODIFIER", 83, 88], ["leakage", "OBSERVATION", 89, 96]]], ["This was noted in an ex vivo study comparing wound leakage between 2.2- and 2.75-mm tips [14].DiscussionFollowing this, we evaluated different methods of attenuating this aerosol plume and demonstrate two potential approaches.", [["wound", "ANATOMY", 45, 50], ["wound", "PATHOLOGICAL_FORMATION", 45, 50], ["an ex vivo study", "TEST", 18, 34], ["wound leakage", "PROBLEM", 45, 58], ["attenuating this aerosol plume", "TREATMENT", 154, 184], ["leakage", "OBSERVATION_MODIFIER", 51, 58]]], ["The first approach involves forced air directed at the microsurgical field to disperse the aerosol downwards and laterally.", [["The first approach", "TREATMENT", 0, 18], ["forced air", "PROBLEM", 28, 38], ["forced air", "OBSERVATION", 28, 38], ["aerosol downwards", "OBSERVATION", 91, 108], ["laterally", "ANATOMY_MODIFIER", 113, 122]]], ["In an operating theatre, this set up would be challenging as the air would have to be filtered and humidified to prevent infection and corneal drying respectively, with the setup of the microsurgical field to incorporate a suitable air flow device potentially being problematic.", [["corneal", "ANATOMY", 135, 142], ["infection", "DISEASE", 121, 130], ["humidified", "TREATMENT", 99, 109], ["infection", "PROBLEM", 121, 130], ["corneal drying", "PROBLEM", 135, 149], ["the microsurgical field", "TREATMENT", 182, 205], ["a suitable air flow device", "TREATMENT", 221, 247], ["infection", "OBSERVATION", 121, 130], ["corneal", "ANATOMY", 135, 142], ["air flow", "OBSERVATION", 232, 240]]], ["Portable surgical laminar flow systems used for cataract surgery may be configured to drive any aerosol produced away from healthcare workers, allowing precipitation onto surgical drapes and subsequent disposal.DiscussionSuction did not influence the plume despite close proximity of the Yankauer suction tip to its source and maximum suction.", [["laminar", "ANATOMY", 18, 25], ["cataract", "DISEASE", 48, 56], ["Portable surgical laminar flow systems", "TREATMENT", 0, 38], ["cataract surgery", "TREATMENT", 48, 64], ["surgical drapes", "TREATMENT", 171, 186], ["the Yankauer suction tip", "TREATMENT", 284, 308], ["maximum suction", "TREATMENT", 327, 342], ["laminar flow", "OBSERVATION", 18, 30]]], ["This is likely to be due to a limitation in the instrument used, as custom devices have been developed to effectively remove vapour during corneal ablation using excimer laser [15].DiscussionThe second approach uses HPMC 2% to coat the corneal surface during phacoemulsification.", [["corneal", "ANATOMY", 139, 146], ["corneal surface", "ANATOMY", 236, 251], ["HPMC", "CHEMICAL", 216, 220], ["corneal", "TISSUE", 139, 146], ["corneal surface", "TISSUE", 236, 251], ["custom devices", "TREATMENT", 68, 82], ["corneal ablation", "TREATMENT", 139, 155], ["excimer laser", "TREATMENT", 162, 175], ["HPMC", "TREATMENT", 216, 220], ["phacoemulsification", "TREATMENT", 259, 278], ["likely to be due to", "UNCERTAINTY", 8, 27], ["corneal", "ANATOMY", 236, 243], ["surface", "ANATOMY_MODIFIER", 244, 251], ["phacoemulsification", "OBSERVATION", 259, 278]]], ["HPMC is a low-viscosity and moderate-viscoelasticity material commonly used to coat the cornea to improve intraocular visualisation during surgery and has proven safety [16].", [["cornea", "ANATOMY", 88, 94], ["intraocular", "ANATOMY", 106, 117], ["HPMC", "CHEMICAL", 0, 4], ["HPMC", "SIMPLE_CHEMICAL", 0, 4], ["cornea", "ORGAN", 88, 94], ["HPMC", "TEST", 0, 4], ["a low-viscosity", "PROBLEM", 8, 23], ["moderate-viscoelasticity material", "PROBLEM", 28, 61], ["intraocular visualisation", "TEST", 106, 131], ["surgery", "TREATMENT", 139, 146], ["low-viscosity", "OBSERVATION_MODIFIER", 10, 23], ["moderate", "OBSERVATION_MODIFIER", 28, 36], ["viscoelasticity material", "OBSERVATION", 37, 61], ["cornea", "ANATOMY", 88, 94]]], ["It is notable that our findings are in agreement with those identified using model eyes [8].DiscussionAnalysis of video recordings highlight that visible aerosol generation is abolished when HPMC is applied to the corneal wound.", [["eyes", "ANATOMY", 83, 87], ["corneal wound", "ANATOMY", 214, 227], ["HPMC", "CHEMICAL", 191, 195], ["HPMC", "SIMPLE_CHEMICAL", 191, 195], ["corneal wound", "PATHOLOGICAL_FORMATION", 214, 227], ["video recordings", "TEST", 114, 130], ["visible aerosol generation", "TREATMENT", 146, 172], ["HPMC", "TREATMENT", 191, 195], ["the corneal wound", "PROBLEM", 210, 227], ["corneal", "ANATOMY", 214, 221], ["wound", "OBSERVATION", 222, 227]]], ["It is possible that when HPMC coats the corneal wound and phacoemulsification probe, it acts as a barrier to either aerosol formation or dispersion.", [["corneal wound", "ANATOMY", 40, 53], ["HPMC", "CHEMICAL", 25, 29], ["corneal wound", "PATHOLOGICAL_FORMATION", 40, 53], ["HPMC coats the corneal wound", "PROBLEM", 25, 53], ["phacoemulsification probe", "TREATMENT", 58, 83], ["corneal", "ANATOMY", 40, 47], ["wound", "OBSERVATION", 48, 53]]], ["Its higher molecular weight and elasticity may also act as a damper to the ultrasonic energy preventing agitation and consequent aerosolisation.", [["agitation", "DISEASE", 104, 113], ["agitation", "PROBLEM", 104, 113], ["consequent aerosolisation", "PROBLEM", 118, 143], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["molecular weight", "OBSERVATION", 11, 27]]], ["This effect was consistent using two different brands of HPMC and may apply to other types of viscoelastic materials.", [["HPMC", "CHEMICAL", 57, 61], ["HPMC", "SIMPLE_CHEMICAL", 57, 61], ["HPMC", "TREATMENT", 57, 61], ["viscoelastic materials", "TREATMENT", 94, 116], ["different", "OBSERVATION_MODIFIER", 37, 46], ["brands", "OBSERVATION_MODIFIER", 47, 53], ["HPMC", "OBSERVATION", 57, 61], ["viscoelastic materials", "OBSERVATION", 94, 116]]], ["This effect was also noted with simulations using model eyes [8].DiscussionEfforts to reproduce the longitudinal action of nuclear sculpting showed that, in contrast to the static model, visible aerosol was only produced when continuous phacoemulsification was performed close to the corneal wound despite HPMC coating.", [["eyes", "ANATOMY", 56, 60], ["nuclear", "ANATOMY", 123, 130], ["corneal wound", "ANATOMY", 284, 297], ["HPMC", "CHEMICAL", 306, 310], ["nuclear", "CELLULAR_COMPONENT", 123, 130], ["corneal wound", "PATHOLOGICAL_FORMATION", 284, 297], ["HPMC", "SIMPLE_CHEMICAL", 306, 310], ["continuous phacoemulsification", "TREATMENT", 226, 256], ["the corneal wound", "PROBLEM", 280, 297], ["HPMC coating", "TREATMENT", 306, 318], ["corneal", "ANATOMY", 284, 291], ["wound", "OBSERVATION", 292, 297], ["HPMC coating", "OBSERVATION", 306, 318]]], ["The close proximity of the ultrasound energy to the cornea may generate aerosol by either agitating the HPMC coat off the cornea or directly diminishing HPMC\u2019s barrier function.", [["cornea", "ANATOMY", 52, 58], ["cornea", "ANATOMY", 122, 128], ["HPMC", "CHEMICAL", 153, 157], ["cornea", "ORGAN", 52, 58], ["cornea", "ORGAN", 122, 128], ["HPMC", "SIMPLE_CHEMICAL", 153, 157], ["barrier", "TISSUE", 160, 167], ["the ultrasound energy", "TEST", 23, 44], ["cornea", "ANATOMY", 52, 58], ["HPMC coat", "OBSERVATION", 104, 113], ["cornea", "ANATOMY", 122, 128], ["diminishing", "OBSERVATION_MODIFIER", 141, 152]]], ["The reduced aerosol production at other points during the dynamic experiment may be due to less deformation of the corneal wound by the surgeon despite efforts to minimise this when using the static model and represents a limitation of this study.", [["corneal wound", "ANATOMY", 115, 128], ["corneal", "TISSUE", 115, 122], ["wound", "PATHOLOGICAL_FORMATION", 123, 128], ["The reduced aerosol production", "PROBLEM", 0, 30], ["the corneal wound", "PROBLEM", 111, 128], ["this study", "TEST", 236, 246], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["aerosol production", "OBSERVATION", 12, 30], ["may be due to", "UNCERTAINTY", 77, 90], ["less", "OBSERVATION_MODIFIER", 91, 95], ["deformation", "OBSERVATION", 96, 107], ["corneal", "ANATOMY", 115, 122], ["wound", "OBSERVATION", 123, 128]]], ["This study only analysed aerosol production using continuous torsional phacoemulsification and may not be representative of other modes of ultrasound energy delivery.DiscussionThis study investigated visible aerosol generation from phacoemulsification using a clear corneal wound and may not represent aerosol produced from a limbal corneal wound.", [["corneal wound", "ANATOMY", 266, 279], ["limbal corneal wound", "ANATOMY", 326, 346], ["corneal wound", "PATHOLOGICAL_FORMATION", 266, 279], ["limbal corneal", "TISSUE", 326, 340], ["wound", "PATHOLOGICAL_FORMATION", 341, 346], ["This study", "TEST", 0, 10], ["continuous torsional phacoemulsification", "TREATMENT", 50, 90], ["ultrasound energy delivery", "TREATMENT", 139, 165], ["This study", "TEST", 176, 186], ["phacoemulsification", "TREATMENT", 232, 251], ["a clear corneal wound", "PROBLEM", 258, 279], ["aerosol", "TREATMENT", 302, 309], ["a limbal corneal wound", "PROBLEM", 324, 346], ["torsional phacoemulsification", "OBSERVATION", 61, 90], ["corneal", "ANATOMY", 266, 273], ["wound", "OBSERVATION", 274, 279], ["may not represent", "UNCERTAINTY", 284, 301], ["aerosol", "OBSERVATION", 302, 309], ["limbal", "ANATOMY_MODIFIER", 326, 332], ["corneal", "ANATOMY", 333, 340], ["wound", "OBSERVATION", 341, 346]]], ["As this study focused on visible aerosol generation only, it is impossible to comment on generation of invisible or ultrafine aerosol particles that are not discernible by this experimental setup.", [["this study", "TEST", 3, 13], ["visible aerosol generation", "TREATMENT", 25, 51], ["ultrafine aerosol particles", "TREATMENT", 116, 143], ["not discernible", "UNCERTAINTY", 153, 168]]], ["There is uncertainty about whether these particles can form in the absence of visible aerosol generation and if so, whether these particles pose a risk of transmitting Covid-19 disease to healthcare workers.DiscussionThe first part of this study aimed to reproduce the \u2018vapour\u2019 plumes observed in real world cataract surgery.", [["Covid-19 disease", "DISEASE", 168, 184], ["cataract", "DISEASE", 308, 316], ["this study", "TEST", 235, 245], ["real world cataract surgery", "TREATMENT", 297, 324], ["aerosol generation", "OBSERVATION", 86, 104], ["cataract surgery", "OBSERVATION", 308, 324]]], ["This study using human tissue, along with others utilising model eyes [8], demonstrates visible aerosol generation during phacoemulsification.DiscussionWe cannot comment on the risk of transmission from an infected patient to healthcare workers by the visible aerosol generated.", [["tissue", "ANATOMY", 23, 29], ["eyes", "ANATOMY", 65, 69], ["human", "ORGANISM", 17, 22], ["tissue", "TISSUE", 23, 29], ["patient", "ORGANISM", 215, 222], ["human", "SPECIES", 17, 22], ["patient", "SPECIES", 215, 222], ["human", "SPECIES", 17, 22], ["This study", "TEST", 0, 10], ["human tissue", "TREATMENT", 17, 29], ["visible aerosol generation during phacoemulsification", "TREATMENT", 88, 141], ["aerosol generation", "OBSERVATION", 96, 114], ["phacoemulsification", "OBSERVATION", 122, 141], ["infected", "OBSERVATION", 206, 214]]], ["Currently, it is unknown whether viable SARS-CoV-2 particles can be aerosolised in sufficient quantities to form an effective inoculum for transmission to healthcare workers.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "ORGANISM", 40, 50], ["viable SARS", "PROBLEM", 33, 44]]], ["The following should be considered when estimating this risk: is there an effective SARS-CoV-2 viral load present in or on the ocular tissues of an asymptomatic or undiagnosed patient undergoing cataract surgery, and is the visible aerosol plume formed during cataract surgery is composed of BSS or intraocular fluids.", [["ocular tissues", "ANATOMY", 127, 141], ["intraocular fluids", "ANATOMY", 299, 317], ["cataract", "DISEASE", 195, 203], ["cataract", "DISEASE", 260, 268], ["CoV-2", "ORGANISM", 89, 94], ["ocular tissues", "TISSUE", 127, 141], ["patient", "ORGANISM", 176, 183], ["patient", "SPECIES", 176, 183], ["an effective SARS", "PROBLEM", 71, 88], ["CoV", "TEST", 89, 92], ["2 viral load", "PROBLEM", 93, 105], ["cataract surgery", "TREATMENT", 195, 211], ["the visible aerosol plume", "TREATMENT", 220, 245], ["cataract surgery", "TREATMENT", 260, 276], ["intraocular fluids", "TREATMENT", 299, 317], ["ocular tissues", "ANATOMY", 127, 141], ["aerosol plume", "OBSERVATION", 232, 245], ["cataract surgery", "OBSERVATION", 260, 276], ["intraocular fluids", "OBSERVATION", 299, 317]]], ["We offer suggestions to deal with these uncertainties.DiscussionTopical povidone-iodine is virucidal with in vitro testing of 0.23% povidone-iodine producing a 10,000-fold reduction in the viral load of SARS-CoV and MERS-CoV within 15 s [17\u201319].", [["povidone-iodine", "CHEMICAL", 72, 87], ["povidone-iodine", "CHEMICAL", 132, 147], ["SARS", "DISEASE", 203, 207], ["povidone-iodine", "CHEMICAL", 72, 87], ["povidone-iodine", "CHEMICAL", 132, 147], ["povidone-iodine", "SIMPLE_CHEMICAL", 72, 87], ["povidone-iodine", "SIMPLE_CHEMICAL", 132, 147], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 203, 211], ["MERS-CoV", "ORGANISM", 216, 224], ["SARS-CoV", "SPECIES", 203, 211], ["MERS-CoV", "SPECIES", 216, 224], ["DiscussionTopical povidone", "TREATMENT", 54, 80], ["iodine", "TREATMENT", 81, 87], ["vitro testing", "TEST", 109, 122], ["povidone", "TREATMENT", 132, 140], ["iodine", "TREATMENT", 141, 147], ["a 10,000-fold reduction", "TREATMENT", 158, 181], ["the viral load", "TEST", 185, 199], ["SARS", "PROBLEM", 203, 207], ["CoV", "TEST", 208, 211], ["MERS", "TEST", 216, 220], ["CoV", "TEST", 221, 224]]], ["Topical povidone-iodine is widely used in ophthalmic surgery for surgical antisepsis and would destroy any viable SARS-CoV-2 particles present on the ocular surface.DiscussionThere may be concern that the aerosol generated by phacoemulsification could contain virus-infected intraocular fluid.", [["ocular surface", "ANATOMY", 150, 164], ["intraocular fluid", "ANATOMY", 275, 292], ["povidone-iodine", "CHEMICAL", 8, 23], ["SARS", "DISEASE", 114, 118], ["povidone-iodine", "CHEMICAL", 8, 23], ["povidone-iodine", "SIMPLE_CHEMICAL", 8, 23], ["ocular surface", "MULTI-TISSUE_STRUCTURE", 150, 164], ["intraocular fluid", "ORGANISM_SUBSTANCE", 275, 292], ["Topical povidone", "TREATMENT", 0, 16], ["iodine", "TREATMENT", 17, 23], ["ophthalmic surgery", "TREATMENT", 42, 60], ["surgical antisepsis", "TREATMENT", 65, 84], ["the aerosol", "TREATMENT", 201, 212], ["phacoemulsification", "TREATMENT", 226, 245], ["virus", "PROBLEM", 260, 265], ["infected intraocular fluid", "PROBLEM", 266, 292], ["SARS", "OBSERVATION", 114, 118], ["ocular", "ANATOMY", 150, 156], ["surface", "ANATOMY_MODIFIER", 157, 164], ["infected", "OBSERVATION_MODIFIER", 266, 274], ["intraocular fluid", "OBSERVATION", 275, 292]]], ["The majority of this intraocular fluid is visco-expressed before capsulorrhexis.", [["intraocular fluid", "ANATOMY", 21, 38], ["intraocular fluid", "ORGANISM_SUBSTANCE", 21, 38], ["this intraocular fluid", "PROBLEM", 16, 38], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["intraocular fluid", "OBSERVATION", 21, 38]]], ["The concern about any remaining infected intraocular fluid should be alleviated by applying statistical and mathematical principles.", [["intraocular fluid", "ANATOMY", 41, 58], ["any remaining infected intraocular fluid", "PROBLEM", 18, 58], ["infected", "OBSERVATION_MODIFIER", 32, 40], ["intraocular fluid", "OBSERVATION", 41, 58]]], ["The mean volume of the anterior chamber measured with optical coherence tomography is 0.17 \u00b1 0.04 ml [20].", [["anterior chamber", "ANATOMY", 23, 39], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 23, 39], ["The mean volume", "TEST", 0, 15], ["optical coherence tomography", "TEST", 54, 82], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["volume", "OBSERVATION_MODIFIER", 9, 15], ["anterior", "ANATOMY_MODIFIER", 23, 31], ["chamber", "ANATOMY_MODIFIER", 32, 39]]], ["If the volume of the anterior chamber is normally distributed, three standard deviations would 99.7% of the population would have an anterior chamber volume of less than 0.29 ml.DiscussionPhacoemulsification cataract surgery occurs in a closed system and irrigating/aspirating BSS through the anterior chamber with the phacoemulsification probe results in a dilution of intraocular fluid that obeys first order decay: for every 0.29 ml of BSS that passes through, the concentration of the original intraocular fluid is decreased by 50%.", [["anterior chamber", "ANATOMY", 21, 37], ["intraocular fluid", "ANATOMY", 370, 387], ["intraocular fluid", "ANATOMY", 498, 515], ["cataract", "DISEASE", 208, 216], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 21, 37], ["an anterior chamber volume", "TEST", 130, 156], ["Phacoemulsification cataract surgery", "TREATMENT", 188, 224], ["a closed system", "TREATMENT", 235, 250], ["irrigating/aspirating BSS", "TREATMENT", 255, 280], ["the phacoemulsification probe", "TREATMENT", 315, 344], ["a dilution of intraocular fluid", "TREATMENT", 356, 387], ["BSS", "TREATMENT", 439, 442], ["the original intraocular fluid", "TREATMENT", 485, 515], ["volume", "OBSERVATION_MODIFIER", 7, 13], ["anterior", "ANATOMY_MODIFIER", 21, 29], ["chamber", "ANATOMY_MODIFIER", 30, 37], ["normally", "OBSERVATION_MODIFIER", 41, 49], ["distributed", "OBSERVATION_MODIFIER", 50, 61], ["anterior", "ANATOMY_MODIFIER", 133, 141], ["chamber volume", "OBSERVATION", 142, 156], ["anterior", "ANATOMY_MODIFIER", 293, 301], ["phacoemulsification", "OBSERVATION", 319, 338], ["intraocular fluid", "OBSERVATION", 370, 387], ["intraocular fluid", "OBSERVATION", 498, 515], ["decreased", "OBSERVATION_MODIFIER", 519, 528]]], ["When 2.03 ml of BSS has circulated in the anterior chamber, the concentration is reduced to less than 1% of the original concentration.", [["BSS", "CHEMICAL", 16, 19], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 42, 58], ["BSS", "TREATMENT", 16, 19], ["anterior", "ANATOMY_MODIFIER", 42, 50], ["chamber", "ANATOMY_MODIFIER", 51, 58], ["concentration", "OBSERVATION_MODIFIER", 64, 77], ["reduced", "OBSERVATION_MODIFIER", 81, 88]]], ["Using conventional aspiration rates ranging from 20 to 40 cc/min, this will take at most 3\u20136 s in 99.7% of the population.", [["conventional aspiration rates", "TREATMENT", 6, 35], ["aspiration", "OBSERVATION", 19, 29]]], ["Performing this irrigation/aspiration step for an aspiration rate-dependent duration prior to phacoemulsification will significantly decrease the proportion of any remaining intraocular fluid (and consequently any theoretical virus load) in any aerosol produced.DiscussionWe then investigated methods of mitigating of any potential risk from the aerosol produced by phacoemulsification, with the prospect of aiding the resumption of elective cataract surgery as we navigate through this pandemic.", [["intraocular fluid", "ANATOMY", 174, 191], ["cataract", "DISEASE", 442, 450], ["intraocular fluid", "TISSUE", 174, 191], ["this irrigation", "TREATMENT", 11, 26], ["aspiration step", "TREATMENT", 27, 42], ["an aspiration rate", "TEST", 47, 65], ["phacoemulsification", "TREATMENT", 94, 113], ["any remaining intraocular fluid", "PROBLEM", 160, 191], ["any theoretical virus load)", "TREATMENT", 210, 237], ["phacoemulsification", "TREATMENT", 366, 385], ["elective cataract surgery", "TREATMENT", 433, 458], ["intraocular fluid", "OBSERVATION", 174, 191], ["phacoemulsification", "OBSERVATION", 366, 385]]], ["Findings from the study show that use of a 2.2-mm phacoemulsification tip where possible and copious administration of HPMC every minute during phacoemulsification reduces visible aerosol generation.What was known before ::: Summary", [["HPMC", "CHEMICAL", 119, 123], ["the study", "TEST", 14, 23], ["a 2.2-mm phacoemulsification tip", "TREATMENT", 41, 73], ["copious administration of HPMC", "TREATMENT", 93, 123], ["phacoemulsification", "TREATMENT", 144, 163], ["copious", "OBSERVATION_MODIFIER", 93, 100], ["aerosol generation", "OBSERVATION", 180, 198]]]], "16da1a723a94177f637e745981853cd923d0098f": [["In Brief Structurally designed EBV vaccine candidates based on self-assembling nanoparticles elicit potent and durable virus-neutralizing antibodies that target the receptor-binding site on the viral envelope protein gp350, a site of vulnerability, serving as a template to develop an EBV vaccine and providing a basis for immunofocusing through rational vaccine design.", [["EBV", "ORGANISM", 31, 34], ["gp350", "GENE_OR_GENE_PRODUCT", 217, 222], ["EBV", "ORGANISM", 285, 288], ["neutralizing antibodies", "PROTEIN", 125, 148], ["viral envelope protein", "PROTEIN", 194, 216], ["gp350", "PROTEIN", 217, 222], ["EBV", "SPECIES", 285, 288], ["EBV vaccine candidates", "TREATMENT", 31, 53], ["self-assembling nanoparticles elicit", "TREATMENT", 63, 99], ["durable virus", "PROBLEM", 111, 124], ["neutralizing antibodies", "TREATMENT", 125, 148], ["the viral envelope protein", "TEST", 190, 216], ["an EBV vaccine", "TREATMENT", 282, 296], ["immunofocusing through rational vaccine", "TREATMENT", 323, 362]]], ["INTRODUCTION Epstein-Barr virus (EBV) infection is associated with multiple human diseases, including infectious mononucleosis (IM) and a variety of malignancies.", [["malignancies", "ANATOMY", 149, 161], ["Epstein-Barr virus (EBV) infection", "DISEASE", 13, 47], ["human diseases", "DISEASE", 76, 90], ["infectious mononucleosis", "DISEASE", 102, 126], ["IM", "DISEASE", 128, 130], ["malignancies", "DISEASE", 149, 161], ["Epstein-Barr virus", "ORGANISM", 13, 31], ["EBV", "ORGANISM", 33, 36], ["human", "ORGANISM", 76, 81], ["malignancies", "CANCER", 149, 161], ["human", "SPECIES", 76, 81], ["Epstein-Barr virus", "SPECIES", 13, 31], ["EBV", "SPECIES", 33, 36], ["human", "SPECIES", 76, 81], ["Barr virus (EBV) infection", "PROBLEM", 21, 47], ["multiple human diseases", "PROBLEM", 67, 90], ["infectious mononucleosis", "PROBLEM", 102, 126], ["malignancies", "PROBLEM", 149, 161], ["Barr virus", "OBSERVATION", 21, 31], ["infection", "OBSERVATION", 38, 47], ["associated with", "UNCERTAINTY", 51, 66], ["multiple", "OBSERVATION_MODIFIER", 67, 75], ["human diseases", "OBSERVATION", 76, 90], ["infectious", "OBSERVATION_MODIFIER", 102, 112], ["variety", "OBSERVATION_MODIFIER", 138, 145], ["malignancies", "OBSERVATION", 149, 161]]], ["Burkitt and Hodgkin lymphoma, gastric, and nasopharyngeal carcinoma are among the neoplasms observed after infection, as are lymphoproliferative disorders.", [["Burkitt", "ANATOMY", 0, 7], ["Hodgkin lymphoma", "ANATOMY", 12, 28], ["gastric", "ANATOMY", 30, 37], ["nasopharyngeal carcinoma", "ANATOMY", 43, 67], ["neoplasms", "ANATOMY", 82, 91], ["Burkitt and Hodgkin lymphoma", "DISEASE", 0, 28], ["nasopharyngeal carcinoma", "DISEASE", 43, 67], ["neoplasms", "DISEASE", 82, 91], ["infection", "DISEASE", 107, 116], ["lymphoproliferative disorders", "DISEASE", 125, 154], ["Burkitt", "CANCER", 0, 7], ["Hodgkin lymphoma", "CANCER", 12, 28], ["gastric", "CANCER", 30, 37], ["nasopharyngeal carcinoma", "CANCER", 43, 67], ["neoplasms", "CANCER", 82, 91], ["Burkitt", "PROBLEM", 0, 7], ["Hodgkin lymphoma", "PROBLEM", 12, 28], ["gastric, and nasopharyngeal carcinoma", "PROBLEM", 30, 67], ["the neoplasms", "PROBLEM", 78, 91], ["infection", "PROBLEM", 107, 116], ["lymphoproliferative disorders", "PROBLEM", 125, 154], ["Hodgkin lymphoma", "OBSERVATION", 12, 28], ["gastric", "ANATOMY", 30, 37], ["nasopharyngeal", "ANATOMY", 43, 57], ["carcinoma", "OBSERVATION", 58, 67], ["neoplasms", "OBSERVATION", 82, 91], ["infection", "OBSERVATION", 107, 116], ["lymphoproliferative disorders", "OBSERVATION", 125, 154]]], ["The prevalence and the severity of these diseases underscore the potential public health benefit of an EBV vaccine .", [["EBV", "ORGANISM", 103, 106], ["these diseases", "PROBLEM", 35, 49], ["an EBV vaccine", "TREATMENT", 100, 114], ["diseases", "OBSERVATION", 41, 49]]]], "51cee1e5798d12660f649c4fab7a6b013637c95a": [["INTRODUCTIONAdiponectin is an atypical factor that is present abundantly in the peripheral circulation and is exclusively secreted by adipocytes as a trimer, hexamer, and high-molecular-weight (HMW) multimer.", [["peripheral circulation", "ANATOMY", 80, 102], ["adipocytes", "ANATOMY", 134, 144], ["INTRODUCTIONAdiponectin", "GENE_OR_GENE_PRODUCT", 0, 23], ["peripheral circulation", "MULTI-TISSUE_STRUCTURE", 80, 102], ["adipocytes", "CELL", 134, 144], ["INTRODUCTIONAdiponectin", "PROTEIN", 0, 23], ["adipocytes", "CELL_TYPE", 134, 144], ["high-molecular-weight (HMW) multimer", "PROTEIN", 171, 207], ["an atypical factor", "PROBLEM", 27, 45], ["hexamer", "TEST", 158, 165], ["atypical", "OBSERVATION_MODIFIER", 30, 38], ["peripheral", "ANATOMY_MODIFIER", 80, 90], ["circulation", "ANATOMY", 91, 102]]], ["Adiponectin circulates at the highest plasma concentrations known among adipocytokines/adipokines.", [["plasma", "ANATOMY", 38, 44], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 0, 11], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["adipocytokines", "GENE_OR_GENE_PRODUCT", 72, 86], ["adipokines", "GENE_OR_GENE_PRODUCT", 87, 97], ["Adiponectin", "PROTEIN", 0, 11], ["adipocytokines", "PROTEIN", 72, 86], ["adipokines", "PROTEIN", 87, 97], ["Adiponectin circulates", "PROBLEM", 0, 22], ["adipocytokines/adipokines", "TREATMENT", 72, 97]]], ["1, 2 Cross-sectional research in humans has demonstrated an inverse correlation between plasma adiponectin concentrations and body weight or body mass index (BMI).", [["plasma", "ANATOMY", 88, 94], ["body", "ANATOMY", 126, 130], ["body", "ANATOMY", 141, 145], ["humans", "ORGANISM", 33, 39], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["adiponectin", "GENE_OR_GENE_PRODUCT", 95, 106], ["body", "ORGANISM_SUBDIVISION", 126, 130], ["body", "ORGANISM_SUBDIVISION", 141, 145], ["adiponectin", "PROTEIN", 95, 106], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39], ["plasma adiponectin concentrations", "TREATMENT", 88, 121], ["body weight", "TEST", 126, 137], ["body mass index", "TEST", 141, 156], ["mass", "OBSERVATION", 146, 150]]], ["3, 4 Functionally, adiponectin had been thought to play various metabolically important roles via adipoRs 2 and dead cell opsonization through calreticulin.", [["cell", "ANATOMY", 117, 121], ["adiponectin", "GENE_OR_GENE_PRODUCT", 19, 30], ["adipoRs 2", "GENE_OR_GENE_PRODUCT", 98, 107], ["cell", "CELL", 117, 121], ["calreticulin", "GENE_OR_GENE_PRODUCT", 143, 155], ["adiponectin", "PROTEIN", 19, 30], ["adipoRs 2", "PROTEIN", 98, 107], ["calreticulin", "PROTEIN", 143, 155], ["dead cell opsonization", "TREATMENT", 112, 134], ["dead cell opsonization", "OBSERVATION", 112, 134]]], ["5 Clinical analyses have confirmed that HMW multimer (R6 mers) adiponectin is the active form and that it possesses pleiotropic effects.", [["HMW multimer", "GENE_OR_GENE_PRODUCT", 40, 52], ["R6 mers", "GENE_OR_GENE_PRODUCT", 54, 61], ["adiponectin", "GENE_OR_GENE_PRODUCT", 63, 74], ["HMW multimer", "PROTEIN", 40, 52], ["R6 mers", "PROTEIN", 54, 61], ["adiponectin", "PROTEIN", 63, 74], ["Clinical analyses", "TEST", 2, 19], ["HMW multimer (R6 mers) adiponectin", "TREATMENT", 40, 74]]], ["[6] [7] [8] [9] HMW multimer adiponectin is abundantly present in various tissues such as the heart, vascular endothe-lium, and skeletal muscles by binding with T-cadherin, 10 ,11 a unique glycosylphosphatidylinositol (GPI)-anchored cadherin.", [["tissues", "ANATOMY", 74, 81], ["heart", "ANATOMY", 94, 99], ["vascular endothe-lium", "ANATOMY", 101, 122], ["skeletal muscles", "ANATOMY", 128, 144], ["[6] [7] [8", "CHEMICAL", 0, 10], ["glycosylphosphatidylinositol", "CHEMICAL", 189, 217], ["[6] [7] [8] [9] HMW multimer", "SIMPLE_CHEMICAL", 0, 28], ["adiponectin", "GENE_OR_GENE_PRODUCT", 29, 40], ["tissues", "TISSUE", 74, 81], ["heart", "ORGAN", 94, 99], ["vascular", "MULTI-TISSUE_STRUCTURE", 101, 109], ["endothe-lium", "TISSUE", 110, 122], ["skeletal muscles", "TISSUE", 128, 144], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 161, 171], ["glycosylphosphatidylinositol", "GENE_OR_GENE_PRODUCT", 189, 217], ["cadherin", "GENE_OR_GENE_PRODUCT", 233, 241], ["[6] [7] [8] [9] HMW multimer adiponectin", "PROTEIN", 0, 40], ["T-cadherin, 10 ,11 a unique glycosylphosphatidylinositol (GPI)-anchored cadherin", "PROTEIN", 161, 241], ["anchored cadherin", "TREATMENT", 224, 241], ["adiponectin", "OBSERVATION", 29, 40], ["heart", "ANATOMY", 94, 99], ["vascular", "ANATOMY", 101, 109], ["skeletal muscles", "ANATOMY", 128, 144]]], ["We recently reported that native adiponectin binds to the cells expressing T-cadherin but not other proposed binding partners of adiponectin, such as adipoRs and calreticulin.", [["cells", "ANATOMY", 58, 63], ["adiponectin", "GENE_OR_GENE_PRODUCT", 33, 44], ["cells", "CELL", 58, 63], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 75, 85], ["adiponectin", "GENE_OR_GENE_PRODUCT", 129, 140], ["adipoRs", "GENE_OR_GENE_PRODUCT", 150, 157], ["calreticulin", "GENE_OR_GENE_PRODUCT", 162, 174], ["adiponectin", "PROTEIN", 33, 44], ["T-cadherin", "PROTEIN", 75, 85], ["binding partners", "PROTEIN", 109, 125], ["adiponectin", "PROTEIN", 129, 140], ["adipoRs", "PROTEIN", 150, 157], ["calreticulin", "PROTEIN", 162, 174], ["native adiponectin binds", "PROBLEM", 26, 50], ["adiponectin", "TREATMENT", 129, 140], ["adipoRs", "TREATMENT", 150, 157], ["calreticulin", "TREATMENT", 162, 174]]], ["12 The presence of HMW adiponectin (HMW-APN) in large amounts in these tissues is revealed as essential for adiponectin-mediated cardiovascular protection [13] [14] [15] and skeletal muscle regeneration.", [["tissues", "ANATOMY", 71, 78], ["cardiovascular", "ANATOMY", 129, 143], ["skeletal muscle", "ANATOMY", 174, 189], ["HMW", "GENE_OR_GENE_PRODUCT", 19, 22], ["adiponectin", "GENE_OR_GENE_PRODUCT", 23, 34], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 36, 43], ["tissues", "TISSUE", 71, 78], ["adiponectin", "GENE_OR_GENE_PRODUCT", 108, 119], ["cardiovascular", "ANATOMICAL_SYSTEM", 129, 143], ["[13] [14] [15]", "SIMPLE_CHEMICAL", 155, 169], ["skeletal muscle", "TISSUE", 174, 189], ["HMW adiponectin", "PROTEIN", 19, 34], ["HMW", "PROTEIN", 36, 39], ["APN", "PROTEIN", 40, 43], ["adiponectin", "PROTEIN", 108, 119], ["HMW adiponectin", "TREATMENT", 19, 34], ["large amounts in these tissues", "PROBLEM", 48, 78], ["adiponectin-mediated cardiovascular protection", "TREATMENT", 108, 154], ["skeletal muscle regeneration", "PROBLEM", 174, 202], ["skeletal muscle", "ANATOMY", 174, 189], ["regeneration", "OBSERVATION", 190, 202]]], ["16 Mesenchymal stem/stromal cells (MSCs) are cultured progenitor cells that originally reside in virtually all tissues and are thought to play a role in tissue homeostasis.", [["Mesenchymal stem/stromal cells", "ANATOMY", 3, 33], ["MSCs", "ANATOMY", 35, 39], ["progenitor cells", "ANATOMY", 54, 70], ["tissues", "ANATOMY", 111, 118], ["tissue", "ANATOMY", 153, 159], ["Mesenchymal stem/stromal cells", "CELL", 3, 33], ["MSCs", "CELL", 35, 39], ["progenitor cells", "CELL", 54, 70], ["tissues", "TISSUE", 111, 118], ["tissue", "TISSUE", 153, 159], ["Mesenchymal stem/stromal cells", "CELL_TYPE", 3, 33], ["MSCs", "CELL_TYPE", 35, 39], ["cultured progenitor cells", "CELL_LINE", 45, 70], ["Mesenchymal stem/stromal cells (MSCs", "TREATMENT", 3, 39], ["progenitor cells", "PROBLEM", 54, 70], ["Mesenchymal stem", "ANATOMY", 3, 19], ["stromal cells", "OBSERVATION", 20, 33], ["progenitor cells", "OBSERVATION", 54, 70]]], ["17, 18 A gain in MSCs is beneficial in a variety of diseases, including graft-versus-host disease, 19 heart disease, 20 type 1 diabetes, 21 and type 2 diabetes.", [["MSCs", "ANATOMY", 17, 21], ["graft", "ANATOMY", 72, 77], ["heart", "ANATOMY", 102, 107], ["graft-versus-host disease", "DISEASE", 72, 97], ["heart disease", "DISEASE", 102, 115], ["type 1 diabetes", "DISEASE", 120, 135], ["type 2 diabetes", "DISEASE", 144, 159], ["MSCs", "CELL", 17, 21], ["graft", "TISSUE", 72, 77], ["heart", "ORGAN", 102, 107], ["MSCs", "CELL_TYPE", 17, 21], ["A gain in MSCs", "PROBLEM", 7, 21], ["a variety of diseases", "PROBLEM", 39, 60], ["graft-versus-host disease", "PROBLEM", 72, 97], ["19 heart disease", "PROBLEM", 99, 115], ["type 1 diabetes", "PROBLEM", 120, 135], ["type 2 diabetes", "PROBLEM", 144, 159], ["graft", "OBSERVATION", 72, 77], ["host disease", "OBSERVATION", 85, 97], ["heart", "ANATOMY", 102, 107], ["disease", "OBSERVATION", 108, 115], ["diabetes", "OBSERVATION", 151, 159]]], ["22 According to the public clinical trials database, 23 more than 893 clinical trials have, so far, used MSCs in the treatment of diverse diseases.", [["MSCs", "ANATOMY", 105, 109], ["MSCs", "CELL", 105, 109], ["MSCs", "CELL_TYPE", 105, 109], ["MSCs", "TREATMENT", 105, 109], ["diverse diseases", "PROBLEM", 130, 146], ["diverse", "OBSERVATION_MODIFIER", 130, 137], ["diseases", "OBSERVATION", 138, 146]]], ["However, there is limited knowledge on the alteration of its efficacy by factors in recipients.INTRODUCTIONExosomes are secreted small vesicles (50-150 nm) delimited by a lipid bi-layer generated by inward budding of the limiting membrane during endosome maturation into multivesicular bodies (MVBs) in the endocytic pathway.", [["vesicles", "ANATOMY", 135, 143], ["lipid bi-layer", "ANATOMY", 171, 185], ["membrane", "ANATOMY", 230, 238], ["endosome", "ANATOMY", 246, 254], ["multivesicular bodies", "ANATOMY", 271, 292], ["MVBs", "ANATOMY", 294, 298], ["recipients", "ORGANISM", 84, 94], ["small vesicles", "CELLULAR_COMPONENT", 129, 143], ["membrane", "CELLULAR_COMPONENT", 230, 238], ["endosome", "CELLULAR_COMPONENT", 246, 254], ["multivesicular bodies", "CELLULAR_COMPONENT", 271, 292], ["MVBs", "CELLULAR_COMPONENT", 294, 298], ["secreted small vesicles", "PROBLEM", 120, 143], ["secreted", "OBSERVATION_MODIFIER", 120, 128], ["small", "OBSERVATION_MODIFIER", 129, 134], ["vesicles", "OBSERVATION_MODIFIER", 135, 143], ["limiting membrane", "OBSERVATION", 221, 238], ["endosome maturation", "OBSERVATION", 246, 265], ["multivesicular bodies", "OBSERVATION", 271, 292]]], ["The exosomal release serves as a disposal pathway alternative to the lysosome.", [["exosomal", "ANATOMY", 4, 12], ["lysosome", "ANATOMY", 69, 77], ["lysosome", "CELLULAR_COMPONENT", 69, 77], ["a disposal pathway", "TREATMENT", 31, 49]]], ["24 In addition to this, exosomes are thought to functionally mediate cell-to-cell communication under normal and pathological conditions by transferring active proteins, lipids, mRNAs, and small non-coding RNAs stably in various biofluids 25, 26 and play important roles in metabolic regulation pathways.", [["exosomes", "ANATOMY", 24, 32], ["cell", "ANATOMY", 69, 73], ["cell", "ANATOMY", 77, 81], ["exosomes", "CELL", 24, 32], ["cell", "CELL", 69, 73], ["cell", "CELL", 77, 81], ["exosomes", "CELL_TYPE", 24, 32], ["lipids,", "RNA", 170, 177], ["mRNAs", "RNA", 178, 183], ["small non-coding RNAs", "RNA", 189, 210], ["lipids", "TEST", 170, 176], ["small non-coding RNAs", "PROBLEM", 189, 210], ["small", "OBSERVATION_MODIFIER", 189, 194], ["non-coding RNAs", "OBSERVATION", 195, 210]]], ["27 Especially stem-cell-secreted exosomes are considered to be organ protective by modulating the immune function of the recipient cells 28 or by stimulating the repair of recipient cells.", [["stem-cell", "ANATOMY", 14, 23], ["exosomes", "ANATOMY", 33, 41], ["organ", "ANATOMY", 63, 68], ["cells", "ANATOMY", 131, 136], ["cells", "ANATOMY", 182, 187], ["stem-cell", "CELL", 14, 23], ["exosomes", "CELL", 33, 41], ["organ", "ORGAN", 63, 68], ["recipient cells 28", "CELL", 121, 139], ["cells", "CELL", 182, 187], ["stem-cell-secreted exosomes", "CELL_LINE", 14, 41], ["recipient cells", "CELL_TYPE", 172, 187], ["secreted exosomes", "PROBLEM", 24, 41], ["the repair of recipient cells", "TREATMENT", 158, 187], ["considered to be", "UNCERTAINTY", 46, 62], ["repair", "OBSERVATION", 162, 168], ["recipient cells", "OBSERVATION", 172, 187]]], ["[29] [30] [31] A recent proteomics study indicated that T-cadherin is one of the most abundantly expressed proteins on the cell surface of MSCs.", [["cell surface", "ANATOMY", 123, 135], ["MSCs", "ANATOMY", 139, 143], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 56, 66], ["cell surface", "CELLULAR_COMPONENT", 123, 135], ["MSCs", "CELL", 139, 143], ["T-cadherin", "PROTEIN", 56, 66], ["MSCs", "CELL_TYPE", 139, 143], ["A recent proteomics study", "TEST", 15, 40], ["T-cadherin", "PROBLEM", 56, 66], ["proteins", "OBSERVATION", 107, 115]]], ["32 In our previous studies, we developed a new one-step purification method of the clinically important multimer adiponectin from serum 11 and demonstrated that the use of adiponectin obtained through this procedure enhances exosome biogenesis and secretion.", [["serum", "ANATOMY", 130, 135], ["exosome", "ANATOMY", 225, 232], ["adiponectin", "GENE_OR_GENE_PRODUCT", 113, 124], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["adiponectin", "GENE_OR_GENE_PRODUCT", 172, 183], ["exosome", "CELLULAR_COMPONENT", 225, 232], ["multimer adiponectin", "PROTEIN", 104, 124], ["adiponectin", "PROTEIN", 172, 183], ["adiponectin", "TREATMENT", 172, 183], ["this procedure", "TREATMENT", 201, 215], ["new", "OBSERVATION_MODIFIER", 43, 46], ["exosome biogenesis", "OBSERVATION", 225, 243]]], ["27, 33 Furthermore, the systemic levels of exosome in the peripheral blood decreased by genetic loss of adiponectin and increased by overexpression of adiponectin in vivo.", [["exosome", "ANATOMY", 43, 50], ["peripheral blood", "ANATOMY", 58, 74], ["exosome", "GENE_OR_GENE_PRODUCT", 43, 50], ["peripheral blood", "ORGANISM_SUBSTANCE", 58, 74], ["adiponectin", "GENE_OR_GENE_PRODUCT", 104, 115], ["adiponectin", "GENE_OR_GENE_PRODUCT", 151, 162], ["exosome", "PROTEIN", 43, 50], ["adiponectin", "PROTEIN", 104, 115], ["adiponectin", "PROTEIN", 151, 162], ["the systemic levels", "TEST", 20, 39], ["the peripheral blood", "TEST", 54, 74], ["adiponectin", "TREATMENT", 104, 115], ["adiponectin in vivo", "TREATMENT", 151, 170], ["exosome", "OBSERVATION", 43, 50], ["peripheral", "ANATOMY_MODIFIER", 58, 68], ["blood", "ANATOMY", 69, 74], ["decreased", "OBSERVATION_MODIFIER", 75, 84], ["genetic loss", "OBSERVATION", 88, 100], ["increased", "OBSERVATION_MODIFIER", 120, 129]]], ["27, 33 Adiponectin increased exosome biogenesis.", [["exosome", "ANATOMY", 29, 36], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 7, 18], ["exosome", "GENE_OR_GENE_PRODUCT", 29, 36], ["Adiponectin", "PROTEIN", 7, 18], ["Adiponectin increased exosome biogenesis", "TREATMENT", 7, 47], ["exosome biogenesis", "OBSERVATION", 29, 47]]], ["It required the presence of T-cadherin but not AdipoRs.", [["T-cadherin", "GENE_OR_GENE_PRODUCT", 28, 38], ["AdipoRs", "GENE_OR_GENE_PRODUCT", 47, 54], ["cadherin", "PROTEIN", 30, 38], ["AdipoRs", "PROTEIN", 47, 54], ["T-cadherin", "TREATMENT", 28, 38], ["AdipoRs", "TREATMENT", 47, 54]]], ["16, 27, 33 Adiponectin-induced stimulation of exosomes was also observed in muscle cells and correlated with improved muscle regeneration by adiponectin.", [["exosomes", "ANATOMY", 46, 54], ["muscle cells", "ANATOMY", 76, 88], ["muscle", "ANATOMY", 118, 124], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 11, 22], ["exosomes", "CELL", 46, 54], ["muscle cells", "CELL", 76, 88], ["muscle", "ORGAN", 118, 124], ["adiponectin", "GENE_OR_GENE_PRODUCT", 141, 152], ["Adiponectin", "PROTEIN", 11, 22], ["exosomes", "CELL_TYPE", 46, 54], ["muscle cells", "CELL_TYPE", 76, 88], ["adiponectin", "PROTEIN", 141, 152], ["Adiponectin", "TEST", 11, 22], ["muscle", "ANATOMY", 76, 82], ["muscle", "ANATOMY", 118, 124], ["regeneration", "OBSERVATION", 125, 137]]], ["16, 27 The present study was designed to determine the role of adiponectin in the beneficial effects of human adipose tissue-derived mesen-chymal stem cells (hMSCs) in heart failure.", [["adipose tissue", "ANATOMY", 110, 124], ["mesen-chymal stem cells", "ANATOMY", 133, 156], ["hMSCs", "ANATOMY", 158, 163], ["heart", "ANATOMY", 168, 173], ["heart failure", "DISEASE", 168, 181], ["adiponectin", "GENE_OR_GENE_PRODUCT", 63, 74], ["human", "ORGANISM", 104, 109], ["adipose tissue-derived mesen-chymal stem cells", "CELL", 110, 156], ["hMSCs", "CELL", 158, 163], ["heart", "ORGAN", 168, 173], ["adiponectin", "PROTEIN", 63, 74], ["mesen-chymal stem cells", "CELL_LINE", 133, 156], ["hMSCs", "CELL_TYPE", 158, 163], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["The present study", "TEST", 7, 24], ["adiponectin", "TREATMENT", 63, 74], ["human adipose tissue", "TEST", 104, 124], ["heart failure", "PROBLEM", 168, 181], ["stem cells", "OBSERVATION", 146, 156], ["heart", "ANATOMY", 168, 173], ["failure", "OBSERVATION", 174, 181]]], ["Systemic injection of hMSCs in the load-induced ventricular hypertrophy mouse model improved left ventricular cardiac function.", [["hMSCs", "ANATOMY", 22, 27], ["ventricular", "ANATOMY", 48, 59], ["left ventricular cardiac", "ANATOMY", 93, 117], ["ventricular hypertrophy", "DISEASE", 48, 71], ["hMSCs", "CELL", 22, 27], ["ventricular", "MULTI-TISSUE_STRUCTURE", 48, 59], ["mouse", "ORGANISM", 72, 77], ["left ventricular cardiac", "MULTI-TISSUE_STRUCTURE", 93, 117], ["hMSCs", "CELL_TYPE", 22, 27], ["mouse", "SPECIES", 72, 77], ["mouse", "SPECIES", 72, 77], ["Systemic injection of hMSCs", "TREATMENT", 0, 27], ["ventricular hypertrophy", "PROBLEM", 48, 71], ["ventricular", "ANATOMY", 48, 59], ["hypertrophy", "OBSERVATION", 60, 71], ["improved", "OBSERVATION_MODIFIER", 84, 92], ["left ventricular", "ANATOMY", 93, 109], ["cardiac", "ANATOMY", 110, 117], ["function", "OBSERVATION", 118, 126]]], ["This therapeutic effect of hMSCs largely depended on circulating adiponectin in recipient mice, T-cadherin expression in hMSCs, and ESCRT (endosomal sorting complex required for transport)-mediated exosome production by hMSCs.", [["hMSCs", "ANATOMY", 27, 32], ["hMSCs", "ANATOMY", 121, 126], ["endosomal", "ANATOMY", 139, 148], ["exosome", "ANATOMY", 198, 205], ["hMSCs", "ANATOMY", 220, 225], ["hMSCs", "CELL", 27, 32], ["adiponectin", "GENE_OR_GENE_PRODUCT", 65, 76], ["mice", "ORGANISM", 90, 94], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 96, 106], ["hMSCs", "CELL", 121, 126], ["ESCRT", "GENE_OR_GENE_PRODUCT", 132, 137], ["endosomal", "CELLULAR_COMPONENT", 139, 148], ["exosome", "CELLULAR_COMPONENT", 198, 205], ["hMSCs", "CELL", 220, 225], ["hMSCs", "CELL_TYPE", 27, 32], ["adiponectin", "PROTEIN", 65, 76], ["cadherin", "PROTEIN", 98, 106], ["hMSCs", "CELL_TYPE", 121, 126], ["ESCRT", "PROTEIN", 132, 137], ["endosomal sorting complex", "PROTEIN", 139, 164], ["hMSCs", "CELL_TYPE", 220, 225], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["hMSCs", "PROBLEM", 27, 32], ["circulating adiponectin", "TREATMENT", 53, 76], ["T-cadherin expression in hMSCs", "TREATMENT", 96, 126]]], ["The use of peroxisome-proliferator-activated receptor g (PPARg) agonist or adenoviral overexpression of adiponectin increased plasma adiponectin levels and thereby enhanced MSCinduced cardioprotection, whereas no such protection was noted in adiponectin knockout (AKO) mice.Adiponectin Stimulated Exosome Production by hMSCs through T-cadherinIn our previous study, we revealed that adiponectin enhances the exosome biogenesis accompanying an increase in the particle number of exosomes.", [["plasma", "ANATOMY", 126, 132], ["hMSCs", "ANATOMY", 319, 324], ["exosome", "ANATOMY", 408, 415], ["exosomes", "ANATOMY", 478, 486], ["peroxisome-proliferator-activated receptor g", "GENE_OR_GENE_PRODUCT", 11, 55], ["PPARg", "GENE_OR_GENE_PRODUCT", 57, 62], ["adenoviral", "ORGANISM", 75, 85], ["adiponectin", "GENE_OR_GENE_PRODUCT", 104, 115], ["plasma", "ORGANISM_SUBSTANCE", 126, 132], ["adiponectin", "GENE_OR_GENE_PRODUCT", 133, 144], ["MSCinduced", "SIMPLE_CHEMICAL", 173, 183], ["adiponectin", "GENE_OR_GENE_PRODUCT", 242, 253], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 274, 285], ["Exosome", "GENE_OR_GENE_PRODUCT", 297, 304], ["hMSCs", "CELL", 319, 324], ["T-cadherinIn", "GENE_OR_GENE_PRODUCT", 333, 345], ["adiponectin", "GENE_OR_GENE_PRODUCT", 383, 394], ["exosome", "CELLULAR_COMPONENT", 408, 415], ["exosomes", "CELL", 478, 486], ["PPARg", "PROTEIN", 57, 62], ["adiponectin", "PROTEIN", 104, 115], ["adiponectin", "PROTEIN", 133, 144], ["adiponectin", "PROTEIN", 242, 253], ["Adiponectin", "PROTEIN", 274, 285], ["Exosome", "PROTEIN", 297, 304], ["hMSCs", "CELL_TYPE", 319, 324], ["adiponectin", "PROTEIN", 383, 394], ["exosomes", "CELL_TYPE", 478, 486], ["mice", "SPECIES", 269, 273], ["mice", "SPECIES", 269, 273], ["peroxisome-proliferator", "TREATMENT", 11, 34], ["activated receptor g (PPARg) agonist", "TREATMENT", 35, 71], ["adenoviral overexpression", "TREATMENT", 75, 100], ["adiponectin increased plasma adiponectin levels", "TREATMENT", 104, 151], ["enhanced MSCinduced cardioprotection", "TREATMENT", 164, 200], ["previous study", "TEST", 350, 364], ["exosome biogenesis", "OBSERVATION", 408, 426], ["increase", "OBSERVATION_MODIFIER", 443, 451], ["particle", "OBSERVATION_MODIFIER", 459, 467], ["number", "OBSERVATION_MODIFIER", 468, 474], ["exosomes", "OBSERVATION", 478, 486]]], ["33 First, we measured the particle number of exosomes produced from hMSCs by nanoparticle tracking analysis (NTA).", [["exosomes", "ANATOMY", 45, 53], ["hMSCs", "ANATOMY", 68, 73], ["exosomes", "CELL", 45, 53], ["hMSCs", "CELL", 68, 73], ["NTA", "SIMPLE_CHEMICAL", 109, 112], ["exosomes", "CELL_TYPE", 45, 53], ["hMSCs", "CELL_TYPE", 68, 73], ["particle", "OBSERVATION_MODIFIER", 26, 34]]], ["HMW-APN increased the exosome-sized particle production from hMSCs in vitro ( Figure 1A ).", [["exosome", "ANATOMY", 22, 29], ["hMSCs", "ANATOMY", 61, 66], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 0, 7], ["hMSCs", "CELL", 61, 66], ["HMW", "PROTEIN", 0, 3], ["APN", "PROTEIN", 4, 7], ["hMSCs", "CELL_TYPE", 61, 66], ["APN", "PROBLEM", 4, 7], ["sized", "OBSERVATION_MODIFIER", 30, 35], ["particle", "OBSERVATION_MODIFIER", 36, 44]]], ["We examined T-cadherin protein expression and accumulation of adiponectin in hMSCs (Figure 1B , WCL [whole-cell lysate]).", [["hMSCs", "ANATOMY", 77, 82], ["WCL", "ANATOMY", 96, 99], ["whole-cell lysate", "ANATOMY", 101, 118], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 12, 22], ["adiponectin", "GENE_OR_GENE_PRODUCT", 62, 73], ["hMSCs", "CELL", 77, 82], ["Figure 1B", "CELL", 84, 93], ["WCL", "CELL", 96, 99], ["whole-cell lysate", "CELL", 101, 118], ["T-cadherin protein", "PROTEIN", 12, 30], ["adiponectin", "PROTEIN", 62, 73], ["hMSCs", "CELL_TYPE", 77, 82], ["WCL", "PROTEIN", 96, 99], ["adiponectin in hMSCs", "PROBLEM", 62, 82], ["WCL", "TEST", 96, 99], ["whole-cell lysate", "TREATMENT", 101, 118]]], ["Western blot analysis confirmed that hMSCs express T-cadherin, as reported previously, 32 and accumulate HMW-APN purified from mouse serum following 48-h incubation ( Figure 1B, WCL) .", [["hMSCs", "ANATOMY", 37, 42], ["serum", "ANATOMY", 133, 138], ["hMSCs", "CELL", 37, 42], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 51, 61], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 105, 112], ["mouse", "ORGANISM", 127, 132], ["serum", "ORGANISM_SUBSTANCE", 133, 138], ["hMSCs", "CELL_TYPE", 37, 42], ["cadherin", "PROTEIN", 53, 61], ["HMW", "PROTEIN", 105, 108], ["APN", "PROTEIN", 109, 112], ["mouse", "SPECIES", 127, 132], ["mouse", "SPECIES", 127, 132], ["Western blot analysis", "TEST", 0, 21], ["mouse serum", "TEST", 127, 138]]], ["11 Next, we tested whether adiponectin enhanced exosome production from hMSCs ( Figure 1B , Exosome).", [["exosome", "ANATOMY", 48, 55], ["hMSCs", "ANATOMY", 72, 77], ["adiponectin", "GENE_OR_GENE_PRODUCT", 27, 38], ["exosome", "CELLULAR_COMPONENT", 48, 55], ["hMSCs", "CELL", 72, 77], ["Exosome", "GENE_OR_GENE_PRODUCT", 92, 99], ["adiponectin", "PROTEIN", 27, 38], ["hMSCs", "CELL_TYPE", 72, 77], ["hMSCs", "TEST", 72, 77]]], ["HMW-APN markedly increased exosome production, judging from the levels of classic exosome markers, such as syntenin, milk fat globule-epidermal growth factor 8 (MFG-E8), CD63, and tumor susceptibility gene 101 (Tsg101) in exosome fractions obtained from the conditioned medium of hMSCs ( Figure 1B , Exosome), which is similar to the results we previously reported in cultured endothelial 33 and muscle cells.", [["exosome", "ANATOMY", 27, 34], ["exosome", "ANATOMY", 82, 89], ["tumor", "ANATOMY", 180, 185], ["exosome fractions", "ANATOMY", 222, 239], ["hMSCs", "ANATOMY", 280, 285], ["endothelial 33", "ANATOMY", 377, 391], ["muscle cells", "ANATOMY", 396, 408], ["tumor", "DISEASE", 180, 185], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 0, 7], ["exosome", "ORGANISM_SUBSTANCE", 27, 34], ["syntenin", "GENE_OR_GENE_PRODUCT", 107, 115], ["milk fat globule-epidermal growth factor 8", "GENE_OR_GENE_PRODUCT", 117, 159], ["MFG-E8", "GENE_OR_GENE_PRODUCT", 161, 167], ["CD63", "GENE_OR_GENE_PRODUCT", 170, 174], ["tumor susceptibility gene 101", "GENE_OR_GENE_PRODUCT", 180, 209], ["Tsg101)", "GENE_OR_GENE_PRODUCT", 211, 218], ["exosome", "ORGANISM_SUBSTANCE", 222, 229], ["hMSCs", "CELL", 280, 285], ["Figure 1B", "CELL", 288, 297], ["Exosome", "GENE_OR_GENE_PRODUCT", 300, 307], ["endothelial 33", "CELL", 377, 391], ["muscle cells", "CELL", 396, 408], ["HMW", "PROTEIN", 0, 3], ["APN", "PROTEIN", 4, 7], ["exosome markers", "PROTEIN", 82, 97], ["syntenin", "PROTEIN", 107, 115], ["milk fat globule-epidermal growth factor 8", "PROTEIN", 117, 159], ["MFG", "PROTEIN", 161, 164], ["E8", "PROTEIN", 165, 167], ["CD63", "PROTEIN", 170, 174], ["tumor susceptibility gene 101", "DNA", 180, 209], ["Tsg101", "DNA", 211, 217], ["hMSCs", "CELL_TYPE", 280, 285], ["cultured endothelial 33", "CELL_LINE", 368, 391], ["muscle cells", "CELL_TYPE", 396, 408], ["APN markedly increased exosome production", "PROBLEM", 4, 45], ["classic exosome markers", "TEST", 74, 97], ["syntenin", "TEST", 107, 115], ["milk fat globule", "TEST", 117, 133], ["epidermal growth factor", "TEST", 134, 157], ["MFG", "TEST", 161, 164], ["CD63", "TEST", 170, 174], ["tumor susceptibility gene", "TEST", 180, 205], ["Tsg", "TEST", 211, 214], ["exosome fractions", "TEST", 222, 239], ["markedly", "OBSERVATION_MODIFIER", 8, 16], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["exosome production", "OBSERVATION", 27, 45], ["exosome markers", "OBSERVATION", 82, 97], ["tumor", "OBSERVATION", 180, 185], ["muscle cells", "ANATOMY", 396, 408]]], ["16 In this condition, calnexin, an endoplasmic reticulum protein, was not detected in the exosome fraction, indicating successful exosome isolation ( Figure 1B , Exosome).", [["endoplasmic reticulum", "ANATOMY", 35, 56], ["exosome", "ANATOMY", 90, 97], ["exosome", "ANATOMY", 130, 137], ["calnexin", "GENE_OR_GENE_PRODUCT", 22, 30], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 35, 56], ["calnexin", "PROTEIN", 22, 30], ["endoplasmic reticulum protein", "PROTEIN", 35, 64], ["Exosome", "PROTEIN", 162, 169], ["calnexin", "TREATMENT", 22, 30], ["an endoplasmic reticulum protein", "TEST", 32, 64], ["successful exosome isolation", "TREATMENT", 119, 147], ["successful", "OBSERVATION_MODIFIER", 119, 129], ["exosome isolation", "OBSERVATION", 130, 147]]], ["The HMW-APN-mediated exosome production was dose dependent within the range of physiological plasma HMW-APN concentrations in control subjects ( Figure 1C ).", [["exosome", "ANATOMY", 21, 28], ["plasma", "ANATOMY", 93, 99], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 4, 11], ["exosome", "CELLULAR_COMPONENT", 21, 28], ["plasma", "ORGANISM_SUBSTANCE", 93, 99], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 100, 107], ["HMW", "PROTEIN", 4, 7], ["APN", "PROTEIN", 8, 11], ["exosome", "PROTEIN", 21, 28], ["APN", "PROTEIN", 104, 107], ["The HMW", "TEST", 0, 7], ["APN-mediated exosome production", "TREATMENT", 8, 39], ["dose dependent", "PROBLEM", 44, 58], ["physiological plasma HMW", "TREATMENT", 79, 103], ["APN concentrations", "PROBLEM", 104, 122]]], ["Similar to the results reported in endothelial 33 and muscle 16 cells, the accumulation of HMW-APN was significantly reduced by T-cadherin knockdown ( Figures 1D and 1E ), which was accompanied by a reduction of HMW-APN-mediated exosome production ( Figure 1E ).Increase of Circulating Exosomes by Intravenous hMSC Injection Accumulating in LungPrevious studies have demonstrated that the vast majority of intravenously (i.v.) injected MSCs accumulate in the lung microvasculature; 34, 35 hence, the therapeutic effects of hMSCs in this study are supposed to rely on secreted factors.", [["endothelial 33", "ANATOMY", 35, 49], ["muscle 16 cells", "ANATOMY", 54, 69], ["exosome", "ANATOMY", 229, 236], ["Exosomes", "ANATOMY", 286, 294], ["hMSC", "ANATOMY", 310, 314], ["intravenously", "ANATOMY", 406, 419], ["MSCs", "ANATOMY", 436, 440], ["lung microvasculature", "ANATOMY", 459, 480], ["hMSCs", "ANATOMY", 523, 528], ["endothelial 33", "CELL", 35, 49], ["muscle 16 cells", "CELL", 54, 69], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 91, 98], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 128, 138], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 212, 219], ["exosome", "CELLULAR_COMPONENT", 229, 236], ["Exosomes", "CELL", 286, 294], ["hMSC", "CELL", 310, 314], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 406, 419], ["MSCs", "CELL", 436, 440], ["lung microvasculature", "MULTI-TISSUE_STRUCTURE", 459, 480], ["hMSCs", "CELL", 523, 528], ["endothelial 33 and muscle 16 cells", "CELL_LINE", 35, 69], ["HMW", "PROTEIN", 91, 94], ["APN", "PROTEIN", 95, 98], ["cadherin", "PROTEIN", 130, 138], ["HMW", "PROTEIN", 212, 215], ["APN", "PROTEIN", 216, 219], ["exosome", "PROTEIN", 229, 236], ["Circulating Exosomes", "CELL_TYPE", 274, 294], ["MSCs", "CELL_TYPE", 436, 440], ["hMSCs", "CELL_TYPE", 523, 528], ["secreted factors", "PROTEIN", 567, 583], ["the accumulation of HMW", "PROBLEM", 71, 94], ["APN", "PROBLEM", 95, 98], ["a reduction of HMW", "PROBLEM", 197, 215], ["APN", "PROBLEM", 216, 219], ["Circulating Exosomes", "TREATMENT", 274, 294], ["Intravenous hMSC Injection", "TREATMENT", 298, 324], ["LungPrevious studies", "TEST", 341, 361], ["hMSCs", "PROBLEM", 523, 528], ["this study", "TEST", 532, 542], ["muscle", "ANATOMY", 54, 60], ["reduction", "OBSERVATION_MODIFIER", 199, 208], ["Circulating Exosomes", "OBSERVATION", 274, 294], ["lung", "ANATOMY", 459, 463], ["microvasculature", "ANATOMY_MODIFIER", 464, 480]]], ["36, 37 To clarify the localization of injected hMSCs, we i.v. injected PKH26-labeled hMSCs for transverse aortic constriction (TAC) in mice and evaluated the sections in the lung, spleen, heart, and liver (Figures 2A and 2B ).", [["hMSCs", "ANATOMY", 47, 52], ["hMSCs", "ANATOMY", 85, 90], ["aortic", "ANATOMY", 106, 112], ["sections", "ANATOMY", 158, 166], ["lung", "ANATOMY", 174, 178], ["spleen", "ANATOMY", 180, 186], ["heart", "ANATOMY", 188, 193], ["liver", "ANATOMY", 199, 204], ["TAC", "CHEMICAL", 127, 130], ["PKH26", "CHEMICAL", 71, 76], ["hMSCs", "CELL", 47, 52], ["PKH26", "SIMPLE_CHEMICAL", 71, 76], ["hMSCs", "CELL", 85, 90], ["transverse aortic", "MULTI-TISSUE_STRUCTURE", 95, 112], ["mice", "ORGANISM", 135, 139], ["lung", "ORGAN", 174, 178], ["spleen", "ORGAN", 180, 186], ["heart", "ORGAN", 188, 193], ["liver", "ORGAN", 199, 204], ["hMSCs", "CELL_TYPE", 47, 52], ["PKH26-labeled hMSCs", "CELL_LINE", 71, 90], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139], ["injected hMSCs", "TREATMENT", 38, 52], ["transverse aortic constriction (TAC)", "TREATMENT", 95, 131], ["transverse aortic", "ANATOMY", 95, 112], ["constriction", "OBSERVATION", 113, 125], ["lung", "ANATOMY", 174, 178], ["spleen", "ANATOMY", 180, 186], ["heart", "ANATOMY", 188, 193], ["liver", "ANATOMY", 199, 204]]], ["In accordance with the previous studies, 38 injected hMSCs were densely localized to the lung, although such dense images were not observed in other organs, like the spleen, heart, and liver ( Figure 2B ).Increase of Circulating Exosomes by Intravenous hMSC Injection Accumulating in LungWhen we checked the number of circulating exosomes by NTA, the injection of hMSCs significantly increased the exosome-sized (50-150 nm) particle numbers in circulation at 4 h after systemic hMSC injection ( Figure 2C ).", [["hMSCs", "ANATOMY", 53, 58], ["lung", "ANATOMY", 89, 93], ["organs", "ANATOMY", 149, 155], ["spleen", "ANATOMY", 166, 172], ["heart", "ANATOMY", 174, 179], ["liver", "ANATOMY", 185, 190], ["Exosomes", "ANATOMY", 229, 237], ["hMSC", "ANATOMY", 253, 257], ["exosomes", "ANATOMY", 330, 338], ["hMSCs", "ANATOMY", 364, 369], ["exosome", "ANATOMY", 398, 405], ["hMSC", "ANATOMY", 478, 482], ["NTA", "CHEMICAL", 342, 345], ["NTA", "CHEMICAL", 342, 345], ["hMSCs", "CELL", 53, 58], ["lung", "ORGAN", 89, 93], ["organs", "ORGAN", 149, 155], ["spleen", "ORGAN", 166, 172], ["heart", "ORGAN", 174, 179], ["liver", "ORGAN", 185, 190], ["Exosomes", "CELL", 229, 237], ["hMSC", "CELL", 253, 257], ["exosomes", "CELL", 330, 338], ["NTA", "SIMPLE_CHEMICAL", 342, 345], ["hMSCs", "CELL", 364, 369], ["hMSC", "CELL", 478, 482], ["hMSCs", "CELL_TYPE", 53, 58], ["Circulating Exosomes", "CELL_TYPE", 217, 237], ["circulating exosomes", "CELL_TYPE", 318, 338], ["hMSCs", "CELL_TYPE", 364, 369], ["the previous studies", "TEST", 19, 39], ["38 injected hMSCs", "TREATMENT", 41, 58], ["such dense images", "TEST", 104, 121], ["Circulating Exosomes", "TREATMENT", 217, 237], ["Intravenous hMSC Injection", "TREATMENT", 241, 267], ["the injection of hMSCs", "TREATMENT", 347, 369], ["systemic hMSC injection", "TREATMENT", 469, 492], ["lung", "ANATOMY", 89, 93], ["spleen", "ANATOMY", 166, 172], ["heart", "ANATOMY", 174, 179], ["liver", "ANATOMY", 185, 190], ["sized", "OBSERVATION_MODIFIER", 406, 411], ["circulation", "ANATOMY", 444, 455]]], ["To determine the amount of exosome specifically produced by hMSCs transplanted in vivo, we developed a new method to detect hMSC-derived exosomes specifically from blood circulation in mice.", [["exosome", "ANATOMY", 27, 34], ["hMSCs", "ANATOMY", 60, 65], ["hMSC", "ANATOMY", 124, 128], ["exosomes", "ANATOMY", 137, 145], ["blood", "ANATOMY", 164, 169], ["exosome", "CELLULAR_COMPONENT", 27, 34], ["hMSCs", "CELL", 60, 65], ["hMSC", "CELL", 124, 128], ["exosomes", "CELL", 137, 145], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["mice", "ORGANISM", 185, 189], ["exosome", "PROTEIN", 27, 34], ["hMSCs", "CELL_TYPE", 60, 65], ["hMSC", "CELL_TYPE", 124, 128], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 185, 189], ["blood circulation", "TEST", 164, 181], ["exosome", "OBSERVATION", 27, 34]]], ["Gaussia luciferase fused with MFG-E8 (gLuc-MFG-E8) was successfully used to label exosomes in vitro and to monitor labeled exosomes in the circulation using small volumes of plasma.", [["exosomes", "ANATOMY", 82, 90], ["exosomes", "ANATOMY", 123, 131], ["plasma", "ANATOMY", 174, 180], ["luciferase", "GENE_OR_GENE_PRODUCT", 8, 18], ["MFG-E8", "GENE_OR_GENE_PRODUCT", 30, 36], ["gLuc-MFG-E8", "GENE_OR_GENE_PRODUCT", 38, 49], ["exosomes", "CELL", 82, 90], ["exosomes", "CELL", 123, 131], ["plasma", "ORGANISM_SUBSTANCE", 174, 180], ["Gaussia luciferase", "PROTEIN", 0, 18], ["MFG", "PROTEIN", 30, 33], ["E8", "DNA", 34, 36], ["gLuc", "PROTEIN", 38, 42], ["MFG", "PROTEIN", 43, 46], ["E8", "DNA", 47, 49], ["exosomes", "CELL_TYPE", 82, 90], ["labeled exosomes", "CELL_TYPE", 115, 131], ["MFG", "TEST", 30, 33], ["gLuc", "TEST", 38, 42], ["small volumes of plasma", "TREATMENT", 157, 180]]], ["39, 40 We exploited this technique to label exosomes produced by the transplanted hMSCs by introducing gLuc-MFG-E8 cDNA into hMSCs (Figures 2D and 2E).", [["exosomes", "ANATOMY", 44, 52], ["hMSCs", "ANATOMY", 82, 87], ["hMSCs", "ANATOMY", 125, 130], ["exosomes", "CELL", 44, 52], ["hMSCs", "CELL", 82, 87], ["gLuc", "GENE_OR_GENE_PRODUCT", 103, 107], ["hMSCs", "CELL", 125, 130], ["transplanted hMSCs", "CELL_LINE", 69, 87], ["gLuc-MFG-E8 cDNA", "DNA", 103, 119], ["hMSCs", "CELL_TYPE", 125, 130], ["this technique", "TREATMENT", 20, 34], ["the transplanted hMSCs", "TREATMENT", 65, 87], ["gLuc", "TEST", 103, 107]]], ["Exosome-associated gLuc activity was successfully monitored during the time course study following intravenous injection of gLuc-MFG-E8-expressing hMSCs ( Figure 2E ).", [["intravenous", "ANATOMY", 99, 110], ["hMSCs", "ANATOMY", 147, 152], ["Exosome", "GENE_OR_GENE_PRODUCT", 0, 7], ["gLuc", "GENE_OR_GENE_PRODUCT", 19, 23], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 99, 110], ["gLuc-MFG-E8", "GENE_OR_GENE_PRODUCT", 124, 135], ["hMSCs", "CELL", 147, 152], ["Figure 2E", "CELL", 155, 164], ["gLuc", "PROTEIN", 19, 23], ["gLuc", "PROTEIN", 124, 128], ["MFG", "PROTEIN", 129, 132], ["E8", "PROTEIN", 133, 135], ["hMSCs", "CELL_TYPE", 147, 152], ["associated gLuc activity", "PROBLEM", 8, 32], ["intravenous injection", "TREATMENT", 99, 120], ["gLuc-MFG", "TREATMENT", 124, 132]]], ["The activity increased with injection of higher cell numbers and gradually decreased within 3 days ( Figure 2G ).", [["cell", "ANATOMY", 48, 52], ["cell", "CELL", 48, 52], ["injection of higher cell numbers", "TREATMENT", 28, 60], ["activity", "OBSERVATION_MODIFIER", 4, 12], ["increased", "OBSERVATION_MODIFIER", 13, 22]]], ["Since exosome-associated gLuc activity in adenovirus-infected cells was in parallel with the growth of hMSCs during 72-h culture after infection in vitro ( Figure S1 ), it is likely that the observed in vivo change in the exosomes is not due to loss of gLuc-MFG-E8 gene expression in hMSCs but rather to the decrease in viability or exosome production by hMSCs.", [["cells", "ANATOMY", 62, 67], ["hMSCs", "ANATOMY", 103, 108], ["exosomes", "ANATOMY", 222, 230], ["hMSCs", "ANATOMY", 284, 289], ["exosome", "ANATOMY", 333, 340], ["hMSCs", "ANATOMY", 355, 360], ["infection", "DISEASE", 135, 144], ["gLuc", "GENE_OR_GENE_PRODUCT", 25, 29], ["adenovirus", "ORGANISM", 42, 52], ["cells", "CELL", 62, 67], ["hMSCs", "CELL", 103, 108], ["exosomes", "CELL", 222, 230], ["gLuc", "GENE_OR_GENE_PRODUCT", 253, 257], ["MFG-E8", "GENE_OR_GENE_PRODUCT", 258, 264], ["hMSCs", "CELL", 284, 289], ["exosome", "CELLULAR_COMPONENT", 333, 340], ["hMSCs", "CELL", 355, 360], ["gLuc", "PROTEIN", 25, 29], ["adenovirus-infected cells", "CELL_TYPE", 42, 67], ["hMSCs", "CELL_TYPE", 103, 108], ["exosomes", "CELL_TYPE", 222, 230], ["gLuc", "PROTEIN", 253, 257], ["MFG", "PROTEIN", 258, 261], ["E8 gene", "DNA", 262, 269], ["hMSCs", "CELL_TYPE", 284, 289], ["hMSCs", "CELL_TYPE", 355, 360], ["exosome-associated gLuc activity in adenovirus", "PROBLEM", 6, 52], ["infected cells", "PROBLEM", 53, 67], ["the growth of hMSCs", "PROBLEM", 89, 108], ["infection", "PROBLEM", 135, 144], ["loss of gLuc", "PROBLEM", 245, 257], ["gene expression in hMSCs", "PROBLEM", 265, 289], ["the decrease in viability", "PROBLEM", 304, 329], ["gLuc activity", "OBSERVATION", 25, 38], ["infected cells", "OBSERVATION", 53, 67], ["is likely", "UNCERTAINTY", 172, 181], ["decrease", "OBSERVATION_MODIFIER", 308, 316], ["exosome production", "OBSERVATION", 333, 351]]], ["In addition, the increase of circulating exosomes by the hMSCs was also detected by western blot analysis of exosome fractions obtained by ultracentrifugation using exosome marker antibodies ( Figure 2G ).", [["exosomes", "ANATOMY", 41, 49], ["hMSCs", "ANATOMY", 57, 62], ["exosome fractions", "ANATOMY", 109, 126], ["exosome", "ANATOMY", 165, 172], ["exosomes", "CELL", 41, 49], ["hMSCs", "CELL", 57, 62], ["circulating exosomes", "CELL_TYPE", 29, 49], ["hMSCs", "CELL_TYPE", 57, 62], ["exosome marker antibodies", "PROTEIN", 165, 190], ["Figure 2G", "PROTEIN", 193, 202], ["exosome fractions", "TEST", 109, 126], ["exosome marker antibodies", "TEST", 165, 190], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["circulating exosomes", "OBSERVATION", 29, 49]]], ["Exosome markers, such as ALG-2 interacting protein (Alix) and Tsg101 (antibodies of these can detect both human and mouse proteins), also significantly increased following hMSC injection ( Figure 2G ).", [["hMSC", "ANATOMY", 172, 176], ["Exosome", "GENE_OR_GENE_PRODUCT", 0, 7], ["ALG-2", "GENE_OR_GENE_PRODUCT", 25, 30], ["Alix", "GENE_OR_GENE_PRODUCT", 52, 56], ["Tsg101", "GENE_OR_GENE_PRODUCT", 62, 68], ["human", "ORGANISM", 106, 111], ["mouse", "ORGANISM", 116, 121], ["hMSC", "CELL", 172, 176], ["Exosome markers", "PROTEIN", 0, 15], ["ALG-2 interacting protein", "PROTEIN", 25, 50], ["Alix", "PROTEIN", 52, 56], ["Tsg101", "PROTEIN", 62, 68], ["antibodies", "PROTEIN", 70, 80], ["human and mouse proteins", "PROTEIN", 106, 130], ["human", "SPECIES", 106, 111], ["mouse", "SPECIES", 116, 121], ["human", "SPECIES", 106, 111], ["mouse", "SPECIES", 116, 121], ["Exosome markers", "TEST", 0, 15], ["ALG", "TEST", 25, 28], ["Tsg101 (antibodies", "TREATMENT", 62, 80], ["hMSC injection", "TREATMENT", 172, 186]]], ["These findings suggest that not only hMSC-derived exosomes but also whole amounts of exosome in blood increased by hMSC injection.Injection of hMSCs Ameliorated Cardiac Dysfunction in Pressure-Overload-Induced Heart FailureNext, we evaluated the therapeutic effect of hMSCs in a pressureoverload-induced heart failure animal model.", [["hMSC", "ANATOMY", 37, 41], ["exosomes", "ANATOMY", 50, 58], ["exosome", "ANATOMY", 85, 92], ["blood", "ANATOMY", 96, 101], ["hMSC", "ANATOMY", 115, 119], ["hMSCs", "ANATOMY", 143, 148], ["Cardiac", "ANATOMY", 161, 168], ["Heart", "ANATOMY", 210, 215], ["hMSCs", "ANATOMY", 268, 273], ["heart", "ANATOMY", 304, 309], ["Cardiac Dysfunction", "DISEASE", 161, 180], ["pressureoverload", "CHEMICAL", 279, 295], ["heart failure", "DISEASE", 304, 317], ["hMSC", "CELL", 37, 41], ["exosomes", "CELL", 50, 58], ["exosome", "GENE_OR_GENE_PRODUCT", 85, 92], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["hMSC", "CELL", 115, 119], ["hMSCs", "CELL", 143, 148], ["Cardiac", "ORGAN", 161, 168], ["hMSCs", "CELL", 268, 273], ["heart", "ORGAN", 304, 309], ["hMSC", "CELL_TYPE", 37, 41], ["exosome", "PROTEIN", 85, 92], ["hMSC", "CELL_TYPE", 115, 119], ["hMSCs", "CELL_TYPE", 143, 148], ["hMSCs", "CELL_TYPE", 268, 273], ["exosome in blood", "PROBLEM", 85, 101], ["hMSC injection", "TREATMENT", 115, 129], ["hMSCs", "PROBLEM", 143, 148], ["Cardiac Dysfunction", "PROBLEM", 161, 180], ["Pressure-Overload", "PROBLEM", 184, 201], ["Induced Heart FailureNext", "PROBLEM", 202, 227], ["hMSCs", "PROBLEM", 268, 273], ["a pressureoverload", "PROBLEM", 277, 295], ["heart failure animal model", "PROBLEM", 304, 330], ["exosome", "OBSERVATION", 85, 92], ["Cardiac", "ANATOMY", 161, 168], ["Dysfunction", "OBSERVATION", 169, 180], ["Pressure", "OBSERVATION_MODIFIER", 184, 192], ["Overload", "OBSERVATION", 193, 201], ["Heart", "ANATOMY", 210, 215], ["heart", "ANATOMY", 304, 309], ["failure", "OBSERVATION", 310, 317]]], ["The model was prepared by TAC, a procedure known to induce chronic heart failure.Injection of hMSCs Ameliorated Cardiac Dysfunction in Pressure-Overload-Induced Heart FailureTo evaluate the therapeutic efficacy of hMSCs, we injected hMSCs via the lateral tail vein within a period of 2 weeks at 2-to 3-day intervals ( Figure 3A ).", [["heart", "ANATOMY", 67, 72], ["hMSCs", "ANATOMY", 94, 99], ["Cardiac", "ANATOMY", 112, 119], ["Heart", "ANATOMY", 161, 166], ["hMSCs", "ANATOMY", 214, 219], ["hMSCs", "ANATOMY", 233, 238], ["lateral tail vein", "ANATOMY", 247, 264], ["TAC", "CHEMICAL", 26, 29], ["heart failure", "DISEASE", 67, 80], ["Cardiac Dysfunction", "DISEASE", 112, 131], ["TAC", "CHEMICAL", 26, 29], ["TAC", "SIMPLE_CHEMICAL", 26, 29], ["heart", "ORGAN", 67, 72], ["hMSCs", "CELL", 94, 99], ["Cardiac", "ORGAN", 112, 119], ["hMSCs", "CELL", 214, 219], ["hMSCs", "CELL", 233, 238], ["lateral tail vein", "MULTI-TISSUE_STRUCTURE", 247, 264], ["hMSCs", "CELL_TYPE", 94, 99], ["hMSCs", "CELL_TYPE", 214, 219], ["hMSCs", "CELL_TYPE", 233, 238], ["a procedure", "TREATMENT", 31, 42], ["chronic heart failure", "PROBLEM", 59, 80], ["Injection of hMSCs", "TREATMENT", 81, 99], ["Cardiac Dysfunction", "PROBLEM", 112, 131], ["Pressure-Overload", "PROBLEM", 135, 152], ["Induced Heart FailureTo", "PROBLEM", 153, 176], ["hMSCs", "PROBLEM", 214, 219], ["hMSCs via the lateral tail vein", "TREATMENT", 233, 264], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["heart", "ANATOMY", 67, 72], ["failure", "OBSERVATION", 73, 80], ["Cardiac", "ANATOMY", 112, 119], ["Dysfunction", "OBSERVATION", 120, 131], ["Pressure", "OBSERVATION_MODIFIER", 135, 143], ["Overload", "OBSERVATION", 144, 152], ["Heart", "ANATOMY", 161, 166], ["lateral", "ANATOMY_MODIFIER", 247, 254], ["tail vein", "ANATOMY", 255, 264]]], ["Cell dose and intervals were determined according to the disappearance of hMSC-produced exosomes ( Figures 2E and 2F) , as well as a pilot dose-finding study ( Figure S2 ).", [["Cell", "ANATOMY", 0, 4], ["hMSC", "ANATOMY", 74, 78], ["exosomes", "ANATOMY", 88, 96], ["Cell", "CELL", 0, 4], ["hMSC", "CELL", 74, 78], ["exosomes", "CELL", 88, 96], ["hMSC", "CELL_LINE", 74, 78], ["exosomes", "CELL_TYPE", 88, 96]]], ["Serum exosomes fractionated by ultracentrifugation were subjected to western blotting.", [["Serum exosomes", "ANATOMY", 0, 14], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["exosomes", "ORGANISM_SUBSTANCE", 6, 14], ["Serum exosomes", "TEST", 0, 14], ["ultracentrifugation", "TEST", 31, 50]]], ["Interestingly, Tsg101 was markedly decreased following TAC ( Figure 3B ).", [["TAC", "CHEMICAL", 55, 58], ["TAC", "CHEMICAL", 55, 58], ["Tsg101", "GENE_OR_GENE_PRODUCT", 15, 21], ["Tsg101", "PROTEIN", 15, 21], ["Tsg", "TEST", 15, 18], ["TAC ( Figure 3B", "TREATMENT", 55, 70], ["markedly", "OBSERVATION_MODIFIER", 26, 34], ["decreased", "OBSERVATION_MODIFIER", 35, 44]]], ["Injection of hMSCs significantly increased the amounts of exosome markers ( Figure 3B ), and such effects appeared to be hMSC cell number dependent ( Figure S2 ).Injection of hMSCs Ameliorated Cardiac Dysfunction in Pressure-Overload-Induced Heart FailureWe evaluated cardiac function in the aforementioned mice by ultrasonic echocardiography ( Figure 3C ).", [["hMSCs", "ANATOMY", 13, 18], ["exosome", "ANATOMY", 58, 65], ["hMSC cell", "ANATOMY", 121, 130], ["hMSCs", "ANATOMY", 175, 180], ["Cardiac", "ANATOMY", 193, 200], ["Heart", "ANATOMY", 242, 247], ["cardiac", "ANATOMY", 268, 275], ["Cardiac Dysfunction", "DISEASE", 193, 212], ["hMSCs", "CELL", 13, 18], ["hMSC cell", "CELL", 121, 130], ["hMSCs", "CELL", 175, 180], ["cardiac", "ORGAN", 268, 275], ["mice", "ORGANISM", 307, 311], ["hMSCs", "CELL_TYPE", 13, 18], ["exosome markers", "PROTEIN", 58, 73], ["Figure 3B", "PROTEIN", 76, 85], ["hMSCs", "CELL_TYPE", 175, 180], ["mice", "SPECIES", 307, 311], ["mice", "SPECIES", 307, 311], ["Injection of hMSCs", "TREATMENT", 0, 18], ["exosome markers", "TEST", 58, 73], ["Injection of hMSCs", "TREATMENT", 162, 180], ["Cardiac Dysfunction", "PROBLEM", 193, 212], ["Pressure-Overload", "PROBLEM", 216, 233], ["Induced Heart FailureWe", "PROBLEM", 234, 257], ["cardiac function", "TEST", 268, 284], ["ultrasonic echocardiography", "TEST", 315, 342], ["amounts", "OBSERVATION_MODIFIER", 47, 54], ["exosome markers", "OBSERVATION", 58, 73], ["hMSC cell", "OBSERVATION", 121, 130], ["Cardiac", "ANATOMY", 193, 200], ["Dysfunction", "OBSERVATION", 201, 212], ["Pressure", "OBSERVATION_MODIFIER", 216, 224], ["Overload", "OBSERVATION", 225, 233], ["Heart", "ANATOMY", 242, 247]]], ["TAC resulted in a significant decrease in cardiac function, including ejection fraction (EF) and fractional shortening (FS) ( Figure 3D ), and i.v. injected hMSCs improved these cardiac functions ( Figure 3D ).", [["cardiac", "ANATOMY", 42, 49], ["hMSCs", "ANATOMY", 157, 162], ["cardiac", "ANATOMY", 178, 185], ["TAC", "CHEMICAL", 0, 3], ["TAC", "CHEMICAL", 0, 3], ["TAC", "SIMPLE_CHEMICAL", 0, 3], ["cardiac", "ORGAN", 42, 49], ["hMSCs", "CELL", 157, 162], ["cardiac", "ORGAN", 178, 185], ["hMSCs", "CELL_TYPE", 157, 162], ["TAC", "TREATMENT", 0, 3], ["a significant decrease in cardiac function", "PROBLEM", 16, 58], ["ejection fraction", "TEST", 70, 87], ["EF", "TEST", 89, 91], ["fractional shortening", "PROBLEM", 97, 118], ["FS", "TEST", 120, 122], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["decrease", "OBSERVATION_MODIFIER", 30, 38], ["cardiac", "ANATOMY", 42, 49], ["function", "OBSERVATION", 50, 58], ["ejection fraction", "OBSERVATION", 70, 87], ["fractional shortening", "OBSERVATION", 97, 118]]], ["TAC also resulted in a significant increase in heart weight, compared to sham operation, and injection of hMSCs tended to decrease the heart-weight/tibialength ratio ( Figure 3E) .", [["heart", "ANATOMY", 47, 52], ["hMSCs", "ANATOMY", 106, 111], ["heart", "ANATOMY", 135, 140], ["TAC", "CHEMICAL", 0, 3], ["TAC", "CHEMICAL", 0, 3], ["TAC", "SIMPLE_CHEMICAL", 0, 3], ["heart", "ORGAN", 47, 52], ["hMSCs", "CELL", 106, 111], ["heart", "ORGAN", 135, 140], ["hMSCs", "CELL_TYPE", 106, 111], ["TAC", "TREATMENT", 0, 3], ["a significant increase in heart weight", "PROBLEM", 21, 59], ["sham operation", "TREATMENT", 73, 87], ["injection of hMSCs", "TREATMENT", 93, 111], ["the heart", "TEST", 131, 140], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["heart", "ANATOMY", 47, 52], ["weight", "OBSERVATION", 53, 59], ["heart", "ANATOMY", 135, 140]]], ["On a molecular level, TAC significantly increased the expression levels of heart failure markers (ANP and BNP), compared to sham operation ( Figure 3F ), and injection of hMSCs significantly decreased these markers.", [["heart", "ANATOMY", 75, 80], ["hMSCs", "ANATOMY", 171, 176], ["TAC", "CHEMICAL", 22, 25], ["heart failure", "DISEASE", 75, 88], ["TAC", "CHEMICAL", 22, 25], ["TAC", "SIMPLE_CHEMICAL", 22, 25], ["heart", "ORGAN", 75, 80], ["ANP", "GENE_OR_GENE_PRODUCT", 98, 101], ["BNP", "GENE_OR_GENE_PRODUCT", 106, 109], ["hMSCs", "CELL", 171, 176], ["heart failure markers", "PROTEIN", 75, 96], ["ANP", "PROTEIN", 98, 101], ["BNP", "PROTEIN", 106, 109], ["hMSCs", "CELL_TYPE", 171, 176], ["a molecular level", "TEST", 3, 20], ["heart failure markers", "PROBLEM", 75, 96], ["ANP", "TEST", 98, 101], ["BNP", "TEST", 106, 109], ["sham operation", "TREATMENT", 124, 138], ["injection of hMSCs", "TREATMENT", 158, 176], ["these markers", "TEST", 201, 214], ["heart", "ANATOMY", 75, 80], ["failure", "OBSERVATION", 81, 88]]], ["We also measured the cross-sectional area (CSA) by wheat germ agglutinin (WGA) plasma membrane staining to evaluate cardiomyocyte hypertrophy ( Figure 3G ).", [["plasma membrane", "ANATOMY", 79, 94], ["cardiomyocyte", "ANATOMY", 116, 129], ["hypertrophy", "DISEASE", 130, 141], ["wheat germ agglutinin", "GENE_OR_GENE_PRODUCT", 51, 72], ["WGA", "SIMPLE_CHEMICAL", 74, 77], ["plasma", "ORGANISM_SUBSTANCE", 79, 85], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["cardiomyocyte", "CELL", 116, 129], ["wheat", "SPECIES", 51, 56], ["wheat", "SPECIES", 51, 56], ["wheat germ agglutinin", "TEST", 51, 72], ["plasma membrane staining", "TEST", 79, 103], ["cardiomyocyte hypertrophy", "PROBLEM", 116, 141], ["cardiomyocyte", "ANATOMY", 116, 129], ["hypertrophy", "OBSERVATION", 130, 141]]], ["The results demonstrated significant TAC-associated left ventricular hypertrophy, while the injection of hMSCs prevented this effect ( Figures 3G and 3H ).", [["left ventricular", "ANATOMY", 52, 68], ["hMSCs", "ANATOMY", 105, 110], ["TAC", "CHEMICAL", 37, 40], ["left ventricular hypertrophy", "DISEASE", 52, 80], ["TAC", "CHEMICAL", 37, 40], ["TAC", "SIMPLE_CHEMICAL", 37, 40], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 52, 68], ["hMSCs", "CELL", 105, 110], ["hMSCs", "CELL_TYPE", 105, 110], ["significant TAC", "PROBLEM", 25, 40], ["left ventricular hypertrophy", "PROBLEM", 52, 80], ["the injection of hMSCs", "TREATMENT", 88, 110], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["TAC", "OBSERVATION", 37, 40], ["left ventricular", "ANATOMY", 52, 68], ["hypertrophy", "OBSERVATION", 69, 80]]], ["Moreover, hMSC treatment during the first 2 weeks improved cardiac function even at 4 weeks (Figure S3 ).", [["hMSC", "ANATOMY", 10, 14], ["cardiac", "ANATOMY", 59, 66], ["hMSC", "CELL", 10, 14], ["cardiac", "ORGAN", 59, 66], ["hMSC", "CELL_TYPE", 10, 14], ["hMSC treatment", "TREATMENT", 10, 24]]], ["Taken together, these results indicate that injection of hMSCs improves left ventricular hypertrophy in the chronic heart failure mouse model, which is associated with an increase of exosomes in the circulation.Dependence of hMSC-Related Cardioprotective Effect on Circulating AdiponectinFirst, we evaluated the effect of circulating adiponectin on exosome production by hMSCs in vivo.", [["hMSCs", "ANATOMY", 57, 62], ["left ventricular", "ANATOMY", 72, 88], ["heart", "ANATOMY", 116, 121], ["exosomes", "ANATOMY", 183, 191], ["hMSC", "ANATOMY", 225, 229], ["exosome", "ANATOMY", 349, 356], ["hMSCs", "ANATOMY", 371, 376], ["ventricular hypertrophy", "DISEASE", 77, 100], ["heart failure", "DISEASE", 116, 129], ["hMSCs", "CELL", 57, 62], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 72, 88], ["heart", "ORGAN", 116, 121], ["mouse", "ORGANISM", 130, 135], ["exosomes", "CELL", 183, 191], ["hMSC", "CELL", 225, 229], ["AdiponectinFirst", "SIMPLE_CHEMICAL", 277, 293], ["adiponectin", "GENE_OR_GENE_PRODUCT", 334, 345], ["exosome", "CELLULAR_COMPONENT", 349, 356], ["hMSCs", "CELL", 371, 376], ["hMSCs", "CELL_TYPE", 57, 62], ["exosomes", "CELL_TYPE", 183, 191], ["adiponectin", "PROTEIN", 334, 345], ["hMSCs", "CELL_TYPE", 371, 376], ["mouse", "SPECIES", 130, 135], ["mouse", "SPECIES", 130, 135], ["injection of hMSCs", "TREATMENT", 44, 62], ["left ventricular hypertrophy", "PROBLEM", 72, 100], ["the chronic heart failure mouse model", "PROBLEM", 104, 141], ["an increase of exosomes in the circulation", "PROBLEM", 168, 210], ["Dependence of hMSC", "PROBLEM", 211, 229], ["Cardioprotective Effect", "PROBLEM", 238, 261], ["Circulating AdiponectinFirst", "TREATMENT", 265, 293], ["circulating adiponectin on exosome production", "TREATMENT", 322, 367], ["left ventricular", "ANATOMY", 72, 88], ["hypertrophy", "OBSERVATION", 89, 100], ["chronic", "OBSERVATION_MODIFIER", 108, 115], ["heart", "ANATOMY", 116, 121], ["failure mouse model", "OBSERVATION", 122, 141], ["increase", "OBSERVATION_MODIFIER", 171, 179], ["exosomes", "OBSERVATION", 183, 191], ["circulation", "OBSERVATION_MODIFIER", 199, 210], ["hMSC", "OBSERVATION", 225, 229], ["Cardioprotective Effect", "OBSERVATION", 238, 261]]], ["Adenovirus-gLuc-MFG-E8-infected hMSCs were injected i.v. in wild-type (WT) and AKO mice under normal conditions using the same protocol described in Figure 2E ( Figure 4A ).", [["hMSCs", "ANATOMY", 32, 37], ["Adenovirus-gLuc-MFG-E8", "ORGANISM", 0, 22], ["hMSCs", "CELL", 32, 37], ["AKO mice", "ORGANISM", 79, 87], ["Adenovirus-gLuc-MFG-E8-infected hMSCs", "CELL_LINE", 0, 37], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["Adenovirus", "TEST", 0, 10], ["MFG", "TEST", 16, 19], ["infected hMSCs", "PROBLEM", 23, 37], ["the same protocol", "TREATMENT", 118, 135]]], ["Exosome-associated gLuc activity was significantly lower in AKO mice than in WT mice at all time points (up to 72 h) (Figure 4B ).", [["Exosome", "GENE_OR_GENE_PRODUCT", 0, 7], ["gLuc", "GENE_OR_GENE_PRODUCT", 19, 23], ["AKO mice", "ORGANISM", 60, 68], ["WT mice", "ORGANISM", 77, 84], ["gLuc", "PROTEIN", 19, 23], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 80, 84], ["Exosome", "TEST", 0, 7], ["associated gLuc activity", "PROBLEM", 8, 32], ["gLuc activity", "OBSERVATION", 19, 32]]], ["The area under the curve (AUC) of gLuc activity was significantly higher after hMSC injection in WT mice and significantly higher than in AKO mice ( Figure 4B ).Dependence of hMSC-Related Cardioprotective Effect on Circulating AdiponectinSecond, to determine the role of adiponectin in the therapeutic effects of hMSCs, hMSCs were injected into AKO mice with load-induced cardiac hypertrophy using the same protocol described in Figure 3A ( Figure 4C ). hMSCs significantly increased all exosome markers tested in WT mice, but such increase was significantly attenuated in AKO mice ( Figures 4D and 4E ).", [["hMSC", "ANATOMY", 79, 83], ["hMSC", "ANATOMY", 175, 179], ["hMSCs", "ANATOMY", 313, 318], ["hMSCs", "ANATOMY", 320, 325], ["cardiac", "ANATOMY", 372, 379], ["hMSCs", "ANATOMY", 454, 459], ["exosome", "ANATOMY", 488, 495], ["cardiac hypertrophy", "DISEASE", 372, 391], ["gLuc", "GENE_OR_GENE_PRODUCT", 34, 38], ["hMSC", "CELL", 79, 83], ["mice", "ORGANISM", 100, 104], ["AKO mice", "ORGANISM", 138, 146], ["hMSC", "CELL", 175, 179], ["adiponectin", "GENE_OR_GENE_PRODUCT", 271, 282], ["hMSCs", "CELL", 313, 318], ["hMSCs", "CELL", 320, 325], ["mice", "ORGANISM", 349, 353], ["cardiac", "ORGAN", 372, 379], ["hMSCs", "CELL", 454, 459], ["WT mice", "ORGANISM", 514, 521], ["AKO mice", "ORGANISM", 573, 581], ["gLuc", "PROTEIN", 34, 38], ["adiponectin", "PROTEIN", 271, 282], ["hMSCs", "CELL_TYPE", 313, 318], ["hMSCs", "CELL_TYPE", 320, 325], ["hMSCs", "CELL_TYPE", 454, 459], ["exosome markers", "PROTEIN", 488, 503], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 349, 353], ["mice", "SPECIES", 517, 521], ["mice", "SPECIES", 577, 581], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 349, 353], ["mice", "SPECIES", 517, 521], ["mice", "SPECIES", 577, 581], ["the curve", "TEST", 15, 24], ["AUC", "TEST", 26, 29], ["gLuc activity", "TEST", 34, 47], ["hMSC injection", "TREATMENT", 79, 93], ["Dependence of hMSC", "PROBLEM", 161, 179], ["Cardioprotective Effect", "PROBLEM", 188, 211], ["Circulating AdiponectinSecond", "TREATMENT", 215, 244], ["adiponectin", "TREATMENT", 271, 282], ["hMSCs", "TREATMENT", 313, 318], ["hMSCs", "TREATMENT", 320, 325], ["cardiac hypertrophy", "PROBLEM", 372, 391], ["the same protocol", "TREATMENT", 398, 415], ["hMSCs", "PROBLEM", 454, 459], ["all exosome markers", "TEST", 484, 503], ["curve", "OBSERVATION_MODIFIER", 19, 24], ["hMSC", "OBSERVATION", 175, 179], ["Cardioprotective Effect", "OBSERVATION", 188, 211], ["cardiac", "ANATOMY", 372, 379], ["hypertrophy", "OBSERVATION", 380, 391], ["significantly", "OBSERVATION_MODIFIER", 460, 473], ["increased", "OBSERVATION_MODIFIER", 474, 483], ["exosome markers", "OBSERVATION", 488, 503]]], ["These results highlight the importance of circulating adiponectin in normal exosome production from hMSCs.", [["exosome", "ANATOMY", 76, 83], ["hMSCs", "ANATOMY", 100, 105], ["adiponectin", "GENE_OR_GENE_PRODUCT", 54, 65], ["exosome", "GENE_OR_GENE_PRODUCT", 76, 83], ["hMSCs", "CELL", 100, 105], ["adiponectin", "PROTEIN", 54, 65], ["hMSCs", "CELL_TYPE", 100, 105], ["circulating adiponectin", "PROBLEM", 42, 65], ["exosome production", "OBSERVATION", 76, 94]]], ["TAC was associated with the worsening of cardiac hypertrophy in AKO compared with WT mice, confirming the findings of a previous study (Fig-ure 4F ).", [["cardiac", "ANATOMY", 41, 48], ["TAC", "CHEMICAL", 0, 3], ["cardiac hypertrophy", "DISEASE", 41, 60], ["TAC", "CHEMICAL", 0, 3], ["TAC", "SIMPLE_CHEMICAL", 0, 3], ["cardiac", "ORGAN", 41, 48], ["WT mice", "ORGANISM", 82, 89], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["TAC", "TREATMENT", 0, 3], ["cardiac hypertrophy", "PROBLEM", 41, 60], ["a previous study", "TEST", 118, 134], ["worsening", "OBSERVATION_MODIFIER", 28, 37], ["cardiac", "ANATOMY", 41, 48], ["hypertrophy", "OBSERVATION", 49, 60]]], ["13 We also evaluated cardiac function by ultrasonic echocardiography ( Figures 4G and 4H ).", [["cardiac", "ANATOMY", 21, 28], ["cardiac", "ORGAN", 21, 28], ["ultrasonic echocardiography", "TEST", 41, 68]]], ["At postoperative day 14, cardiac function was equally decreased by TAC in both WT and AKO mice ( Figures 4G and 4H ), although a previous study reported that further prolongation of pressure overload caused more severe cardiac dysfunction in AKO than WT mice.", [["cardiac", "ANATOMY", 25, 32], ["cardiac", "ANATOMY", 219, 226], ["TAC", "CHEMICAL", 67, 70], ["pressure overload", "DISEASE", 182, 199], ["cardiac dysfunction", "DISEASE", 219, 238], ["TAC", "CHEMICAL", 67, 70], ["cardiac", "ORGAN", 25, 32], ["TAC", "SIMPLE_CHEMICAL", 67, 70], ["AKO mice", "ORGANISM", 86, 94], ["cardiac", "ORGAN", 219, 226], ["AKO", "GENE_OR_GENE_PRODUCT", 242, 245], ["WT mice", "ORGANISM", 251, 258], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 254, 258], ["mice", "SPECIES", 254, 258], ["cardiac function", "TEST", 25, 41], ["a previous study", "TEST", 127, 143], ["pressure overload", "PROBLEM", 182, 199], ["more severe cardiac dysfunction", "PROBLEM", 207, 238], ["cardiac", "ANATOMY", 25, 32], ["decreased", "OBSERVATION", 54, 63], ["pressure overload", "OBSERVATION", 182, 199], ["severe", "OBSERVATION_MODIFIER", 212, 218], ["cardiac", "ANATOMY", 219, 226], ["dysfunction", "OBSERVATION", 227, 238]]], ["13 Injection of hMSCs improved cardiac function in WT mice but not in AKO mice (Figures 4G and 4H; Table S1 ).", [["hMSCs", "ANATOMY", 16, 21], ["cardiac", "ANATOMY", 31, 38], ["hMSCs", "CELL", 16, 21], ["cardiac", "ORGAN", 31, 38], ["mice", "ORGANISM", 54, 58], ["AKO mice", "ORGANISM", 70, 78], ["hMSCs", "CELL_TYPE", 16, 21], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 74, 78]]], ["These results indicate that hMSCs require circulating adiponectin to produce many exosomes and effectively improve cardiac functions in mice.High Adiponectin Levels Augmented the Cardioprotective Effect of hMSCsThe therapeutic effects of injected hMSCs are mediated by circulating adiponectin.", [["hMSCs", "ANATOMY", 28, 33], ["exosomes", "ANATOMY", 82, 90], ["cardiac", "ANATOMY", 115, 122], ["hMSCs", "ANATOMY", 206, 211], ["hMSCs", "ANATOMY", 247, 252], ["hMSCs", "CELL", 28, 33], ["adiponectin", "GENE_OR_GENE_PRODUCT", 54, 65], ["exosomes", "CELL", 82, 90], ["cardiac", "ORGAN", 115, 122], ["mice", "ORGANISM", 136, 140], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 146, 157], ["hMSCs", "CELL", 206, 211], ["hMSCs", "CELL", 247, 252], ["adiponectin", "GENE_OR_GENE_PRODUCT", 281, 292], ["hMSCs", "CELL_TYPE", 28, 33], ["adiponectin", "PROTEIN", 54, 65], ["exosomes", "CELL_TYPE", 82, 90], ["Adiponectin", "PROTEIN", 146, 157], ["hMSCs", "CELL_TYPE", 206, 211], ["hMSCs", "CELL_TYPE", 247, 252], ["adiponectin", "PROTEIN", 281, 292], ["mice", "SPECIES", 136, 140], ["mice", "SPECIES", 136, 140], ["circulating adiponectin", "TREATMENT", 42, 65], ["High Adiponectin Levels", "PROBLEM", 141, 164], ["injected hMSCs", "TREATMENT", 238, 252], ["circulating adiponectin", "TREATMENT", 269, 292], ["Cardioprotective Effect", "OBSERVATION", 179, 202]]], ["Importantly, exosome production increased in a dosedependent manner by purified HMW-APN in vitro ( Figure 1C ).", [["exosome", "ANATOMY", 13, 20], ["exosome", "CELLULAR_COMPONENT", 13, 20], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 80, 87], ["exosome", "PROTEIN", 13, 20], ["HMW", "PROTEIN", 80, 83], ["APN", "PROTEIN", 84, 87], ["production", "OBSERVATION_MODIFIER", 21, 31], ["increased", "OBSERVATION_MODIFIER", 32, 41]]], ["Next, we examined whether exogenous adiponectin enhances the therapeutic efficacy of injected hMSCs.", [["hMSCs", "ANATOMY", 94, 99], ["adiponectin", "CHEMICAL", 36, 47], ["adiponectin", "GENE_OR_GENE_PRODUCT", 36, 47], ["hMSCs", "CELL", 94, 99], ["adiponectin", "PROTEIN", 36, 47], ["hMSCs", "CELL_TYPE", 94, 99], ["injected hMSCs", "PROBLEM", 85, 99]]], ["To test this, mice were orally administrated pioglitazone, a well-known thiazolidinedione class of PPARg agonists, from 1 day before TAC to 2 weeks after TAC (Figure 5A ).", [["pioglitazone", "CHEMICAL", 45, 57], ["TAC", "CHEMICAL", 133, 136], ["TAC", "CHEMICAL", 154, 157], ["pioglitazone", "CHEMICAL", 45, 57], ["thiazolidinedione", "CHEMICAL", 72, 89], ["TAC", "CHEMICAL", 154, 157], ["mice", "ORGANISM", 14, 18], ["pioglitazone", "SIMPLE_CHEMICAL", 45, 57], ["PPARg", "SIMPLE_CHEMICAL", 99, 104], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["pioglitazone", "TREATMENT", 45, 57], ["a well-known thiazolidinedione class of PPARg agonists", "TREATMENT", 59, 113], ["TAC (Figure 5A", "TREATMENT", 154, 168]]], ["To evaluate the improvement in the therapeutic effect of hMSCs, cells were injected at a submaximal number of 1.67 \u00c2 10 5 cells per body (one third of that used in the other studies) within a period of 2 weeks at 2-to 3-day intervals ( Figure 5A ).", [["hMSCs", "ANATOMY", 57, 62], ["cells", "ANATOMY", 64, 69], ["cells", "ANATOMY", 122, 127], ["body", "ANATOMY", 132, 136], ["hMSCs", "CELL", 57, 62], ["cells", "CELL", 64, 69], ["cells", "CELL", 122, 127], ["body", "ORGANISM_SUBDIVISION", 132, 136], ["hMSCs", "CELL_TYPE", 57, 62], ["hMSCs, cells", "TREATMENT", 57, 69], ["improvement", "OBSERVATION_MODIFIER", 16, 27], ["therapeutic", "OBSERVATION_MODIFIER", 35, 46]]], ["Two weeks after administration of pioglitazone, serum adiponectin levels were significantly higher in the pioglitazone-treated group compared with the vehicle group (vehicle: 12.7 \u00b1 0.5 mg/mL; pioglitazone: 36.8 \u00b1 1.7 mg/mL).", [["serum", "ANATOMY", 48, 53], ["pioglitazone", "CHEMICAL", 34, 46], ["pioglitazone", "CHEMICAL", 106, 118], ["pioglitazone", "CHEMICAL", 193, 205], ["pioglitazone", "CHEMICAL", 34, 46], ["pioglitazone", "CHEMICAL", 106, 118], ["pioglitazone", "CHEMICAL", 193, 205], ["pioglitazone", "SIMPLE_CHEMICAL", 34, 46], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["adiponectin", "GENE_OR_GENE_PRODUCT", 54, 65], ["pioglitazone", "SIMPLE_CHEMICAL", 106, 118], ["pioglitazone", "SIMPLE_CHEMICAL", 193, 205], ["adiponectin", "PROTEIN", 54, 65], ["pioglitazone", "TREATMENT", 34, 46], ["serum adiponectin levels", "TEST", 48, 72], ["the pioglitazone", "TREATMENT", 102, 118], ["pioglitazone", "TREATMENT", 193, 205]]], ["No such changes were noted in the AKO mice (Figure 5B ).", [["AKO mice", "ORGANISM", 34, 42], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["such changes", "PROBLEM", 3, 15]]], ["Pioglitazone, in combination with hMSC injection, significantly increased all exosome markers tested in the exosome fractions obtained from serum ( Figures 5C and 5D ).", [["hMSC", "ANATOMY", 34, 38], ["exosome", "ANATOMY", 78, 85], ["exosome fractions", "ANATOMY", 108, 125], ["serum", "ANATOMY", 140, 145], ["Pioglitazone", "CHEMICAL", 0, 12], ["Pioglitazone", "CHEMICAL", 0, 12], ["Pioglitazone", "SIMPLE_CHEMICAL", 0, 12], ["hMSC", "CELL", 34, 38], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["exosome markers", "PROTEIN", 78, 93], ["Pioglitazone", "TREATMENT", 0, 12], ["hMSC injection", "TREATMENT", 34, 48], ["all exosome markers", "TEST", 74, 93], ["the exosome fractions", "TEST", 104, 125], ["serum", "TEST", 140, 145], ["exosome markers", "OBSERVATION", 78, 93]]], ["These results demonstrate that hMSCs plus pioglitazone treatment enhanced hMSC-based exosome production.High Adiponectin Levels Augmented the Cardioprotective Effect of hMSCsHeart weight was significantly larger in TAC-operated mice compared to sham-operated mice, regardless of pioglitazone administration ( Figure 5E ).", [["hMSCs", "ANATOMY", 31, 36], ["hMSC", "ANATOMY", 74, 78], ["exosome", "ANATOMY", 85, 92], ["hMSCs", "ANATOMY", 169, 174], ["Heart", "ANATOMY", 174, 179], ["pioglitazone", "CHEMICAL", 42, 54], ["TAC", "CHEMICAL", 215, 218], ["pioglitazone", "CHEMICAL", 279, 291], ["pioglitazone", "CHEMICAL", 42, 54], ["TAC", "CHEMICAL", 215, 218], ["pioglitazone", "CHEMICAL", 279, 291], ["hMSCs", "CELL", 31, 36], ["pioglitazone", "SIMPLE_CHEMICAL", 42, 54], ["hMSC", "CELL", 74, 78], ["exosome", "CELLULAR_COMPONENT", 85, 92], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 109, 120], ["hMSCs", "CELL", 169, 174], ["Heart", "ORGAN", 174, 179], ["TAC", "SIMPLE_CHEMICAL", 215, 218], ["mice", "ORGANISM", 228, 232], ["mice", "ORGANISM", 259, 263], ["pioglitazone", "SIMPLE_CHEMICAL", 279, 291], ["hMSCs", "CELL_TYPE", 31, 36], ["hMSC", "CELL_TYPE", 74, 78], ["exosome", "PROTEIN", 85, 92], ["Adiponectin", "PROTEIN", 109, 120], ["hMSCs", "CELL_TYPE", 169, 174], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 259, 263], ["hMSCs", "TEST", 31, 36], ["pioglitazone treatment", "TREATMENT", 42, 64], ["High Adiponectin Levels", "PROBLEM", 104, 127], ["Heart weight", "TEST", 174, 186], ["pioglitazone administration", "TREATMENT", 279, 306], ["exosome production", "OBSERVATION", 85, 103], ["Cardioprotective Effect", "OBSERVATION", 142, 165], ["weight", "OBSERVATION", 180, 186], ["significantly", "OBSERVATION_MODIFIER", 191, 204], ["larger", "OBSERVATION_MODIFIER", 205, 211]]], ["Compared to the TAC-operated control mice, hMSC injection tended to decrease heart weight in the vehicle group ( Figure 5E ) and significantly decrease heart weight in the pioglitazone group ( Figure 5E ).", [["hMSC", "ANATOMY", 43, 47], ["heart", "ANATOMY", 77, 82], ["heart", "ANATOMY", 152, 157], ["TAC", "CHEMICAL", 16, 19], ["pioglitazone", "CHEMICAL", 172, 184], ["TAC", "CHEMICAL", 16, 19], ["pioglitazone", "CHEMICAL", 172, 184], ["TAC", "SIMPLE_CHEMICAL", 16, 19], ["mice", "ORGANISM", 37, 41], ["hMSC", "CELL", 43, 47], ["heart", "ORGAN", 77, 82], ["heart", "ORGAN", 152, 157], ["pioglitazone", "SIMPLE_CHEMICAL", 172, 184], ["hMSC", "CELL_TYPE", 43, 47], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["the TAC-operated control mice", "TREATMENT", 12, 41], ["hMSC injection", "TREATMENT", 43, 57], ["significantly decrease heart weight", "PROBLEM", 129, 164], ["the pioglitazone group", "TREATMENT", 168, 190], ["heart", "ANATOMY", 77, 82], ["heart", "ANATOMY", 152, 157]]], ["TAC decreased cardiac function, as measured by EF and FS, regardless of pioglitazone administration (Figures 5F and 5G).", [["cardiac", "ANATOMY", 14, 21], ["TAC", "CHEMICAL", 0, 3], ["pioglitazone", "CHEMICAL", 72, 84], ["TAC", "CHEMICAL", 0, 3], ["pioglitazone", "CHEMICAL", 72, 84], ["TAC", "SIMPLE_CHEMICAL", 0, 3], ["cardiac", "ORGAN", 14, 21], ["pioglitazone", "SIMPLE_CHEMICAL", 72, 84], ["EF", "TEST", 47, 49], ["FS", "TEST", 54, 56], ["pioglitazone administration", "TREATMENT", 72, 99], ["cardiac", "ANATOMY", 14, 21], ["function", "OBSERVATION", 22, 30]]], ["Compared to these TAC-operated control mice, hMSCs with or without pioglitazone significantly improved cardiac function ( Figures 5F and 5G ).", [["hMSCs", "ANATOMY", 45, 50], ["cardiac", "ANATOMY", 103, 110], ["TAC", "CHEMICAL", 18, 21], ["pioglitazone", "CHEMICAL", 67, 79], ["TAC", "CHEMICAL", 18, 21], ["pioglitazone", "CHEMICAL", 67, 79], ["TAC", "SIMPLE_CHEMICAL", 18, 21], ["mice", "ORGANISM", 39, 43], ["hMSCs", "CELL", 45, 50], ["pioglitazone", "SIMPLE_CHEMICAL", 67, 79], ["cardiac", "ORGAN", 103, 110], ["hMSCs", "CELL_TYPE", 45, 50], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["these TAC", "TEST", 12, 21], ["pioglitazone", "TREATMENT", 67, 79]]], ["However, compared to the vehicle, hMSCs with pioglitazone significantly improved cardiac function (Figures 5F and 5G, orange versus red; Table S2 ).", [["hMSCs", "ANATOMY", 34, 39], ["cardiac", "ANATOMY", 81, 88], ["pioglitazone", "CHEMICAL", 45, 57], ["pioglitazone", "CHEMICAL", 45, 57], ["hMSCs", "CELL", 34, 39], ["pioglitazone", "SIMPLE_CHEMICAL", 45, 57], ["cardiac", "ORGAN", 81, 88], ["hMSCs", "CELL_TYPE", 34, 39], ["pioglitazone", "TREATMENT", 45, 57]]], ["Importantly, all such experiments in AKO mice showed that pioglitazone had no effect on heart weight or cardiac function ( Figures 5E-5G ), strongly suggesting that pioglitazone indirectly affects the therapeutic effects of hMSCs through elevation of circulating adiponectin.High Adiponectin Levels Augmented the Cardioprotective Effect of hMSCsWe reported previously that adenoviral adiponectin overexpression increased plasma exosome levels.", [["heart", "ANATOMY", 88, 93], ["cardiac", "ANATOMY", 104, 111], ["hMSCs", "ANATOMY", 224, 229], ["plasma exosome", "ANATOMY", 421, 435], ["pioglitazone", "CHEMICAL", 58, 70], ["pioglitazone", "CHEMICAL", 165, 177], ["pioglitazone", "CHEMICAL", 58, 70], ["pioglitazone", "CHEMICAL", 165, 177], ["AKO mice", "ORGANISM", 37, 45], ["pioglitazone", "SIMPLE_CHEMICAL", 58, 70], ["heart", "ORGAN", 88, 93], ["cardiac", "ORGAN", 104, 111], ["pioglitazone", "SIMPLE_CHEMICAL", 165, 177], ["hMSCs", "CELL", 224, 229], ["adiponectin", "GENE_OR_GENE_PRODUCT", 263, 274], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 280, 291], ["adenoviral", "ORGANISM", 373, 383], ["adiponectin", "GENE_OR_GENE_PRODUCT", 384, 395], ["plasma", "ORGANISM_SUBSTANCE", 421, 427], ["exosome", "ORGANISM_SUBSTANCE", 428, 435], ["hMSCs", "CELL_TYPE", 224, 229], ["adiponectin", "PROTEIN", 263, 274], ["Adiponectin", "PROTEIN", 280, 291], ["hMSCsWe", "PROTEIN", 340, 347], ["adiponectin", "PROTEIN", 384, 395], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["pioglitazone", "TREATMENT", 58, 70], ["heart weight", "TEST", 88, 100], ["Figures", "TEST", 123, 130], ["pioglitazone", "TREATMENT", 165, 177], ["hMSCs", "PROBLEM", 224, 229], ["circulating adiponectin", "TREATMENT", 251, 274], ["High Adiponectin Levels", "PROBLEM", 275, 298], ["adenoviral adiponectin overexpression", "TREATMENT", 373, 410], ["plasma exosome levels", "TEST", 421, 442], ["cardiac", "ANATOMY", 104, 111]]], ["33 We showed here that the adenoviral adiponectin overexpression, but not b-galactosidase, increased plasma adiponectin levels ( Figures S4A and S4B ) and significantly augmented the cardioprotective effects of MSCs ( Figures S4C-S4E) .High Adiponectin Levels Augmented the Cardioprotective Effect of hMSCsCollectively, these results demonstrate that hyperadiponectinemia can improve the efficacy of injected MSCs through increased exosome production.High Adiponectin Levels Augmented the Cardioprotective Effect of hMSCsT-cadherin Expression Is Important for hMSC/Adiponectin-Related Increase in Exosome Production In VivoHigh Adiponectin Levels Augmented the Cardioprotective Effect of hMSCsTo investigate the role of T-cadherin on the effects of hMSCs, we injected T-cadherin knockdown hMSCs into WT mice with a loadinduced ventricular hypertrophy model ( Figure 6A ).", [["plasma", "ANATOMY", 101, 107], ["MSCs", "ANATOMY", 211, 215], ["MSCs", "ANATOMY", 409, 413], ["exosome", "ANATOMY", 432, 439], ["hMSC", "ANATOMY", 560, 564], ["hMSCs", "ANATOMY", 749, 754], ["hMSCs", "ANATOMY", 789, 794], ["ventricular", "ANATOMY", 827, 838], ["hyperadiponectinemia", "DISEASE", 351, 371], ["ventricular hypertrophy", "DISEASE", 827, 850], ["adenoviral", "ORGANISM", 27, 37], ["adiponectin", "GENE_OR_GENE_PRODUCT", 38, 49], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 74, 89], ["plasma", "ORGANISM_SUBSTANCE", 101, 107], ["adiponectin", "GENE_OR_GENE_PRODUCT", 108, 119], ["MSCs", "CELL", 211, 215], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 241, 252], ["hyperadiponectinemia", "SIMPLE_CHEMICAL", 351, 371], ["MSCs", "CELL", 409, 413], ["exosome", "GENE_OR_GENE_PRODUCT", 432, 439], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 456, 467], ["hMSCsT-cadherin", "GENE_OR_GENE_PRODUCT", 516, 531], ["hMSC", "CELL", 560, 564], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 565, 576], ["Exosome", "SIMPLE_CHEMICAL", 597, 604], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 628, 639], ["hMSCsTo", "SIMPLE_CHEMICAL", 688, 695], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 720, 730], ["hMSCs", "CELL", 749, 754], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 768, 778], ["hMSCs", "CELL", 789, 794], ["mice", "ORGANISM", 803, 807], ["ventricular", "MULTI-TISSUE_STRUCTURE", 827, 838], ["adiponectin", "PROTEIN", 38, 49], ["b-galactosidase", "PROTEIN", 74, 89], ["adiponectin", "PROTEIN", 108, 119], ["S4B", "PROTEIN", 145, 148], ["MSCs", "CELL_TYPE", 211, 215], ["Adiponectin", "PROTEIN", 241, 252], ["MSCs", "CELL_TYPE", 409, 413], ["Adiponectin", "PROTEIN", 456, 467], ["hMSCsT", "PROTEIN", 516, 522], ["cadherin", "PROTEIN", 523, 531], ["hMSC", "CELL_TYPE", 560, 564], ["Adiponectin", "PROTEIN", 565, 576], ["Adiponectin", "PROTEIN", 628, 639], ["hMSCsTo", "PROTEIN", 688, 695], ["T-cadherin", "PROTEIN", 720, 730], ["hMSCs", "CELL_TYPE", 749, 754], ["T-cadherin knockdown hMSCs", "CELL_TYPE", 768, 794], ["mice", "SPECIES", 803, 807], ["mice", "SPECIES", 803, 807], ["the adenoviral adiponectin overexpression", "PROBLEM", 23, 64], ["increased plasma adiponectin levels", "PROBLEM", 91, 126], ["MSCs", "PROBLEM", 211, 215], ["High Adiponectin Levels", "PROBLEM", 236, 259], ["hyperadiponectinemia", "PROBLEM", 351, 371], ["injected MSCs", "PROBLEM", 400, 413], ["increased exosome production", "PROBLEM", 422, 450], ["High Adiponectin Levels", "PROBLEM", 451, 474], ["hMSCsT-cadherin Expression", "TREATMENT", 516, 542], ["hMSC/Adiponectin", "TREATMENT", 560, 576], ["Exosome Production", "TREATMENT", 597, 615], ["VivoHigh Adiponectin Levels", "TREATMENT", 619, 646], ["hMSCs", "TREATMENT", 749, 754], ["T-cadherin knockdown hMSCs", "TREATMENT", 768, 794], ["a loadinduced ventricular hypertrophy model", "TREATMENT", 813, 856], ["cardioprotective effects", "OBSERVATION", 183, 207], ["Cardioprotective Effect", "OBSERVATION_MODIFIER", 274, 297], ["increased", "OBSERVATION_MODIFIER", 422, 431], ["exosome production", "OBSERVATION", 432, 450], ["Exosome Production", "OBSERVATION", 597, 615], ["ventricular", "ANATOMY", 827, 838], ["hypertrophy", "OBSERVATION", 839, 850]]], ["In this set of experiments, small interfering RNA (siRNA) transfection was used to markedly reduce T-cadherin expression and the knockdown efficacy was confirmed to persist for more than 6 days in a cell-culture study ( Figure 6B ).", [["cell", "ANATOMY", 199, 203], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 99, 109], ["cell", "CELL", 199, 203], ["small interfering RNA", "RNA", 28, 49], ["cadherin", "PROTEIN", 101, 109], ["small interfering RNA (siRNA) transfection", "PROBLEM", 28, 70], ["T-cadherin expression", "TREATMENT", 99, 120], ["the knockdown efficacy", "PROBLEM", 125, 147], ["a cell-culture study", "TEST", 197, 217], ["small", "OBSERVATION_MODIFIER", 28, 33], ["interfering RNA", "OBSERVATION", 34, 49]]], ["The use of the T-cadherin knockdown hMSCs produced fewer exosomes in vitro in response to adiponectin ( Figure 1E ).", [["hMSCs", "ANATOMY", 36, 41], ["exosomes", "ANATOMY", 57, 65], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 15, 25], ["hMSCs", "CELL", 36, 41], ["exosomes", "CELL", 57, 65], ["adiponectin", "GENE_OR_GENE_PRODUCT", 90, 101], ["T-cadherin knockdown hMSCs", "CELL_LINE", 15, 41], ["exosomes", "CELL_TYPE", 57, 65], ["adiponectin", "PROTEIN", 90, 101], ["the T-cadherin knockdown hMSCs", "TREATMENT", 11, 41], ["adiponectin ( Figure 1E", "TREATMENT", 90, 113]]], ["Control siRNA (siCont)-transfected or T-cadherin siRNA (siTcad)-transfected hMSCs were injected i.v. after TAC operation ( Figure 6A ), followed by measurement of serum exosome levels. siCont hMSC injection significantly increased exosome markers hMFG-E8, hCD63, and Alix and tended to increase Tsg101 ( Figures 6C and 6D ).", [["hMSCs", "ANATOMY", 76, 81], ["serum exosome", "ANATOMY", 163, 176], ["hMSC", "ANATOMY", 192, 196], ["exosome", "ANATOMY", 231, 238], ["TAC", "CHEMICAL", 107, 110], ["TAC", "CHEMICAL", 107, 110], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 38, 48], ["siTcad", "GENE_OR_GENE_PRODUCT", 56, 62], ["hMSCs", "CELL", 76, 81], ["serum", "ORGANISM_SUBSTANCE", 163, 168], ["exosome", "ORGANISM_SUBSTANCE", 169, 176], ["hMSC", "CELL", 192, 196], ["hMFG-E8", "GENE_OR_GENE_PRODUCT", 247, 254], ["hCD63", "GENE_OR_GENE_PRODUCT", 256, 261], ["Alix", "GENE_OR_GENE_PRODUCT", 267, 271], ["T-cadherin siRNA (siTcad)-transfected hMSCs", "CELL_LINE", 38, 81], ["serum exosome", "PROTEIN", 163, 176], ["exosome markers", "PROTEIN", 231, 246], ["hMFG", "PROTEIN", 247, 251], ["E8", "PROTEIN", 252, 254], ["hCD63", "PROTEIN", 256, 261], ["Alix", "PROTEIN", 267, 271], ["Tsg101", "PROTEIN", 295, 301], ["Control siRNA (siCont)", "TREATMENT", 0, 22], ["T-cadherin siRNA (siTcad)", "TREATMENT", 38, 63], ["transfected hMSCs", "TREATMENT", 64, 81], ["TAC operation", "TREATMENT", 107, 120], ["serum exosome levels", "TEST", 163, 183], ["siCont hMSC injection", "TREATMENT", 185, 206], ["hMFG", "TEST", 247, 251], ["Alix", "TREATMENT", 267, 271], ["Tsg", "TEST", 295, 298]]], ["In comparison, injection of T-cadherin knockdown hMSCs significantly decreased all those exosome markers ( Figures 6C and 6D ) and exosome-sized particle numbers in the blood to the level of the vehicle control ( Figure S5 ).", [["hMSCs", "ANATOMY", 49, 54], ["exosome", "ANATOMY", 89, 96], ["exosome", "ANATOMY", 131, 138], ["blood", "ANATOMY", 169, 174], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 28, 38], ["hMSCs", "CELL", 49, 54], ["blood", "ORGANISM_SUBSTANCE", 169, 174], ["T-cadherin knockdown hMSCs", "CELL_LINE", 28, 54], ["exosome markers", "PROTEIN", 89, 104], ["exosome", "PROTEIN", 131, 138], ["T-cadherin knockdown hMSCs", "TREATMENT", 28, 54], ["Figures", "TEST", 107, 114], ["exosome", "TEST", 131, 138], ["sized", "OBSERVATION_MODIFIER", 139, 144], ["particle", "OBSERVATION_MODIFIER", 145, 153], ["numbers", "OBSERVATION_MODIFIER", 154, 161], ["blood", "ANATOMY", 169, 174]]], ["These results demonstrate the importance of T-cadherin expression on the exosome production function of the hMSCs in vivo.", [["exosome", "ANATOMY", 73, 80], ["hMSCs", "ANATOMY", 108, 113], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 44, 54], ["hMSCs", "CELL", 108, 113], ["cadherin", "PROTEIN", 46, 54], ["hMSCs", "CELL_TYPE", 108, 113], ["T-cadherin expression", "TREATMENT", 44, 65]]], ["TAC, but not sham, operation was associated with a significant increase in heart weight, compared to sham-operated mice.", [["heart", "ANATOMY", 75, 80], ["TAC", "CHEMICAL", 0, 3], ["TAC", "CHEMICAL", 0, 3], ["TAC", "SIMPLE_CHEMICAL", 0, 3], ["heart", "ORGAN", 75, 80], ["mice", "ORGANISM", 115, 119], ["mice", "SPECIES", 115, 119], ["operation", "TREATMENT", 19, 28], ["a significant increase in heart weight", "PROBLEM", 49, 87], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["increase", "OBSERVATION_MODIFIER", 63, 71], ["heart", "ANATOMY", 75, 80]]], ["Heart weight significantly decreased by siCont hMSC injection, but not by siTcad hMSC injection ( Figure 6E ).High Adiponectin Levels Augmented the Cardioprotective Effect of hMSCsNext, we examined cardiac function by echocardiography ( Figures 6F and 6G ).", [["Heart", "ANATOMY", 0, 5], ["hMSC", "ANATOMY", 47, 51], ["hMSC", "ANATOMY", 81, 85], ["cardiac", "ANATOMY", 198, 205], ["Heart", "ORGAN", 0, 5], ["hMSC", "CELL", 47, 51], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 115, 126], ["cardiac", "ORGAN", 198, 205], ["Adiponectin", "PROTEIN", 115, 126], ["Heart weight", "TEST", 0, 12], ["siCont hMSC injection", "TREATMENT", 40, 61], ["High Adiponectin Levels", "PROBLEM", 110, 133], ["echocardiography", "TEST", 218, 234], ["weight", "OBSERVATION_MODIFIER", 6, 12], ["significantly", "OBSERVATION_MODIFIER", 13, 26], ["decreased", "OBSERVATION_MODIFIER", 27, 36], ["Cardioprotective Effect", "OBSERVATION", 148, 171]]], ["TAC significantly decreased cardiac function, such as EF and FS, while siCont hMSC injection improved cardiac function (Figure 6G ), similar to non-transfected hMSCs ( Figures 3D and 4H ).", [["cardiac", "ANATOMY", 28, 35], ["hMSC", "ANATOMY", 78, 82], ["cardiac", "ANATOMY", 102, 109], ["hMSCs", "ANATOMY", 160, 165], ["TAC", "CHEMICAL", 0, 3], ["TAC", "CHEMICAL", 0, 3], ["TAC", "SIMPLE_CHEMICAL", 0, 3], ["cardiac", "ORGAN", 28, 35], ["hMSC", "CELL", 78, 82], ["cardiac", "ORGAN", 102, 109], ["hMSCs", "CELL", 160, 165], ["non-transfected hMSCs", "CELL_LINE", 144, 165], ["TAC significantly decreased cardiac function", "PROBLEM", 0, 44], ["EF", "TEST", 54, 56], ["FS", "TEST", 61, 63], ["siCont hMSC injection", "TREATMENT", 71, 92], ["decreased", "OBSERVATION_MODIFIER", 18, 27], ["cardiac function", "OBSERVATION", 28, 44]]], ["In contrast, T-cadherin knockdown in hMSCs significantly attenuated such an effect of hMSCs ( Figure 6G ; Table S3 ), demonstrating that the observed cardioprotective effects of hMSCs are mediated through T-cadherin expression.", [["hMSCs", "ANATOMY", 37, 42], ["hMSCs", "ANATOMY", 86, 91], ["hMSCs", "ANATOMY", 178, 183], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 13, 23], ["hMSCs", "CELL", 37, 42], ["hMSCs", "CELL", 86, 91], ["hMSCs", "CELL", 178, 183], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 205, 215], ["cadherin", "PROTEIN", 15, 23], ["hMSCs", "CELL_TYPE", 37, 42], ["hMSCs", "CELL_TYPE", 86, 91], ["hMSCs", "CELL_TYPE", 178, 183], ["cadherin", "PROTEIN", 207, 215], ["T-cadherin knockdown in hMSCs", "TREATMENT", 13, 42], ["hMSCs", "PROBLEM", 86, 91], ["hMSCs", "PROBLEM", 178, 183]]], ["Collectively, these results highlight the importance of T-cadherin expression on MSCs for both normal exosome production and the cardioprotective function.Exosomes Mediated the Cardioprotective Effects of hMSCsThe therapeutic effects of MSCs are considered to depend largely on their secretomes, such as cytokines and exosomes.", [["MSCs", "ANATOMY", 81, 85], ["exosome", "ANATOMY", 102, 109], ["Exosomes", "ANATOMY", 155, 163], ["hMSCs", "ANATOMY", 205, 210], ["MSCs", "ANATOMY", 237, 241], ["exosomes", "ANATOMY", 318, 326], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 56, 66], ["MSCs", "CELL", 81, 85], ["exosome", "CELLULAR_COMPONENT", 102, 109], ["Exosomes", "ORGANISM_SUBSTANCE", 155, 163], ["hMSCs", "CELL", 205, 210], ["MSCs", "CELL", 237, 241], ["exosomes", "CELL", 318, 326], ["cadherin", "PROTEIN", 58, 66], ["MSCs", "CELL_TYPE", 81, 85], ["hMSCs", "CELL_TYPE", 205, 210], ["MSCs", "CELL_TYPE", 237, 241], ["cytokines", "PROTEIN", 304, 313], ["exosomes", "CELL_TYPE", 318, 326], ["T-cadherin expression on MSCs", "TREATMENT", 56, 85], ["MSCs", "TREATMENT", 237, 241], ["exosome production", "OBSERVATION", 102, 120], ["cardioprotective function", "OBSERVATION", 129, 154], ["Cardioprotective Effects", "OBSERVATION", 177, 201], ["therapeutic", "OBSERVATION_MODIFIER", 214, 225]]], ["Loss of adiponectin in the circulation or T-cadherin expression in hMSCs significantly attenuates the therapeutic effects of hMSCs as described earlier.Exosomes Mediated the Cardioprotective Effects of hMSCsTo evaluate the importance of hMSCs-derived exosomes, we examined the effects of injection of exosome-deficient hMSCs on load-induced ventricular hypertrophy in mice.", [["hMSCs", "ANATOMY", 67, 72], ["hMSCs", "ANATOMY", 125, 130], ["Exosomes", "ANATOMY", 152, 160], ["hMSCs", "ANATOMY", 202, 207], ["hMSCs", "ANATOMY", 237, 242], ["exosomes", "ANATOMY", 251, 259], ["hMSCs", "ANATOMY", 319, 324], ["ventricular", "ANATOMY", 341, 352], ["ventricular hypertrophy", "DISEASE", 341, 364], ["adiponectin", "GENE_OR_GENE_PRODUCT", 8, 19], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 42, 52], ["hMSCs", "CELL", 67, 72], ["hMSCs", "CELL", 125, 130], ["Exosomes", "ORGANISM_SUBSTANCE", 152, 160], ["hMSCs", "CELL", 202, 207], ["hMSCs", "CELL", 237, 242], ["exosomes", "CELL", 251, 259], ["hMSCs", "CELL", 319, 324], ["ventricular", "MULTI-TISSUE_STRUCTURE", 341, 352], ["mice", "ORGANISM", 368, 372], ["adiponectin", "PROTEIN", 8, 19], ["cadherin", "PROTEIN", 44, 52], ["hMSCs", "CELL_TYPE", 67, 72], ["hMSCs", "CELL_TYPE", 125, 130], ["hMSCs", "CELL_TYPE", 202, 207], ["hMSCs", "CELL_TYPE", 237, 242], ["exosomes", "CELL_TYPE", 251, 259], ["exosome", "PROTEIN", 301, 308], ["hMSCs", "CELL_TYPE", 319, 324], ["mice", "SPECIES", 368, 372], ["mice", "SPECIES", 368, 372], ["Loss of adiponectin in the circulation", "PROBLEM", 0, 38], ["hMSCs", "PROBLEM", 67, 72], ["hMSCs", "PROBLEM", 125, 130], ["exosome-deficient hMSCs", "TREATMENT", 301, 324], ["ventricular hypertrophy", "PROBLEM", 341, 364], ["adiponectin", "OBSERVATION", 8, 19], ["circulation", "ANATOMY", 27, 38], ["therapeutic", "OBSERVATION_MODIFIER", 102, 113], ["Cardioprotective Effects", "OBSERVATION", 174, 198], ["ventricular", "ANATOMY", 341, 352], ["hypertrophy", "OBSERVATION", 353, 364]]], ["Various cellular machineries are known to play a role in exosome biogenesis and/or secretion, depending on the cell type.", [["cellular", "ANATOMY", 8, 16], ["exosome", "ANATOMY", 57, 64], ["cell", "ANATOMY", 111, 115], ["cellular", "CELL", 8, 16], ["exosome", "CELLULAR_COMPONENT", 57, 64], ["cell type", "CELL", 111, 120], ["secretion", "PROBLEM", 83, 92], ["cellular machineries", "OBSERVATION", 8, 28]]], ["These include ESCRT components (e.g., Alix and syntenin), vesicle transport molecules (e.g., Rab27a and Rab27b), and ceramide metabolism proteins (e.g., neutral sphingomyelinase and sphingosine 1-phosphate receptor).", [["vesicle", "ANATOMY", 58, 65], ["ceramide", "CHEMICAL", 117, 125], ["sphingosine 1-phosphate", "CHEMICAL", 182, 205], ["ceramide", "CHEMICAL", 117, 125], ["sphingosine 1-phosphate", "CHEMICAL", 182, 205], ["ESCRT", "GENE_OR_GENE_PRODUCT", 14, 19], ["Alix", "GENE_OR_GENE_PRODUCT", 38, 42], ["syntenin", "GENE_OR_GENE_PRODUCT", 47, 55], ["vesicle transport molecules", "GENE_OR_GENE_PRODUCT", 58, 85], ["Rab27a", "GENE_OR_GENE_PRODUCT", 93, 99], ["Rab27b", "GENE_OR_GENE_PRODUCT", 104, 110], ["ceramide", "SIMPLE_CHEMICAL", 117, 125], ["neutral sphingomyelinase", "GENE_OR_GENE_PRODUCT", 153, 177], ["sphingosine 1-phosphate receptor", "GENE_OR_GENE_PRODUCT", 182, 214], ["ESCRT components", "PROTEIN", 14, 30], ["Alix", "PROTEIN", 38, 42], ["syntenin", "PROTEIN", 47, 55], ["vesicle transport molecules", "PROTEIN", 58, 85], ["Rab27a", "PROTEIN", 93, 99], ["Rab27b", "PROTEIN", 104, 110], ["ceramide metabolism proteins", "PROTEIN", 117, 145], ["neutral sphingomyelinase", "PROTEIN", 153, 177], ["sphingosine 1-phosphate receptor", "PROTEIN", 182, 214], ["vesicle transport molecules", "TEST", 58, 85], ["Rab27a and Rab27b)", "TEST", 93, 111], ["ceramide metabolism proteins", "TEST", 117, 145], ["neutral sphingomyelinase", "TEST", 153, 177], ["sphingosine 1-phosphate receptor", "TREATMENT", 182, 214]]], ["41S6).", [["41S6", "CELL_LINE", 0, 4]]], ["Under such conditions, Alix knockdown decreased basal and adiponectin-stimulated exosome production ( Figures 7B and S6 ) but did not alter cytokine secretion and multilineage differentiation potential ( Figures S7 and S8 ).", [["exosome", "ANATOMY", 81, 88], ["Alix", "GENE_OR_GENE_PRODUCT", 23, 27], ["adiponectin", "GENE_OR_GENE_PRODUCT", 58, 69], ["exosome", "CELLULAR_COMPONENT", 81, 88], ["S6", "GENE_OR_GENE_PRODUCT", 117, 119], ["Alix", "PROTEIN", 23, 27], ["adiponectin", "PROTEIN", 58, 69], ["exosome", "PROTEIN", 81, 88], ["S6", "PROTEIN", 117, 119], ["cytokine", "PROTEIN", 140, 148], ["Alix knockdown", "TREATMENT", 23, 37], ["adiponectin", "TEST", 58, 69], ["cytokine secretion", "TEST", 140, 158], ["Alix knockdown", "OBSERVATION", 23, 37], ["decreased", "OBSERVATION_MODIFIER", 38, 47], ["basal", "OBSERVATION_MODIFIER", 48, 53]]], ["With regard to exosome production, Alix forms an important component of the ESCRT complex.", [["exosome", "ANATOMY", 15, 22], ["exosome", "CELLULAR_COMPONENT", 15, 22], ["Alix", "GENE_OR_GENE_PRODUCT", 35, 39], ["ESCRT", "GENE_OR_GENE_PRODUCT", 76, 81], ["Alix", "PROTEIN", 35, 39], ["ESCRT complex", "PROTEIN", 76, 89], ["the ESCRT complex", "PROBLEM", 72, 89], ["exosome production", "OBSERVATION", 15, 33], ["ESCRT complex", "OBSERVATION", 76, 89]]], ["42 TAC operation was followed by injection of siCont-transfected or Alix-siRNA-(siAlix)-transfected hMSCs ( Figure 7C ) and measurement of serum exosome level (Figures 7D and 7E ).", [["hMSCs", "ANATOMY", 100, 105], ["serum exosome", "ANATOMY", 139, 152], ["TAC", "CHEMICAL", 3, 6], ["TAC", "CHEMICAL", 3, 6], ["Alix", "GENE_OR_GENE_PRODUCT", 68, 72], ["siAlix", "SIMPLE_CHEMICAL", 80, 86], ["hMSCs", "CELL", 100, 105], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["exosome", "ORGANISM_SUBSTANCE", 145, 152], ["siCont-transfected or Alix-siRNA-(siAlix)-transfected hMSCs", "CELL_LINE", 46, 105], ["serum exosome", "PROTEIN", 139, 152], ["TAC operation", "TREATMENT", 3, 16], ["siCont-transfected", "TREATMENT", 46, 64], ["Alix-siRNA", "TREATMENT", 68, 78], ["serum exosome level", "TEST", 139, 158]]], ["Injection of siCont hMSCs significantly increased exosome markers hMFG-E8 and hCD63 and tended to increase Alix and Tsg101.", [["hMSCs", "ANATOMY", 20, 25], ["exosome", "ANATOMY", 50, 57], ["siCont hMSCs", "CELL", 13, 25], ["hMFG-E8", "GENE_OR_GENE_PRODUCT", 66, 73], ["hCD63", "GENE_OR_GENE_PRODUCT", 78, 83], ["Alix", "GENE_OR_GENE_PRODUCT", 107, 111], ["Tsg101", "GENE_OR_GENE_PRODUCT", 116, 122], ["siCont hMSCs", "CELL_LINE", 13, 25], ["exosome markers", "PROTEIN", 50, 65], ["hMFG", "PROTEIN", 66, 70], ["E8", "PROTEIN", 71, 73], ["hCD63", "PROTEIN", 78, 83], ["Alix", "PROTEIN", 107, 111], ["Tsg101", "PROTEIN", 116, 122], ["siCont hMSCs", "TEST", 13, 25], ["Tsg", "TEST", 116, 119]]], ["In contrast, the use of Alixknockdown hMSCs significantly decreased all the aforementioned exosome markers (Figures 7D and 7E) .", [["hMSCs", "ANATOMY", 38, 43], ["exosome", "ANATOMY", 91, 98], ["Alixknockdown hMSCs", "CELL", 24, 43], ["Alixknockdown hMSCs", "CELL_LINE", 24, 43], ["exosome markers", "PROTEIN", 91, 106], ["Alixknockdown hMSCs", "TREATMENT", 24, 43]]], ["Furthermore, heart weight increased significantly after TAC, compared to sham operation, and significantly decreased by injection of siCont hMSCs.", [["heart", "ANATOMY", 13, 18], ["hMSCs", "ANATOMY", 140, 145], ["TAC", "CHEMICAL", 56, 59], ["TAC", "CHEMICAL", 56, 59], ["heart", "ORGAN", 13, 18], ["TAC", "SIMPLE_CHEMICAL", 56, 59], ["hMSCs", "CELL", 140, 145], ["siCont hMSCs", "CELL_LINE", 133, 145], ["heart weight", "TEST", 13, 25], ["TAC", "TREATMENT", 56, 59], ["sham operation", "TREATMENT", 73, 87], ["siCont hMSCs", "TREATMENT", 133, 145], ["heart", "ANATOMY", 13, 18], ["weight", "OBSERVATION", 19, 25], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["significantly", "OBSERVATION_MODIFIER", 93, 106], ["decreased", "OBSERVATION_MODIFIER", 107, 116]]], ["On the other hand, the use of Alix-knockdown hMSCs significantly attenuated such effects ( Figure 7F ).", [["hMSCs", "ANATOMY", 45, 50], ["Alix", "GENE_OR_GENE_PRODUCT", 30, 34], ["hMSCs", "CELL", 45, 50], ["Alix-knockdown hMSCs", "CELL_LINE", 30, 50], ["Alix-knockdown hMSCs", "TREATMENT", 30, 50]]], ["We also used echocardiography to evaluate the cardioprotective effects of the exosome-deficient hMSCs (Figure 7G ).", [["exosome", "ANATOMY", 78, 85], ["hMSCs", "ANATOMY", 96, 101], ["exosome", "GENE_OR_GENE_PRODUCT", 78, 85], ["hMSCs", "CELL", 96, 101], ["exosome", "PROTEIN", 78, 85], ["hMSCs", "CELL_TYPE", 96, 101], ["echocardiography", "TEST", 13, 29], ["the exosome-deficient hMSCs", "TREATMENT", 74, 101]]], ["As shown in Figures 3D, 4H , 5G, and 6G, TAC decreased cardiac function, as determined by EF and FS, and injection of siCont hMSCs significantly improved cardiac function ( Figure 7H ).", [["cardiac", "ANATOMY", 55, 62], ["hMSCs", "ANATOMY", 125, 130], ["cardiac", "ANATOMY", 154, 161], ["TAC", "CHEMICAL", 41, 44], ["TAC", "CHEMICAL", 41, 44], ["6G", "SIMPLE_CHEMICAL", 37, 39], ["TAC", "SIMPLE_CHEMICAL", 41, 44], ["cardiac", "ORGAN", 55, 62], ["hMSCs", "CELL", 125, 130], ["cardiac", "ORGAN", 154, 161], ["siCont hMSCs", "CELL_LINE", 118, 130], ["EF", "TEST", 90, 92], ["FS", "TEST", 97, 99], ["siCont hMSCs", "TREATMENT", 118, 130], ["cardiac", "ANATOMY", 55, 62]]], ["In contrast, Alix-knockdown hMSCs significantly attenuated the cardioprotective effects of hMSCs ( Figure 7H ; Table S4 ).", [["hMSCs", "ANATOMY", 28, 33], ["hMSCs", "ANATOMY", 91, 96], ["Alix", "GENE_OR_GENE_PRODUCT", 13, 17], ["hMSCs", "CELL", 28, 33], ["hMSCs", "CELL", 91, 96], ["Alix-knockdown hMSCs", "CELL_LINE", 13, 33], ["hMSCs", "CELL_TYPE", 91, 96], ["Alix-knockdown hMSCs", "TREATMENT", 13, 33], ["cardioprotective effects", "OBSERVATION_MODIFIER", 63, 87]]], ["Collectively, these results indicate that hMSCs require exosome biogenesis for both normal exosome production and therapeutic effects in the heart failure model.MicroRNAs in Exosomes of hMSCsMicroRNA (miRNA) mediates intercellular communication with exosomes.", [["hMSCs", "ANATOMY", 42, 47], ["exosome", "ANATOMY", 56, 63], ["exosome", "ANATOMY", 91, 98], ["heart", "ANATOMY", 141, 146], ["Exosomes", "ANATOMY", 174, 182], ["intercellular", "ANATOMY", 217, 230], ["exosomes", "ANATOMY", 250, 258], ["heart failure", "DISEASE", 141, 154], ["hMSCs", "CELL", 42, 47], ["exosome", "CELLULAR_COMPONENT", 56, 63], ["heart", "ORGAN", 141, 146], ["Exosomes", "CELL", 174, 182], ["hMSCsMicroRNA", "GENE_OR_GENE_PRODUCT", 186, 199], ["exosomes", "CELL", 250, 258], ["hMSCs", "CELL_TYPE", 42, 47], ["Exosomes", "CELL_TYPE", 174, 182], ["hMSCsMicroRNA", "PROTEIN", 186, 199], ["exosomes", "CELL_TYPE", 250, 258], ["exosome biogenesis", "TREATMENT", 56, 74], ["the heart failure model", "PROBLEM", 137, 160], ["MicroRNAs", "TEST", 161, 170], ["hMSCsMicroRNA (miRNA)", "TREATMENT", 186, 207], ["exosome production", "OBSERVATION", 91, 109], ["heart", "ANATOMY", 141, 146], ["failure", "OBSERVATION", 147, 154]]], ["25, 26 We performed miRNA sequencing (miRNA-seq) and compared the miRNA profile of hMSCs-produced exosomes in the presence or absence of 20 mg/mL adiponectin in vitro ( Figure 8A ).MicroRNAs in Exosomes of hMSCsThe resultant scatterplot suggested that adiponectin had little or no effect on the miRNA profile of the produced exosomes ( Figure 8A ).", [["hMSCs", "ANATOMY", 83, 88], ["exosomes", "ANATOMY", 98, 106], ["Exosomes", "ANATOMY", 194, 202], ["hMSCs", "ANATOMY", 206, 211], ["exosomes", "ANATOMY", 325, 333], ["hMSCs", "CELL", 83, 88], ["exosomes", "CELL", 98, 106], ["adiponectin", "GENE_OR_GENE_PRODUCT", 146, 157], ["Exosomes", "CELL", 194, 202], ["hMSCs", "CELL", 206, 211], ["adiponectin", "GENE_OR_GENE_PRODUCT", 252, 263], ["exosomes", "CELL", 325, 333], ["miRNA-seq", "DNA", 38, 47], ["hMSCs", "CELL_TYPE", 83, 88], ["exosomes", "CELL_TYPE", 98, 106], ["adiponectin", "PROTEIN", 146, 157], ["Exosomes", "CELL_TYPE", 194, 202], ["hMSCs", "CELL_TYPE", 206, 211], ["adiponectin", "PROTEIN", 252, 263], ["exosomes", "CELL_TYPE", 325, 333], ["miRNA sequencing", "TEST", 20, 36], ["MicroRNAs", "TEST", 181, 190], ["adiponectin", "PROBLEM", 252, 263], ["hMSCs", "OBSERVATION", 206, 211]]], ["Among the meaningfully abundant miRNAs (fragments per kilobase of exon per million mapped fragments [FPKM] > 100), over half were accounted for by the seven highest expressing miRNAs and their families, including let-7 family, miR-21, -100, -148a, -10, -26, and -199 ( Figure 8B ).", [["let-7", "GENE_OR_GENE_PRODUCT", 213, 218], ["miR-21", "GENE_OR_GENE_PRODUCT", 227, 233], ["-100", "GENE_OR_GENE_PRODUCT", 235, 239], ["148a", "GENE_OR_GENE_PRODUCT", 242, 246], ["10", "GENE_OR_GENE_PRODUCT", 249, 251], ["Figure 8B", "GENE_OR_GENE_PRODUCT", 269, 278], ["miRNAs", "DNA", 32, 38], ["exon", "DNA", 66, 70], ["FPKM", "DNA", 101, 105], ["let-7 family", "DNA", 213, 225], ["miR-21", "DNA", 227, 233], ["148a", "DNA", 242, 246], ["Figure 8B", "DNA", 269, 278], ["exon per million mapped fragments", "TREATMENT", 66, 99], ["FPKM", "TEST", 101, 105], ["abundant", "OBSERVATION_MODIFIER", 23, 31], ["miRNAs", "OBSERVATION", 32, 38]]], ["These miRNAs are known to mediate cardiovascular protection.", [["cardiovascular", "ANATOMY", 34, 48], ["cardiovascular", "ANATOMICAL_SYSTEM", 34, 48], ["cardiovascular protection", "OBSERVATION", 34, 59]]], ["[43] [44] [45] [46] Next, we evaluated the change in cardiac transcriptome induced by hMSCs in vivo.", [["cardiac", "ANATOMY", 53, 60], ["hMSCs", "ANATOMY", 86, 91], ["[43] [44] [45] [46", "SIMPLE_CHEMICAL", 0, 18], ["cardiac", "ORGAN", 53, 60], ["hMSCs", "CELL", 86, 91], ["hMSCs", "CELL_TYPE", 86, 91], ["cardiac transcriptome", "TREATMENT", 53, 74], ["cardiac", "ANATOMY", 53, 60], ["transcriptome", "OBSERVATION", 61, 74]]], ["Since TAC resulted in cardiac dysfunction, hMSCs with siCont significantly protected against such dysfunction, and Alix-knockdown hMSCs had poor effect on the heart, we extracted the differentially expressed genes evident on the heatmap that were associated with the aforementioned changes in cardiac function (Figure 8C ).", [["cardiac", "ANATOMY", 22, 29], ["hMSCs", "ANATOMY", 43, 48], ["hMSCs", "ANATOMY", 130, 135], ["heart", "ANATOMY", 159, 164], ["cardiac", "ANATOMY", 293, 300], ["TAC", "CHEMICAL", 6, 9], ["cardiac dysfunction", "DISEASE", 22, 41], ["TAC", "CHEMICAL", 6, 9], ["TAC", "SIMPLE_CHEMICAL", 6, 9], ["cardiac", "ORGAN", 22, 29], ["hMSCs", "CELL", 43, 48], ["Alix", "GENE_OR_GENE_PRODUCT", 115, 119], ["hMSCs", "CELL", 130, 135], ["heart", "ORGAN", 159, 164], ["cardiac", "ORGAN", 293, 300], ["TAC", "PROTEIN", 6, 9], ["hMSCs", "CELL_TYPE", 43, 48], ["Alix", "PROTEIN", 115, 119], ["hMSCs", "CELL_TYPE", 130, 135], ["TAC", "TREATMENT", 6, 9], ["cardiac dysfunction", "PROBLEM", 22, 41], ["hMSCs", "PROBLEM", 43, 48], ["such dysfunction", "PROBLEM", 93, 109], ["Alix-knockdown hMSCs", "TREATMENT", 115, 135], ["poor effect on the heart", "PROBLEM", 140, 164], ["the heatmap", "PROBLEM", 225, 236], ["the aforementioned changes in cardiac function", "PROBLEM", 263, 309], ["cardiac", "ANATOMY", 22, 29], ["dysfunction", "OBSERVATION", 30, 41], ["heart", "ANATOMY", 159, 164], ["cardiac", "ANATOMY", 293, 300]]], ["Ontology analysis of all genes in the heatmap indicated association with \"TGFb signaling,\" \"cellular metabolic process,\" and \"apoptotic signaling pathway\" ( Figure 8D ).", [["cellular", "ANATOMY", 92, 100], ["TGFb", "GENE_OR_GENE_PRODUCT", 74, 78], ["cellular", "CELL", 92, 100], ["TGFb", "PROTEIN", 74, 78], ["Ontology analysis", "TEST", 0, 17], ["TGFb signaling", "PROBLEM", 74, 88], ["cellular metabolic process", "PROBLEM", 92, 118], ["metabolic process", "OBSERVATION", 101, 118]]], ["We also analyzed the predicted biological target of miRNAs by searching the TargetScan database.", [["miRNAs", "DNA", 52, 58]]], ["The results identified eight genes ( Figure 8C , red) among the differentially expressed genes that were probable targets of miRNAs in hMSC-derived exosomes ( Figure 8A , FPKM > 100; Table S5 ).", [["hMSC", "ANATOMY", 135, 139], ["exosomes", "ANATOMY", 148, 156], ["Figure 8C", "GENE_OR_GENE_PRODUCT", 37, 46], ["hMSC", "CELL", 135, 139], ["exosomes", "CELL", 148, 156], ["miRNAs", "DNA", 125, 131], ["hMSC", "CELL_TYPE", 135, 139], ["exosomes", "CELL_TYPE", 148, 156], ["miRNAs in hMSC", "PROBLEM", 125, 139], ["Figure", "TEST", 159, 165], ["FPKM", "TEST", 171, 175]]], ["Considered together, these results suggest that hMSCs-derived exosomes regulated, at least in part, the fibrogenic and adhesion pathways, and the cellular metabolic process, in the damaged heart.DISCUSSIONHere, we report that adiponectin stimulates exosome release to enhance MSC-driven therapy of heart failure in mice.", [["hMSCs", "ANATOMY", 48, 53], ["exosomes", "ANATOMY", 62, 70], ["cellular", "ANATOMY", 146, 154], ["heart", "ANATOMY", 189, 194], ["exosome", "ANATOMY", 249, 256], ["MSC", "ANATOMY", 276, 279], ["heart", "ANATOMY", 298, 303], ["heart failure", "DISEASE", 298, 311], ["hMSCs", "CELL", 48, 53], ["exosomes", "CELL", 62, 70], ["cellular", "CELL", 146, 154], ["heart", "ORGAN", 189, 194], ["adiponectin", "GENE_OR_GENE_PRODUCT", 226, 237], ["exosome", "CELLULAR_COMPONENT", 249, 256], ["MSC", "CELL", 276, 279], ["heart", "ORGAN", 298, 303], ["mice", "ORGANISM", 315, 319], ["hMSCs", "CELL_TYPE", 48, 53], ["exosomes", "CELL_TYPE", 62, 70], ["adiponectin", "PROTEIN", 226, 237], ["MSC", "CELL_TYPE", 276, 279], ["mice", "SPECIES", 315, 319], ["mice", "SPECIES", 315, 319], ["the fibrogenic and adhesion pathways", "PROBLEM", 100, 136], ["the cellular metabolic process", "PROBLEM", 142, 172], ["adiponectin stimulates exosome release", "TREATMENT", 226, 264], ["heart failure", "PROBLEM", 298, 311], ["fibrogenic", "OBSERVATION", 104, 114], ["cellular", "OBSERVATION_MODIFIER", 146, 154], ["metabolic process", "OBSERVATION", 155, 172], ["damaged", "ANATOMY_MODIFIER", 181, 188], ["heart", "ANATOMY", 189, 194], ["heart", "ANATOMY", 298, 303], ["failure", "OBSERVATION", 304, 311]]], ["This therapeutic effect of hMSCs was dependent on circulating adiponectin in recipient mice, T-cadherin expression in hMSCs, and ESCRT-mediated exosome production by hMSCs and was associated with increases in hMSC-derived exosomes in the circulation.", [["hMSCs", "ANATOMY", 27, 32], ["hMSCs", "ANATOMY", 118, 123], ["exosome", "ANATOMY", 144, 151], ["hMSCs", "ANATOMY", 166, 171], ["hMSC", "ANATOMY", 209, 213], ["exosomes", "ANATOMY", 222, 230], ["hMSCs", "CELL", 27, 32], ["adiponectin", "GENE_OR_GENE_PRODUCT", 62, 73], ["mice", "ORGANISM", 87, 91], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 93, 103], ["hMSCs", "CELL", 118, 123], ["ESCRT", "GENE_OR_GENE_PRODUCT", 129, 134], ["exosome", "CELLULAR_COMPONENT", 144, 151], ["hMSCs", "CELL", 166, 171], ["hMSC", "CELL", 209, 213], ["exosomes", "CELL", 222, 230], ["hMSCs", "CELL_TYPE", 27, 32], ["adiponectin", "PROTEIN", 62, 73], ["cadherin", "PROTEIN", 95, 103], ["hMSCs", "CELL_TYPE", 118, 123], ["ESCRT", "PROTEIN", 129, 134], ["hMSCs", "CELL_TYPE", 166, 171], ["hMSC", "CELL_TYPE", 209, 213], ["exosomes", "CELL_TYPE", 222, 230], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 87, 91], ["hMSCs", "PROBLEM", 27, 32], ["circulating adiponectin", "TREATMENT", 50, 73], ["circulation", "ANATOMY", 238, 249]]], ["An increase in plasma adiponectin level by the administration of PPARg agonist or adenoviral overexpression enhanced the therapeutic efficacy of hMSCs in the cardiac hypertrophy model.", [["plasma", "ANATOMY", 15, 21], ["hMSCs", "ANATOMY", 145, 150], ["cardiac", "ANATOMY", 158, 165], ["cardiac hypertrophy", "DISEASE", 158, 177], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["adiponectin", "GENE_OR_GENE_PRODUCT", 22, 33], ["PPARg", "GENE_OR_GENE_PRODUCT", 65, 70], ["adenoviral", "ORGANISM", 82, 92], ["hMSCs", "CELL", 145, 150], ["cardiac", "ORGAN", 158, 165], ["adiponectin", "PROTEIN", 22, 33], ["hMSCs", "CELL_TYPE", 145, 150], ["An increase in plasma adiponectin level", "PROBLEM", 0, 39], ["the administration of PPARg agonist", "TREATMENT", 43, 78], ["adenoviral overexpression", "PROBLEM", 82, 107], ["hMSCs", "PROBLEM", 145, 150], ["the cardiac hypertrophy model", "PROBLEM", 154, 183], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["plasma adiponectin", "OBSERVATION", 15, 33], ["therapeutic", "OBSERVATION_MODIFIER", 121, 132], ["cardiac", "ANATOMY", 158, 165], ["hypertrophy", "OBSERVATION", 166, 177]]], ["Our findings provide both a method to enhance MSC therapy and novel insights into the importance of exosome-mediated pleiotropic organ protection by adiponectin.DISCUSSIONWe demonstrated that plasma adiponectin level is a critical determinant of MSC-related effects in a heart failure model.", [["MSC", "ANATOMY", 46, 49], ["exosome", "ANATOMY", 100, 107], ["organ", "ANATOMY", 129, 134], ["plasma", "ANATOMY", 192, 198], ["MSC", "ANATOMY", 246, 249], ["heart", "ANATOMY", 271, 276], ["heart failure", "DISEASE", 271, 284], ["MSC", "CELL", 46, 49], ["exosome", "GENE_OR_GENE_PRODUCT", 100, 107], ["organ", "ORGAN", 129, 134], ["adiponectin", "GENE_OR_GENE_PRODUCT", 149, 160], ["plasma", "ORGANISM_SUBSTANCE", 192, 198], ["adiponectin", "GENE_OR_GENE_PRODUCT", 199, 210], ["MSC", "CELL", 246, 249], ["heart", "ORGAN", 271, 276], ["MSC", "CELL_TYPE", 46, 49], ["exosome", "PROTEIN", 100, 107], ["adiponectin", "PROTEIN", 149, 160], ["adiponectin", "PROTEIN", 199, 210], ["MSC", "CELL_TYPE", 246, 249], ["a method", "TREATMENT", 26, 34], ["MSC therapy", "TREATMENT", 46, 57], ["exosome-mediated pleiotropic organ protection", "TREATMENT", 100, 145], ["adiponectin", "TREATMENT", 149, 160], ["plasma adiponectin level", "TEST", 192, 216], ["a heart failure model", "PROBLEM", 269, 290], ["heart", "ANATOMY", 271, 276], ["failure", "OBSERVATION", 277, 284]]], ["Loss of adiponectin diminished, and its increase enhanced, the therapeutic efficacy of hMSCs.", [["hMSCs", "ANATOMY", 87, 92], ["adiponectin", "GENE_OR_GENE_PRODUCT", 8, 19], ["hMSCs", "CELL", 87, 92], ["adiponectin", "PROTEIN", 8, 19], ["hMSCs", "CELL_TYPE", 87, 92], ["Loss of adiponectin diminished", "PROBLEM", 0, 30], ["hMSCs", "PROBLEM", 87, 92], ["adiponectin", "OBSERVATION_MODIFIER", 8, 19], ["diminished", "OBSERVATION_MODIFIER", 20, 30], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["enhanced", "OBSERVATION_MODIFIER", 49, 57], ["therapeutic", "OBSERVATION_MODIFIER", 63, 74]]], ["It will be intriguing to determine the baseline plasma adiponectin levels between responders and non-responders in hMSC-based clinical trials.", [["plasma", "ANATOMY", 48, 54], ["hMSC", "ANATOMY", 115, 119], ["plasma", "ORGANISM_SUBSTANCE", 48, 54], ["adiponectin", "GENE_OR_GENE_PRODUCT", 55, 66], ["hMSC", "CELL", 115, 119], ["adiponectin", "PROTEIN", 55, 66], ["hMSC", "CELL_TYPE", 115, 119], ["the baseline plasma adiponectin levels", "TEST", 35, 73]]], ["Notably, the cardioprotective effects of hMSCs were not significant in adiponectin-deficient mice; hence, one can conclude that the PPARg agonist used in this study did not directly affect hMSCs but exerted the observed cardioprotective effect by increasing plasma adiponectin levels.", [["hMSCs", "ANATOMY", 41, 46], ["hMSCs", "ANATOMY", 189, 194], ["plasma", "ANATOMY", 258, 264], ["hMSCs", "CELL", 41, 46], ["adiponectin", "GENE_OR_GENE_PRODUCT", 71, 82], ["mice", "ORGANISM", 93, 97], ["PPARg", "GENE_OR_GENE_PRODUCT", 132, 137], ["hMSCs", "CELL", 189, 194], ["plasma", "ORGANISM_SUBSTANCE", 258, 264], ["adiponectin", "GENE_OR_GENE_PRODUCT", 265, 276], ["hMSCs", "CELL_TYPE", 41, 46], ["adiponectin", "PROTEIN", 71, 82], ["hMSCs", "CELL_TYPE", 189, 194], ["adiponectin", "PROTEIN", 265, 276], ["mice", "SPECIES", 93, 97], ["the cardioprotective effects of hMSCs", "PROBLEM", 9, 46], ["the PPARg agonist", "TREATMENT", 128, 145], ["this study", "TEST", 154, 164], ["increasing plasma adiponectin levels", "TREATMENT", 247, 283]]], ["We reported previously that the use of a PPARg agonist enhanced the therapeutic effect of a surgical fibrin graft containing stromal-vascular cells in a chronic myocardial infarction model.", [["stromal-vascular cells", "ANATOMY", 125, 147], ["myocardial", "ANATOMY", 161, 171], ["chronic myocardial infarction", "DISEASE", 153, 182], ["PPARg", "SIMPLE_CHEMICAL", 41, 46], ["fibrin", "GENE_OR_GENE_PRODUCT", 101, 107], ["stromal-vascular cells", "CELL", 125, 147], ["myocardial", "MULTI-TISSUE_STRUCTURE", 161, 171], ["stromal-vascular cells", "CELL_TYPE", 125, 147], ["a PPARg agonist", "TREATMENT", 39, 54], ["a surgical fibrin graft", "TREATMENT", 90, 113], ["stromal-vascular cells", "PROBLEM", 125, 147], ["a chronic myocardial infarction model", "PROBLEM", 151, 188], ["surgical fibrin graft", "OBSERVATION", 92, 113], ["vascular cells", "ANATOMY", 133, 147], ["chronic", "OBSERVATION_MODIFIER", 153, 160], ["myocardial", "ANATOMY", 161, 171], ["infarction", "OBSERVATION", 172, 182]]], ["47 Another group reported that a PPARg agonist enhanced the therapeutic effects of MSCs in the type 2 diabetes model through a decrease in plasma glucose levels.", [["MSCs", "ANATOMY", 83, 87], ["plasma", "ANATOMY", 139, 145], ["type 2 diabetes", "DISEASE", 95, 110], ["glucose", "CHEMICAL", 146, 153], ["glucose", "CHEMICAL", 146, 153], ["PPARg", "SIMPLE_CHEMICAL", 33, 38], ["MSCs", "CELL", 83, 87], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["glucose", "SIMPLE_CHEMICAL", 146, 153], ["MSCs", "CELL_TYPE", 83, 87], ["a PPARg agonist", "TREATMENT", 31, 46], ["MSCs", "PROBLEM", 83, 87], ["the type 2 diabetes model", "PROBLEM", 91, 116], ["plasma glucose levels", "TEST", 139, 160]]], ["48 Importantly, the increase of adiponectin by pioglitazone treatment accompanied the improved cardiac function only when hMSCs were injected ( Figures 5F and 5G) .", [["cardiac", "ANATOMY", 95, 102], ["hMSCs", "ANATOMY", 122, 127], ["pioglitazone", "CHEMICAL", 47, 59], ["pioglitazone", "CHEMICAL", 47, 59], ["adiponectin", "GENE_OR_GENE_PRODUCT", 32, 43], ["pioglitazone", "SIMPLE_CHEMICAL", 47, 59], ["cardiac", "ORGAN", 95, 102], ["hMSCs", "CELL", 122, 127], ["adiponectin", "PROTEIN", 32, 43], ["hMSCs", "CELL_TYPE", 122, 127], ["adiponectin", "TREATMENT", 32, 43], ["pioglitazone treatment", "TREATMENT", 47, 69], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["improved", "OBSERVATION_MODIFIER", 86, 94], ["cardiac", "ANATOMY", 95, 102]]], ["Further, in AKO mice, hMSC transplantation with a PPARg agonist did not affect cardiac functions (Figures 5F and 5G) .", [["hMSC", "ANATOMY", 22, 26], ["cardiac", "ANATOMY", 79, 86], ["AKO mice", "ORGANISM", 12, 20], ["hMSC", "CELL", 22, 26], ["PPARg", "GENE_OR_GENE_PRODUCT", 50, 55], ["cardiac", "ORGAN", 79, 86], ["hMSC", "CELL_TYPE", 22, 26], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["hMSC transplantation", "TREATMENT", 22, 42], ["a PPARg agonist", "TREATMENT", 48, 63]]], ["Taken together, a PPARg-agonist-mediated adiponectin increment strengthened the efficacy of hMSC transplantation rather than a PPARg agonist or adiponectin affected independently of transplanted hMSCs.", [["hMSC", "ANATOMY", 92, 96], ["hMSCs", "ANATOMY", 195, 200], ["PPARg", "GENE_OR_GENE_PRODUCT", 18, 23], ["adiponectin", "GENE_OR_GENE_PRODUCT", 41, 52], ["hMSC", "CELL", 92, 96], ["PPARg", "GENE_OR_GENE_PRODUCT", 127, 132], ["adiponectin", "GENE_OR_GENE_PRODUCT", 144, 155], ["hMSCs", "CELL", 195, 200], ["PPARg", "PROTEIN", 18, 23], ["adiponectin", "PROTEIN", 41, 52], ["PPARg", "PROTEIN", 127, 132], ["adiponectin", "PROTEIN", 144, 155], ["transplanted hMSCs", "CELL_TYPE", 182, 200], ["a PPARg-agonist-mediated adiponectin increment", "TREATMENT", 16, 62], ["hMSC transplantation", "TREATMENT", 92, 112], ["a PPARg agonist", "TREATMENT", 125, 140], ["adiponectin affected", "PROBLEM", 144, 164], ["transplanted hMSCs", "TREATMENT", 182, 200], ["hMSC transplantation", "OBSERVATION", 92, 112]]], ["Therefore, no equivalent MSC-like cells and other T-cadherin-expressing cells in mice appeared to respond to adiponectin in our TAC model, except by superphysiological overexpression of adiponectin by adenovirus ( Figure S4 ).", [["MSC-like cells", "ANATOMY", 25, 39], ["cells", "ANATOMY", 72, 77], ["TAC", "CHEMICAL", 128, 131], ["MSC-like cells", "CELL", 25, 39], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 50, 60], ["cells", "CELL", 72, 77], ["mice", "ORGANISM", 81, 85], ["adiponectin", "GENE_OR_GENE_PRODUCT", 109, 120], ["TAC", "SIMPLE_CHEMICAL", 128, 131], ["adiponectin", "GENE_OR_GENE_PRODUCT", 186, 197], ["adenovirus", "ORGANISM", 201, 211], ["MSC", "CELL_TYPE", 25, 28], ["T-cadherin-expressing cells", "CELL_TYPE", 50, 77], ["adiponectin", "PROTEIN", 109, 120], ["adiponectin", "PROTEIN", 186, 197], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["like cells", "PROBLEM", 29, 39], ["expressing cells", "PROBLEM", 61, 77], ["adiponectin", "TREATMENT", 109, 120], ["no", "UNCERTAINTY", 11, 13]]], ["Our study in the normoglycemic heart failure model indicates that exosome stimulation through an increase in circulating adiponectin level should be one of the key mechanisms of such action of PPARg agonists and provide the future opportunity of advanced therapeutic applications.DISCUSSIONAlthough the initial applications selected for MSC therapy focused on their multi-lineage differentiation capacity, the importance of secreting mediators has been gained momentum recently.", [["heart", "ANATOMY", 31, 36], ["exosome", "ANATOMY", 66, 73], ["MSC", "ANATOMY", 337, 340], ["multi-lineage", "ANATOMY", 366, 379], ["heart failure", "DISEASE", 31, 44], ["heart", "ORGAN", 31, 36], ["exosome", "CELLULAR_COMPONENT", 66, 73], ["adiponectin", "GENE_OR_GENE_PRODUCT", 121, 132], ["PPARg", "GENE_OR_GENE_PRODUCT", 193, 198], ["MSC", "CELL", 337, 340], ["multi-lineage", "CELL", 366, 379], ["adiponectin", "PROTEIN", 121, 132], ["Our study", "TEST", 0, 9], ["exosome stimulation", "TREATMENT", 66, 85], ["an increase in circulating adiponectin level", "PROBLEM", 94, 138], ["PPARg agonists", "TREATMENT", 193, 207], ["advanced therapeutic applications", "TREATMENT", 246, 279], ["MSC therapy", "TREATMENT", 337, 348], ["heart", "ANATOMY", 31, 36], ["failure", "OBSERVATION", 37, 44], ["exosome stimulation", "OBSERVATION", 66, 85], ["increase", "OBSERVATION_MODIFIER", 97, 105]]], ["49 MSC therapy reduced the severity of inflammation, apoptosis, and fibrosis in numerous disease models, despite little differentiation and engraftment in the injured tissue.", [["MSC", "ANATOMY", 3, 6], ["tissue", "ANATOMY", 167, 173], ["inflammation", "DISEASE", 39, 51], ["fibrosis", "DISEASE", 68, 76], ["MSC", "CELL", 3, 6], ["tissue", "TISSUE", 167, 173], ["MSC therapy", "TREATMENT", 3, 14], ["inflammation", "PROBLEM", 39, 51], ["apoptosis", "PROBLEM", 53, 62], ["fibrosis in numerous disease models", "PROBLEM", 68, 103], ["engraftment in the injured tissue", "PROBLEM", 140, 173], ["severity", "OBSERVATION_MODIFIER", 27, 35], ["inflammation", "OBSERVATION", 39, 51], ["apoptosis", "OBSERVATION_MODIFIER", 53, 62], ["fibrosis", "OBSERVATION", 68, 76], ["numerous", "OBSERVATION_MODIFIER", 80, 88], ["disease", "OBSERVATION", 89, 96], ["little differentiation", "OBSERVATION_MODIFIER", 113, 135], ["engraftment", "OBSERVATION", 140, 151], ["injured tissue", "OBSERVATION", 159, 173]]], ["51 Indeed, MSCs secrete a variety of bioactive molecules, such as cytokines, chemokines, growth factors, and exosomes.", [["MSCs", "ANATOMY", 11, 15], ["exosomes", "ANATOMY", 109, 117], ["MSCs", "CELL", 11, 15], ["exosomes", "CELL", 109, 117], ["MSCs", "CELL_TYPE", 11, 15], ["cytokines", "PROTEIN", 66, 75], ["chemokines", "PROTEIN", 77, 87], ["growth factors", "PROTEIN", 89, 103], ["exosomes", "CELL_TYPE", 109, 117], ["bioactive molecules", "PROBLEM", 37, 56], ["bioactive molecules", "OBSERVATION", 37, 56]]], ["52 In our study, we used a systemic injection of hMSCs and confirmed that the vast majority of them accumulated in the lung.", [["hMSCs", "ANATOMY", 49, 54], ["lung", "ANATOMY", 119, 123], ["hMSCs", "CELL", 49, 54], ["lung", "ORGAN", 119, 123], ["hMSCs", "CELL_TYPE", 49, 54], ["our study", "TEST", 6, 15], ["a systemic injection of hMSCs", "TREATMENT", 25, 54], ["lung", "ANATOMY", 119, 123]]], ["34, 35 Hence, the effects of hMSCs are supposed to mainly rely on paracrinesecreting mediators.", [["hMSCs", "ANATOMY", 29, 34], ["hMSCs", "CELL", 29, 34], ["hMSCs", "CELL_TYPE", 29, 34], ["paracrinesecreting mediators", "PROTEIN", 66, 94], ["hMSCs", "TREATMENT", 29, 34]]], ["More specifically, genetic loss of Alix, an ESCRT machinery important for exosome biogenesis, 42 resulted in markedly diminished exosome production by MSCs in vivo and therapeutic effects on the heart failure model, implicating the exosome in mediating MSC effects.", [["exosome", "ANATOMY", 74, 81], ["exosome", "ANATOMY", 129, 136], ["MSCs", "ANATOMY", 151, 155], ["heart", "ANATOMY", 195, 200], ["exosome", "ANATOMY", 232, 239], ["MSC", "ANATOMY", 253, 256], ["heart failure", "DISEASE", 195, 208], ["Alix", "GENE_OR_GENE_PRODUCT", 35, 39], ["ESCRT", "GENE_OR_GENE_PRODUCT", 44, 49], ["exosome", "CELLULAR_COMPONENT", 74, 81], ["MSCs", "CELL", 151, 155], ["heart", "ORGAN", 195, 200], ["MSC", "CELL", 253, 256], ["Alix", "PROTEIN", 35, 39], ["MSCs", "CELL_TYPE", 151, 155], ["exosome", "PROTEIN", 232, 239], ["MSC", "CELL_TYPE", 253, 256], ["genetic loss of Alix", "PROBLEM", 19, 39], ["an ESCRT machinery", "TREATMENT", 41, 59], ["markedly diminished exosome production", "PROBLEM", 109, 147], ["the heart failure model", "PROBLEM", 191, 214], ["markedly", "OBSERVATION_MODIFIER", 109, 117], ["diminished", "OBSERVATION_MODIFIER", 118, 128], ["exosome production", "OBSERVATION", 129, 147], ["heart", "ANATOMY", 195, 200], ["failure", "OBSERVATION", 201, 208], ["MSC effects", "OBSERVATION", 253, 264]]], ["Our loss-of-exosome study is the first direct demonstration that exosomes mediate the paracrine therapeutic activity of injected MSCs.", [["exosomes", "ANATOMY", 65, 73], ["MSCs", "ANATOMY", 129, 133], ["exosomes", "CELL", 65, 73], ["MSCs", "CELL", 129, 133], ["exosomes", "CELL_TYPE", 65, 73], ["MSCs", "CELL_TYPE", 129, 133], ["exosome study", "TEST", 12, 25], ["injected MSCs", "PROBLEM", 120, 133]]], ["Moreover, we confirmed that neither Alix knockdown nor adiponectin treatment altered cytokine secretion from cultured MSCs and multilineage differentiation potential (Figures S7 and S8) .DISCUSSIONFunctionally, exosomes mediate cell-to-cell communication under normal and pathological conditions, by transferring several factors, like active proteins, lipids, and small non-coding RNAs, stably in various biofluids.", [["MSCs", "ANATOMY", 118, 122], ["exosomes", "ANATOMY", 211, 219], ["cell", "ANATOMY", 228, 232], ["cell", "ANATOMY", 236, 240], ["biofluids", "ANATOMY", 405, 414], ["adiponectin", "CHEMICAL", 55, 66], ["Alix", "GENE_OR_GENE_PRODUCT", 36, 40], ["adiponectin", "GENE_OR_GENE_PRODUCT", 55, 66], ["MSCs", "CELL", 118, 122], ["exosomes", "CELL", 211, 219], ["cell", "CELL", 228, 232], ["cell", "CELL", 236, 240], ["lipids", "SIMPLE_CHEMICAL", 352, 358], ["Alix", "PROTEIN", 36, 40], ["adiponectin", "PROTEIN", 55, 66], ["cytokine", "PROTEIN", 85, 93], ["MSCs", "CELL_TYPE", 118, 122], ["exosomes", "CELL_TYPE", 211, 219], ["small non-coding RNAs", "RNA", 364, 385], ["Alix knockdown", "TREATMENT", 36, 50], ["adiponectin treatment", "TREATMENT", 55, 76], ["altered cytokine secretion", "PROBLEM", 77, 103], ["cultured MSCs", "TEST", 109, 122], ["lipids", "TEST", 352, 358], ["small non-coding RNAs", "PROBLEM", 364, 385], ["Alix knockdown", "OBSERVATION", 36, 50], ["small", "OBSERVATION_MODIFIER", 364, 369], ["non-coding RNAs", "OBSERVATION", 370, 385]]], ["25, 26 The results of the miRNA-seq of hMSCsderived exosomes indicate that these extracellular structures contain large amounts of the let-7 family and miR-21, -148, and -10 ( Figure 8 ), which are known to be beneficial for cardiovascular disease.", [["hMSCsderived exosomes", "ANATOMY", 39, 60], ["extracellular structures", "ANATOMY", 81, 105], ["cardiovascular", "ANATOMY", 225, 239], ["cardiovascular disease", "DISEASE", 225, 247], ["hMSCsderived exosomes", "CELL", 39, 60], ["extracellular structures", "CELLULAR_COMPONENT", 81, 105], ["let-7", "GENE_OR_GENE_PRODUCT", 135, 140], ["miR-21", "GENE_OR_GENE_PRODUCT", 152, 158], ["-148", "GENE_OR_GENE_PRODUCT", 160, 164], ["-10", "GENE_OR_GENE_PRODUCT", 170, 173], ["cardiovascular", "ANATOMICAL_SYSTEM", 225, 239], ["hMSCsderived exosomes", "CELL_LINE", 39, 60], ["the miRNA", "TEST", 22, 31], ["cardiovascular disease", "PROBLEM", 225, 247], ["large", "OBSERVATION_MODIFIER", 114, 119], ["amounts", "OBSERVATION_MODIFIER", 120, 127]]], ["[44] [45] [46] Integrating the results of miRNA-seq in exosomes and mRNA sequencing in hearts, a large part of the differentially expressed genes with or without MSC-derived exosome was found to be potentially regulated by major miRNAs contained in hMSC-derived exosomes.", [["exosomes", "ANATOMY", 55, 63], ["hearts", "ANATOMY", 87, 93], ["MSC", "ANATOMY", 162, 165], ["exosome", "ANATOMY", 174, 181], ["hMSC", "ANATOMY", 249, 253], ["exosomes", "ANATOMY", 262, 270], ["[44] [45] [46]", "SIMPLE_CHEMICAL", 0, 14], ["exosomes", "CELL", 55, 63], ["hearts", "ORGAN", 87, 93], ["MSC", "CELL", 162, 165], ["exosome", "CELLULAR_COMPONENT", 174, 181], ["hMSC", "CELL", 249, 253], ["exosomes", "CELL", 262, 270], ["exosomes", "CELL_TYPE", 55, 63], ["MSC", "CELL_TYPE", 162, 165], ["exosome", "PROTEIN", 174, 181], ["hMSC", "CELL_TYPE", 249, 253], ["exosomes", "CELL_TYPE", 262, 270], ["miRNA", "TEST", 42, 47], ["mRNA sequencing", "TEST", 68, 83], ["hearts", "ANATOMY", 87, 93], ["large", "OBSERVATION_MODIFIER", 97, 102]]], ["These findings are in agreement with the current concept that exosomes transfer miRNAs to regulate host cell gene expression, 25,26 but they do not exclude the importance of other bioactive components.", [["exosomes", "ANATOMY", 62, 70], ["cell", "ANATOMY", 104, 108], ["exosomes", "CELL", 62, 70], ["host cell", "CELL", 99, 108], ["exosomes", "CELL_TYPE", 62, 70], ["bioactive components", "OBSERVATION", 180, 200]]], ["We did not evaluate the roles of other extracellular vesicles like membrane vesicles.", [["extracellular vesicles", "ANATOMY", 39, 61], ["membrane vesicles", "ANATOMY", 67, 84], ["extracellular vesicles", "CELLULAR_COMPONENT", 39, 61], ["membrane vesicles", "CELLULAR_COMPONENT", 67, 84], ["membrane vesicles", "PROBLEM", 67, 84], ["extracellular", "ANATOMY_MODIFIER", 39, 52], ["vesicles", "OBSERVATION", 53, 61], ["membrane vesicles", "OBSERVATION", 67, 84]]], ["Although few changes were observed in the numbers of such larger vesicles (Figures 1A, 2C , and S5), our study does not exclude the possibility that such particles play some role.DISCUSSIONA growing number of clinical studies have demonstrated the usefulness of stem/progenitor cell transplantation for various diseases.", [["vesicles", "ANATOMY", 65, 73], ["stem/progenitor cell", "ANATOMY", 262, 282], ["vesicles", "CELLULAR_COMPONENT", 65, 73], ["stem", "CELL", 262, 266], ["progenitor cell", "CELL", 267, 282], ["stem/progenitor cell", "CELL_TYPE", 262, 282], ["few changes", "PROBLEM", 9, 20], ["our study", "TEST", 101, 110], ["clinical studies", "TEST", 209, 225], ["stem/progenitor cell transplantation", "TREATMENT", 262, 298], ["various diseases", "PROBLEM", 303, 319], ["few", "OBSERVATION_MODIFIER", 9, 12], ["larger", "OBSERVATION_MODIFIER", 58, 64], ["progenitor cell transplantation", "OBSERVATION", 267, 298]]], ["[19] [20] [21] [22] [23] There are still many challenges facing the use of this emerging cell therapy.", [["cell", "ANATOMY", 89, 93], ["[19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 0, 24], ["cell", "CELL", 89, 93], ["this emerging cell therapy", "TREATMENT", 75, 101]]], ["53 In our study, we used systemic injection of hMSCs and developed a new method using gLuc-fusion MFG-E8 to monitor the amount of exosome produced by the injected MSCs.", [["hMSCs", "ANATOMY", 47, 52], ["exosome", "ANATOMY", 130, 137], ["MSCs", "ANATOMY", 163, 167], ["hMSCs", "CELL", 47, 52], ["gLuc", "GENE_OR_GENE_PRODUCT", 86, 90], ["MFG-E8", "GENE_OR_GENE_PRODUCT", 98, 104], ["exosome", "CELLULAR_COMPONENT", 130, 137], ["MSCs", "CELL", 163, 167], ["hMSCs", "CELL_TYPE", 47, 52], ["gLuc", "PROTEIN", 86, 90], ["MFG", "PROTEIN", 98, 101], ["E8", "PROTEIN", 102, 104], ["exosome", "PROTEIN", 130, 137], ["MSCs", "CELL_TYPE", 163, 167], ["our study", "TEST", 6, 15], ["systemic injection of hMSCs", "TREATMENT", 25, 52], ["gLuc-fusion MFG", "TREATMENT", 86, 101]]], ["The activities of gLuc-MFG-E8 correlated with the number of exosomes in vitro and gradually decreased during the 3 days after injection in vivo ( Figures 2F and 4B ).", [["exosomes", "ANATOMY", 60, 68], ["gLuc-MFG-E8", "GENE_OR_GENE_PRODUCT", 18, 29], ["exosomes", "CELL", 60, 68], ["gLuc", "PROTEIN", 18, 22], ["MFG", "PROTEIN", 23, 26], ["E8", "DNA", 27, 29], ["exosomes", "CELL_TYPE", 60, 68], ["gLuc", "TEST", 18, 22]]], ["These results are in sharp contrast to the very fast disappearance of exosomes from the circulation within 2 h by macrophage-mediated phagocytosis in the liver when isolated exosomes were directly injected i.v.", [["exosomes", "ANATOMY", 70, 78], ["macrophage", "ANATOMY", 114, 124], ["liver", "ANATOMY", 154, 159], ["exosomes", "ANATOMY", 174, 182], ["exosomes", "CELL", 70, 78], ["macrophage", "CELL", 114, 124], ["liver", "ORGAN", 154, 159], ["exosomes", "CELL", 174, 182], ["exosomes", "CELL_TYPE", 70, 78], ["exosomes", "CELL_TYPE", 174, 182], ["macrophage-mediated phagocytosis in the liver", "PROBLEM", 114, 159], ["isolated exosomes", "TREATMENT", 165, 182], ["exosomes", "OBSERVATION", 70, 78], ["phagocytosis", "OBSERVATION", 134, 146], ["liver", "ANATOMY", 154, 159]]], ["39, 40 These results suggest that MSC therapy may have a different profile than cell-free exosome injection, at least in maintaining high concentrations of exosomes in the blood circulation.DISCUSSIONOur study did not completely rule out the possibility that hMSCs might exert their effect independent of exosomes.", [["MSC", "ANATOMY", 34, 37], ["cell", "ANATOMY", 80, 84], ["exosome", "ANATOMY", 90, 97], ["exosomes", "ANATOMY", 156, 164], ["blood", "ANATOMY", 172, 177], ["hMSCs", "ANATOMY", 259, 264], ["exosomes", "ANATOMY", 305, 313], ["MSC", "CELL", 34, 37], ["cell", "CELL", 80, 84], ["exosome", "ORGANISM_SUBSTANCE", 90, 97], ["exosomes", "CELL", 156, 164], ["blood", "ORGANISM_SUBSTANCE", 172, 177], ["hMSCs", "CELL", 259, 264], ["exosomes", "CELL", 305, 313], ["MSC", "CELL_TYPE", 34, 37], ["exosomes", "CELL_TYPE", 156, 164], ["hMSCs", "CELL_TYPE", 259, 264], ["exosomes", "CELL_TYPE", 305, 313], ["MSC therapy", "TREATMENT", 34, 45], ["cell-free exosome injection", "TREATMENT", 80, 107], ["DISCUSSIONOur study", "TEST", 190, 209], ["MSC therapy", "OBSERVATION", 34, 45], ["high concentrations", "OBSERVATION", 133, 152], ["exosomes", "OBSERVATION", 156, 164], ["blood circulation", "ANATOMY", 172, 189]]], ["However, this study strongly suggested that i.v. administrated hMSCs exerted their effects, at least partly, through exosome secretion in our TAC model.", [["hMSCs", "ANATOMY", 63, 68], ["exosome", "ANATOMY", 117, 124], ["TAC", "CHEMICAL", 142, 145], ["i.v.", "SIMPLE_CHEMICAL", 44, 48], ["hMSCs", "CELL", 63, 68], ["hMSCs", "CELL_TYPE", 63, 68], ["this study", "TEST", 9, 19], ["i.v. administrated hMSCs", "TREATMENT", 44, 68]]], ["Similar to findings in previous reports, we found that injected hMSCs mainly localized in the lung, not in the heart ( Figure 2B ).", [["hMSCs", "ANATOMY", 64, 69], ["lung", "ANATOMY", 94, 98], ["heart", "ANATOMY", 111, 116], ["hMSCs", "CELL", 64, 69], ["lung", "ORGAN", 94, 98], ["heart", "ORGAN", 111, 116], ["hMSCs", "CELL_TYPE", 64, 69], ["injected hMSCs", "PROBLEM", 55, 69], ["lung", "ANATOMY", 94, 98], ["heart", "ANATOMY", 111, 116]]], ["Transplantation of Alix-deficient hMSCs with significantly less exosome production did not improve cardiac function ( Figures 7G and 7H ), although these Alix-deficient hMSCs exerted profiles of cytokine production and differentiation activities similar to those of the control hMSCs ( Figures S7 and S8) .DISCUSSIONWe performed a set of experiments using TAC-induced hypertrophy as a heart failure model and demonstrated that hMSC injections from an early time point prevented cardiac dysfunction.", [["hMSCs", "ANATOMY", 34, 39], ["exosome", "ANATOMY", 64, 71], ["cardiac", "ANATOMY", 99, 106], ["hMSCs", "ANATOMY", 169, 174], ["hMSCs", "ANATOMY", 278, 283], ["heart", "ANATOMY", 385, 390], ["hMSC", "ANATOMY", 427, 431], ["cardiac", "ANATOMY", 478, 485], ["TAC", "CHEMICAL", 356, 359], ["hypertrophy", "DISEASE", 368, 379], ["heart failure", "DISEASE", 385, 398], ["cardiac dysfunction", "DISEASE", 478, 497], ["TAC", "CHEMICAL", 356, 359], ["Alix", "GENE_OR_GENE_PRODUCT", 19, 23], ["hMSCs", "CELL", 34, 39], ["cardiac", "ORGAN", 99, 106], ["Alix", "GENE_OR_GENE_PRODUCT", 154, 158], ["hMSCs", "CELL", 169, 174], ["hMSCs", "CELL", 278, 283], ["TAC", "SIMPLE_CHEMICAL", 356, 359], ["heart", "ORGAN", 385, 390], ["hMSC", "CELL", 427, 431], ["cardiac", "ORGAN", 478, 485], ["Alix-deficient hMSCs", "CELL_LINE", 19, 39], ["Alix", "PROTEIN", 154, 158], ["hMSCs", "CELL_TYPE", 169, 174], ["cytokine", "PROTEIN", 195, 203], ["hMSCs", "CELL_TYPE", 278, 283], ["hMSC", "CELL_TYPE", 427, 431], ["Transplantation of Alix-deficient hMSCs", "TREATMENT", 0, 39], ["significantly less exosome production", "PROBLEM", 45, 82], ["Figures", "TEST", 118, 125], ["cytokine production", "PROBLEM", 195, 214], ["differentiation activities", "PROBLEM", 219, 245], ["TAC", "TREATMENT", 356, 359], ["hypertrophy", "PROBLEM", 368, 379], ["a heart failure model", "PROBLEM", 383, 404], ["hMSC injections", "TREATMENT", 427, 442], ["cardiac dysfunction", "PROBLEM", 478, 497], ["Alix", "OBSERVATION", 19, 23], ["cytokine production", "OBSERVATION", 195, 214], ["hypertrophy", "OBSERVATION", 368, 379], ["heart", "ANATOMY", 385, 390], ["failure", "OBSERVATION", 391, 398], ["cardiac", "ANATOMY", 478, 485], ["dysfunction", "OBSERVATION", 486, 497]]], ["There will be also a possibility that hMSCs exert curative and/or regenerative effects on the heart after the development of heart failure, which remains to be determined.", [["hMSCs", "ANATOMY", 38, 43], ["heart", "ANATOMY", 94, 99], ["heart", "ANATOMY", 125, 130], ["heart failure", "DISEASE", 125, 138], ["hMSCs", "CELL", 38, 43], ["heart", "ORGAN", 94, 99], ["heart", "ORGAN", 125, 130], ["hMSCs", "CELL_TYPE", 38, 43], ["regenerative effects on the heart", "PROBLEM", 66, 99], ["heart failure", "PROBLEM", 125, 138], ["curative", "OBSERVATION", 50, 58], ["heart", "ANATOMY", 94, 99], ["heart", "ANATOMY", 125, 130], ["failure", "OBSERVATION", 131, 138]]], ["Also, the TAC model does not completely reflect the condition of clinical heart failure.", [["heart", "ANATOMY", 74, 79], ["heart failure", "DISEASE", 74, 87], ["TAC", "CHEMICAL", 10, 13], ["heart", "ORGAN", 74, 79], ["clinical heart failure", "PROBLEM", 65, 87], ["does not completely reflect", "UNCERTAINTY", 20, 47], ["heart", "ANATOMY", 74, 79], ["failure", "OBSERVATION", 80, 87]]], ["Further studies in different heart failure models should be important.", [["heart", "ANATOMY", 29, 34], ["heart failure", "DISEASE", 29, 42], ["heart", "ORGAN", 29, 34], ["Further studies", "TEST", 0, 15], ["different heart failure models", "PROBLEM", 19, 49], ["heart", "ANATOMY", 29, 34], ["failure", "OBSERVATION", 35, 42]]], ["The beneficial effects of hMSC injections for mortality and cardiovascular remodelings in severe conditions, such as end-stage heart failure and myocardial infarction, would be worth testing in the future.DISCUSSIONWe have established in the present study the importance of circulating adiponectin and exosomes on the cardioprotective properties of MSC therapy in a heart failure mouse model, in which progressive deterioration through loss of adiponectin or T-cadherin in mice was reported.", [["hMSC", "ANATOMY", 26, 30], ["cardiovascular", "ANATOMY", 60, 74], ["heart", "ANATOMY", 127, 132], ["myocardial", "ANATOMY", 145, 155], ["exosomes", "ANATOMY", 302, 310], ["MSC", "ANATOMY", 349, 352], ["heart", "ANATOMY", 366, 371], ["cardiovascular remodelings", "DISEASE", 60, 86], ["heart failure", "DISEASE", 127, 140], ["myocardial infarction", "DISEASE", 145, 166], ["heart failure", "DISEASE", 366, 379], ["hMSC", "CELL", 26, 30], ["cardiovascular", "ANATOMICAL_SYSTEM", 60, 74], ["heart", "ORGAN", 127, 132], ["myocardial", "MULTI-TISSUE_STRUCTURE", 145, 155], ["adiponectin", "GENE_OR_GENE_PRODUCT", 286, 297], ["exosomes", "CELL", 302, 310], ["MSC", "CELL", 349, 352], ["heart", "ORGAN", 366, 371], ["mouse", "ORGANISM", 380, 385], ["adiponectin", "GENE_OR_GENE_PRODUCT", 444, 455], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 459, 469], ["mice", "ORGANISM", 473, 477], ["adiponectin", "PROTEIN", 286, 297], ["adiponectin", "PROTEIN", 444, 455], ["T-cadherin", "PROTEIN", 459, 469], ["mouse", "SPECIES", 380, 385], ["mice", "SPECIES", 473, 477], ["mouse", "SPECIES", 380, 385], ["mice", "SPECIES", 473, 477], ["hMSC injections", "TREATMENT", 26, 41], ["mortality", "PROBLEM", 46, 55], ["cardiovascular remodelings", "PROBLEM", 60, 86], ["severe conditions", "PROBLEM", 90, 107], ["end-stage heart failure", "PROBLEM", 117, 140], ["myocardial infarction", "PROBLEM", 145, 166], ["worth testing", "TEST", 177, 190], ["circulating adiponectin", "TREATMENT", 274, 297], ["MSC therapy", "TREATMENT", 349, 360], ["a heart failure mouse model", "PROBLEM", 364, 391], ["progressive deterioration through loss of adiponectin", "PROBLEM", 402, 455], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["conditions", "OBSERVATION", 97, 107], ["stage", "OBSERVATION_MODIFIER", 121, 126], ["heart", "ANATOMY", 127, 132], ["failure", "OBSERVATION", 133, 140], ["myocardial", "ANATOMY", 145, 155], ["infarction", "OBSERVATION", 156, 166], ["heart", "ANATOMY", 366, 371], ["failure", "OBSERVATION", 372, 379], ["progressive", "OBSERVATION_MODIFIER", 402, 413], ["deterioration", "OBSERVATION", 414, 427]]], ["13 Adiponectin is a well-known pleiotropic humoral factor with anti-apoptotic, -fibrotic, and -diabetic effects.", [["diabetic", "DISEASE", 95, 103], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 3, 14], ["Adiponectin", "PROTEIN", 3, 14], ["pleiotropic humoral factor", "PROTEIN", 31, 57], ["fibrotic", "PROBLEM", 80, 88], ["diabetic effects", "PROBLEM", 95, 111], ["humoral", "ANATOMY", 43, 50], ["fibrotic", "OBSERVATION", 80, 88], ["diabetic", "OBSERVATION", 95, 103]]], ["2 Our RNAsequencing (RNA-seq) analysis identified differential expression of genes associated with transforming growth factor b (TGF-b) and apoptotic signaling following injection of hMSCs, i.e., a gain of MSCs ( Figures 8C and 8D ), well overlapping with known functional pathways of adiponectin.", [["hMSCs", "ANATOMY", 183, 188], ["MSCs", "ANATOMY", 206, 210], ["transforming growth factor b", "GENE_OR_GENE_PRODUCT", 99, 127], ["TGF-b", "GENE_OR_GENE_PRODUCT", 129, 134], ["hMSCs", "CELL", 183, 188], ["MSCs", "CELL", 206, 210], ["adiponectin", "GENE_OR_GENE_PRODUCT", 285, 296], ["transforming growth factor b", "PROTEIN", 99, 127], ["TGF-b", "PROTEIN", 129, 134], ["hMSCs", "CELL_TYPE", 183, 188], ["MSCs", "CELL_TYPE", 206, 210], ["adiponectin", "PROTEIN", 285, 296], ["transforming growth factor", "PROBLEM", 99, 125], ["TGF", "TEST", 129, 132], ["apoptotic signaling", "PROBLEM", 140, 159], ["injection of hMSCs", "TREATMENT", 170, 188], ["MSCs", "PROBLEM", 206, 210], ["adiponectin", "TREATMENT", 285, 296]]], ["MSC-like cells reside in virtually all tissues and are thought to maintain organ homeostasis.", [["MSC-like cells", "ANATOMY", 0, 14], ["tissues", "ANATOMY", 39, 46], ["organ", "ANATOMY", 75, 80], ["MSC-like cells", "CELL", 0, 14], ["tissues", "TISSUE", 39, 46], ["organ", "ORGAN", 75, 80], ["MSC", "CELL_TYPE", 0, 3], ["MSC", "PROBLEM", 0, 3], ["like cells", "PROBLEM", 4, 14]]], ["17 Analyses on the expression of T-cadherin in multiple single-cell RNA sequence databases in a variety of tissues suggested that tissue-resident MSC-like cells express T-cadherin ( Figure S9 ).", [["tissues", "ANATOMY", 107, 114], ["tissue", "ANATOMY", 130, 136], ["MSC-like cells", "ANATOMY", 146, 160], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 33, 43], ["tissues", "TISSUE", 107, 114], ["tissue-resident MSC-like cells", "CELL", 130, 160], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 169, 179], ["Figure S9", "GENE_OR_GENE_PRODUCT", 182, 191], ["T-cadherin", "PROTEIN", 33, 43], ["tissue-resident MSC-like cells", "CELL_TYPE", 130, 160], ["T-cadherin", "PROTEIN", 169, 179], ["Figure S9", "PROTEIN", 182, 191], ["T-cadherin", "TREATMENT", 33, 43], ["MSC", "TEST", 146, 149]]], ["The t-distributed stochastic neighbor embedding (tSNE) cluster positive for PDGFRa (Pdgfra), a marker of MSC-like cells or mesenchymal progenitors, 54, 55 and Meflin (Islr), which is specifically expressed in mesenchymal progenitors, 56, 57 contains cells expressing T-cadherin (Cdh13) in different tissues ( Figure S9 ).", [["MSC-like cells", "ANATOMY", 105, 119], ["mesenchymal progenitors", "ANATOMY", 123, 146], ["mesenchymal progenitors", "ANATOMY", 209, 232], ["cells", "ANATOMY", 250, 255], ["tissues", "ANATOMY", 299, 306], ["PDGFRa", "GENE_OR_GENE_PRODUCT", 76, 82], ["Pdgfra", "GENE_OR_GENE_PRODUCT", 84, 90], ["MSC-like cells", "CELL", 105, 119], ["mesenchymal progenitors", "CELL", 123, 146], ["55", "GENE_OR_GENE_PRODUCT", 152, 154], ["Meflin", "GENE_OR_GENE_PRODUCT", 159, 165], ["Islr", "GENE_OR_GENE_PRODUCT", 167, 171], ["mesenchymal progenitors", "CELL", 209, 232], ["cells", "CELL", 250, 255], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 267, 277], ["Cdh13", "GENE_OR_GENE_PRODUCT", 279, 284], ["tissues", "TISSUE", 299, 306], ["PDGFRa", "PROTEIN", 76, 82], ["Pdgfra", "PROTEIN", 84, 90], ["MSC-like cells", "CELL_TYPE", 105, 119], ["mesenchymal progenitors", "CELL_TYPE", 123, 146], ["Meflin", "PROTEIN", 159, 165], ["Islr", "PROTEIN", 167, 171], ["mesenchymal progenitors", "CELL_TYPE", 209, 232], ["T-cadherin", "PROTEIN", 267, 277], ["Cdh13", "PROTEIN", 279, 284], ["The t-distributed stochastic neighbor embedding (tSNE) cluster positive", "PROBLEM", 0, 71], ["PDGFRa (Pdgfra)", "PROBLEM", 76, 91], ["MSC", "TEST", 105, 108], ["mesenchymal progenitors", "TEST", 123, 146], ["Meflin", "TEST", 159, 165], ["stochastic neighbor", "OBSERVATION", 18, 37], ["mesenchymal progenitors", "OBSERVATION", 123, 146], ["mesenchymal progenitors", "OBSERVATION", 209, 232], ["different tissues", "ANATOMY", 289, 306]]], ["Enhancement of exosome production from such tissue-resident MSC-like cells may account for at least a part of adiponectin's pleiotropic organ protections and requires future studies.Cell TransplantationhMSCs were freshly prepared before each experiment.", [["exosome", "ANATOMY", 15, 22], ["tissue", "ANATOMY", 44, 50], ["MSC-like cells", "ANATOMY", 60, 74], ["organ", "ANATOMY", 136, 141], ["Cell", "ANATOMY", 182, 186], ["exosome", "GENE_OR_GENE_PRODUCT", 15, 22], ["tissue-resident MSC-like cells", "CELL", 44, 74], ["adiponectin", "GENE_OR_GENE_PRODUCT", 110, 121], ["organ", "ORGAN", 136, 141], ["Cell", "CELL", 182, 186], ["exosome", "PROTEIN", 15, 22], ["MSC", "CELL_TYPE", 60, 63], ["like cells", "CELL_TYPE", 64, 74], ["adiponectin", "PROTEIN", 110, 121], ["exosome production", "PROBLEM", 15, 33], ["such tissue", "PROBLEM", 39, 50], ["like cells", "PROBLEM", 64, 74], ["adiponectin's pleiotropic organ protections", "TREATMENT", 110, 153], ["future studies", "TEST", 167, 181], ["Cell TransplantationhMSCs", "TEST", 182, 207], ["exosome production", "OBSERVATION", 15, 33]]], ["The cellsprepared at three doses: low (0.5 \u00c2 10 5 cells), mid (1.67 \u00c2 10 5 cells), and high (5.0 \u00c2 10 5 cells)-were mixed with saline at onethird dilution and injected using a 27G needle inserted through the tail vein at 2-to 3-day intervals within a period of 2 weeks.", [["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 75, 80], ["cells", "ANATOMY", 104, 109], ["tail vein", "ANATOMY", 208, 217], ["cells", "CELL", 50, 55], ["cells", "CELL", 75, 80], ["cells", "CELL", 104, 109], ["saline", "SIMPLE_CHEMICAL", 127, 133], ["tail vein", "MULTI-TISSUE_STRUCTURE", 208, 217], ["mid", "TEST", 58, 61], ["saline at onethird dilution", "TREATMENT", 127, 154], ["a 27G needle", "TREATMENT", 174, 186], ["the tail vein", "TREATMENT", 204, 217], ["mid", "ANATOMY_MODIFIER", 58, 61], ["high", "OBSERVATION_MODIFIER", 87, 91], ["tail vein", "ANATOMY", 208, 217]]], ["In each session, the cells were injected slowly over a period of at least 30 s.", [["cells", "ANATOMY", 21, 26], ["cells", "CELL", 21, 26]]], ["For PKH-labeled hMSC transplantation experiments, hMSCs were labeled with a PKH26 red fluorescent dye (Sigma) according to the protocol supplied by the manufacturer.", [["hMSC", "ANATOMY", 16, 20], ["hMSCs", "ANATOMY", 50, 55], ["PKH", "CHEMICAL", 4, 7], ["PKH", "CHEMICAL", 4, 7], ["PKH26 red", "CHEMICAL", 76, 85], ["PKH", "SIMPLE_CHEMICAL", 4, 7], ["hMSC", "CELL", 16, 20], ["hMSCs", "CELL", 50, 55], ["PKH", "PROTEIN", 4, 7], ["hMSCs", "CELL_TYPE", 50, 55], ["PKH", "TEST", 4, 7], ["hMSC transplantation experiments", "TREATMENT", 16, 48], ["a PKH26 red fluorescent dye", "TREATMENT", 74, 101]]], ["For RNAi experiments, hMSCs were transfected with Silencer Select siRNA (Ambion) using Lipofectamine RNAiMAX Reagent (Life Technologies) according to the protocol supplied by the manufacturer, followed by injection of the cells the next day.", [["hMSCs", "ANATOMY", 22, 27], ["cells", "ANATOMY", 222, 227], ["hMSCs", "CELL", 22, 27], ["cells", "CELL", 222, 227], ["hMSCs", "CELL_TYPE", 22, 27], ["RNAi experiments", "PROBLEM", 4, 20], ["hMSCs", "PROBLEM", 22, 27], ["Silencer Select siRNA (Ambion)", "TREATMENT", 50, 80], ["Lipofectamine RNAiMAX Reagent (Life Technologies", "TREATMENT", 87, 135]]], ["For adenovirus-infected cell injection, hMSCs were infected with Gaussia luciferasefusion MFG-E8 adenovirus, and the infected cells were injected via the tail vein on the next day.", [["cell", "ANATOMY", 24, 28], ["hMSCs", "ANATOMY", 40, 45], ["cells", "ANATOMY", 126, 131], ["tail vein", "ANATOMY", 154, 163], ["adenovirus", "ORGANISM", 4, 14], ["cell", "CELL", 24, 28], ["hMSCs", "CELL", 40, 45], ["adenovirus", "ORGANISM", 97, 107], ["cells", "CELL", 126, 131], ["tail vein", "MULTI-TISSUE_STRUCTURE", 154, 163], ["hMSCs", "CELL_TYPE", 40, 45], ["infected cells", "CELL_TYPE", 117, 131], ["Gaussia luciferasefusion MFG-E8 adenovirus", "SPECIES", 65, 107], ["adenovirus", "PROBLEM", 4, 14], ["infected cell injection", "TREATMENT", 15, 38], ["hMSCs", "PROBLEM", 40, 45], ["Gaussia luciferasefusion MFG", "TREATMENT", 65, 93], ["E8 adenovirus", "TREATMENT", 94, 107], ["the infected cells", "TREATMENT", 113, 131], ["infected cell injection", "OBSERVATION", 15, 38], ["infected cells", "OBSERVATION", 117, 131], ["tail vein", "ANATOMY", 154, 163]]], ["The injected cells were used within five passages in all experiments.Adiponectin PurificationHMW-APN purification was performed as reported previously.", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 69, 80], ["PurificationHMW-APN", "GENE_OR_GENE_PRODUCT", 81, 100], ["injected cells", "CELL_LINE", 4, 18], ["Adiponectin", "PROTEIN", 69, 80], ["APN", "PROTEIN", 97, 100], ["The injected cells", "TREATMENT", 0, 18], ["Adiponectin PurificationHMW", "TEST", 69, 96], ["APN purification", "TEST", 97, 113], ["injected cells", "OBSERVATION", 4, 18]]], ["11 Briefly, serum samples were obtained from WT mice at 4 days after infection with adenovirus adiponectin and applied onto T-cadherin-Fc conjugated with Protein G Sepharose (GE Healthcare).", [["serum samples", "ANATOMY", 12, 25], ["infection", "DISEASE", 69, 78], ["serum samples", "ORGANISM_SUBSTANCE", 12, 25], ["mice", "ORGANISM", 48, 52], ["adenovirus", "ORGANISM", 84, 94], ["adiponectin", "GENE_OR_GENE_PRODUCT", 95, 106], ["T-cadherin", "GENE_OR_GENE_PRODUCT", 124, 134], ["Protein G Sepharose", "SIMPLE_CHEMICAL", 154, 173], ["adenovirus adiponectin", "PROTEIN", 84, 106], ["cadherin", "PROTEIN", 126, 134], ["Fc", "PROTEIN", 135, 137], ["Protein G Sepharose", "PROTEIN", 154, 173], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["adenovirus", "SPECIES", 84, 94], ["serum samples", "TEST", 12, 25], ["infection", "PROBLEM", 69, 78], ["adenovirus adiponectin", "TREATMENT", 84, 106], ["T-cadherin", "TREATMENT", 124, 134], ["Protein G Sepharose (GE Healthcare", "TREATMENT", 154, 188]]], ["Adiponectin was eluted with 5 mM EDTA.Exosome IsolationExosomes were isolated from the cell culture supernatant as described previously.", [["Exosomes", "ANATOMY", 55, 63], ["cell culture supernatant", "ANATOMY", 87, 111], ["EDTA", "CHEMICAL", 33, 37], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 0, 11], ["EDTA", "SIMPLE_CHEMICAL", 33, 37], ["Exosomes", "CELL", 55, 63], ["cell", "CELL", 87, 91], ["Adiponectin", "PROTEIN", 0, 11], ["Adiponectin", "TREATMENT", 0, 11], ["Exosome IsolationExosomes", "TREATMENT", 38, 63], ["the cell culture supernatant", "TEST", 83, 111], ["IsolationExosomes", "OBSERVATION", 46, 63]]], ["33 Briefly, hMSCs were cultured with a xenofree hMSC culture medium with or without HMW-APN for 48 h.", [["hMSCs", "ANATOMY", 12, 17], ["hMSC", "ANATOMY", 48, 52], ["hMSCs", "CELL", 12, 17], ["hMSC", "CELL", 48, 52], ["HMW-APN", "GENE_OR_GENE_PRODUCT", 84, 91], ["hMSCs", "CELL_TYPE", 12, 17], ["HMW", "PROTEIN", 84, 87], ["APN", "PROTEIN", 88, 91], ["a xenofree hMSC culture", "TEST", 37, 60]]], ["Then, the conditioned medium was collected and centrifuged at 800 \u00c2 g for 10 min to deplete floating cells and at 10,000 \u00c2 g for 30 min to remove cell debris.", [["cells", "ANATOMY", 101, 106], ["cell", "ANATOMY", 146, 150], ["cells", "CELL", 101, 106], ["cell", "CELL", 146, 150], ["floating cells", "CELL_TYPE", 92, 106], ["deplete floating cells", "PROBLEM", 84, 106], ["cell debris", "PROBLEM", 146, 157], ["floating cells", "OBSERVATION", 92, 106], ["cell debris", "OBSERVATION", 146, 157]]], ["The plasma sample was mixed with thrombin (500 U/mL) for 10 min to remove fibrin, followed by centrifugation at 12,000 \u00c2 g for 20 min.", [["plasma sample", "ANATOMY", 4, 17], ["plasma", "ORGANISM_SUBSTANCE", 4, 10], ["thrombin", "GENE_OR_GENE_PRODUCT", 33, 41], ["fibrin", "GENE_OR_GENE_PRODUCT", 74, 80], ["thrombin", "PROTEIN", 33, 41], ["fibrin", "PROTEIN", 74, 80], ["The plasma sample", "TEST", 0, 17], ["thrombin", "TREATMENT", 33, 41], ["fibrin", "TREATMENT", 74, 80], ["fibrin", "OBSERVATION", 74, 80]]], ["For exosome isolation, the supernatant, plasma, and serum were ultracentrifuged at an average of 110,000 \u00c2 g for 2 h, followed by a washing step of the exosome pellet with Dulbecco's phosphate-buffered saline with calcium and magnesium [PBS (+)] at an average of 110,000 \u00c2 g for 2 h (TLA100.1 rotor, Beckman Coulter).", [["exosome", "ANATOMY", 4, 11], ["supernatant", "ANATOMY", 27, 38], ["plasma", "ANATOMY", 40, 46], ["serum", "ANATOMY", 52, 57], ["exosome", "ANATOMY", 152, 159], ["phosphate", "CHEMICAL", 183, 192], ["calcium", "CHEMICAL", 214, 221], ["magnesium", "CHEMICAL", 226, 235], ["phosphate", "CHEMICAL", 183, 192], ["calcium", "CHEMICAL", 214, 221], ["magnesium", "CHEMICAL", 226, 235], ["PBS (+)", "CHEMICAL", 237, 244], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 183, 208], ["calcium", "SIMPLE_CHEMICAL", 214, 221], ["magnesium", "SIMPLE_CHEMICAL", 226, 235], ["PBS (+)", "SIMPLE_CHEMICAL", 237, 244], ["exosome isolation", "TREATMENT", 4, 21], ["Dulbecco's phosphate", "TREATMENT", 172, 192], ["buffered saline", "TREATMENT", 193, 208], ["calcium", "TREATMENT", 214, 221], ["magnesium [PBS", "TREATMENT", 226, 240]]], ["The exosome pellets were solubilized directly in Laemmli sample buffer.", [["exosome", "ANATOMY", 4, 11], ["The exosome pellets", "TREATMENT", 0, 19], ["exosome pellets", "OBSERVATION", 4, 19]]], ["Essentially, none of the mouse serum treatments, overexpression, or RNAi treatment significantly affected cell viability.", [["serum", "ANATOMY", 31, 36], ["cell", "ANATOMY", 106, 110], ["mouse", "ORGANISM", 25, 30], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["cell", "CELL", 106, 110], ["mouse", "SPECIES", 25, 30], ["mouse", "SPECIES", 25, 30], ["the mouse serum treatments", "TREATMENT", 21, 47], ["overexpression", "PROBLEM", 49, 63], ["RNAi treatment", "TREATMENT", 68, 82], ["significantly affected cell viability", "PROBLEM", 83, 120], ["cell viability", "OBSERVATION", 106, 120]]], ["Concentration and size distribution of exosomes were analyzed by NTA (NanoSight LM10 System, Quantum Design).", [["exosomes", "ANATOMY", 39, 47], ["NTA", "CHEMICAL", 65, 68], ["NTA", "CHEMICAL", 65, 68], ["exosomes", "CELL", 39, 47], ["NTA", "SIMPLE_CHEMICAL", 65, 68], ["exosomes", "CELL_TYPE", 39, 47], ["Concentration and size distribution of exosomes", "PROBLEM", 0, 47], ["NTA (NanoSight LM10 System", "TREATMENT", 65, 91], ["size", "OBSERVATION_MODIFIER", 18, 22], ["distribution", "OBSERVATION_MODIFIER", 23, 35], ["exosomes", "OBSERVATION", 39, 47]]], ["Serum exosomes were purified by a phosphatidylserine affinity magnetic resin, MagCapture Exosome Isolation Kit PS (Fujifilm Wako Pure Chemical).", [["Serum exosomes", "ANATOMY", 0, 14], ["phosphatidylserine", "CHEMICAL", 34, 52], ["phosphatidylserine", "CHEMICAL", 34, 52], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["exosomes", "ORGANISM_SUBSTANCE", 6, 14], ["phosphatidylserine", "SIMPLE_CHEMICAL", 34, 52], ["Serum exosomes", "TEST", 0, 14], ["a phosphatidylserine affinity magnetic resin", "TREATMENT", 32, 76], ["MagCapture Exosome Isolation Kit PS", "TREATMENT", 78, 113]]], ["The recovery rate of exosomes was estimated as 16% by spiking the known amounts of gLuc-fusion MFG-E8-labeled exosomes into mouse serum and purifying by the affinity resin as described earlier.Animal ProceduresC57B6/J male mice were purchased from CLEA Japan.", [["exosomes", "ANATOMY", 21, 29], ["exosomes", "ANATOMY", 110, 118], ["serum", "ANATOMY", 130, 135], ["exosomes", "CELL", 21, 29], ["gLuc", "GENE_OR_GENE_PRODUCT", 83, 87], ["MFG-E8", "GENE_OR_GENE_PRODUCT", 95, 101], ["exosomes", "CELL", 110, 118], ["mouse", "ORGANISM", 124, 129], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["ProceduresC57B6/J male mice", "ORGANISM", 200, 227], ["exosomes", "CELL_TYPE", 21, 29], ["gLuc", "PROTEIN", 83, 87], ["MFG", "PROTEIN", 95, 98], ["E8", "PROTEIN", 99, 101], ["mouse", "SPECIES", 124, 129], ["mice", "SPECIES", 223, 227], ["mouse", "SPECIES", 124, 129], ["mice", "SPECIES", 223, 227], ["The recovery rate", "TEST", 0, 17], ["gLuc-fusion MFG", "TREATMENT", 83, 98], ["mouse serum", "TEST", 124, 135], ["the affinity resin", "TREATMENT", 153, 171], ["Animal ProceduresC57B6/J male mice", "TREATMENT", 193, 227]]], ["AKO mice intensively backcrossed to C57BL/6J background were used.", [["AKO", "ORGANISM", 0, 3], ["mice", "ORGANISM", 4, 8], ["C57BL/6J background", "ORGANISM", 36, 55], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["C57BL/6J background", "TREATMENT", 36, 55]]], ["33 After the incubation with differentiation medium, staining with Oil Red O, Alizarin Red S, and Alcian Blue was performed to detect the adipocytes, osteoblasts, and chondrocytes, respectively.AntibodiesThe following primary antibodies were used: goat polyclonal anti-adiponectin (AF1119, R&D Systems); goat polyclonal anti-T-cadherin (AF3264, R&D Systems); rabbit monoclonal anti-a-tubulin (11H10, Cell Signaling Technology); sheep polyclonal anti-human MFG-E8 (AF2767, R&D Systems); mouse monoclonal anti-human CD63 (H5C6, BD Biosciences); rabbit monoclonal anti-Tsg101 (ab125011, R&D Systems); rabbit polyclonal anti-syntenin (ab19903, Abcam); and mouse monoclonal anti-ALIX (3A9, Santa Cruz Biotechnology).AntibodiesThe following secondary antibodies were used: horseradish-peroxidase-conjugated (HRP-conjugated) rabbit anti-sheep immunoglobulin G (IgG) (Invitrogen); HRP-conjugated donkey anti-goat IgG (R&D systems); and HRP-conjugated sheep anti-mouse IgG antibodies and donkey anti-rabbit IgG antibody (GE Healthcare).Western BlottingWCLs were loaded onto 4%-20% gradient SDS-PAGE gels (Bio-Rad) and transferred onto nitrocellulose membranes.", [["adipocytes", "ANATOMY", 138, 148], ["osteoblasts", "ANATOMY", 150, 161], ["chondrocytes", "ANATOMY", 167, 179], ["Cell", "ANATOMY", 400, 404], ["membranes", "ANATOMY", 1141, 1150], ["Alizarin Red S", "CHEMICAL", 78, 92], ["Oil Red O", "CHEMICAL", 67, 76], ["Alizarin Red S", "CHEMICAL", 78, 92], ["Alcian Blue", "CHEMICAL", 98, 109], ["nitrocellulose", "CHEMICAL", 1126, 1140], ["Oil Red O", "SIMPLE_CHEMICAL", 67, 76], ["Alizarin Red S", "SIMPLE_CHEMICAL", 78, 92], ["Alcian Blue", "SIMPLE_CHEMICAL", 98, 109], ["adipocytes", "CELL", 138, 148], ["osteoblasts", "CELL", 150, 161], ["chondrocytes", "CELL", 167, 179], ["goat", "ORGANISM", 248, 252], ["anti-adiponectin", "GENE_OR_GENE_PRODUCT", 264, 280], ["AF1119", "SIMPLE_CHEMICAL", 282, 288], ["anti-T-cadherin", "GENE_OR_GENE_PRODUCT", 320, 335], ["AF3264", "GENE_OR_GENE_PRODUCT", 337, 343], ["rabbit", "ORGANISM", 359, 365], ["anti-a-tubulin", "GENE_OR_GENE_PRODUCT", 377, 391], ["Cell", "CELL", 400, 404], ["sheep", "ORGANISM", 428, 433], ["MFG-E8", "GENE_OR_GENE_PRODUCT", 456, 462], ["AF2767", "GENE_OR_GENE_PRODUCT", 464, 470], ["R&D", "GENE_OR_GENE_PRODUCT", 472, 475], ["mouse", "ORGANISM", 486, 491], ["CD63", "GENE_OR_GENE_PRODUCT", 514, 518], ["rabbit", "ORGANISM", 543, 549], ["monoclonal anti-Tsg101", "GENE_OR_GENE_PRODUCT", 550, 572], ["ab125011", "SIMPLE_CHEMICAL", 574, 582], ["rabbit", "ORGANISM", 598, 604], ["anti-syntenin", "GENE_OR_GENE_PRODUCT", 616, 629], ["ab19903", "GENE_OR_GENE_PRODUCT", 631, 638], ["Abcam", "GENE_OR_GENE_PRODUCT", 640, 645], ["mouse", "ORGANISM", 652, 657], ["horseradish-peroxidase", "SIMPLE_CHEMICAL", 767, 789], ["conjugated", "SIMPLE_CHEMICAL", 790, 800], ["HRP", "SIMPLE_CHEMICAL", 802, 805], ["rabbit", "ORGANISM", 818, 824], ["anti-sheep immunoglobulin G", "SIMPLE_CHEMICAL", 825, 852], ["IgG", "GENE_OR_GENE_PRODUCT", 854, 857], ["Invitrogen", "SIMPLE_CHEMICAL", 860, 870], ["HRP", "SIMPLE_CHEMICAL", 873, 876], ["donkey", "ORGANISM", 888, 894], ["anti-goat IgG", "SIMPLE_CHEMICAL", 895, 908], ["HRP", "SIMPLE_CHEMICAL", 928, 931], ["sheep", "ORGANISM", 943, 948], ["donkey", "ORGANISM", 979, 985], ["membranes", "CELLULAR_COMPONENT", 1141, 1150], ["adipocytes", "CELL_TYPE", 138, 148], ["osteoblasts", "CELL_TYPE", 150, 161], ["chondrocytes", "CELL_TYPE", 167, 179], ["primary antibodies", "PROTEIN", 218, 236], ["goat polyclonal anti-adiponectin", "PROTEIN", 248, 280], ["AF1119", "PROTEIN", 282, 288], ["R&D", "PROTEIN", 290, 293], ["goat polyclonal anti-T", "PROTEIN", 304, 326], ["cadherin", "PROTEIN", 327, 335], ["AF3264", "PROTEIN", 337, 343], ["R&D Systems", "PROTEIN", 345, 356], ["rabbit monoclonal anti-a-tubulin", "PROTEIN", 359, 391], ["11H10", "PROTEIN", 393, 398], ["Cell Signaling Technology); sheep polyclonal anti-human MFG", "PROTEIN", 400, 459], ["E8", "PROTEIN", 460, 462], ["AF2767", "PROTEIN", 464, 470], ["R&D Systems", "PROTEIN", 472, 483], ["mouse monoclonal anti-human CD63", "PROTEIN", 486, 518], ["H5C6", "PROTEIN", 520, 524], ["BD Biosciences", "PROTEIN", 526, 540], ["rabbit monoclonal anti-Tsg101", "PROTEIN", 543, 572], ["ab125011", "PROTEIN", 574, 582], ["R&D Systems", "PROTEIN", 584, 595], ["rabbit polyclonal anti-syntenin", "PROTEIN", 598, 629], ["ab19903", "PROTEIN", 631, 638], ["Abcam", "PROTEIN", 640, 645], ["mouse monoclonal anti-ALIX", "PROTEIN", 652, 678], ["3A9", "PROTEIN", 680, 683], ["Santa Cruz Biotechnology", "PROTEIN", 685, 709], ["secondary antibodies", "PROTEIN", 735, 755], ["horseradish-peroxidase", "PROTEIN", 767, 789], ["conjugated (HRP-conjugated) rabbit anti-sheep immunoglobulin G", "PROTEIN", 790, 852], ["IgG", "PROTEIN", 854, 857], ["Invitrogen", "PROTEIN", 860, 870], ["HRP", "PROTEIN", 873, 876], ["conjugated donkey anti-goat IgG", "PROTEIN", 877, 908], ["R&D systems", "PROTEIN", 910, 921], ["HRP", "PROTEIN", 928, 931], ["conjugated sheep anti-mouse IgG antibodies", "PROTEIN", 932, 974], ["donkey anti-rabbit IgG antibody", "PROTEIN", 979, 1010], ["goat", "SPECIES", 248, 252], ["goat", "SPECIES", 304, 308], ["rabbit", "SPECIES", 359, 365], ["sheep", "SPECIES", 428, 433], ["anti-human", "SPECIES", 445, 455], ["mouse", "SPECIES", 486, 491], ["anti-human", "SPECIES", 503, 513], ["rabbit", "SPECIES", 543, 549], ["rabbit", "SPECIES", 598, 604], ["mouse", "SPECIES", 652, 657], ["horseradish", "SPECIES", 767, 778], ["rabbit", "SPECIES", 818, 824], ["donkey", "SPECIES", 888, 894], ["anti-goat", "SPECIES", 895, 904], ["sheep", "SPECIES", 943, 948], ["anti-mouse", "SPECIES", 949, 959], ["donkey", "SPECIES", 979, 985], ["anti-rabbit", "SPECIES", 986, 997], ["goat", "SPECIES", 248, 252], ["goat", "SPECIES", 304, 308], ["rabbit", "SPECIES", 359, 365], ["sheep", "SPECIES", 428, 433], ["mouse", "SPECIES", 486, 491], ["rabbit", "SPECIES", 543, 549], ["rabbit", "SPECIES", 598, 604], ["mouse", "SPECIES", 652, 657], ["rabbit", "SPECIES", 818, 824], ["donkey", "SPECIES", 888, 894], ["sheep", "SPECIES", 943, 948], ["donkey", "SPECIES", 979, 985], ["anti-rabbit", "SPECIES", 986, 997], ["differentiation medium", "PROBLEM", 29, 51], ["Alizarin Red S", "TEST", 78, 92], ["Alcian Blue", "TEST", 98, 109], ["Antibodies", "TEST", 194, 204], ["goat polyclonal anti-adiponectin", "TREATMENT", 248, 280], ["goat polyclonal anti-T-cadherin", "TREATMENT", 304, 335], ["rabbit monoclonal anti-a-tubulin", "TREATMENT", 359, 391], ["Cell Signaling Technology", "TREATMENT", 400, 425], ["sheep polyclonal anti-human MFG", "TREATMENT", 428, 459], ["mouse monoclonal anti-human CD63", "TREATMENT", 486, 518], ["BD Biosciences", "TREATMENT", 526, 540], ["rabbit monoclonal anti-Tsg", "TREATMENT", 543, 569], ["rabbit polyclonal anti-syntenin", "TREATMENT", 598, 629], ["Antibodies", "TEST", 711, 721], ["secondary antibodies", "TEST", 735, 755], ["horseradish", "TEST", 767, 778], ["peroxidase", "TEST", 779, 789], ["HRP", "TEST", 802, 805], ["rabbit anti-sheep immunoglobulin G", "TREATMENT", 818, 852], ["IgG", "TEST", 854, 857], ["Invitrogen", "TEST", 860, 870], ["HRP", "TEST", 873, 876], ["HRP", "TEST", 928, 931], ["conjugated sheep anti-mouse IgG antibodies", "TEST", 932, 974], ["donkey anti-rabbit IgG antibody", "TEST", 979, 1010], ["20% gradient SDS", "TREATMENT", 1068, 1084], ["nitrocellulose membranes", "TREATMENT", 1126, 1150], ["adipocytes", "ANATOMY", 138, 148], ["osteoblasts", "ANATOMY", 150, 161], ["chondrocytes", "ANATOMY", 167, 179]]], ["The membranes were blocked with Block-One blocking reagent (Nakarai Tesque) and then incubated with primary antibodies using Can Get Signal Solution 1 (TOYOBO) overnight at 4 C, followed by incubation with secondary antibodies conjugated with HRP using Can Get Signal Solution 2 (TOYOBO) for 60 min at room temperature.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["HRP", "SIMPLE_CHEMICAL", 243, 246], ["primary antibodies", "PROTEIN", 100, 118], ["secondary antibodies", "PROTEIN", 206, 226], ["HRP", "PROTEIN", 243, 246], ["Block", "TREATMENT", 32, 37], ["One blocking reagent (Nakarai Tesque", "TREATMENT", 38, 74], ["primary antibodies", "TREATMENT", 100, 118], ["Signal Solution", "TREATMENT", 133, 148], ["secondary antibodies conjugated", "TREATMENT", 206, 237], ["HRP", "TREATMENT", 243, 246]]], ["Chemiluminescence signals developed with Chemi-Lumi One Super (Nakarai Tesque) were visualized by ChemiDoc Touch and quantitated using Image Lab software (Bio-Rad).TAC OperationThe TAC operation was performed using the minimally aortic transverse banding method described in detail by Martin et al. 58 In brief, C57BL/6 male mice (8-9 weeks old, 23-27 g) were anesthetized with a mixture of pentobarbital sodium (50 mg/kg intraperitoneally [i.p.]) and ketamine (25 mg/kg i.p.), as described previously.", [["aortic", "ANATOMY", 229, 235], ["TAC", "CHEMICAL", 164, 167], ["TAC", "CHEMICAL", 181, 184], ["pentobarbital sodium", "CHEMICAL", 391, 411], ["ketamine", "CHEMICAL", 452, 460], ["TAC", "CHEMICAL", 164, 167], ["TAC", "CHEMICAL", 181, 184], ["pentobarbital sodium", "CHEMICAL", 391, 411], ["ketamine", "CHEMICAL", 452, 460], ["TAC", "SIMPLE_CHEMICAL", 164, 167], ["C57BL/6 male mice", "ORGANISM", 312, 329], ["pentobarbital", "SIMPLE_CHEMICAL", 391, 404], ["sodium", "SIMPLE_CHEMICAL", 405, 411], ["ketamine", "SIMPLE_CHEMICAL", 452, 460], ["mice", "SPECIES", 325, 329], ["mice", "SPECIES", 325, 329], ["Chemiluminescence signals", "TEST", 0, 25], ["Chemi-", "TEST", 41, 47], ["Image Lab software", "TEST", 135, 153], ["TAC Operation", "TREATMENT", 164, 177], ["The TAC operation", "TREATMENT", 177, 194], ["the minimally aortic transverse banding method", "TREATMENT", 215, 261], ["a mixture of pentobarbital sodium", "TREATMENT", 378, 411], ["ketamine", "TREATMENT", 452, 460], ["aortic", "ANATOMY", 229, 235], ["transverse banding", "OBSERVATION", 236, 254]]], ["16 The thymus was gently put away to expose the aortic arch.", [["thymus", "ANATOMY", 7, 13], ["aortic arch", "ANATOMY", 48, 59], ["thymus", "ORGAN", 7, 13], ["aortic arch", "MULTI-TISSUE_STRUCTURE", 48, 59], ["thymus", "ANATOMY", 7, 13], ["aortic arch", "ANATOMY", 48, 59]]], ["After isolation of the transverse aorta, it was constricted by a 7-0 silk suture ligature fastened stiffly to a 27G needle to yield a constriction of 0.4 mm in diameter.", [["transverse aorta", "ANATOMY", 23, 39], ["transverse aorta", "MULTI-TISSUE_STRUCTURE", 23, 39], ["isolation of the transverse aorta", "TREATMENT", 6, 39], ["a 7-0 silk suture ligature", "TREATMENT", 63, 89], ["a 27G needle", "TREATMENT", 110, 122], ["transverse aorta", "ANATOMY", 23, 39], ["constricted", "OBSERVATION_MODIFIER", 48, 59], ["constriction", "OBSERVATION", 134, 146], ["0.4 mm", "OBSERVATION_MODIFIER", 150, 156]]], ["Sham-operated mice underwent a similar surgical procedure, including the exposure of the transverse aorta but without the constriction.", [["transverse aorta", "ANATOMY", 89, 105], ["mice", "ORGANISM", 14, 18], ["transverse aorta", "MULTI-TISSUE_STRUCTURE", 89, 105], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["a similar surgical procedure", "TREATMENT", 29, 57], ["the constriction", "PROBLEM", 118, 134], ["surgical", "OBSERVATION", 39, 47], ["transverse aorta", "ANATOMY", 89, 105], ["without", "UNCERTAINTY", 110, 117], ["constriction", "OBSERVATION", 122, 134]]], ["The chest was closed with a 5-0 silk suture, and mice were allowed to recover.", [["chest", "ANATOMY", 4, 9], ["chest", "ORGAN", 4, 9], ["mice", "ORGANISM", 49, 53], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["a 5-0 silk suture", "TREATMENT", 26, 43], ["chest", "ANATOMY", 4, 9], ["closed", "OBSERVATION", 14, 20]]], ["The procedure was performed under a surgical microscope and was completed in 10 min.EchocardiographyTransthoracic echocardiography was performed as described in detail previously.", [["The procedure", "TREATMENT", 0, 13], ["a surgical microscope", "TREATMENT", 34, 55], ["Echocardiography", "TEST", 84, 100], ["Transthoracic echocardiography", "TEST", 100, 130]]], ["59 Briefly, it was performed in each mouse using theMeasurement of Gaussia Luciferase ActivityThe exosome fraction was prepared as described earlier in the Exosome Isolation section.", [["exosome", "ANATOMY", 98, 105], ["mouse", "ORGANISM", 37, 42], ["mouse", "SPECIES", 37, 42], ["mouse", "SPECIES", 37, 42], ["The exosome fraction", "TEST", 94, 114], ["the Exosome Isolation section", "TREATMENT", 152, 181], ["Luciferase Activity", "OBSERVATION", 75, 94], ["exosome fraction", "OBSERVATION", 98, 114]]], ["The Gaussia luciferase activity in the exosome was measured by using the Gaussia Luciferase Flash Assay Kit (Thermo Fisher Scientific) according to the protocol supplied by the manufacturer.Cytokine ArrayThe conditioned medium was collected and centrifuged at 800 \u00c2 g for 10 min to deplete floating cells, and the pooled sample of four separate cells was analyzed by using the Cytokine Array -Human Cytokine Antibody Array (Membrane, 42 Targets, Abcam) according to the protocol supplied by the manufacturer.Measurement of Plasma Adiponectin Levels by ELISABlood samples were collected from the respective mice, and plasma adiponectin levels were measured by adiponectin ELISA (Otsuka Pharmaceutical) according to the protocol supplied by the manufacturer.HistochemistryThe heart tissue was collected from each mouse, and the LV was embedded in paraffin following 10% formalin fixation.", [["exosome", "ANATOMY", 39, 46], ["cells", "ANATOMY", 299, 304], ["sample", "ANATOMY", 321, 327], ["cells", "ANATOMY", 345, 350], ["ELISABlood samples", "ANATOMY", 552, 570], ["plasma", "ANATOMY", 616, 622], ["heart tissue", "ANATOMY", 774, 786], ["LV", "ANATOMY", 826, 828], ["formalin", "CHEMICAL", 868, 876], ["paraffin", "CHEMICAL", 845, 853], ["formalin", "CHEMICAL", 868, 876], ["luciferase", "GENE_OR_GENE_PRODUCT", 12, 22], ["exosome", "CELLULAR_COMPONENT", 39, 46], ["cells", "CELL", 299, 304], ["cells", "CELL", 345, 350], ["Human", "ORGANISM", 393, 398], ["Plasma", "ORGANISM_SUBSTANCE", 523, 529], ["Adiponectin", "GENE_OR_GENE_PRODUCT", 530, 541], ["ELISABlood samples", "CANCER", 552, 570], ["mice", "ORGANISM", 606, 610], ["plasma", "ORGANISM_SUBSTANCE", 616, 622], ["adiponectin", "GENE_OR_GENE_PRODUCT", 623, 634], ["adiponectin", "GENE_OR_GENE_PRODUCT", 659, 670], ["heart tissue", "TISSUE", 774, 786], ["mouse", "ORGANISM", 811, 816], ["LV", "MULTI-TISSUE_STRUCTURE", 826, 828], ["formalin", "SIMPLE_CHEMICAL", 868, 876], ["luciferase", "PROTEIN", 12, 22], ["exosome", "PROTEIN", 39, 46], ["Cytokine", "PROTEIN", 190, 198], ["floating cells", "CELL_TYPE", 290, 304], ["Cytokine", "PROTEIN", 377, 385], ["Abcam", "PROTEIN", 446, 451], ["Adiponectin", "PROTEIN", 530, 541], ["adiponectin", "PROTEIN", 623, 634], ["adiponectin", "PROTEIN", 659, 670], ["Human", "SPECIES", 393, 398], ["mice", "SPECIES", 606, 610], ["mouse", "SPECIES", 811, 816], ["mice", "SPECIES", 606, 610], ["mouse", "SPECIES", 811, 816], ["Cytokine Array", "TREATMENT", 190, 204], ["deplete floating cells", "PROBLEM", 282, 304], ["the pooled sample", "TEST", 310, 327], ["the Cytokine Array", "TEST", 373, 391], ["Abcam", "TEST", 446, 451], ["Plasma Adiponectin Levels", "TEST", 523, 548], ["ELISABlood samples", "TEST", 552, 570], ["plasma adiponectin levels", "TEST", 616, 641], ["adiponectin ELISA", "TEST", 659, 676], ["the protocol", "TREATMENT", 714, 726], ["10% formalin fixation", "TREATMENT", 864, 885], ["luciferase activity", "OBSERVATION", 12, 31], ["floating cells", "OBSERVATION", 290, 304], ["heart", "ANATOMY", 774, 779], ["tissue", "OBSERVATION", 780, 786], ["LV", "ANATOMY", 826, 828]]], ["Mouse heart sections (4 mm thick) were prepared and stained with hematoxylin and eosin (H&E).", [["heart sections", "ANATOMY", 6, 20], ["hematoxylin", "CHEMICAL", 65, 76], ["eosin", "CHEMICAL", 81, 86], ["Mouse", "ORGANISM", 0, 5], ["heart sections", "MULTI-TISSUE_STRUCTURE", 6, 20], ["hematoxylin", "SIMPLE_CHEMICAL", 65, 76], ["eosin", "SIMPLE_CHEMICAL", 81, 86], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse heart sections", "TEST", 0, 20], ["hematoxylin", "TREATMENT", 65, 76], ["eosin", "TREATMENT", 81, 86], ["heart", "ANATOMY", 6, 11]]], ["Other sections were also stained with CFTM594conjugated WGA (Biotium) to evaluate the myocyte cross-section area (CSA).", [["sections", "ANATOMY", 6, 14], ["myocyte cross-section area", "ANATOMY", 86, 112], ["WGA", "SIMPLE_CHEMICAL", 56, 59], ["Biotium", "SIMPLE_CHEMICAL", 61, 68], ["myocyte", "CELL", 86, 93], ["Other sections", "TEST", 0, 14], ["CFTM594conjugated WGA", "TEST", 38, 59], ["myocyte", "ANATOMY", 86, 93]]], ["For the quantification of CSA, the area was detected and analyzed using a BZ-X700 microscope and the built-in software (Keyence).", [["BZ", "CHEMICAL", 74, 76], ["CSA", "PROBLEM", 26, 29], ["a BZ-X700 microscope", "TREATMENT", 72, 92], ["CSA", "OBSERVATION", 26, 29]]], ["Mouse lung tissue was collected from mice injected with PKH-labeled hMSCs, and the tissue was embedded in Tissue-Tek O.C.T. Compound (Sakura).", [["lung tissue", "ANATOMY", 6, 17], ["hMSCs", "ANATOMY", 68, 73], ["tissue", "ANATOMY", 83, 89], ["PKH", "CHEMICAL", 56, 59], ["Mouse", "ORGANISM", 0, 5], ["lung tissue", "TISSUE", 6, 17], ["mice", "ORGANISM", 37, 41], ["PKH", "SIMPLE_CHEMICAL", 56, 59], ["hMSCs", "CELL", 68, 73], ["tissue", "TISSUE", 83, 89], ["PKH", "PROTEIN", 56, 59], ["hMSCs", "CELL_TYPE", 68, 73], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 37, 41], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 37, 41], ["Mouse lung tissue", "PROBLEM", 0, 17], ["PKH-labeled hMSCs", "TREATMENT", 56, 73], ["lung", "ANATOMY", 6, 10], ["tissue", "OBSERVATION", 11, 17], ["tissue", "ANATOMY", 83, 89]]], ["Tissue sections prepared were 20 mm thick and stained with DAPI.Ethical ConsiderationsThe experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Osaka University School of Medicine.", [["Tissue sections", "ANATOMY", 0, 15], ["DAPI", "CHEMICAL", 59, 63], ["Tissue sections", "CANCER", 0, 15], ["DAPI", "SIMPLE_CHEMICAL", 59, 63], ["Tissue sections", "TEST", 0, 15], ["DAPI", "TEST", 59, 63], ["20 mm", "OBSERVATION_MODIFIER", 30, 35]]], ["This study also conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health.Statistical AnalysisData were expressed as mean \u00b1 SEM.", [["This study", "TEST", 0, 10]]], ["Differences between the experimental groups were assessed by Student's t test or one-way ANOVA, followed by post hoc Dunnett's test and Tukey's test.", [["Student's t test", "TEST", 61, 77], ["hoc Dunnett's test", "TEST", 113, 131], ["Tukey's test", "TEST", 136, 148]]], ["The p values < 0.05 were considered statistically significant.", [["The p values", "TEST", 0, 12]]], ["All analyses were performed with JMP Software v.13.0 (SAS Institute, Cary, NC, USA).Data and Code AccessibilityWe submitted all raw datasets except RNA-seq data to DRYAD (https://doi.org/10.5061/dryad.t76hdr7xq).", [["DRYAD", "DNA", 164, 169], ["All analyses", "TEST", 0, 12], ["JMP Software", "TEST", 33, 45], ["RNA", "TEST", 148, 151], ["DRYAD", "PROBLEM", 164, 169]]], ["RNA-seq datasets were deposited to the DNA Data Bank of Japan as DDBJ: DRA009757 (in vitro exosome miRNA-seq) and DRA009758 (in vivo mouse heart RNA-seq).SUPPLEMENTAL INFORMATIONSupplemental Information can be found online at https://doi.org/10.", [["heart", "ANATOMY", 139, 144], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["mouse", "ORGANISM", 133, 138], ["heart", "ORGAN", 139, 144], ["DRA009758", "DNA", 114, 123], ["mouse", "SPECIES", 133, 138], ["mouse", "SPECIES", 133, 138], ["RNA", "TEST", 0, 3], ["heart", "ANATOMY", 139, 144]]], ["1016/j.ymthe.2020.06.026.AUTHOR CONTRIBUTIONSY.N. and S.K. designed the research protocol; performed the biochemical, cellular, and in vivo experiments; analyzed the data; and co-wrote the manuscript.", [["cellular", "ANATOMY", 118, 126], ["cellular", "CELL", 118, 126], ["the research protocol", "TEST", 68, 89]]], ["Y. TanakaCONFLICTS OF INTERESTOsaka University filed a patent claim regarding adiponectin-mediated stimulation of exosome production, the Japanese Patent #6618079", [["exosome", "ANATOMY", 114, 121], ["#6618079", "CHEMICAL", 154, 162], ["adiponectin", "GENE_OR_GENE_PRODUCT", 78, 89], ["exosome", "CELLULAR_COMPONENT", 114, 121], ["adiponectin", "PROTEIN", 78, 89], ["exosome", "PROTEIN", 114, 121], ["Y.", "SPECIES", 0, 2], ["Japanese Patent #6618079", "SPECIES", 138, 162], ["adiponectin", "TEST", 78, 89], ["exosome production", "PROBLEM", 114, 132], ["patent", "OBSERVATION", 55, 61], ["Patent", "OBSERVATION", 147, 153]]]], "1a51ed0b7e0043d57c87a5a0400348a79e1b9fef": [["INTRODUCTIONThe emergence of the 2019 novel coronavirus SARS-CoV-2, the cause of the COVID-19 pandemic, is the pre-eminent public health issue of this decade.", [["SARS", "DISEASE", 56, 60], ["COVID-19 pandemic", "DISEASE", 85, 102], ["coronavirus SARS-CoV-2", "ORGANISM", 44, 66], ["coronavirus SARS-CoV", "SPECIES", 44, 64], ["SARS-CoV-2", "SPECIES", 56, 66], ["novel coronavirus SARS", "TEST", 38, 60], ["CoV", "TEST", 61, 64], ["the COVID", "TEST", 81, 90]]], ["There has been significant global concern due to the widespread and uncertain modes of transmission, and severe disease in a significant proportion.", [["severe disease", "PROBLEM", 105, 119], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["global", "OBSERVATION_MODIFIER", 27, 33], ["widespread", "OBSERVATION_MODIFIER", 53, 63], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["disease", "OBSERVATION", 112, 119], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["proportion", "OBSERVATION_MODIFIER", 137, 147]]], ["Patients on immunomodulators, including biologic agents and small molecular inhibitors, for cutaneous disease, represent a potentially vulnerable population who require specialised care and advice.", [["cutaneous", "ANATOMY", 92, 101], ["cutaneous disease", "DISEASE", 92, 109], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["immunomodulators", "TREATMENT", 12, 28], ["biologic agents", "TREATMENT", 40, 55], ["small molecular inhibitors", "TREATMENT", 60, 86], ["cutaneous disease", "PROBLEM", 92, 109]]], ["Experience and research evidence on COVID-19 is limited; however, we aim to provide guidance for dermatologists and other clinicians in managing and counselling patients who are on immunomodulators.SARS-CoV-2 VirologyCOVID-19 is the disease caused by an enveloped singlestrand RNA virus from the coronaviridae family -SARS-CoV-2.", [["SARS", "DISEASE", 198, 202], ["patients", "ORGANISM", 161, 169], ["SARS-CoV-2", "ORGANISM", 318, 328], ["patients", "SPECIES", 161, 169], ["SARS-CoV-2 VirologyCOVID-19", "SPECIES", 198, 225], ["COVID", "TEST", 36, 41], ["immunomodulators", "TREATMENT", 181, 197], ["SARS", "TEST", 198, 202], ["CoV", "TEST", 203, 206], ["VirologyCOVID", "TEST", 209, 222], ["the disease", "PROBLEM", 229, 240], ["an enveloped singlestrand RNA virus", "PROBLEM", 251, 286]]], ["Coronaviruses are so-named due to characteristic 'crown-like' projections visible on electron microscopy.", [["Coronaviruses", "PROBLEM", 0, 13], ["electron microscopy", "TEST", 85, 104]]], ["Coronaviruses are subdivided into four genera (alpha, beta, gamma and delta) and typically infect birds and mammals.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["alpha, beta", "GENE_OR_GENE_PRODUCT", 47, 58], ["gamma", "GENE_OR_GENE_PRODUCT", 60, 65], ["delta", "GENE_OR_GENE_PRODUCT", 70, 75], ["birds", "ORGANISM", 98, 103], ["alpha, beta, gamma and delta", "PROTEIN", 47, 75], ["Coronaviruses", "PROBLEM", 0, 13], ["beta, gamma and delta)", "TREATMENT", 54, 76], ["infect birds", "OBSERVATION", 91, 103]]], ["Seven species in the alpha-and beta-coronavirus genera are known to cause human disease from animal-to-human spillover.", [["alpha", "GENE_OR_GENE_PRODUCT", 21, 26], ["human", "ORGANISM", 74, 79], ["human", "ORGANISM", 103, 108], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 103, 108], ["Seven species", "PROBLEM", 0, 13], ["the alpha", "TEST", 17, 26], ["beta-coronavirus genera", "TREATMENT", 31, 54], ["human disease", "PROBLEM", 74, 87]]], ["Other notable disease outbreaks have been caused by coronaviridae including SARS-CoV in 2002-2003 and MERS-CoV in 2012-ongoing.", [["SARS-CoV", "DISEASE", 76, 84], ["SARS-CoV", "ORGANISM", 76, 84], ["MERS-CoV", "ORGANISM", 102, 110], ["SARS-CoV", "SPECIES", 76, 84], ["MERS-CoV", "SPECIES", 102, 110], ["Other notable disease outbreaks", "PROBLEM", 0, 31], ["SARS", "PROBLEM", 76, 80], ["CoV", "TEST", 81, 84], ["notable", "OBSERVATION_MODIFIER", 6, 13], ["disease", "OBSERVATION", 14, 21]]], ["1 Understanding of transmission of SARS-CoV-2 remains incomplete, although it appears to share similar transmission characteristics as SARS-CoV-1.", [["SARS", "DISEASE", 35, 39], ["SARS", "DISEASE", 135, 139], ["SARS-CoV-2", "ORGANISM", 35, 45], ["SARS-CoV-1", "ORGANISM", 135, 145], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV-1", "SPECIES", 135, 145], ["SARS", "PROBLEM", 35, 39], ["CoV", "TEST", 40, 43]]], ["2 Human-to-human transmission is thought to occur predominantly via droplets; transmission via fomites is especially relevant as the virus has been shown to be viable for up to 48-72 h on plastic and steel surfaces.", [["Human", "ORGANISM", 2, 7], ["human", "ORGANISM", 11, 16], ["Human", "SPECIES", 2, 7], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["the virus", "PROBLEM", 129, 138], ["steel surfaces", "OBSERVATION_MODIFIER", 200, 214]]], ["2 Many health services are also assuming airborne precautions, particularly for aerosolised procedures, due to the uncertainty and rapid spread.", [["airborne precautions", "TREATMENT", 41, 61], ["aerosolised procedures", "TREATMENT", 80, 102], ["the uncertainty and rapid spread", "PROBLEM", 111, 143]]], ["Indeed, SARS-CoV-2 remained viable in aerosols for around 3 h.", [["SARS", "DISEASE", 8, 12], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 8, 18]]], ["2 Detection of the virus in stool samples of COVID-19 patients may suggest potential faecal-oral transmission or asymptomatic shedding in faeces.", [["stool samples", "ANATOMY", 28, 41], ["faecal", "ANATOMY", 85, 91], ["oral", "ANATOMY", 92, 96], ["faeces", "ANATOMY", 138, 144], ["faecal-oral transmission", "DISEASE", 85, 109], ["stool", "ORGANISM", 28, 33], ["patients", "ORGANISM", 54, 62], ["faecal", "ORGANISM_SUBDIVISION", 85, 91], ["oral", "ORGANISM_SUBDIVISION", 92, 96], ["faeces", "ORGANISM_SUBSTANCE", 138, 144], ["patients", "SPECIES", 54, 62], ["the virus", "PROBLEM", 15, 24], ["stool samples", "TEST", 28, 41], ["COVID", "TEST", 45, 50], ["potential faecal-oral transmission", "PROBLEM", 75, 109], ["asymptomatic shedding in faeces", "PROBLEM", 113, 144], ["virus", "OBSERVATION", 19, 24]]], ["3 It may also persist on human hair.", [["hair", "ANATOMY", 31, 35], ["human", "ORGANISM", 25, 30], ["hair", "ORGAN", 31, 35], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30]]], ["Transmission from asymptomatic or minimally symptomatic hosts has also been reported, raising the possibility of infectivity during the incubation period.", [["asymptomatic", "PROBLEM", 18, 30], ["minimally symptomatic hosts", "PROBLEM", 34, 61], ["infectivity", "PROBLEM", 113, 124], ["minimally", "OBSERVATION_MODIFIER", 34, 43], ["symptomatic", "OBSERVATION", 44, 55], ["raising the possibility of", "UNCERTAINTY", 86, 112], ["infectivity", "OBSERVATION", 113, 124]]], ["4,5COVID-19 disease characteristicsThe median incubation period for COVID-19 is around 4 to 5 days, but can extend to 1 month.", [["19 disease characteristics", "PROBLEM", 9, 35], ["COVID", "TEST", 68, 73]]], ["6, 7 Severity of the disease peaks around day 7-10, whilst viral shedding usually persists for 3-4 weeks.", [["the disease peaks", "PROBLEM", 17, 34], ["viral shedding", "PROBLEM", 59, 73], ["disease", "OBSERVATION", 21, 28], ["peaks", "OBSERVATION_MODIFIER", 29, 34]]], ["In most cases, the clinical signs and symptoms are indistinguishable from upper respiratory tract infections.", [["upper respiratory tract", "ANATOMY", 74, 97], ["respiratory tract infections", "DISEASE", 80, 108], ["upper respiratory", "ORGANISM_SUBDIVISION", 74, 91], ["tract", "ORGANISM_SUBDIVISION", 92, 97], ["the clinical signs", "TEST", 15, 33], ["symptoms", "PROBLEM", 38, 46], ["upper respiratory tract infections", "PROBLEM", 74, 108], ["upper", "ANATOMY_MODIFIER", 74, 79], ["respiratory tract", "ANATOMY", 80, 97], ["infections", "OBSERVATION", 98, 108]]], ["Most commonly reported symptoms in hospitalised cases include the following: 6, 7, 8 \u2022 Fever (in almost all) \u2022 Cough (often dry)COVID-19 disease characteristicsSevere disease occurs in around 5-15% of patients and is primarily due to the development of pneumonia/pneumonitis and respiratory failure.", [["respiratory", "ANATOMY", 279, 290], ["Fever", "DISEASE", 87, 92], ["Cough", "DISEASE", 111, 116], ["pneumonia", "DISEASE", 253, 262], ["pneumonitis", "DISEASE", 263, 274], ["respiratory failure", "DISEASE", 279, 298], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["symptoms", "PROBLEM", 23, 31], ["Fever", "PROBLEM", 87, 92], ["Cough", "PROBLEM", 111, 116], ["COVID-19 disease characteristics", "PROBLEM", 128, 160], ["Severe disease", "PROBLEM", 160, 174], ["pneumonia", "PROBLEM", 253, 262], ["pneumonitis", "PROBLEM", 263, 274], ["respiratory failure", "PROBLEM", 279, 298], ["disease", "OBSERVATION", 167, 174], ["pneumonia", "OBSERVATION", 253, 262], ["pneumonitis", "OBSERVATION", 263, 274], ["respiratory failure", "OBSERVATION", 279, 298]]], ["6, 9 Cardiovascular disease, chronic pulmonary disease, hypertension, diabetes and other chronic medical comorbidities were common in severe, hospitalised cases 8 and may be predictors of poor outcome.", [["Cardiovascular", "ANATOMY", 5, 19], ["pulmonary", "ANATOMY", 37, 46], ["Cardiovascular disease", "DISEASE", 5, 27], ["chronic pulmonary disease", "DISEASE", 29, 54], ["hypertension", "DISEASE", 56, 68], ["diabetes", "DISEASE", 70, 78], ["pulmonary", "ORGAN", 37, 46], ["9 Cardiovascular disease", "PROBLEM", 3, 27], ["chronic pulmonary disease", "PROBLEM", 29, 54], ["hypertension", "PROBLEM", 56, 68], ["diabetes", "PROBLEM", 70, 78], ["other chronic medical comorbidities", "PROBLEM", 83, 118], ["Cardiovascular", "ANATOMY", 5, 19], ["disease", "OBSERVATION", 20, 27], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["pulmonary", "ANATOMY", 37, 46], ["disease", "OBSERVATION", 47, 54], ["hypertension", "OBSERVATION", 56, 68], ["diabetes", "OBSERVATION", 70, 78], ["chronic", "OBSERVATION_MODIFIER", 89, 96]]], ["Smoking may also be a risk factor.", [["Smoking", "DISEASE", 0, 7]]], ["Mortality estimates remain imprecise; however, recent case-fatality rates around 2-3% were reported in China.", [["Mortality estimates", "TEST", 0, 19], ["fatality rates", "TEST", 59, 73], ["imprecise", "OBSERVATION", 27, 36]]], ["9 Older age is the most important predictor for mortality, with a 15% fatality ratio in patients over the age of 80 in Chinese cohorts.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["9 Children seem to be at much lower risk of severe disease (especially over the age of 5), 10 but may be a significant vector for infection.Coronavirus in the immunocompromised patientFrom previous coronavirus outbreaks, immunosuppression is thought to increase susceptibility and cause more severe infection, 11, 12 although this is usually in the context of disease driven immunosuppression (e.g. severe inflammatory bowel disease and cancer).", [["bowel", "ANATOMY", 419, 424], ["cancer", "ANATOMY", 437, 443], ["infection", "DISEASE", 130, 139], ["Coronavirus", "CHEMICAL", 140, 151], ["coronavirus outbreaks", "DISEASE", 198, 219], ["infection", "DISEASE", 299, 308], ["inflammatory bowel disease", "DISEASE", 406, 432], ["cancer", "DISEASE", 437, 443], ["Children", "ORGANISM", 2, 10], ["patient", "ORGANISM", 177, 184], ["coronavirus", "ORGANISM", 198, 209], ["bowel", "ORGAN", 419, 424], ["cancer", "CANCER", 437, 443], ["Children", "SPECIES", 2, 10], ["patient", "SPECIES", 177, 184], ["coronavirus", "SPECIES", 198, 209], ["severe disease", "PROBLEM", 44, 58], ["infection", "PROBLEM", 130, 139], ["Coronavirus", "PROBLEM", 140, 151], ["previous coronavirus outbreaks", "PROBLEM", 189, 219], ["immunosuppression", "TREATMENT", 221, 238], ["severe infection", "PROBLEM", 292, 308], ["disease driven immunosuppression", "PROBLEM", 360, 392], ["severe inflammatory bowel disease", "PROBLEM", 399, 432], ["cancer", "PROBLEM", 437, 443], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["disease", "OBSERVATION", 51, 58], ["infection", "OBSERVATION", 130, 139], ["immunocompromised", "OBSERVATION", 159, 176], ["coronavirus", "OBSERVATION_MODIFIER", 198, 209], ["severe", "OBSERVATION_MODIFIER", 292, 298], ["infection", "OBSERVATION", 299, 308], ["disease", "OBSERVATION", 360, 367], ["severe", "OBSERVATION_MODIFIER", 399, 405], ["inflammatory", "OBSERVATION_MODIFIER", 406, 418], ["bowel", "ANATOMY", 419, 424], ["disease", "OBSERVATION", 425, 432], ["cancer", "OBSERVATION", 437, 443]]], ["Case reports also describe atypical presentations of coronavirus infections in immunocompromised hosts, including prolonged incubation periods, persistent asymptomatic viral shedding, diarrhoea, weight loss and encephalitis as primary manifestations.", [["coronavirus infections", "DISEASE", 53, 75], ["viral shedding", "DISEASE", 168, 182], ["diarrhoea", "DISEASE", 184, 193], ["weight loss", "DISEASE", 195, 206], ["encephalitis", "DISEASE", 211, 223], ["coronavirus", "ORGANISM", 53, 64], ["coronavirus infections", "PROBLEM", 53, 75], ["immunocompromised hosts", "PROBLEM", 79, 102], ["prolonged incubation periods", "PROBLEM", 114, 142], ["persistent asymptomatic viral shedding", "PROBLEM", 144, 182], ["diarrhoea", "PROBLEM", 184, 193], ["weight loss", "PROBLEM", 195, 206], ["encephalitis", "PROBLEM", 211, 223], ["primary manifestations", "PROBLEM", 227, 249], ["atypical", "OBSERVATION_MODIFIER", 27, 35], ["coronavirus infections", "OBSERVATION", 53, 75], ["persistent", "OBSERVATION_MODIFIER", 144, 154], ["asymptomatic", "OBSERVATION_MODIFIER", 155, 167], ["viral shedding", "OBSERVATION", 168, 182], ["encephalitis", "OBSERVATION", 211, 223]]], ["13, 14, 15, 16 Initial Chinese observational studies on COVID-19 did not report a high rate of immunocompromised patients in severe hospitalised cases; however, this is likely underestimated due to a difference in demography compared to Western populations.", [["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Initial Chinese observational studies", "TEST", 15, 52], ["COVID", "TEST", 56, 61], ["a difference in demography", "PROBLEM", 198, 224], ["severe", "OBSERVATION_MODIFIER", 125, 131]]], ["Overall, there is currently insufficient evidence to suggest that COVID-19 infection is aggravated by immunomodulators used in skin disease; however, all COVID-19 infections should be considered serious and a precautionary approach is necessary.Infection risk of immunomodulator and biologic therapiesA range of immunomodulators, including conventional immunomodulators, biologics and newer small-molecule inhibitors, are used in autoimmune and immune-mediated skin diseases.", [["skin", "ANATOMY", 127, 131], ["skin", "ANATOMY", 461, 465], ["COVID-19", "CHEMICAL", 66, 74], ["infection", "DISEASE", 75, 84], ["skin disease", "DISEASE", 127, 139], ["infections", "DISEASE", 163, 173], ["autoimmune and immune-mediated skin diseases", "DISEASE", 430, 474], ["COVID-19", "ORGANISM", 66, 74], ["skin", "ORGAN", 127, 131], ["COVID-19", "ORGANISM", 154, 162], ["skin", "ORGAN", 461, 465], ["COVID-19 infection", "PROBLEM", 66, 84], ["immunomodulators", "TREATMENT", 102, 118], ["skin disease", "PROBLEM", 127, 139], ["all COVID-19 infections", "PROBLEM", 150, 173], ["a precautionary approach", "TREATMENT", 207, 231], ["immunomodulator", "TREATMENT", 263, 278], ["biologic therapies", "TREATMENT", 283, 301], ["immunomodulators", "TREATMENT", 312, 328], ["conventional immunomodulators", "TREATMENT", 340, 369], ["biologics", "TREATMENT", 371, 380], ["newer small-molecule inhibitors", "TREATMENT", 385, 416], ["autoimmune", "PROBLEM", 430, 440], ["mediated skin diseases", "PROBLEM", 452, 474], ["infection", "OBSERVATION", 75, 84], ["skin", "ANATOMY", 127, 131], ["disease", "OBSERVATION", 132, 139], ["immunomodulator", "OBSERVATION_MODIFIER", 263, 278], ["skin", "ANATOMY", 461, 465], ["diseases", "OBSERVATION", 466, 474]]], ["Most conventional immunomodulators are associated with an increased risk of infection.", [["infection", "DISEASE", 76, 85], ["conventional immunomodulators", "TREATMENT", 5, 34], ["infection", "PROBLEM", 76, 85], ["immunomodulators", "OBSERVATION", 18, 34], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["infection", "OBSERVATION", 76, 85]]], ["Table 1 summarises commonly used non-biologic immunomodulators and their infection risks.", [["infection", "DISEASE", 73, 82], ["non-biologic immunomodulators", "TREATMENT", 33, 62], ["their infection risks", "PROBLEM", 67, 88]]], ["Although immunomodulatory in action, retinoids (including acitretin, isotretinoin, alitretinoin), dapsone and phosphodiesterase (PDE)-4 inhibitors are not immunosuppressive.Infection risk of immunomodulator and biologic therapiesRecently, biologic agents such as monoclonal antibodies and small-molecule agents such as Janus kinase (JAK) and PDE-4 inhibitors have provided a novel approach in the treatment of various skin diseases.", [["skin", "ANATOMY", 418, 422], ["retinoids", "CHEMICAL", 37, 46], ["acitretin", "CHEMICAL", 58, 67], ["isotretinoin", "CHEMICAL", 69, 81], ["alitretinoin", "CHEMICAL", 83, 95], ["dapsone", "CHEMICAL", 98, 105], ["skin diseases", "DISEASE", 418, 431], ["retinoids", "CHEMICAL", 37, 46], ["acitretin", "CHEMICAL", 58, 67], ["isotretinoin", "CHEMICAL", 69, 81], ["alitretinoin", "CHEMICAL", 83, 95], ["dapsone", "CHEMICAL", 98, 105], ["retinoids", "SIMPLE_CHEMICAL", 37, 46], ["acitretin", "SIMPLE_CHEMICAL", 58, 67], ["isotretinoin", "SIMPLE_CHEMICAL", 69, 81], ["alitretinoin", "SIMPLE_CHEMICAL", 83, 95], ["dapsone", "SIMPLE_CHEMICAL", 98, 105], ["phosphodiesterase (PDE)-4", "GENE_OR_GENE_PRODUCT", 110, 135], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 319, 331], ["JAK", "GENE_OR_GENE_PRODUCT", 333, 336], ["PDE-4", "GENE_OR_GENE_PRODUCT", 342, 347], ["skin", "ORGAN", 418, 422], ["monoclonal antibodies", "PROTEIN", 263, 284], ["Janus kinase", "PROTEIN", 319, 331], ["JAK", "PROTEIN", 333, 336], ["immunomodulatory in action", "TREATMENT", 9, 35], ["retinoids", "TREATMENT", 37, 46], ["acitretin", "TREATMENT", 58, 67], ["isotretinoin", "TREATMENT", 69, 81], ["alitretinoin", "TREATMENT", 83, 95], ["dapsone", "TREATMENT", 98, 105], ["phosphodiesterase (PDE)", "TREATMENT", 110, 133], ["inhibitors", "TREATMENT", 136, 146], ["immunomodulator", "TREATMENT", 191, 206], ["biologic therapies", "TREATMENT", 211, 229], ["biologic agents", "TREATMENT", 239, 254], ["monoclonal antibodies", "TREATMENT", 263, 284], ["small-molecule agents", "TREATMENT", 289, 310], ["Janus kinase (JAK)", "TREATMENT", 319, 337], ["PDE-4 inhibitors", "TREATMENT", 342, 358], ["a novel approach", "TREATMENT", 373, 389], ["various skin diseases", "PROBLEM", 410, 431], ["immunomodulatory", "OBSERVATION_MODIFIER", 9, 25], ["immunomodulator", "OBSERVATION", 191, 206], ["skin", "ANATOMY", 418, 422], ["diseases", "OBSERVATION", 423, 431]]], ["By targeting single molecules or proteins that are critical in the disease pathogenesis, immunomodulation is thought to be more selective.", [["the disease pathogenesis", "PROBLEM", 63, 87], ["disease", "OBSERVATION", 67, 74], ["thought to be", "UNCERTAINTY", 109, 122]]], ["Table 2 summarises the short-term rates of upper respiratory tract infection and serious infection in pivotal phase III clinical trials for biologics and small-molecule agents.Infection risk of immunomodulator and biologic therapiesOverall, some biologics and small-molecule inhibitors have a small increase in upper respiratory tract infections or nasopharyngitis in clinical trials; however, infections are usually mild or self-limiting and serious infection rates are very low.", [["upper respiratory tract", "ANATOMY", 43, 66], ["upper respiratory tract", "ANATOMY", 311, 334], ["respiratory tract infection", "DISEASE", 49, 76], ["infection", "DISEASE", 89, 98], ["respiratory tract infections", "DISEASE", 317, 345], ["nasopharyngitis", "DISEASE", 349, 364], ["infections", "DISEASE", 394, 404], ["infection", "DISEASE", 451, 460], ["upper respiratory", "ORGANISM_SUBDIVISION", 43, 60], ["tract", "ORGANISM_SUBDIVISION", 61, 66], ["small-molecule agents", "SIMPLE_CHEMICAL", 154, 175], ["upper", "ORGANISM_SUBDIVISION", 311, 316], ["respiratory tract", "ORGANISM_SUBDIVISION", 317, 334], ["upper respiratory tract infection", "PROBLEM", 43, 76], ["serious infection", "PROBLEM", 81, 98], ["biologics", "TREATMENT", 140, 149], ["small-molecule agents", "TREATMENT", 154, 175], ["immunomodulator", "TREATMENT", 194, 209], ["biologic therapies", "TREATMENT", 214, 232], ["some biologics", "TREATMENT", 241, 255], ["small-molecule inhibitors", "TREATMENT", 260, 285], ["a small increase", "PROBLEM", 291, 307], ["upper respiratory tract infections", "PROBLEM", 311, 345], ["nasopharyngitis", "PROBLEM", 349, 364], ["infections", "PROBLEM", 394, 404], ["serious infection rates", "PROBLEM", 443, 466], ["upper", "ANATOMY_MODIFIER", 43, 48], ["respiratory tract", "ANATOMY", 49, 66], ["infection", "OBSERVATION", 67, 76], ["serious", "OBSERVATION_MODIFIER", 81, 88], ["infection", "OBSERVATION", 89, 98], ["immunomodulator", "OBSERVATION_MODIFIER", 194, 209], ["small", "OBSERVATION_MODIFIER", 293, 298], ["increase", "OBSERVATION_MODIFIER", 299, 307], ["upper", "ANATOMY_MODIFIER", 311, 316], ["respiratory tract", "ANATOMY", 317, 334], ["infections", "OBSERVATION", 335, 345], ["nasopharyngitis", "OBSERVATION", 349, 364], ["infections", "OBSERVATION", 394, 404], ["mild", "OBSERVATION_MODIFIER", 417, 421], ["self-limiting", "OBSERVATION_MODIFIER", 425, 438], ["serious", "OBSERVATION_MODIFIER", 443, 450], ["infection", "OBSERVATION", 451, 460]]], ["There is no high-quality evidence to suggest that biologics used in otherwise healthy dermatology patients is associated with an increased rate of severe infection or more severe influenza illnesses.", [["infection", "DISEASE", 154, 163], ["influenza illnesses", "DISEASE", 179, 198], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["high-quality evidence", "PROBLEM", 12, 33], ["an increased rate of severe infection", "PROBLEM", 126, 163], ["more severe influenza illnesses", "PROBLEM", 167, 198], ["no", "UNCERTAINTY", 9, 11], ["high-quality", "OBSERVATION_MODIFIER", 12, 24], ["biologics", "OBSERVATION", 50, 59], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["infection", "OBSERVATION", 154, 163], ["severe", "OBSERVATION_MODIFIER", 172, 178], ["influenza", "OBSERVATION", 179, 188]]], ["On the other hand, patients with severe skin disorders (e.g. severe psoriasis) are inherently at increased risk of developing pneumonias, of any cause.", [["skin", "ANATOMY", 40, 44], ["skin disorders", "DISEASE", 40, 54], ["psoriasis", "DISEASE", 68, 77], ["pneumonias", "DISEASE", 126, 136], ["patients", "ORGANISM", 19, 27], ["skin", "ORGAN", 40, 44], ["patients", "SPECIES", 19, 27], ["severe skin disorders", "PROBLEM", 33, 54], ["severe psoriasis)", "PROBLEM", 61, 78], ["developing pneumonias", "PROBLEM", 115, 136], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["skin", "ANATOMY", 40, 44], ["disorders", "OBSERVATION", 45, 54], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["psoriasis", "OBSERVATION", 68, 77], ["developing", "OBSERVATION_MODIFIER", 115, 125], ["pneumonias", "OBSERVATION", 126, 136]]], ["17 Furthermore, discontinuation of biologic therapy may result in a loss of treatment response when rechallenged and/or development of drug antibodies.", [["drug antibodies", "PROTEIN", 135, 150], ["biologic therapy", "TREATMENT", 35, 51], ["a loss of treatment response", "PROBLEM", 66, 94], ["drug antibodies", "PROBLEM", 135, 150]]], ["If cessation of a biologic is being considered due to the pandemic, patients should be unambiguously counselled on the aforementioned risks.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]], ["Please consider registering your patient with the Australasian Psoriasis Registry (or equivalent international registry) so experiences can be shared.", [["Psoriasis", "DISEASE", 63, 72], ["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["Psoriasis", "OBSERVATION", 63, 72]]], ["Nonetheless, transmission prevention measures should be emphasised in all patients and their immediate contacts, as this is likely the most effective measure to prevent SARS-CoV-2 infection.Risk assessment and management for patients on immunomodulators\u2022 There is currently insufficient evidence to determine whether dermatology patients on systemic immunomodulators are at increased risk of developing COVID-19 infection or more likely to have severe disease; as such clinicians need to assess the benefit-to-risk ratio on a case-by-case basis. \u2022 Patient factors that may indicate a higher risk of severe COVID-19 disease include the following:Risk assessment and management for patients on immunomodulatorsa Age over 60. b Uncontrolled or multiple chronic comorbidities including, but not limited to cardiovascular or chronic pulmonary disease, chronic kidney disease, diabetes, hypertension and some malignancies.Risk assessment and management for patients on immunomodulatorsc High doses or multiple immunomodulators. d History of severe or recurrent respiratory tract infections.Risk assessment and management for patients on immunomodulators\u2022 For most patients who are low-risk, immunomodulators should be continued. \u2022 Dose reductions (see Table 3 on possible lower dosages) or drug cessation may be considered in those who are identified as high risk; however, care should be taken with dose reduction of corticosteroid therapy. \u2022 Dose reduction or cessation of immunomodulators and biologics is not necessary in most children.Risk assessment and management for patients on immunomodulatorsCorticosteroid therapy during the COVID-19 pandemicRisk assessment and management for patients on immunomodulators\u2022 Corticosteroids are significantly immunosuppressive at dosages above 20 mg predniso(lo)ne equivalent; longterm use of such dosages during the pandemic should be avoided. \u2022 Use of predniso(lo)ne at 15 mg or more for 3 weeks is also associated with adrenal axis suppression.", [["cardiovascular", "ANATOMY", 802, 816], ["pulmonary", "ANATOMY", 828, 837], ["kidney", "ANATOMY", 855, 861], ["malignancies", "ANATOMY", 903, 915], ["respiratory tract", "ANATOMY", 1055, 1072], ["adrenal axis", "ANATOMY", 1960, 1972], ["SARS-CoV-2 infection", "DISEASE", 169, 189], ["infection", "DISEASE", 412, 421], ["COVID", "DISEASE", 606, 611], ["cardiovascular or chronic pulmonary disease", "DISEASE", 802, 845], ["chronic kidney disease", "DISEASE", 847, 869], ["diabetes", "DISEASE", 871, 879], ["hypertension", "DISEASE", 881, 893], ["malignancies", "DISEASE", 903, 915], ["respiratory tract infections", "DISEASE", 1055, 1083], ["predniso", "CHEMICAL", 1788, 1796], ["predniso", "CHEMICAL", 1892, 1900], ["adrenal axis suppression", "DISEASE", 1960, 1984], ["predniso", "CHEMICAL", 1788, 1796], ["predniso", "CHEMICAL", 1892, 1900], ["patients", "ORGANISM", 74, 82], ["SARS-CoV-2", "ORGANISM", 169, 179], ["patients", "ORGANISM", 225, 233], ["patients", "ORGANISM", 329, 337], ["patients", "ORGANISM", 680, 688], ["pulmonary", "ORGAN", 828, 837], ["kidney", "ORGAN", 855, 861], ["malignancies", "CANCER", 903, 915], ["patients", "ORGANISM", 951, 959], ["tract", "ORGANISM_SUBDIVISION", 1067, 1072], ["patients", "ORGANISM", 1119, 1127], ["patients", "ORGANISM", 1158, 1166], ["corticosteroid", "SIMPLE_CHEMICAL", 1412, 1426], ["children", "ORGANISM", 1525, 1533], ["patients", "ORGANISM", 1569, 1577], ["Corticosteroid", "SIMPLE_CHEMICAL", 1597, 1611], ["patients", "ORGANISM", 1683, 1691], ["predniso", "SIMPLE_CHEMICAL", 1788, 1796], ["predniso", "SIMPLE_CHEMICAL", 1892, 1900], ["adrenal", "ORGAN", 1960, 1967], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 329, 337], ["Patient", "SPECIES", 548, 555], ["patients", "SPECIES", 680, 688], ["patients", "SPECIES", 951, 959], ["patients", "SPECIES", 1119, 1127], ["patients", "SPECIES", 1158, 1166], ["children", "SPECIES", 1525, 1533], ["patients", "SPECIES", 1569, 1577], ["patients", "SPECIES", 1683, 1691], ["SARS-CoV-2", "SPECIES", 169, 179], ["transmission prevention measures", "TREATMENT", 13, 45], ["SARS", "PROBLEM", 169, 173], ["CoV-2 infection", "PROBLEM", 174, 189], ["Risk assessment", "TEST", 190, 205], ["immunomodulators", "TREATMENT", 237, 253], ["systemic immunomodulators", "TREATMENT", 341, 366], ["developing COVID-19 infection", "PROBLEM", 392, 421], ["severe disease", "PROBLEM", 445, 459], ["severe COVID-19 disease", "PROBLEM", 599, 622], ["Risk assessment", "TEST", 645, 660], ["management", "TREATMENT", 665, 675], ["immunomodulatorsa", "TREATMENT", 692, 709], ["Uncontrolled or multiple chronic comorbidities", "PROBLEM", 725, 771], ["chronic pulmonary disease", "PROBLEM", 820, 845], ["chronic kidney disease", "PROBLEM", 847, 869], ["diabetes", "PROBLEM", 871, 879], ["hypertension", "PROBLEM", 881, 893], ["some malignancies", "PROBLEM", 898, 915], ["Risk assessment", "TEST", 916, 931], ["management", "TREATMENT", 936, 946], ["immunomodulatorsc", "TREATMENT", 963, 980], ["multiple immunomodulators", "TREATMENT", 995, 1020], ["severe or recurrent respiratory tract infections", "PROBLEM", 1035, 1083], ["Risk assessment", "TEST", 1084, 1099], ["immunomodulators", "TREATMENT", 1131, 1147], ["immunomodulators", "TREATMENT", 1185, 1201], ["Dose reductions", "TREATMENT", 1225, 1240], ["lower dosages", "TREATMENT", 1266, 1279], ["drug cessation", "TREATMENT", 1284, 1298], ["corticosteroid therapy", "TREATMENT", 1412, 1434], ["Dose reduction", "TREATMENT", 1438, 1452], ["immunomodulators", "TREATMENT", 1469, 1485], ["biologics", "TREATMENT", 1490, 1499], ["Risk assessment", "TEST", 1534, 1549], ["management", "TREATMENT", 1554, 1564], ["immunomodulators", "TREATMENT", 1581, 1597], ["Corticosteroid therapy", "TREATMENT", 1597, 1619], ["the COVID", "TEST", 1627, 1636], ["pandemicRisk assessment", "TEST", 1640, 1663], ["management", "TREATMENT", 1668, 1678], ["immunomodulators", "TREATMENT", 1695, 1711], ["Corticosteroids", "TREATMENT", 1713, 1728], ["immunosuppressive at dosages", "TREATMENT", 1747, 1775], ["such dosages", "TREATMENT", 1831, 1843], ["the pandemic", "TREATMENT", 1851, 1863], ["predniso(lo)ne", "TREATMENT", 1892, 1906], ["adrenal axis suppression", "PROBLEM", 1960, 1984], ["infection", "OBSERVATION", 180, 189], ["infection", "OBSERVATION", 412, 421], ["severe", "OBSERVATION_MODIFIER", 445, 451], ["disease", "OBSERVATION", 452, 459], ["severe", "OBSERVATION_MODIFIER", 599, 605], ["multiple", "OBSERVATION_MODIFIER", 741, 749], ["chronic", "OBSERVATION_MODIFIER", 750, 757], ["comorbidities", "OBSERVATION", 758, 771], ["chronic", "OBSERVATION_MODIFIER", 820, 827], ["pulmonary", "ANATOMY", 828, 837], ["disease", "OBSERVATION", 838, 845], ["chronic", "OBSERVATION_MODIFIER", 847, 854], ["kidney", "ANATOMY", 855, 861], ["disease", "OBSERVATION", 862, 869], ["diabetes", "OBSERVATION", 871, 879], ["hypertension", "OBSERVATION", 881, 893], ["some", "OBSERVATION_MODIFIER", 898, 902], ["malignancies", "OBSERVATION", 903, 915], ["multiple", "OBSERVATION_MODIFIER", 995, 1003], ["immunomodulators", "OBSERVATION", 1004, 1020], ["severe", "OBSERVATION_MODIFIER", 1035, 1041], ["recurrent", "OBSERVATION_MODIFIER", 1045, 1054], ["respiratory tract", "ANATOMY", 1055, 1072], ["infections", "OBSERVATION", 1073, 1083], ["significantly", "OBSERVATION_MODIFIER", 1733, 1746], ["immunosuppressive", "OBSERVATION_MODIFIER", 1747, 1764], ["adrenal axis", "ANATOMY", 1960, 1972]]], ["18 \u2022 We recommend against sudden cessation or significant dose reductions due to risks of adrenal insufficiency.", [["adrenal", "ANATOMY", 90, 97], ["adrenal insufficiency", "DISEASE", 90, 111], ["adrenal", "ORGAN", 90, 97], ["significant dose reductions", "TREATMENT", 46, 73], ["adrenal insufficiency", "PROBLEM", 90, 111], ["adrenal", "ANATOMY", 90, 97], ["insufficiency", "OBSERVATION", 98, 111]]], ["Indeed, corticosteroid therapy may need to be increased in times of physiological stress including COVID-19, acute respiratory distress syndrome and other serious infection. \u2022 If reduction of corticosteroid therapy is indicated to mitigate infection risk during the pandemic, a graduated reduction is advised, aiming for a dose of \u226410 mg of predniso(lo)ne or equivalent.Patients on immunomodulators with suspected or confirmed COVID-19 infection\u2022 In patients with suspected or confirmed COVID-19 infection, all immunomodulators used for skin diseases should be immediately withheld, with the possible exception of corticosteroid therapy (as outlined above).Preventative measures during COVID-19 pandemicIn all patients, we emphasise the importance of preventative measures to minimise human-to-human transmission, including but not limited to: 19 \u2022 Regular washing of hands with soap and water; especially prior to applying creams to the face and body.", [["respiratory", "ANATOMY", 115, 126], ["skin", "ANATOMY", 537, 541], ["face", "ANATOMY", 938, 942], ["body", "ANATOMY", 947, 951], ["respiratory distress syndrome", "DISEASE", 115, 144], ["infection", "DISEASE", 163, 172], ["infection", "DISEASE", 240, 249], ["predniso", "CHEMICAL", 341, 349], ["infection", "DISEASE", 436, 445], ["infection", "DISEASE", 496, 505], ["skin diseases", "DISEASE", 537, 550], ["predniso", "CHEMICAL", 341, 349], ["corticosteroid", "SIMPLE_CHEMICAL", 8, 22], ["corticosteroid", "SIMPLE_CHEMICAL", 192, 206], ["predniso", "SIMPLE_CHEMICAL", 341, 349], ["Patients", "ORGANISM", 370, 378], ["patients", "ORGANISM", 450, 458], ["skin", "ORGAN", 537, 541], ["corticosteroid", "SIMPLE_CHEMICAL", 614, 628], ["patients", "ORGANISM", 710, 718], ["human", "ORGANISM", 785, 790], ["human", "ORGANISM", 794, 799], ["hands", "ORGANISM_SUBDIVISION", 868, 873], ["face", "ORGANISM_SUBDIVISION", 938, 942], ["body", "ORGANISM_SUBDIVISION", 947, 951], ["Patients", "SPECIES", 370, 378], ["patients", "SPECIES", 450, 458], ["patients", "SPECIES", 710, 718], ["human", "SPECIES", 785, 790], ["human", "SPECIES", 794, 799], ["COVID-19", "SPECIES", 487, 495], ["human", "SPECIES", 785, 790], ["human", "SPECIES", 794, 799], ["corticosteroid therapy", "TREATMENT", 8, 30], ["physiological stress", "PROBLEM", 68, 88], ["COVID", "TEST", 99, 104], ["acute respiratory distress syndrome", "PROBLEM", 109, 144], ["other serious infection", "PROBLEM", 149, 172], ["corticosteroid therapy", "TREATMENT", 192, 214], ["infection risk", "PROBLEM", 240, 254], ["a graduated reduction", "TREATMENT", 276, 297], ["\u2264", "TREATMENT", 331, 332], ["predniso(lo)ne", "TREATMENT", 341, 355], ["immunomodulators", "TREATMENT", 382, 398], ["COVID", "TEST", 427, 432], ["infection", "PROBLEM", 436, 445], ["COVID-19 infection", "PROBLEM", 487, 505], ["all immunomodulators", "TREATMENT", 507, 527], ["skin diseases", "PROBLEM", 537, 550], ["corticosteroid therapy", "TREATMENT", 614, 636], ["Preventative measures", "TREATMENT", 657, 678], ["preventative measures", "TREATMENT", 751, 772], ["soap and water", "TREATMENT", 879, 893], ["creams", "TREATMENT", 924, 930], ["corticosteroid therapy", "OBSERVATION", 8, 30], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["respiratory distress syndrome", "OBSERVATION", 115, 144], ["serious", "OBSERVATION_MODIFIER", 155, 162], ["infection", "OBSERVATION", 163, 172], ["corticosteroid therapy", "OBSERVATION", 192, 214], ["infection", "OBSERVATION", 436, 445], ["infection", "OBSERVATION", 496, 505], ["skin", "ANATOMY", 537, 541], ["diseases", "OBSERVATION", 542, 550], ["hands", "ANATOMY", 868, 873], ["face", "ANATOMY", 938, 942], ["body", "ANATOMY", 947, 951]]], ["Delay using emollient hand creams for 10-30 min after washing hands. \u2022 Avoid touching of face, eyes or mouth with unwashed hands. \u2022 Covering mouth and nose whilst coughing or sneezing.Preventative measures during COVID-19 pandemic\u2022 Avoiding overseas or interstate travel.Preventative measures during COVID-19 pandemic\u2022 Staying at home unless for medical care or necessary work. \u2022 Avoid sharing of household items such as cutlery and towels. \u2022 Regular cleaning of high-touch everyday objects.Preventative measures during COVID-19 pandemic\u2022 Wearing a face mask is not necessary if you are well.Preventative measures during COVID-19 pandemic\u2022 Practice good social-distancing techniques -this includes standing at least a metre and a half from the person standing next to you. \u2022 Stop shaking hands, hongi, kissing or hugging as a greeting. \u2022 Avoiding large gatherings, crowded places, or enclosed spaces (e.g. lifts). \u2022 For cleaning around the house, any usual household detergent should be effective at killing SARS-CoV-2. \u2022 Follow the current advice from your state/federal government regarding non-essential activities.Preventative measures during COVID-19 pandemicIn addition, we recommend annual influenza vaccination (except live intranasal influenza vaccines) for all and pneumococcal vaccination in appropriate populations.", [["hand", "ANATOMY", 22, 26], ["face", "ANATOMY", 89, 93], ["eyes", "ANATOMY", 95, 99], ["mouth", "ANATOMY", 103, 108], ["mouth", "ANATOMY", 141, 146], ["nose", "ANATOMY", 151, 155], ["emollient hand creams", "CHEMICAL", 12, 33], ["coughing", "DISEASE", 163, 171], ["sneezing", "DISEASE", 175, 183], ["SARS", "DISEASE", 1008, 1012], ["face", "ORGANISM_SUBDIVISION", 89, 93], ["eyes", "ORGAN", 95, 99], ["mouth", "ORGANISM_SUBDIVISION", 103, 108], ["hands", "ORGANISM_SUBDIVISION", 123, 128], ["mouth", "ORGANISM_SUBDIVISION", 141, 146], ["nose", "ORGANISM_SUBDIVISION", 151, 155], ["person", "SPECIES", 744, 750], ["SARS-CoV", "SPECIES", 1008, 1016], ["pneumococcal", "SPECIES", 1275, 1287], ["emollient hand creams", "TREATMENT", 12, 33], ["coughing", "PROBLEM", 163, 171], ["sneezing", "PROBLEM", 175, 183], ["Preventative measures", "TREATMENT", 184, 205], ["COVID", "TEST", 213, 218], ["Preventative measures", "TREATMENT", 271, 292], ["COVID", "TEST", 300, 305], ["Preventative measures", "TREATMENT", 491, 512], ["COVID", "TEST", 520, 525], ["a face mask", "TREATMENT", 547, 558], ["Preventative measures", "TREATMENT", 592, 613], ["COVID", "TEST", 621, 626], ["shaking hands", "PROBLEM", 780, 793], ["Preventative measures", "TREATMENT", 1118, 1139], ["COVID-19 pandemicIn addition", "TREATMENT", 1147, 1175], ["annual influenza vaccination", "TREATMENT", 1190, 1218], ["live intranasal influenza vaccines", "TREATMENT", 1227, 1261], ["pneumococcal vaccination", "TREATMENT", 1275, 1299], ["face", "ANATOMY", 89, 93], ["eyes", "ANATOMY", 95, 99], ["mouth", "ANATOMY", 103, 108], ["mouth", "ANATOMY", 141, 146], ["nose", "ANATOMY", 151, 155], ["sneezing", "OBSERVATION", 175, 183], ["cleaning", "OBSERVATION", 451, 459], ["large", "OBSERVATION_MODIFIER", 847, 852], ["gatherings", "OBSERVATION", 853, 863], ["crowded", "OBSERVATION_MODIFIER", 865, 872]]], ["Note that vaccine effectiveness may be diminished by higher dosages of some immunomodulators.Follow-up of dermatology patients on immunomodulatorsIn addition to minimising risk, it is important to consider rational use of health-care resources during the COVID-19 pandemic:Follow-up of dermatology patients on immunomodulators\u2022 Consider conducting follow-up visits by telemedicine.", [["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 298, 306], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 298, 306], ["vaccine effectiveness", "TREATMENT", 10, 31], ["some immunomodulators", "TREATMENT", 71, 92], ["immunomodulators", "TREATMENT", 130, 146], ["immunomodulators", "TREATMENT", 310, 326]]], ["20 \u2022 Consider reducing the frequency of routine monitoring investigations.", [["routine monitoring investigations", "TEST", 40, 73]]], ["21 \u2022 Re-enforce advice to improve comorbidities, in particular smoking and obesity. \u2022 For omalizumab, after the first injections, consider letting patients self inject at home.CONCLUSIONThis consensus statement draws upon the knowledge and experience of dermatologists specialised in the care of the immunosuppressed patient.", [["obesity", "DISEASE", 75, 82], ["omalizumab", "CHEMICAL", 90, 100], ["omalizumab", "SIMPLE_CHEMICAL", 90, 100], ["patients", "ORGANISM", 147, 155], ["patient", "ORGANISM", 317, 324], ["patients", "SPECIES", 147, 155], ["patient", "SPECIES", 317, 324], ["comorbidities", "PROBLEM", 34, 47], ["obesity", "PROBLEM", 75, 82], ["omalizumab", "TREATMENT", 90, 100], ["the first injections", "TREATMENT", 108, 128], ["obesity", "OBSERVATION", 75, 82], ["immunosuppressed", "OBSERVATION", 300, 316]]], ["More data and studies are required in characterising COVID-19 disease and its", [["studies", "TEST", 14, 21], ["19 disease", "PROBLEM", 59, 69]]]]}